• Aagaard CS, Hoang TT, Vingsbo-Lundberg C, Dietrich J, Andersen P. Quality and vaccine efficacy of CD4+ T cell responses directed to dominant and subdominant epitopes in ESAT-6 from Mycobacterium tuberculosis. J. Immunol. 183: 2659-2668 (2009).

• Abbas AK, Lohr J, Knoechel B. Balancing autoaggressive and protective T cell responses. J. Autoimmun. 28: 59-61 (2007).

• Abbas M, Bobo LD, Hsieh YH, Berka N, Dunston G, Bonney G, Apprey V, Quinn TC, West SK. Human leukocyte antigen (HLA)-B, -DRB1 and -DQB1 allotypes associated with disease and protection in trachoma endemic villages. Invest. Ophthalmol. Vis. Sci. 50: 1734-1738 (2009). *

• Abdel-Motal UM, Wigglesworth K, Galili U. Intratumoral injection of alpha-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity. Cancer Immunol. Immunother. 58: 1545-1556 (2009).

• Abplanalp AL, Morris IR, Parida BK, Teale JM, Berton MT. TLR-dependent control of Francisella tularensis infection and host inflammatory responses. PLoS One 4: e7920 (2009). *

• Abulafia-Lapid R, Afentoulis M, Vandenbark AA. Peptide therapy for anti-CD4 autoimmunity in HIV-1 infection: toward the development of an autoimmune animal model. Vaccine 27: 3475-3480 (2009). *

• Acharya AP, Clare-Salzler MJ, Keselowsky BG. A high-throughput microparticle microarray platform for dendritic cell-targeting vaccines. Biomaterials 30: 4168-4177 (2009).

• Adair SJ, Carr TM, Fink MJ, Slingluff CL Jr, Hogan KT. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes. J. Immunother. 31: 7-17 (2008).

• Ademokun A, Wu YC, Dunn-Walters D. The ageing B cell population: composition and function. Biogerontology Nov 25 [Epub ahead of print] (2009).

• Adler AJ. Mechanisms of T cell tolerance and suppression in cancer mediated by tumor-associated antigens and hormones. Curr. Cancer Drug Targets 7: 3-14 (2007).

• Adler EM. Focus issue - tailoring the immune response. Sci. STKE 241: EG9 (2004). *

• Afenyi-Annan A, Brecher ME, Bandarenko N. Update on multi-center clinical trials in the United States. Transfus. Apher. Sci. 36: 5-12 (2007).

• Afzal MA, Minor PD, Schild GC. Clinical safety issues of measles, mumps and rubella vaccines. Bull. World Health Organ. 78: 199-204 (2000).

• Agace WW. T-cell recruitment to the intestinal mucosa. Trends Immunol. 29: 514-522 (2008). *

• Agger EM, Cassidy JP, Brady J, Korsholm KS, Vingsbo-Lundberg C, Andersen P. Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection. Immunology 124: 175-185 (2008). *

• Aghamohammadi A, Cheraghi T, Gharagozlou M, Movahedi M, Rezaei N, Yeganeh M, Parvaneh N, Abolhassani H, Pourpak Z, Moin M. IgA deficiency: correlation between clinical and immunological phenotypes. J. Clin. Immunol. 29: 130-136 (2009). *

• Agmon-Levin N, Kivity S, Szyper-Kravitz M, Shoenfeld Y. Transverse myelitis and vaccines: a multi-analysis. Lupus 18: 1198-1204 (2009).

• Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y. Vaccines and autoimmunity. Nat. Rev. Rheumatol. 5: 648-652 (2009).

• Agmon-Levin N, Zafrir Y, Paz Z, Shilton T, Zandman-Goddard G, Shoenfeld Y. Ten cases of systemic lupus erythematosus related to hepatitis B vaccine. Lupus 18: 1192-1197 (2009).

• Agnholt J, Kaltoft K, Jakobsen NO, Dahlerup JF. T-cell vaccination in Crohn's disease: principles and presentation of the first two cases. Cytokines Cell Mol. Ther. 7: 117-123 (2002).

• Agrawal S, Gupta S, Agrawal A. Vaccinia virus proteins activate human dendritic cells to induce T cell responses in vitro. Vaccine 27: 88-92 (2009). *

• Aguillon G JC, Cruzat C A, Contreras-Levicoy J, Dotte G A, Pesce R B, Aravena MO, Salazar A L, Catalan M D, Abello C P, Aguirre D A, Llanos M C, Cuchacovich TM. Emergent therapies for rheumatoid arthritis. Rev. Med. Chil. 133: 969-976 (2005).

• Ahishali E, Boztas G, Akyuz F, Ibrisim D, Poturoglu S, Pinarbasi B, Ozdil S, Mungan Z. Response to hepatitis B vaccination in patients with celiac disease. Dig. Dis. Sci. 53: 2156-2159 (2007). *

• Ahlers JD, Belyakov IM. Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS. Trends Immunol. Jan 18 [Epub ahead of print] (2010). *

• Ahmad G, Zhang W, Torben W, Haskins C, Diggs S, Noor Z, Le L, Siddiqui AA. Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine. Parasitol. Res. Oct 7 [Epub ahead of print] (2009). *

• Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan GC. Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Mol. Ther. 17: 1101-1108 (2009).

• Ahmad SM, Haskell MJ, Raqib R, Stephensen CB. Markers of innate immune function are associated with vitamin A stores in men. J. Nutr. 139: 377-385 (2009). *

• Ahmad SM, Haskell MJ, Raqib R, Stephensen CB. Men with low vitamin A stores respond adequately to primary yellow fever and secondary tetanus toxoid vaccination. J. Nutr. 138: 2276-2283 (2008). *

• Ahmed R, Bevan MJ, Reiner SL, Fearon DT. The precursors of memory: models and controversies. Nat. Rev. Immunol. 9: 662-668 (2009). *

• Ahn SY, Ingulli E. Acute poststreptococcal glomerulonephritis: an update. Curr. Opin. Pediatr. 20: 157-162 (2008).

• Aires da Silva F, Corte-Real S, Goncalves J. Recombinant antibodies as therapeutic agents: pathways for modeling new biodrugs. BioDrugs 22: 301-314 (2008).

• Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, Scaramuzza S, Andolfi G, Mirolo M, Brigida I, Tabucchi A, Carlucci F, Eibl M, Aker M, Slavin S, Al-Mousa H, Al Ghonaium A, Ferster A, Duppenthaler A, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 360: 447-458 (2009). *

• Akatsuka Y, Morishima Y, Kuzushima K, Kodera Y, Takahashi T. Minor histocompatibility antigens as targets for immunotherapy using allogeneic immune reactions. Cancer Sci. 98: 1139-1146 (2007). *

• Akay BN, Arslan A, Cekirge S, Erkin G, Anadolu-Brasie R. The first reported case of lichen planus following inactivated influenza vaccination. J. Drugs Dermatol. 6: 536-538 (2007).

• Al-Attiyah R, Mustafa AS. Characterization of human cellular immune responses to novel Mycobacterium tuberculosis antigens encoded by genomic regions absent in Mycobacterium bovis BCG. Infect. Immun. 76: 4190-4198 (2008). *

• Albarran B, Goncalves L, Salmen S, Borges L, Fields H, Soyano A, Montes H, Berrueta L. Profiles of NK, NKT cell activation and cytokine production following vaccination against hepatitis B. APMIS 113: 526-535 (2005). *

• Albers R, Antoine JM, Bourdet-Sicard R, Calder PC, Gleeson M, Lesourd B, Samartín S, Sanderson IR, Van Loo J, Vas Dias FW, Watzl B. Markers to measure immunomodulation in human nutrition intervention studies. Br. J. Nutr. 94: 452-481 (2005). *

• Alberu J, Morales-Buenrostro LE, de Leo C, Vargas-Rojas MI, Marino-Vazquez LA, Crispin JC. A non-allogeneic stimulus triggers the production of de novo HLA antibodies in healthy adults. Transpl. Immunol. 18: 166-171 (2007).

• Alderson MR, McGowan P, Baldridge JR, Probst P. TLR4 agonists as immunomodulatory agents. J. Endotoxin Res. 12: 313-319 (2006). *

• Alexander J, Bilsel P, Del Guercio MF, Marinkovic-Petrovic A, Southwood S, Stewart S, Ishioka G, Kotturi MF, Botten J, Sidney J, Newman M, Sette A. Identification of broad binding class I HLA supertype epitopes to provide universal coverage of influenza A virus. Hum. Immunol. Feb 12 [Epub ahead of print] (2010).

• Ali FR, Larche M. Peptide-based immunotherapy: a novel strategy for allergic disease. Expert Rev. Vaccines 4: 881-889 (2005).

• Alibek K, Grechanyi L, Klimenko T, Pashkova A. Fifth revolution in medicine: on the role of infections in pathogenesis of aging and chronic diseases. Lik. Sprava. 1-2: 3-30 (2008).

• Alipour M, Omri A, Smith MG, Suntres ZE. Prophylactic effect of liposomal N-acetylcysteine against LPS-induced liver injuries. J. Endotoxin Res. 13: 297-304 (2007). *

• Alipour M, Suntres ZE, Halwani M, Azghani AO, Omri A. Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis. PLoS ONE 4: e5724 (2009). *

• Alipour M, Suntres ZE, Omri A. Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa. J. Antimicrob. Chemother. 64: 317-325 (2009).

• Alm JS, Sanjeevi CB, Miller EN, Dabadghao P, Lilja G, Pershagen G, Blackwell JM, Scheynius A. Atopy in children in relation to BCG vaccination and genetic polymorphisms at SLC11A1 (formerly NRAMP1) and D2S1471. Genes Immun. 3: 71-77 (2002). *

• Almadi MA, Ghosh S, Aljebreen AM. Differentiating intestinal tuberculosis from Crohn's disease: a diagnostic challenge. Am. J. Gastroenterol. 104: 1003-1012 (2009). *

• Alteri CJ, Hagan EC, Sivick KE, Smith SN, Mobley HL. Mucosal immunization with iron receptor antigens protects against urinary tract infection. PLoS Pathog. 5: e1000586 (2009). *

• Altiparmak F, Akalin A, Ferhatosmanoglu H. Predicting the binding affinity of MHC class II peptides. Comput. Syst. Bioinformatics Conf. 2006: 331-334 (2006). *

• Altman A, Szyper-Kravitz M, Shoenfeld Y. HBV vaccine and dermatomyositis: is there an association? Rheumatol. Int. 28: 609-612 (2008). *

• Alvarez E, Moga E, Barquinero J, Sierra J, Briones J. Dendritic and tumor cell fusions transduced with adenovirus encoding CD40L eradicate B-cell lymphoma and induce a Th17-type response. Gene Ther. Dec 14 [Epub ahead of print] (2009).

• Alvarez-Pellitero P. Fish immunity and parasite infections: from innate immunity to immunoprophylactic prospects. Vet. Immunol. Immunopathol. 126: 171-198 (2008).

• Alves-Leon SV, Veluttini-Pimentel ML, Gouveia ME, Malfetano FR, Gaspareto EL, Alvarenga MP, Frugulhetti I, Quirico-Santos T. Acute disseminated encephalomyelitis: clinical features, HLA DRB1*1501, HLA DRB1*1503, HLA DQA1*0102, HLA DQB1*0602, and HLA DPA1*0301 allelic association study. Arq. Neuropsiquiatr. 67: 643-651 (2009).

• Amador-Canizares Y, Alvarez-Lajonchere L, Guerra I, Rodriguez-Alonso I, Martinez-Donato G, Triana J, Gonzalez-Horta EE, Perez A, Duenas-Carrera S. Induction of IgA and sustained deficiency of cell proliferative response in chronic hepatitis C. World J. Gastroenterol. 14: 6844-6852 (2008). *

• Amela I, Cedano J, Querol E. Pathogen proteins eliciting antibodies do not share epitopes with host proteins: a bioinformatics approach. PLoS ONE 2: e512 (2007). *

• Amin J, Wong M. Measles-Mumps-Rubella immunisation, autism and inflammatory bowel disease: update. CDI: Current Issues in Immunisation 23: 222 [http://www.cda.gov.au/pubs/cdi/1999/cdi2308/pdf/cdi2308e.pdf] (1999). *

• Amirzargar AA, Mohseni N, Shokrgozar MA, Arjang Z, Ahmadi N, Yousefi Behzadi M, Amanzadeh A, Shokri F. HLA-DRB1, DQA1 and DQB1 alleles and haplotypes frequencies in Iranian healthy adult responders and non-responders to recombinant hepatitis B vaccine. Iran. J. Immunol. 5: 92-99 (2008).

• Amlong CA, Nardelli DT, Peterson SH, Warner TF, Callister SM, Schell RF. Anti-interleukin-15 prevents arthritis in Borrelia-vaccinated and -infected mice. Clin. Vaccine Immunol. 13: 289-296 (2006). *

• Ampel NM. The complex immunology of human coccidioidomycosis. Ann. N. Y. Acad. Sci. 1111: 245-258 (2007). *

• An P, Winkler CA. Host genes associated with HIV/AIDS: advances in gene discovery. Trends Genet. Feb 9 [Epub ahead of print] (2010). *

• Anders HJ. A Toll for lupus. Lupus 14: 417-422 (2005).

• Anderson KS, Wong J, Polyak K, Aronzon D, Enerback C. Detection of psoriasin/S100A7 in the sera of patients with psoriasis. Br. J. Dermatol. 160: 325-332 (2009). *

• Anderson RC, Fox CB, Dutill TS, Shaverdian N, Evers TL, Poshusta GR, Chesko J, Coler RN, Friede M, Reed SG, Vedvick TS. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf. B. Biointerfaces 75: 123-132 (2010).

• Andersson A, Isaksson M, Wefer J, Norling A, Flores-Morales A, Rorsman F, Kampe O, Harris RA, Lobell A. Impaired autoimmune T helper 17 cell responses following DNA vaccination against rat experimental autoimmune encephalomyelitis. PLoS ONE 3: e3682 (2008). *

• Andersson HA, Passeri MF, Barry MA. Rad23 as a reciprocal agent for stimulating or repressing immune responses. Hum. Gene Ther. 16: 634-641 (2005).

• Andersson IE, Dzhambazov B, Holmdahl R, Linusson A, Kihlberg J. Probing molecular interactions within class II MHC A(q)/glycopeptide/T-cell receptor complexes associated with collagen-induced arthritis. J. Med. Chem. 50: 5627-5643 (2007). *

• Anjuere F, Czerkinsky C. Mucosal immunity and vaccine development. Med. Sci. (Paris) 23: 371-378 (2007).

• Anolik JH, Looney RJ, Lund FE, Randall TD, Sanz I. Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol. Res. Apr 7 [Epub ahead of print] (2009). *

• Ansari AA. Autoimmunity, anergy, lentiviral immunity and disease. Autoimmun. Rev. 3: 530-540 (2004).

• Aoshi T, Nagata T, Suzuki M, Uchijima M, Hashimoto D, Rafiei A, Suda T, Chida K, Koide Y. Identification of HLA-A*0201-restricted T-cell epitope on MPT51 protein, a major secreted protein derived from Mycobacterium tuberculosis using MPT51 overlapping peptides screening. Infect. Immun. 76: 1565-1571 (2008). *

• Appay V, Voelter V, Rufer N, Reynard S, Jandus C, Gasparini D, Lienard D, Speiser DE, Schneider P, Cerottini JC, Romero P, Leyvraz S. Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma. J. Immunother. 30: 240-250 (2007).

• Appledorn DM, Patial S, McBride A, Godbehere S, Van Rooijen N, Parameswaran N, Amalfitano A. Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J. Immunol. 181: 2134-2144 (2008). *

• Apte SH, Baz A, Groves P, Kelso A, Kienzle N. Interferon-gamma and interleukin-4 reciprocally regulate CD8 expression in CD8+ T cells. Proc. Natl. Acad. Sci. U.S.A. 105: 17475-17480 (2008). *

• Aptsiauri N, Carretero R, Garcia-Lora A, Real LM, Cabrera T, Garrido F. Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol. Immunother. 57: 1727-1733 (2008).

• Arimilli S, Johnson JB, Clark KM, Graff AH, Alexander-Miller MA, Mizel SB, Parks GD. Engineered expression of the TLR5 ligand flagellin enhances paramyxovirus activation of human dendritic cell function. J. Virol. 82: 10975-10985 (2008). *

• Aroeira LS. TCR vaccination in aluminum adjuvant protects against autoimmune encephalomyelitis. Clin. Immunol. 119: 252-260 (2006). *

• Aron-Maor A, Shoenfeld Y. Vaccination and systemic lupus erythematosus: the bidirectional dilemmas. Lupus 10: 237-240 (2001).

• Arrode-Bruses G, Sheffer D, Hegde R, Dhillon S, Liu Z, Villinger F, Narayan O, Chebloune Y. Characterization of T cell responses in macaques immunized with a single dose of HIV DNA vaccine. J. Virol. Nov 18 [Epub ahead of print] (2009). *

• Artis D, Grencis RK. The intestinal epithelium: sensors to effectors in nematode infection. Mucosal Immunol. 1: 252-264 (2008). *

• Ascherio A, Zhang SM, Hernan MA, Olek MJ, Coplan PM, Brodovicz K, Walker AM. Hepatitis B vaccination and the risk of multiple sclerosis. N. Engl. J. Med. 344: 327-332 (2001). *

• Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect. Dis. 5: 549-557 (2005).

• Asquith DL, McInnes IB. Emerging cytokine targets in rheumatoid arthritis. Curr. Opin. Rheumatol. 19: 246-251 (2007). *

• Assarsson E, Bui HH, Sidney J, Zhang Q, Glenn J, Oseroff C, Mbawuike IN, Alexander J, Newman MJ, Grey H, Sette A. Immunomic analysis of the repertoire of T cell specificities for influenza A virus in humans. J. Virol. 82: 12241-12251 (2008). *

• Astakhov V, Cherkasov A. Prediction of HLA-A2 binding peptides using Bayesian network. Bioinformation 1: 58-63 (2005). *

• Atik B, Skwor TA, Kandel RP, Sharma B, Adhikari HK, Steiner L, Erlich H, Dean D. Identification of novel single nucleotide polymorphisms in inflammatory genes as risk factors associated with trachomatous trichiasis. PLoS ONE 3: e3600 (2008). *

• Atkins GJ, Cosby SL. Is an improved measles-mumps-rubella vaccine necessary or feasible? Crit. Rev. Immunol. 23: 323-338 2003.

• Atzeni F, Bendtzen K, Bobbio-Pallavicini F, Conti F, Cutolo M, Montecucco C, Sulli A, Valesini G, Sarzi-Puttini P. Infections and treatment of patients with rheumatic diseases. Clin. Exp. Rheumatol. 26: S67-S73 (2008).

• Autenrieth SE, Autenrieth IB. Variable antigen uptake due to different expression of the macrophage mannose receptor by dendritic cells in various inbred mouse strains. Immunology 127: 523-529 (2009).

• Autran B, Carcelain G, Combadiere B, Debre P. Therapeutic vaccines for chronic infections. Science 305: 205-208 (2004). *

• Autran B, Debre P, Walker B, Katlama C. Therapeutic vaccines against HIV need international partnerships. Nat. Rev. Immunol. 3: 503-508 (2003).

• Autret-Leca E, Bensouda-Grimaldi L, Jonville-Bera AP, Beau-Salinas F. Pharmacovigilance of vaccines. Arch. Pediatr. 13: 175-180 (2006).

• Autret-Leca E, Jonville-Bera AP, Beau-Salinas F. Vaccines pharmacovigilance. Rev. Prat. 54: 526-531 (2004).

• Avalos P, Camacho FM. Practical management of adalimumab. Actas. Dermosifiliogr. 99 Suppl. 3: 25-27 (2008).

• Avaniss-Aghajani E, Berzon S, Sarkissian A. Clinical value of multiplexed bead based immunoassays for detection of autoantibodies to nuclear antigens. Clin. Vaccine Immunol. 14: 505-509 (2007). *

• Awomoyi AA, Marchant A, Howson JM, McAdam KP, Blackwell JM, Newport MJ. Interleukin-10, polymorphism in SLC11A1 (formerly NRAMP1), and susceptibility to tuberculosis. J. Infect. Dis. 186: 1808-1814 (2002). *

• Axelsson-Robertson R, Weichold F, Sizemore D, Wulf M, Skeiky YA, Sadoff J, Maeurer MJ. Extensive major histocompatibility complex class I binding promiscuity for Mycobacterium tuberculosis TB10.4 peptides and immune dominance of human leucocyte antigen (HLA)-B*0702 and HLA-B*0801 alleles in TB10.4 CD8(+) T-cell responses. Immunology Dec 14 [Epub ahead of print] (2009). *

• Baban B, Chandler PR, Sharma MD, Pihkala J, Koni PA, Munn DH, Mellor AL. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J. Immunol. 183: 2475-2483 (2009).

• Babiuk S, Mookherjee N, Pontarollo R, Griebel P, Van Drunen Littel-Van Den Hurk S, Hecker R, Babiuk L. TLR9(+/+) and TLR9(-/-) mice display similar immune responses to a DNA vaccine. Immunology 113: 114-120 (2004). *

• Bach JF. Protective role of infections and vaccinations on autoimmune diseases. J. Autoimmun. 16: 347-353 (2001).

• Badr MZ, Shnyra A, Zoubine M, Norkin M, Herndon B, Quinn T, Miranda RN, Cunningham ML, Molteni A. Phthalate-induced liver protection against deleterious effects of the Th1 response: a potentially serious health hazard. PPAR Res. 2007: 49671 (2007). *

• Bahador M, Cross AS. From therapy to experimental model: a hundred years of endotoxin administration to human subjects. J. Endotoxin Res. 13: 251-279 (2007). *

• Baharav E, Mor F, Halpern M, Quintana F, Weinberger A. Tropomyosin-induced arthritis in rats. Clin. Exp. Rheumatol. 25: S86-S92 (2007).

• Bahceciler NN, Ozdemir C, Barlan IB. Immunologic aspects of sublingual immunotherapy in the treatment of allergy and asthma. Curr. Med. Chem. 14: 265-269 (2007).

• Bahey-El-Din M, Gahan CG, Griffin BT. Lactococcus lactis as a cell factory for delivery of therapeutic proteins. Curr. Gene Ther. Feb 16 [Epub ahead of print] (2010).

• Baig S, Alamgir M. The extrahepatic manifestations of hepatitis B virus. J. Coll. Physicians Surg. Pak. 18: 451-457 (2008).

• Baio P, Brucato A, Buskila D, Gershwin ME, Giacomazzi D, Lopez LR, Luzzati R, Matsuura E, Selmi C, Sarzi-Puttini P, Atzeni F. Autoimmune diseases and infections: controversial issues. Clin. Exp. Rheumatol. 26: S74-S80 (2008).

• Baker BS, Owles AV, Fry L. A possible role for vaccination in the treatment of psoriasis? G. Ital. Dermatol. Venereol. 143: 105-117 (2008).

• Baker VS, Imade GE, Molta NB, Tawde P, Pam SD, Obadofin MO, Sagay SA, Egah DZ, Iya D, Afolabi BB, Baker M, Ford K, Ford R, Roux KH, Keller TC 3rd. Cytokine-associated neutrophil extracellular traps and antinuclear antibodies in Plasmodium falciparum infected children under six years of age. Malar. J. 7: 41 (2008). *

• Baldridge JR, McGowan P, Evans JT, Cluff C, Mossman S, Johnson D, Persing D. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin. Biol. Ther. 4: 1129-1138 (2004).

• Balfe P, McKeating JA. The complexities of hepatitis C virus entry. J. Hepatol. 51: 609-611 (2009).

• Ball R, Shadomy SV, Meyer A, Huber BT, Leffell MS, Zachary A, Belotto M, Hilton E, Bryant-Genevier M, Schriefer ME, Miller FW, Braun MM. HLA type and immune response to Borrelia burgdorferi outer surface protein a in people in whom arthritis developed after Lyme disease vaccination. Arthritis Rheum. 60: 1179-1186 (2009). *

• Ballotti S, Chiarelli F, de Martino M. Autoimmunity: basic mechanisms and implications in endocrine diseases. Part II. Horm. Res. 66: 142-152 (2006).

• Ballow M, Notarangelo L, Grimbacher B, Cunningham-Rundles C, Stein M, Helbert M, Gathmann B, Kindle G, Knight AK, Ochs HD, Sullivan K, Franco JL. Immunodeficiencies. Clin. Exp. Immunol. 158 Suppl. 1: 14-22 (2009). *

• Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5: 296-306 (2005). *

• Banerjee S, Michetti P. Strategies for developing a Helicobacter pylori vaccine. Curr. Opin. Gastroenterol. 15: 557 (1999).

• Banham AH, Pulford K. Therapeutic targeting of FOXP3-positive regulatory T cells using a FOXP3 peptide vaccine WO2008081581. Expert Opin. Ther. Pat. 19: 1023-1028 (2009).

• Banks RE, Roy M, Hellems-Lewis G, Hadick C. Antigen delivery to gut associated lymphoid tissue of rabbits. Lab. Anim. Sci. 39: 582-586 (1989).

• Bannwarth B. Drug-induced musculoskeletal disorders. Drug Saf. 30: 27-46 (2007).

• Bansal K, Elluru SR, Narayana Y, Chaturvedi R, Patil SA, Kaveri SV, Bayry J, Balaji KN. PE_PGRS antigens of Mycobacterium tuberculosis induce maturation and activation of human dendritic cells. J. Immunol. Feb 22 [Epub ahead of print] (2010).

• Bansal K, Narayana Y, Balaji KN. Inhibition of TNF-alpha-induced cyclooxygenase-2 expression by Mycobacterium bovis BCG in human alveolar epithelial A549 cells. Scand. J. Immunol. 69: 11-19 (2009). *

• Banus HA, Vandebriel RJ, de Ruiter H, Dormans JA, Nagelkerke NJ, Mooi FR, Hoebee B, van Kranen HJ, Kimman TG. Host genetics of Bordetella pertussis infection in mice: significance of Toll-like receptor 4 in genetic susceptibility and pathobiology. Infect. Immun. 74: 2596-2605 (2006). *

• Banus S, Bottema RW, Siezen CL, Vandebriel RJ, Reimerink J, Mommers M, Koppelman GH, Hoebee B, Thijs C, Postma DS, Kimman TG, Stelma FF. A Toll-like receptor 4 polymorphism is associated with the response to whole-cell pertussis vaccination in children from the KOALA study. Clin. Vaccine Immunol. 14: 1377-1380 (2007).

• Banus S, Pennings J, Vandebriel R, Wester P, Breit T, Mooi F, Hoebee B, Kimman T. Lung response to Bordetella pertussis infection in mice identified by gene-expression profiling. Immunogenetics 59: 555-564 (2007). *

• Banus S, Stenger RM, Gremmer ER, Dormans JA, Mooi FR, Kimman TG, Vandebriel RJ. The role of Toll-like receptor-4 in pertussis vaccine-induced immunity. BMC Immunol. 9: 21 (2008). *

• Baquir B, Lin L, Ibrahim AS, Fu Y, Avanesian V, Tu A, Edwards Jr J, Spellberg B. Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine protein. J. Infect. Dis. Dec 29 [Epub ahead of print] (2009). *

• Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Robinson WH, Shi FD, Utz PJ, Valone F, Weiner L, Steinman L, Garren H. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch. Neurol. 64: 1407-1415 (2007). *

• Barabas AZ, Cole CD, Barabas AD, Bahlis NJ, Lafreniere R. New vaccination technology for endogenous antigen-derived ailments. IDrugs 11: 111-115 (2008).

• Barabas AZ, Cole CD, Barabas AD, Graeff RM, Lafreniere R, Weir DM. Correcting autoimmune anomalies in autoimmune disorders by immunological means, employing the modified vaccination technique. Autoimmun. Rev. 8: 552-557 (2009).

• Barabas AZ, Cole CD, Barabas AD, Lafreniere R. A modified vaccination technique for the prevention and treatment of an experimental autoimmune kidney disease. Ann. N. Y. Acad. Sci. 1110: 619-629 (2007). *

• Barabas AZ, Weir DM, Cole CD, Barabas AD, Bahlis NJ, Graeff RM, Lafreniere R. Preventing and treating chronic disorders using the modified vaccination technique. Front. Biosci. 14: 3892-3898 (2009).

• Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687 (2006). *

• Baron S, Turck D, Leplat C, Merle V, Gower-Rousseau C, Marti R, Yzet T, Lerebours E, Dupas JL, Debeugny S, Salomez JL, Cortot A, Colombel JF. Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut 54: 357-363 (2005). *

• Barrett AD, Teuwen DE. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place? Curr. Opin. Immunol. 21: 308-313 (2009).

• Bartalena L, Tanda ML, Medea A, Marcocci C, Pinchera A. Novel approaches to the management of Graves' ophthalmopathy. Hormones (Athens) 1: 76-90 (2002).

• Bartalesi F, Vicidomini S, Goletti D, Fiorelli C, Fiori G, Melchiorre D, Tortoli E, Mantella A, Benucci M, Girardi E, Cerinic MM, Bartoloni A. QuantiFERON-TB Gold and TST are both useful for latent TB screening in autoimmune diseases. Eur. Respir. J. 33: 586-593 (2009).

• Bartee E, McCormack A, Fruh K. Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog. 2: e107 (2006). *

• Bartosik-Psujek H, Stelmasiak Z. Multiple sclerosis - difficult answers to easy questions. Neurol. Neurochir. Pol. 40: 441-445 (2006).

• Barzilai O, Ram M, Shoenfeld Y. Viral infection can induce the production of autoantibodies. Curr. Opin. Rheumatol. 19: 636-643 (2007).

• Bassaganya-Riera J, Guri AJ, Noble AM, Reynolds KA, King J, Wood CM, Ashby M, Rai D, Hontecillas R. Arachidonic acid-and docosahexaenoic acid-enriched formulas modulate antigen-specific T cell responses to influenza virus in neonatal piglets. Am. J. Clin. Nutr. 85: 824-836 (2007). *

• Basta S, Alatery A. The cross-priming pathway: a portrait of an intricate immune system. Scand. J. Immunol. 65: 311-319 (2007). *

• Basu R, Roy S, Walden P. HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages. J. Infect. Dis. 195: 1373-1380 (2007). *

• Batdelger D, Dandii D, Dahgwahdorj Y, Erdenetsogt E, Oyunbileg J, Tsend N, Bayarmagnai B, Jirathitikal V, Bourinbaiar AS. Clinical experience with therapeutic vaccines designed for patients with hepatitis. Curr. Pharm. Des. 15: 1159-1171 (2009).

• Bauer S, Pigisch S, Hangel D, Kaufmann A, Hamm S. Recognition of nucleic acid and nucleic acid analogs by Toll-like receptors 7, 8 and 9. Immunobiology 213: 315-328 (2008).

• Bauer T, Gunther M, Bienzle U, Neuhaus R, Jilg W. Vaccination against hepatitis B in liver transplant recipients: pilot analysis of cellular immune response shows evidence of HBsAg-specific regulatory T cells. Liver Transpl. 13: 434-442 (2007). *

• Baumert TF. Novel vaccine strategies. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 58-59. October 20 - 21 (2003). *

• Bayer AL, Jones M, Chirinos J, de Armas L, Schreiber TH, Malek TR, Levy RB. Host CD4+CD25+ T cells can expand and comprise a major component of the Treg compartment following experimental HCT. Blood 113: 733-743 (2009). *

• Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find. Exp. Clin. Pharmacol. 27: 265-284 (2005).

• Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find. Exp. Clin. Pharmacol. 26: 587-612 (2004).

• Bayry J, Triebel F, Kaveri SV, Tough DF. Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells. J. Immunol. 178: 4184-4193 (2007). *

• Beadling C, Slifka MK. Regulation of innate and adaptive immune responses by the related cytokines IL-12, IL-23, and IL-27. Arch. Immunol. Ther. Exp. (Warsz.) 54: 15-24 (2006).

• Bedoui S, Prato S, Mintern J, Gebhardt T, Zhan Y, Lew AM, Heath WR, Villadangos JA, Segura E. Characterization of an immediate splenic precursor of CD8+ dendritic cells capable of inducing antiviral T cell responses. J. Immunol. 182: 4200-4207 (2009).

• Beeton C, Garcia A, Chandy KG. Induction and clinical scoring of chronic-relapsing experimental autoimmune encephalomyelitis. J. Vis. Exp. 5: 224 (2007). *

• Befeler AS. New developments in hepatocellular carcinoma. 54th Annual Meeting of the American Association for the Study of Liver Diseases (2003).

• Begum D, Umemura M, Yahagi A, Okamoto Y, Hamada S, Oshiro K, Matsuzaki G. Accelerated induction of mycobacterial antigen-specific CD8(+) T cells in the Mycobacterium tuberculosis-infected lung by subcutaneous vaccination with Mycobacterium bovis bacille Calmette-Guerin. Immunology 128: 556-563 (2009). *

• Bekeredjian-Ding I, Jego G. Toll-like receptors - sentries in the B-cell response. Immunology 128: 311-323 (2009). *

• Bell EB, Westermann J. CD4 memory T cells on trial: immunological memory without a memory T cell. Trends Immunol. 29: 405-411 (2008). *

• Bell MJ, Abbott RJ, Croft NP, Hislop AD, Burrows SR. An HLA-A2-restricted T cell epitope mapped to the BNLF2a immune evasion protein of EBV that inhibits TAP. J. Virol. 83: 2783-2788 (2009). *

• Bell SC, Robinson PJ. Exacerbations in cystic fibrosis. 2. Prevention. Thorax 62: 723-732 (2007). *

• Bellanti JA, Sabra A, Zeligs BJ. Gastrointestinal immunopathology and food allergy. Ann. Allergy Asthma Immunol. 93: S26-S32 (2004).

• Bellone M, Mondino A, Corti A. Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer. Trends Immunol. 29: 235-241 (2008). *

• Belloni G, Talamazzini A, Soldati PM, Bernini L, Di Gennaro F, Bergamaschi P. Primary biliary cirrhosis with onset in pregnancy: a case report. Medicina (Firenze) 10: 31-32 (1990).

• Belogurov A Jr, Kozyr A, Ponomarenko N, Gabibov A. Catalytic antibodies: balancing between Dr. Jekyll and Mr. Hyde. Bioessays 31: 1161-1171 (2009). *

• Belyakov IM, Ahlers JD. Functional CD8(+) CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine. Trends Immunol. 29: 574-585 (2008). *

• Belyakov IM, Ahlers JD. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J. Immunol. 183: 6883-6892 (2009). *

• Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu. Rev. Immunol. 25: 297-336 (2007). *

• Bendiak GN, Ratjen F. The approach to Pseudomonas aeruginosa in cystic fibrosis. Semin. Respir. Crit. Care Med. 30: 587-595 (2009).

• Benko S, Magyarics Z, Szabo A, Rajnavolgyi E. Dendritic cell subtypes as primary targets of vaccines: the emerging role and cross-talk of pattern recognition receptors. Biol. Chem. 389: 469-485 (2008).

• Benko S, Magyarics Z, Szabo A, Rajnavolgyi E. Dendritic cell subtypes as primary targets of vaccines: the emerging role and cross-talk of pattern recognition receptors. Biol. Chem. 389: 469-485 (2008). *

• Benlahrech A, Harris J, Meiser A, Papagatsias T, Hornig J, Hayes P, Lieber A, Athanasopoulos T, Bachy V, Csomor E, Daniels R, Fisher K, Gotch F, Seymour L, Logan K, Barbagallo R, Klavinskis L, Dickson G, Patterson S. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc. Natl. Acad. Sci. U.S.A. 106: 19940-19945 (2009). *

• Benn CS, Aaby P, Nielsen J, Binka FN, Ross DA. Does vitamin A supplementation interact with routine vaccinations? An analysis of the Ghana vitamin A supplementation trial. Am. J. Clin. Nutr. 90: 629-639 (2009). *

• Benn CS, Diness BR, Roth A, Nante E, Fisker AB, Lisse IM, Yazdanbakhsh M, Whittle H, Rodrigues A, Aaby P. Effect of 50,000 IU vitamin A given with BCG vaccine on mortality in infants in Guinea-Bissau: randomised placebo controlled trial. BMJ 336: 1416-1420 (2008). *

• Benn CS, Fisker AB, Jorgensen MJ, Aaby P. Conflicting evidence for neonatal vitamin A supplementation. Vaccine 26: 4111-4112 (2008).

• Benn CS, Lund S, Fisker A, Jorgensen MJ, Aaby P. Should infant girls receive micronutrient supplements? Int. J. Epidemiol. 38: 586-590 (2009).

• Benn CS, Martins C, Rodrigues A, Ravn H, Fisker AB, Christoffersen D, Aaby P. The effect of vitamin A supplementation administered with missing vaccines during national immunization days in Guinea-Bissau. Int. J. Epidemiol. 38: 304-311 (2009). *

• Benson MJ, Elgueta R, Schpero W, Molloy M, Zhang W, Usherwood E, Noelle RJ. Distinction of the memory B cell response to cognate antigen versus bystander inflammatory signals. J. Exp. Med. 206: 2013-2025 (2009). *

• Beran J, Dedek P, Stepanova V, Spliio M, Pozler O. Safety and immunogenicity of a combined vaccine against hepatitis A and B in patients with autoimmune hepatitis. Cent. Eur. J. Public Health 13: 20-23 (2005).

• Berg DT, Gerlitz B, Sharma GR, Richardson MA, Stephens EJ, Grubbs RL, Holmes KC, Fynboe K, Montani D, Cramer MS, Engle SD, Jakubowski JA, Heuer JG, Grinnell BW. FoxA2 involvement in suppression of protein C, an outcome predictor in experimental sepsis. Clin. Vaccine Immunol. 13: 426-432 (2006). *

• Bergamaschi C, Jalah R, Kulkarni V, Rosati M, Zhang GM, Alicea C, Zolotukhin AS, Felber BK, Pavlakis GN. Secretion and biological activity of short signal peptide IL-15 is chaperoned by IL-15 receptor alpha in vivo. J. Immunol. 183: 3064-3072 (2009).

• Berger JR, Houff S. Opportunistic infections and other risks with newer multiple sclerosis therapies. Ann. Neurol. 65: 367-377 (2009).

• Berger S, Hinz D, Bannantine JP, Griffin JF. Isolation of high-affinity single-chain antibodies against Mycobacterium avium subsp. paratuberculosis surface proteins from sheep with Johne's disease. Clin. Vaccine Immunol. 13: 1022-1029 (2006). *

• Berger SG, de Pee S, Bloem MW, Halati S, Semba RD. Malnutrition and morbidity among children not reached by the national vitamin A capsule programme in urban slum areas of Indonesia. Public Health 122: 371-378 (2008).

• Berghofer B, Frommer T, Konig IR, Ziegler A, Chakraborty T, Bein G, Hackstein H. Common human Toll-like receptor 9 polymorphisms and haplotypes: association with atopy and functional relevance. Clin. Exp. Allergy 35: 1147-1154 (2005).

• Berlec A, Strukelj B. Novel applications of recombinant lactic acid bacteria in therapy and in metabolic engineering. Recent Pat. Biotechnol. 3: 77-87 (2009).

• Bernard MP, Phipp RP. Inhibition of cyclooxygenase-2 impairs the expression of essential plasma cell transcription factors and human B-lymphocyte differentiation. Immunology 129: 87-96 (2010). *

• Bernatoniene J, Zhang Q, Dogan S, Mitchell TJ, Paton JC, Finn A. Induction of CC and CXC chemokines in human antigen-presenting dendritic cells by the pneumococcal proteins pneumolysin and CbpA, and the role played by Toll-like receptor 4, NF-kappaB, and mitogen-activated protein kinases. J. Infect. Dis. 198: 1823-1833 (2008). *

• Bernstein CN, Rawsthorne P, Blanchard JF. Population-based case-control study of measles, mumps, and rubella and inflammatory bowel disease. Inflamm. Bowel Dis. 13: 759-762 (2007). *

• Berrih-Aknin S, Fuchs S, Souroujon MC. Vaccines against myasthenia gravis. Expert Opin. Biol. Ther. 5: 983-995 (2005). *

• Berry PA, Smith-Laing G. Hepatitis A vaccine associated with autoimmune hepatitis. World J. Gastroenterol. 13: 2238-2239 (2007). *

• Bertholet S, Ireton GC, Kahn M, Guderian J, Mohamath R, Stride N, Laughlin EM, Baldwin SL, Vedvick TS, Coler RN, Reed SG. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J. Immunol. 181: 7948-7957 (2008). *

• Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 1: 209-219 (2001). *

• Bessa J, Jegerlehner A, Hinton HJ, Pumpens P, Saudan P, Schneider P, Bachmann MF. Alveolar macrophages and lung dendritic cells sense RNA and drive mucosal IgA responses. J. Immunol. 183: 3788-3799 (2009).

• Beverley PC. Primer: making sense of T-cell memory. Nat. Clin. Pract. Rheumatol. 4: 43-49 (2008). *

• Beyer AM, Wandinger KP, Siebert E, Zschenderlein R, Klehmet J. Neuromyelitis optica in a patient with an early onset demyelinating episode: clinical and autoantibody findings. Clin. Neurol. Neurosurg. 109: 926-930 (2007).

• Beyer M, Karbach J, Mallmann MR, Zander T, Eggle D, Classen S, Debey-Pascher S, Famulok M, Jager E, Schultze JL. Cancer vaccine enhanced, non-tumor-reactive CD8+ T cells exhibit a distinct molecular program associated with "division arrest anergy" Cancer Res. 69: 4346-4354 (2009). *

• Beyersdorf N, Braun A, Vogtle T, Varga-Szabo D, Galdos RR, Kissler S, Kerkau T, Nieswandt B. STIM1-independent T cell development and effector function in vivo. J. Immunol. 182: 3390-3397 (2009).

• Beytout J, Tournilhac O, Laurichesse H. Asplenia and hyposplenism. Presse. Med. 32: S5-S9 (2003).

• Bhagyalaxmi A, Kedia G, Rawal VS. Study of incidence of measles and vaccination coverage in Ahmedabad urban slums. Indian J. Public Health 51: 52-53 (2007).

• Bhat A, Naguwa S, Cheema G, Gershwin ME. The epidemiology of transverse myelitis. Autoimmun. Rev. Dec 22 [Epub ahead of print] (2009).

• Bhavsar MD, Amiji MM. Polymeric nano- and microparticle technologies for oral gene delivery. Expert Opin. Drug Deliv. 4: 197-213 (2007).

• Bian H, Hammer J. Discovery of promiscuous HLA-II-restricted T cell epitopes with TEPITOPE. Methods 34: 468-475 (2004). *

• Bickston SJ, Comerford LW, Cominelli F. Future therapies for inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 518-523 (2003).

• Biggioggero M, Borghi M, Gerosa M, Trespidi L, Cimaz R, Meroni P. Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants. Lupus 16: 651-656 (2007). *

• Biggioggero M, Meroni PL. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun. Rev. Nov 19 [Epub ahead of print] (2009).

• Bioley G, Guillaume P, Luescher I, Yeh A, Dupont B, Bhardwaj N, Mears G, Old LJ, Valmori D, Ayyoub M. HLA class I-associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine. Clin. Cancer Res. 15: 299-306 (2009). *

• Biragyn A. Defensins - non-antibiotic use for vaccine development. Curr. Protein Pept. Sci. 6: 53-60 (2005).

• Birck R, Kaelsch I, Schnuelle P, Flores-Suarez LF, Nowack R. ANCA-associated vasculitis following influenza vaccination: causal association or mere coincidence? J. Clin. Rheumatol. 15: 289-291 (2009).

• Bisceglie MB, Lucchese A, Crincoli V. Pemphigus: the promises of peptide immunotherapy. Immunopharmacol. Immunotoxicol. Mar 30 [Epub ahead of print] (2009).

• Bischoff S, Crowe SE. Food allergy and the gastrointestinal tract. Curr. Opin. Gastroenterol. 20: 156-161 (2004).

• Blakelock RT, Beasley SW. Infection and the gut. Semin. Pediatr. Surg. 12: 265-274 (2003).

• Blasi C. The role of the infectious agents in the pathogenesis and evolution of atherosclerosis. Ann. Ital. Med. Int. 19: 249-261 (2004).

• Blaylock RL. A possible central mechanism in autism spectrum disorders, part 1. Altern. Ther. Health Med. 14: 46-53 (2008).

• Block SL, Brown DR, Chatterjee A, Gold MA, Sings HL, Meibohm A, Dana A, Haupt RM, Barr E, Tamms GM, Zhou H, Reisinger KS. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine. Pediatr. Infect. Dis. J. Nov 30 [Epub ahead of print] (2009).

• Bluestone JA, Tang Q. Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells. Proc. Natl. Acad. Sci. U.S.A. 101: 14622-14626 (2004). *

• Blum HE. Gene therapy for liver diseases: experimental strategies. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 44-45 (2006). *

• Blumberg RS, MacDonald TT. Mucosal immunology: a frontier no longer. Mucosal Immunol. 1: 3 (2008). *

• Blumerman SL, Herzig CT, Wang F, Coussens PM, Baldwin CL. Comparison of gene expression by co-cultured WC1(+) gammadelta and CD4(+) alphabeta T cells exhibiting a recall response to bacterial antigen. Mol. Immunol. 44: 2033-2045 (2007). *

• Boberg KM, Schrumpf E. Diagnosis and treatment of cholangiocarcinoma. Curr. Gastroenterol. Rep. 6: 52-59 (2004).

• Bochtler P, Riedl P, Gomez I, Schirmbeck R, Reimann J. Local accumulation and activation of regulatory Foxp3(+) CD4 T(R) cells accompanies the appearance of activated CD8 T cells in the liver. Hepatology 48: 1954-1963 (2008). *

• Boczkowski D, Lee J, Pruitt S, Nair S. Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. Cancer Gene Ther. 16: 900-911 (2009).

• Boedeker EC. Crohn's mucosa harbors adherent-invasive E. coli. Inflamm. Bowel Dis. 6: 155 (2000). *

• Boedeker EC. Gastrointestinal infections. Curr. Opin. Gastroenterol. 19: 1-3 (2003).

• Boehm I. Apoptosis in physiological and pathological skin: implications for therapy. Curr. Mol. Med. 6: 375-394 (2006).

• Boesteanu AC, Katsikis PD. Memory T cells need CD28 costimulation to remember. Semin. Immunol. 21: 69-77 (2009). *

• Bogaert D, Weinberger D, Thompson C, Lipsitch M, Malley R. Impaired innate and adaptive immunity to Streptococcus pneumoniae and its effect on colonization in an infant mouse model. Infect. Immun. 77: 1613-1622 (2009). *

• Bogdanos D, Pusl T, Rust C, Vergani D, Beuers U. Primary biliary cirrhosis following Lactobacillus vaccination for recurrent vaginitis. J. Hepatol. 49: 466-473 (2008). *

• Bogdanos DP, Smith H, Ma Y, Baum H, Mieli-Vergani G, Vergani D. A study of molecular mimicry and immunological cross-reactivity between hepatitis B surface antigen and myelin mimics. Clin. Dev. Immunol. 12: 217-224 (2005). *

• Bogen B, Ruffini P. Review: to what extent are T cells tolerant to immunoglobulin variable regions? Scand. J. Immunol. 70: 526-530 (2009). *

• Bogstedt AK, Nava S, Wadstrom T, Hammarstrom L. Helicobacter pylori infections in IgA deficiency: lack of role for the secretory immune system. Clin. Exp. Immunol. 105: 202-204 (1996). *

• Bokszczanin A, Levinson AI. Coexistent yellow nail syndrome and selective antibody deficiency. Ann. Allergy Asthma Immunol. 91: 496-500 (2003).

• Bolton DL, Minang JT, Trivett MT, Song K, Tuscher JJ, Li Y, Piatak M Jr, O'Connor D, Lifson JD, Roederer M, Ohlen C. Trafficking, persistence, and activation state of adoptively transferred allogeneic and autologous simian immunodeficiency virus-specific CD8+ T cell clones during acute and chronic infection of Rhesus macaques. J. Immunol. 184: 303-314 (2010).

• Bond E, Adams WC, Smed-Sorensen A, Sandgren KJ, Perbeck L, Hofmann A, Andersson J, Lore K. Techniques for time-efficient isolation of human skin dendritic cell subsets and assessment of their antigen uptake capacity. J. Immunol. Methods 348: 42-56 (2009). *

• Bonifacio E, Achenbach P, Pan L, Ziegler AG. Mucosal insulin vaccination for type 1 diabetes prevention. Exp. Clin. Endocrinol. Diabetes 116 Suppl. 1: S26-S29 (2008).

• Bonifacio E, Ziegler A, Achenbach P, Barker J, Eisenbarth G. Translating mucosal antigen based prevention of autoimmune diabetes to human. Novartis Found. Symp. 292: 187-199 (2008).

• Bonsignori M, Moody MA, Parks RJ, Holl TM, Kelsoe G, Hicks CB, Vandergrift N, Tomaras GD, Haynes BF. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J. Immunol. 183: 2708-2717 (2009).

• Bontrop RE, Watkins DI. MHC polymorphism: AIDS susceptibility in non-human primates. Trends Immunol. 26: 227-233 (2005). *

• Boot HJ, van der Waaij LA, Schirm J, Kallenberg CG, van Steenbergen J, Wolters B. Acute hepatitis B in a healthcare worker: a case report of genuine vaccination failure. J. Hepatol. 50: 426-431 (2009).

• Boot HJ, Van der Waaij LA, Schirm J, Kallenberg CG, van Steenbergen J, Wolters B. Acute hepatitis B in a healthcare worker: a lesson in awareness of failure of hepatitis B vaccination. J. Hepatol. 51: 826-827 (2009).

• Booth JS, Griebel PJ, Babiuk LA, Mutwiri GK. A novel regulatory B-cell population in sheep Peyer's patches spontaneously secretes IL-10 and downregulates TLR9-induced IFN responses. Mucosal Immunol. 2: 265-275 (2009).

• Booth JS, Nichani AK, Benjamin P, Dar A, Krieg AM, Babiuk LA, Mutwiri GK. Innate immune responses induced by classes of CpG oligodeoxynucleotides in ovine lymph node and blood mononuclear cells. Vet. Immunol. Immunopathol. 115: 24-34 (2007). *

• Borbulevych OY, Insaidoo FK, Baxter TK, Powell DJ Jr, Johnson LA, Restifo NP, Baker BM. Structures of MART-1(26/27-35) peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition. J. Mol. Biol. 372: 1123-1136 (2007). *

• Borchers AT, Keen CL, Shoenfeld Y, Silva J Jr, Gershwin ME. Vaccines, viruses, and voodoo. J. Investig. Allergol. Clin. Immunol. 12: 155-168 (2002).

• Bordner AJ, Mittelmann HD. Prediction of the binding affinities of peptides to class II MHC using a regularized thermodynamic model. BMC Bioinformatics 11: 41 (2010). *

• Borges VF, Kufe D, Avigan DE. Update on cancer vaccines. Curr. Opin. Gastroenterol. 18: 723-731 (2002).

• Borsutzky S, Cazac BB, Roes J, Guzman CA. TGF-beta receptor signaling is critical for mucosal IgA responses. J. Immunol. 173: 3305-3309 (2004). *

• Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127 (5 Suppl. 2): S5-S16 (2004). *

• Bosch JJ, Iheagwara UK, Reid S, Srivastava MK, Wolf J, Lotem M, Ksander BR, Ostrand-Rosenberg S. Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8(+) cytotoxic, tumor-specific T cells. Cancer Immunol. Immunother. 59: 103-112 (2010). *

• Boudier A, Aubert-Pouessel A, Louis-Plence P, Gerardin C, Jorgensen C, Devoisselle JM, Begu S. The control of dendritic cell maturation by pH-sensitive polyion complex micelles. Biomaterials 30: 233-241 (2009). *

• Boulter-Bitzer JI, Lee H, Trevors JT. Molecular targets for detection and immunotherapy in Cryptosporidium parvum. Biotechnol. Adv. 25: 13-44 (2007).

• Bourinbaiar AS, Abulafia-Lapid R. Autoimmunity, alloimmunization and immunotherapy of AIDS. Autoimmun. Rev. 4: 403-409 (2005).

• Bourquin C, van der Haar ME, Anz D, Sandholzer N, Neumaier I, Endres S, Skerra A, Schwab ME, Linington C. DNA vaccination efficiently induces antibodies to Nogo-A and does not exacerbate experimental autoimmune encephalomyelitis. Eur. J. Pharmacol. 588: 99-105 (2008).

• Boutlis CS, Yeo TW, Anstey NM. Malaria tolerance - for whom the cell tolls? Trends Parasitol. 22: 371-377 (2006). *

• Bowen DG, McCaughan GW, Bertolino P. Intrahepatic immunity: a tale of two sites? Trends Immunol. 26: 512-517 (2005). *

• Bowlus CL. Chapter 11. Tumor immunology: hepatocellular carcinoma, cholangiocarcinoma, and metastatic neoplasms. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 137-149 (2007). *

• Boxall S, McCormick J, Beverley P, Strobel S, De Filippi P, Dawes R, Klersy C, Clementi R, De Juli E, Ferster A, Wallace D, Arico M, Danesino C, Tchilian E. Abnormal cell surface antigen expression in individuals with variant CD45 splicing and histiocytosis. Pediatr. Res. 55: 478-484 (2004). *

• Boxall S, Stanton T, Hirai K, Ward V, Yasui T, Tahara H, Tamori A, Nishiguchi S, Shiomi S, Ishiko O, Inaba M, Nishizawa Y, Dawes R, Bodmer W, Beverley PC, Tchilian EZ. Disease associations and altered immune function in CD45 138G variant carriers. Hum. Mol. Genet. 13: 2377-2384 (2004). *

• Bozza S, Clavaud C, Giovannini G, Fontaine T, Beauvais A, Sarfati J, D'Angelo C, Perruccio K, Bonifazi P, Zagarella S, Moretti S, Bistoni F, Latge JP, Romani L. Immune sensing of Aspergillus fumigatus proteins, glycolipids, and polysaccharides and the impact on Th immunity and vaccination. J. Immunol. 183: 2407-2414 (2009).

• Braat H, McGuirk P, Kate FT, Huibregtse I, Dunne P, Hommes D, Deventer S, Mills K. Prevention of experimental colitis by parenteral administration of a pathogen-derived immunomodulatory molecule. Gut 56: 351-357 (2007). *

• Braga-Neto UM, Marques ET. From functional genomics to functional immunomics: new challenges, old problems, big rewards. PLoS Comput. Biol. 2: e81 (2006). *

• Braillon A. A new French paradox: HBV vaccination. J. Hepatol. 51: 597-598 (2009).

• Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T cells. Science 309: 264-268 (2005). *

• Brandtzaeg P. Do salivary antibodies reliably reflect both mucosal and systemic immunity? Ann. N. Y. Acad. Sci. 1098: 288-311 (2007). *

• Brandtzaeg P. Review article: homing of mucosal immune cells - a possible connection between intestinal and articular inflammation. Aliment. Pharmacol. Ther. 11 Suppl. 3: 24-37 (1997).

• Brandtzaeg P. The human intestinal immune system: basic cellular and humoral mechanisms. Baillieres Clin. Rheumatol. 10: 1-24 (1996).

• Brandtzaeg P. Role of secretory antibodies in the defence against infections. Int. J. Med. Microbiol. 293: 3-15 (2003).

• Brandtzaeg P. Mucosal immunity: integration between mother and the breast-fed infant. Vaccine 21: 3382-3388 (2003). *

• Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25: 5467-5484 (2007). *

• Brandtzaeg P. Mucosal immunity: induction, dissemination, and effector functions. Scand. J. Immunol. 70: 505-515 (2009). *

• Brandtzaeg P, Berstad AE, Farstad IN, Haraldsen G, Helgeland L, Jahnsen FL, Johansen FE, Natvig IB, Nilsen EM, Rugtveit J. Mucosal immunity - a major adaptive defence mechanism. Behring Inst. Mitt. 98: 1-23 (1997).

• Brandtzaeg P, Farstad IN, Haraldsen G, Jahnsen FL. Cellular and molecular mechanisms for induction of mucosal immunity. Dev. Biol. Stand. 92: 93-108 (1998).

• Brandtzaeg P, Johansen FE. Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties. Immunol. Rev. 206: 32-63 (2005). *

• Breckpot K, Emeagi P, Dullaers M, Michiels A, Heirman C, Thielemans K. Activation of immature monocyte-derived dendritic cells after transduction with high doses of lentiviral vectors. Hum. Gene Ther. 18: 536-546 (2007).

• Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal Immunol. 1: 23-30 (2008). *

• Brenchley JM, Douek DC, Ambrozak DR, Chatterji M, Betts MR, Davis LS, Koup RA. Expansion of activated human naive T-cells precedes effector function. Clin. Exp. Immunol. 130: 432-440 (2002). *

• Brenchley JM, Knox KS, Asher AI, Price DA, Kohli LM, Gostick E, Hill BJ, Hage CA, Brahmi Z, Khoruts A, Twigg III HL, Schacker TW, Douek DC. High frequencies of polyfunctional HIV-specific T cells are associated with preservation of mucosal CD4 T cells in bronchoalveolar lavage. Mucosal Immunol. 1: 49-58 (2008).

• Brentjens MH, Yeung-Yue KA, Lee PC, Tyring SK. Vaccines for viral diseases with dermatologic manifestations. Dermatol. Clin. 21: 349-369 (2003).

• Brigden ML. Detection, education and management of the asplenic or hyposplenic patient. Am. Fam. Physician 63: 499-506, 508 (2001). *

• Brigden ML, Pattullo A, Brown G. Practising physician's knowledge and patterns of practice regarding the asplenic state: the need for improved education and a practical checklist. Can. J. Surg. 44: 210-216 (2001).

• Brinkman DM, Jol-van der Zijde CM, Ten Dam MM, Te Boekhorst PA, Ten Cate R, Wulffraat NM, Hintzen RQ, Vossen JM, van Tol MJ. Resetting the adaptive immune system after autologous stem cell transplantation: lessons from responses to vaccines. J. Clin. Immunol. 27: 647-658 (2007). *

• Bristeau-Leprince A, Mateo V, Lim A, Magerus-Chatinet A, Solary E, Fischer A, Rieux-Laucat F, Gougeon ML. Human TCR alpha/beta+ CD4-CD8- double-negative T cells in patients with autoimmune lymphoproliferative syndrome express restricted Vbeta TCR diversity and are clonally related to CD8+ T cells. J. Immunol. 181: 440-448 (2008). *

• Broide DH. Immunomodulation of allergic disease. Annu. Rev. Med. 60: 279-291 (2009). *

• Brown DA, Sawchenko PE. Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis. J. Comp. Neurol. 502: 236-260 (2007).

• Brumme ZL, John M, Carlson JM, Brumme CJ, Chan D, Brockman MA, Swenson LC, Tao I, Szeto S, Rosato P, Sela J, Kadie CM, Frahm N, Brander C, Haas DW, Riddler SA, Haubrich R, Walker BD, Harrigan PR, Heckerman D, Mallal S. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One 4: e6687 (2009). *

• Brunham RC, Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat. Rev. Immunol. 5: 149-161 (2005). *

• Bruschi F. Modulation of inflammatory cells in helminth infections. Ann. Ist Super. Sanita. 33: 541-549 (1997).

• Buch T, Waisman A. Protection from autoimmunity by DNA vaccination against T-cell receptor. Methods Mol. Med. 127: 269-280 (2006).

• Buchan GS, Lee R, Wilson M, Slobbe L, Buddle BM, Young SL. Strains of Mycobacterium avium differentially activate human dendritic cells. Immunol. Cell Biol. Aug 4 [Epub ahead of print] (2009). *

• Buckland M, Lombardi G. Aspirin and the induction of tolerance by dendritic cells. Handb. Exp. Pharmacol. 188: 197-213 (2009).

• Bueso MB, Caballero R, Castro HJ, Barakat A, Bellanti JA. Recurrent infections and joint pain. Allergy Asthma Proc. 27: 164-171 (2006).

• Buhler LA, Samara R, Guzman E, Wilson CL, Krizanac-Bengez L, Janigro D, Ethell DW. Matrix metalloproteinase-7 facilitates immune access to the CNS in experimental autoimmune encephalomyelitis. BMC Neurosci. 10: 17 (2009). *

• Buhler OT, Wiedig CA, Schmid Y, Grassl GA, Bohn E, Autenrieth IB. The Yersinia enterocolitica invasin protein promotes major histocompatibility complex class I- and class II-restricted T-cell responses. Infect. Immun. 74: 4322-4329 (2006). *

• Bui HH, Schiewe AJ, von Grafenstein H, Haworth IS. Structural prediction of peptides binding to MHC class I molecules. Proteins 63: 43-52 (2006). *

• Bui HH, Sidney J, Dinh K, Southwood S, Newman MJ, Sette A. Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC Bioinformatics 7: 153 (2006). *

• Bukreyev A, Serra ME, Laham FR, Melendi GA, Kleeberger SR, Collins PL, Polack FP. The cysteine-rich region and secreted form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T-lymphocyte response despite lacking major histocompatibility complex class I-restricted epitopes. J. Virol. 80: 5854-5861 (2006). *

• Bulut Y, Michelsen KS, Hayrapetian L, Naiki Y, Spallek R, Singh M, Arditi M. Mycobacterium tuberculosis heat shock proteins use diverse Toll-like receptor pathways to activate pro-inflammatory signals. J. Biol. Chem. 280: 20961-20967 (2005). *

• Bundy DG, Strouse JJ, Casella JF, Miller MR. Burden of influenza-related hospitalizations among children with sickle cell disease. Pediatrics Jan 25 [Epub ahead of print] (2010). *

• Burgdorf SK, Claesson MH, Nielsen HJ, Rosenberg J. Changes in cytokine and biomarker blood levels in patients with colorectal cancer during dendritic cell-based vaccination. Acta Oncol. Jul 27 [Epub ahead of print] (2009).

• Burke ML, Jones MK, Gobert GN, Li YS, Ellis MK, McManus DP. Immunopathogenesis of human schistosomiasis. Parasite Immunol. 31: 163-176 (2009). *

• Burlet-Schiltz O, Claverol S, Gairin JE, Monsarrat B. The use of mass spectrometry to identify antigens from proteasome processing. Methods Enzymol. 405: 264-300 (2005).

• Burrows JM, Bell MJ, Brennan R, Miles JJ, Khanna R, Burrows SR. Preferential binding of unusually long peptides to MHC class I and its influence on the selection of target peptides for T cell recognition. Mol. Immunol. 45: 1818-1824 (2008). *

• Burton DR. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2: 706-713 (2002). *

• Bush TJ, Bishop GA. TLR7 and CD40 cooperate in IL-6 production via enhanced JNK and AP-1 activation. Eur. J. Immunol. 38: 400-409 (2008). *

• Butler NS, Schmidt NW, Harty JT. Differential effector pathways regulate memory CD8 T cell immunity against Plasmodium berghei versus P. yoelii sporozoites. J. Immunol. Jan 22 [Epub ahead of print] (2010).

• Buza J, Benjamin P, Zhu J, Wilson HL, Lipford G, Krieg AM, Babiuk LA, Mutwiri GK. CD14(+) cells are required for IL-12 response in bovine blood mononuclear cells activated with Toll-like receptor (TLR) 7 and TLR8 ligands. Vet. Immunol. Immunopathol. 126: 273-282 (2008).

• Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev. 23: 77-99 (2004). *

• Cacoub P, Terrier B. Hepatitis B-related autoimmune manifestations. Rheum. Dis. Clin. North Am. 35: 125-137 (2009).

• Cadogan M, Austen B, Heeney JL, Dalgleish AG. HLA homology within the C5 domain promotes peptide binding by HIV type 1 gp120. AIDS Res. Hum. Retroviruses 24: 845-855 (2008).

• Caillat-Zucman S, Gimenez JJ, Wambergue F, Albouze G, Lebkiri B, Naret C, Moynot A, Jungers P, Bach JF. Distinct HLA class II alleles determine antibody response to vaccination with hepatitis B surface antigen. Kidney Int. 53: 1626-1630 (1998). *

• Calabuig E, Salavert M. Infectious risk. Actas Dermosifiliogr. 99 Suppl. 4: 14-22 (2008).

• Calder PC, Kew S. The immune system: a target for functional foods? Br. J. Nutr. 88 Suppl. 2: S165-S177 (2002). *

• Calista D, Morri M. Lichen planus induced by hepatitis B vaccination: a new case and review of the literature. Int. J. Dermatol. 43: 562-564 (2004).

• Calvopina M, Barroso PA, Marco JD, Korenaga M, Cooper PJ, Nonaka S, Hashiguchi Y. Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis. Vaccine 24: 5645-5652 (2006). *

• Camacho RE, Wnek R, Fischer P, Shah K, Zaller DM, Woods A, La Monica N, Aurisicchio L, Fitzgerald-Bocarsly P, Koo GC. Characterization of the NOD/scid-[Tg]DR1 mouse expressing HLA-DRB1( *)01 transgene: a model of SCID-hu mouse for vaccine development. Exp. Hematol. 35: 1219-1230 (2007).

• Camilleri M. GIH clinical research update: 2004-2005. Clin. Gastroenterol. Hepatol. 3: 1161-1166 (2005).

• Campbell DJ. Angiotensin vaccination: what is the prospect of success? Curr. Hypertens. Rep. 11: 63-68 (2009).

• Campo DS, Dimitrova Z, Mitchell RJ, Lara J, Khudyakov Y. Coordinated evolution of the hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 105: 9685-9690 (2008). *

• Cany J, Avril A, Pichard V, Aubert D, Ferry N, Conchon S. A transgenic mouse with beta-galactosidase as a fetal liver self-antigen for immunotherapy studies. J. Hepatol. 47: 396-403 (2007). *

• Cao S, Guo A, Liu Z, Tan Y, Wu G, Zhang C, Zhao Y, Chen H. Investigation of new dominant negative inhibitors of anthrax protective antigen mutants for use in therapy and vaccination. Infect. Immun. 77: 4679-4687 (2009). *

• Cardinaud S, Bouziat R, Rohrlich PS, Tourdot S, Weiss L, Langlade-Demoyen P, Burgevin A, Fiorentino S, van Endert P, Lemonnier FA. Design of a HIV-1-derived HLA-B07.02-restricted polyepitope construct. AIDS 23: 1945-1954 (2009).

• Cardoso FC, Macedo GC, Gava E, Kitten GT, Mati VL, de Melo AL, Caliari MV, Almeida GT, Venancio TM, Verjovski-Almeida S, Oliveira SC. Schistosoma mansoni tegument protein Sm29 is able to induce a Th1-type of immune response and protection against parasite infection. PLoS Negl. Trop. Dis. 2: e308 (2008). *

• Carmichael MG, Benavides LC, Holmes JP, Gates JD, Mittendorf EA, Ponniah S, Peoples GE. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer Nov 18 [Epub ahead of print] (2009). *

• Carralot JP, Lemmel C, Stevanovic S, Pascolo S. Mass spectrometric identification of an HLA-A*0201 epitope from Plasmodium falciparum MSP-1. Int. Immunol. 20: 1451-1456 (2008).

• Carrion J, Nieto A, Soto M, Alonso C. Adoptive transfer of dendritic cells pulsed with Leishmania infantum nucleosomal histones confers protection against cutaneous leishmaniosis in BALB/c mice. Microbes Infect. 9: 735-743 (2007). *

• Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: hiding in plain sight. Immunol. Rev. 213: 48-65 (2006). *

• Carter CJ. Schizophrenia susceptibility genes directly implicated in the life cycles of pathogens: cytomegalovirus, influenza, Herpes simplex, Rubella, and Toxoplasma gondii. Schizophr. Bull. 35: 1163-1182 (2009).

• Carter PJ. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6: 343-357 (2006). *

• Carvalho JF, Pereira RM, Shoenfeld Y. Systemic polyarteritis nodosa following hepatitis B vaccination. Eur. J. Intern. Med. 19: 575-578 (2008).

• Carvalho JF, Pereira RM, Shoenfeld Y. Vaccination, atherosclerosis and systemic lupus erythematosus. Lupus 18: 1209-1212 (2009).

• Caspi R. Autoimmunity in the immune privileged eye: pathogenic and regulatory T cells. Immunol. Res. 42: 41-50 (2008). *

• Cassell S, Kavanaugh A. Psoriatic arthritis: pathogenesis and novel immunomodulatory approaches to treatment. J. Immune Based Ther. Vaccines 3: 6 (2005). *

• Castagnola E, Fioredda F. Prevention of life-threatening infections due to encapsulated bacteria in children with hyposplenia or asplenia: a brief review of current recommendations for practical purposes. Eur. J. Haematol. 71: 319-326 (2003). *

• Castelletti E, Lo Caputo S, Kuhn L, Borelli M, Gajardo J, Sinkala M, Trabattoni D, Kankasa C, Lauri E, Clivio A, Piacentini L, Bray DH, Aldrovandi GM, Thea DM, Veas F, Nebuloni M, Mazzotta F, Clerici M. The mucosae-associated epithelial chemokine (MEC/CCL28) modulates immunity in HIV infection. PLoS One 2: e969 (2007). *

• Castells L. Hepatitis B vaccine and inflammatory bowel disease. Med. Clin. (Barc.) 132: 348-350 (2009).

• Castera L, Hatzfeld-Charbonnier AS, Ballot C, Charbonnel F, Dhuiege E, Velu T, Formstecher P, Mortier L, Marchetti P. Apoptosis-related mitochondrial dysfunction defines human monocyte-derived dendritic cells with impaired immuno-stimulatory capacities. J. Cell. Mol. Med. 13: 1321-1335 (2009). *

• Castilow EM, Legge KL, Varga SM. Cutting edge: eosinophils do not contribute to respiratory syncytial virus vaccine-enhanced disease. J. Immunol. 181: 6692-6696 (2008). *

• Catano G, Kulkarni H, He W, Marconi VC, Agan BK, Landrum M, Anderson S, Delmar J, Telles V, Song L, Castiblanco J, Clark RA, Dolan MJ, Ahuja SK. HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B*57 alleles. PLoS ONE 3: e3636 (2008). *

• Cayabyab MJ, Hovav AH, Hsu T, Krivulka GR, Lifton MA, Gorgone DA, Fennelly GJ, Haynes BF, Jacobs WR Jr, Letvin NL. Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env. J. Virol. 80: 1645-1652 (2006). *

• Cecchinato V, Trindade CJ, Laurence A, Heraud JM, Brenchley JM, Ferrari MG, Zaffiri L, Tryniszewska E, Tsai WP, Vaccari M, Washington Parks R, Venzon D, Douek DC, O'Shea JJ, Franchini G. Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol. 1: 279-288 (2008). *

• Celik U, Kocabas E. New approaches in antibiotic therapies in chronic pulmonary diseases. Tuberk. Toraks. 56: 353-363 (2008).

• Center KJ, Hansen JR, Lewis E, Fireman BH, Hilton B. Lack of association of Kawasaki disease after immunization in a cohort of infants followed for multiple autoimmune diagnoses in a large, phase-4 observational database safety study of seven-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 28: 438-440 (2009).

• Centers for Disease Control and Prevention (CDC). Update: Guillain-Barre syndrome among recipients of Menactra meningococcal conjugate vaccine - United States, October 2005-February 2006. MMWR Morb. Mortal. Wkly. Rep. 55: 364-366 (2006).

• Centers for Disease Control and Prevention (CDC). Update: Guillain-Barre syndrome among recipients of Menactra meningococcal conjugate vaccine - United States, June 2005-September 2006. MMWR Morb. Mortal. Wkly. Rep. 55: 1120-1124 (2006).

• Centers for Disease Control and Prevention (CDC). Human vaccinia infection after contact with a raccoon rabies vaccine bait - Pennsylvania, 2009. MMWR Morb. Mortal. Wkly Rep. 58: 1204-207 (2009).

• Cerundolo V, Salio M. Harnessing NKT cells for therapeutic applications. Curr. Top. Microbiol. Immunol. 314: 325-340 (2007).

• Cerutti A. The regulation of IgA class switching. Nat. Rev. Immunol. 8: 421-434 (2008). *

• Cervantes-Barragan L, Gil-Cruz C, Pastelin-Palacios R, Lang KS, Isibasi A, Ludewig B, Lopez-Macías C. TLR2 and TLR4 signaling shapes specific antibody responses to Salmonella typhi antigens. Eur. J. Immunol. 39: 126-135 (2009). *

• Chaise C, Buchan SL, Rice J, Marquet J, Rouard H, Kuentz M, Vittes GE, Molinier-Frenkel V, Farcet JP, Stauss HJ, Delfau-Larue MH, Stevenson FK. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood 112: 2956-2964 (2008). *

• Chaitra MG, Shaila MS, Nayak R. Evaluation of T-cell responses to peptides with MHC class I-binding motifs derived from PE_PGRS 33 protein of Mycobacterium tuberculosis. J. Med. Microbiol. 56: 466-474 (2007). *

• Cham GK, Turner L, Lusingu J, Vestergaard L, Mmbando BP, Kurtis JD, Jensen AT, Salanti A, Lavstsen T, Theander TG. Sequential, ordered acquisition of antibodies to Plasmodium falciparum erythrocyte membrane protein 1 domains. J. Immunol. 183: 3356-3363 (2009).

• Chan KG, Mayer M, Davis EM, Halperin SA, Lin TJ, Lee SF. The role of D-alanylation of Streptococcus gordonii lipoteichoic acid in innate and adaptive immunity. Infect. Immun. 75: 3033-3042 (2007). *

• Chang SY, Cha HR, Chang JH, Ko HJ, Yang H, Malissen B, Iwata M, Kweon MN. Lack of retinoic acid leads to increased langerin-expressing dendritic cells in gut-associated lymphoid tissues. Gastroenterology Nov 12 [Epub ahead of print] (2009). *

• Chang SY, Cha HR, Igarashi O, Rennert PD, Kissenpfennig A, Malissen B, Nanno M, Kiyono H, Kweon MN. Cutting edge: langerin+ dendritic cells in the mesenteric lymph node set the stage for skin and gut immune system cross-talk. J. Immunol. 180: 4361-4365 (2008). *

• Chang SY, Cha HR, Uematsu S, Akira S, Igarashi O, Kiyono H, Kweon MN. Colonic patches direct the cross-talk between systemic compartments and large intestine independently of innate immunity. J. Immunol. 180: 1609-1618 (2008). *

• Chang Y, Yap S, Ge X, Piganelli J, Bertera S, Giannokakis N, Mathews C, Prud'homme G, Trucco M. DNA vaccination with an insulin construct and a chimeric protein binding to both CTLA4 and CD40 ameliorates type 1 diabetes in NOD mice. Gene Ther. 12: 1679-1685 (2005). *

• Chapat L, Chemin K, Dubois B, Bourdet-Sicard R, Kaiserlian D. Lactobacillus casei reduces CD8(+) T cell-mediated skin inflammation. Eur. J. Immunol. 34: 2520-2528 (2004). *

• Chaturvedi M, Nandan D, Gupta SC. Rapid assessment of immunization practices in Agra district. Indian J. Public Health 51: 132-134 (2007).

• Chaudhuri N, Dower SK, Whyte MK, Sabroe I. Toll-like receptors and chronic lung disease. Clin. Sci. (Lond.) 109: 125-133 (2005). *

• Chawla PS, Kochar MS. What's new in clinical pharmacology and therapeutics. WMJ 105: 24-29 (2006).

• Chen CH, Floyd H, Olson NE, Magaletti D, Li C, Draves K, Clark EA. Dendritic cell-associated C-type lectin 2 (DCAL-2) alters dendritic cell maturation and cytokine production. Blood 107: 1459-1467 (2006). *

• Chen DS. Hepatitis B vaccine and multiple sclerosis: a case of repeated deja vu? J. Hepatol. 51: 598-599 (2009).

• Chen G, Han G, Wang J, Wang R, Xu R, Shen B, Qian J, Li Y. Essential roles of TGF-beta in anti-CD3 antibody therapy: reversal of diabetes in nonobese diabetic mice independent of Foxp3+CD4+ regulatory T cells. J. Leukoc. Biol. 83: 280-287 (2008). *

• Chen G, Han G, Wang J, Wang R, Xu R, Shen B, Qian J, Li Y. Induction of active tolerance and involvement of CD1d-restricted natural killer T cells in anti-CD3 F(ab')2 treatment-reversed new-onset diabetes in nonobese diabetic mice. Am. J. Pathol. 172: 972-979 (2008). *

• Chen G, Li N, Zang YC, Zhang D, He D, Feng G, Ni L, Xu R, Wang L, Shen B, Zhang JZ. Vaccination with selected synovial T cells in rheumatoid arthritis. Arthritis Rheum. 56: 453-463 (2007). *

• Chen HW, Leng CH, Liu HY, Cheng WF, Chang YW, Wu PY, Lien SP, Huang TY, Chiang SK, Lin MH, Tao MH, Chong P, Liu SJ. Identification of HLA-A11-restricted CTL epitopes derived from HPV type 18 using DNA immunization. Cancer Biol. Ther. Nov 5 [Epub ahead of print] (2009).

• Chen HW, Zhang Z, Huber E, Chao CC, Wang H, Dasch GA, Ching WM. Identification of cross-reactive epitopes on the conserved 47 kDa antigen of Orientia tsutsugamushi and human serine protease. Infect. Immun. 77: 2311-2319 (2009). *

• Chen RT, Pless R, Destefano F. Epidemiology of autoimmune reactions induced by vaccination. J. Autoimmun. 16: 309-318 (2001).

• Chen SS, Barankiewicz TJ, Yang YM, Goebel P, Liu FT. IgE peptide-specific CTL inhibit IgE production: a transient IgE suppression model in wild-type and HLA-A2.1 transgenic mice. Cell. Immunol. 254: 28-38 (2008). *

• Chen T, Tang XD, Wan Y, Chen L, Yu ST, Xiong Z, Fang DC, Liang GP, Yang SM. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy. Neoplasia 10: 977-986 (2008).

• Chen W, Cai MY, Wei DP, Wang X. Pivotal molecules of MHC I pathway in human primary hepatocellular carcinoma. World J. Gastroenterol. 11: 3297-3299 (2005). *

• Chen WH, Kozlovsky BF, Effros RB, Grubeck-Loebenstein B, Edelman R, Sztein MB. Vaccination in the elderly: an immunological perspective. Trends Immunol. 30: 351-359 (2009). *

• Chen WH, Wang XX, Lin W, He XW, Wu ZQ, Lin Y, Hu SN, Wang XN. Analysis of 10,000 ESTs from lymphocytes of the cynomolgus monkey to improve our understanding of its immune system. BMC Genomics 7: 82 (2006). *

• Chen X, Zhang M, Liao M, Graner MW, Wu C, Yang Q, Liu H, Zhou B. Reduced Th17 response in patients with tuberculosis correlate with IL-6R expression on CD4+ T cells. Am. J. Respir. Crit. Care Med. Dec 17 [Epub ahead of print] (2009). *

• Chen XZ, Mao XH, Zhu KJ, Jin N, Ye J, Cen JP, Zhou Q, Cheng H. Toll like receptor agonists augment HPV 11 E7-specific T cell responses by modulating monocyte-derived dendritic cells. Arch. Dermatol. Res. Jul 4 [Epub ahead of print] (2009). *

• Chen YX, Man K, Ling GS, Chen Y, Sun BS, Cheng Q, Wong OH, Lo CK, Ng IO, Chan LC, Lau GK, Lin CL, Huang F, Huang FP. A crucial role for dendritic cell (DC) IL-10 in inhibiting successful DC-based immunotherapy: superior antitumor immunity against hepatocellular carcinoma evoked by DC devoid of IL-10. J. Immunol. 179: 6009-6015 (2007). *

• Chentoufi AA, Zhang X, Lamberth K, Dasgupta G, Bettahi I, Nguyen A, Wu M, Zhu X, Mohebbi A, Buus S, Wechsler SL, Nesburn AB, Benmohamed L. HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from Herpes simplex virus glycoprotein D. J. Immunol. 180: 426-437 (2008). *

• Cheung YK, Cheng SC, Sin FW, Chan KT, Xie Y. Induction of T-cell response by a DNA vaccine encoding a novel HLA-A*0201 severe acute respiratory syndrome coronavirus epitope. Vaccine 25: 6070-6077 (2007).

• Chevaux JB, Bigard MA, Bensenane M, Oussalah A, Jarlot S, Belle A, Nani A, Bronowicki JP, Peyrin-Biroulet L. Inflammatory bowel disease and hepatitis B and C. Gastroenterol. Clin. Biol. 33: 1082-1093 (2009).

• Chevaux JB, Nani A, Oussalah A, Venard V, Bensenane M, Belle A, Gueant JL, Bigard MA, Bronowicki JP, Peyrin-Biroulet L. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm. Bowel Dis. Nov 2 [Epub ahead of print] (2009).

• Chez MG, Chin K, Hung PC. Immunizations, immunology, and autism. Semin. Pediatr. Neurol. 11: 214-217 (2004).

• Chiang KC, Shimada Y, Nakano T, Lai CY, Hsu LW, Goto S, Ohmori N, Mori K, Miyagi T, Kawamoto S, Ono K, Chen CL, Goto T, Sato S. A novel peptide mimotope identified as a potential immunosuppressive vaccine for organ transplantation. J. Immunol. 182: 4282-4288 (2009).

• Chiarella P, Massi E, De Robertis M, Signori E, Fazio VM. Adjuvants in vaccines and for immunisation: current trends. Expert Opin. Biol. Ther. 7: 1551-1562 (2007).

• Chiavaroli C, Moore A. An hypothesis to link the opposing immunological effects induced by the bacterial lysate OM-89 in urinary tract infection and rheumatoid arthritis. BioDrugs 20: 141-149 (2006).

• Chichlowski M, Hale LP. Effects of Helicobacter infection on research: the case for eradication of Helicobacter from rodent research colonies. Comp. Med. 59: 10-17 (2009). *

• Chin JJ. Revisiting the "hygiene hypothesis" in gastrointestinal allergy. Curr. Opin. Gastroenterol. 18: 705-710 (2002).

• Chinen J, Shearer WT. Advances in basic and clinical immunology in 2006. J. Allergy Clin. Immunol. 120: 263-270 (2007). *

• Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, Bataille R, Jego G. Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood 112: 2205-2213 (2008). *

• Chmiela M, Michetti P. Inflammation, immunity, vaccines for Helicobacter infection. Helicobacter 11 Suppl. 1: 21-26 (2006). *

• Cho KH, Caparon MG. tRNA modification by GidA/MnmE is necessary for Streptococcus pyogenes virulence: a new strategy to make live attenuated strains. Infect. Immun. 76: 3176-3186 (2008). *

• Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Pharm. Sci. 6: 33-66 (2003). *

• Chowdhry IA, Kowal C, Hardin J, Zhou Z, Diamond B. Autoantibodies that bind glomeruli: cross-reactivity with bacterial antigen. Arthritis Rheum. 52: 2403-2410 (2005). *

• Christou L, Pappas G, Falagas ME. Bacterial infection-related morbidity and mortality in cirrhosis. Am. J. Gastroenterol. 102: 1510-1517 (2007). *

• Chua BY, Zeng W, Jackson DC. Synthesis of Toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccines. Methods Mol. Biol. 494: 247-261 (2008).

• Chui CS, Li D, Xu XN. The role of ILT family receptors and their ligands in suppressor T cell-induced dendritic cell tolerisation. Hum. Immunol. 70: 686-691 (2009).

• Chute JP, Muramoto GG, Whitesides J, Colvin M, Safi R, Chao NJ, McDonnell DP. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc. Natl. Acad. Sci. U.S.A. 103: 11707-11712 (2006). *

• Cicin-Sain L, Messaoudi I, Park B, Currier N, Planer S, Fischer M, Tackitt S, Nikolich-Zugich D, Legasse A, Axthelm MK, Picker LJ, Mori M, Nikolich-Zugich J. Dramatic increase in naive T cell turnover is linked to loss of naive T cells from old primates. Proc. Natl. Acad. Sci. U.S.A. 104: 19960-19965 (2007). *

• Cicinnati VR, Zhang X, Yu Z, Ferencik S, Schmitz KJ, Dworacki G, Kaczmarek E, Oldhafer K, Frilling A, Baba HA, Schmid KW, Grosse-Wilde H, Broelsch CE, Deleo AB, Gerken G, Beckebaum S. Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma. Int. J. Cancer 119: 2851-2860 (2006). *

• Cimaz R, Meregalli E, Biggioggero M, Airo P, Danieli E, Antonioli CM, Motta M, Chirico G, Columbrita D, Frassi M, Meroni PL, Tincani A. Response to tetanus vaccination in infants exposed in utero to immunosuppressants for maternal autoimmune disorders. Lupus 16: 129-132 (2007). *

• Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin. Hematol. 46: S2-S14 (2009).

• Cizman M, Mozetic M, Radescek-Rakar R, Pleterski-Rigler D, Susec-Michieli M. Aseptic meningitis after vaccination against measles and mumps. Pediatr. Infect. Dis. J. 8: 302-308 (1989).

• Clark RT, Hope A, Lopez-Fraga M, Schiller N, Lo DD. Bacterial particle endocytosis by epithelial cells is selective and enhanced by tumor necrosis factor-receptor ligands. Clin. Vaccine Immunol. 16: 397-407 (2009). *

• Classen JB, Classen DC. Clustering of cases of type 1 diabetes mellitus occurring 2-4 years after vaccination is consistent with clustering after infections and progression to type 1 diabetes mellitus in autoantibody positive individuals. J. Pediatr. Endocrinol. Metab. 16: 495-508 (2003).

• Clement MJ, Fortune A, Phalipon A, Marcel-Peyre V, Simenel C, Imberty A, Delepierre M, Mulard LA. Towards a better understanding of the basis of molecular mimicry of polysaccharide antigens by peptides: the example of Shigella flexneri 5a. J. Biol. Chem. 281: 2317-2332 (2006). *

• Cloosen S, Arnold J, Thio M, Bos GM, Kyewski B, Germeraad WT. Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: implications for self-tolerance and tumor therapy. Cancer Res. 67: 3919-3926 (2007). *

• Co MD, Kilpatrick ED, Rothman AL. Dynamics of the CD8 T-cell response following yellow fever virus 17D immunization. Immunology 128: e718-e727 (2009).

• Cohen AD, Shoenfeld Y. Vaccine-induced autoimmunity. J. Autoimmun. 9: 699-703 (1996).

• Cohen IR, Quintana FJ, Mimran A. Tregs in T cell vaccination: exploring the regulation of regulation. J. Clin. Invest. 114: 1227-1232 (2004). *

• Cohen-Kaminsky S, Jambou F. Prospects for a T-cell receptor vaccination against myasthenia gravis. Expert Rev. Vaccines 4: 473-492 (2005).

• Cohly HH, Panja A. Immunological findings in autism. Int. Rev. Neurobiol. 71: 317-341 (2005).

• Colino J, Chattopadhyay G, Sen G, Chen Q, Lees A, Canaday DH, Rubtsov A, Torres R, Snapper CM. Parameters underlying distinct T cell-dependent polysaccharide-specific IgG responses to an intact Gram-positive bacterium versus a soluble conjugate vaccine. J. Immunol. 183: 1551-1559 (2009).

• Collins MT, Lisby G, Moser C, Chicks D, Christensen S, Reichelderfer M, Hoiby N, Harms BA, Thomsen OO, Skibsted U, Binder V. Results of multiple diagnostic tests for Mycobacterium avium subsp. paratuberculosis in patients with inflammatory bowel disease and in controls. J. Clin. Microbiol. 38: 4373-4381 (2000). *

• Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DA. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450: 566-569 (2007). *

• Colombo M, Donato MF. Prevention of hepatocellular carcinoma. Semin. Liver Dis. 25: 155-161 (2005).

• Conforti R, Ma Y, Morel Y, Paturel C, Terme M, Viaud S, Ryffel B, Ferrantini M, Uppaluri R, Schreiber R, Combadiere C, Chaput N, Andre F, Kroemer G, Zitvogel L. Opposing effects of Toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res. Jan 12 [Epub ahead of print] (2010). *

• Connerotte T, Van Pel A, Godelaine D, Tartour E, Schuler-Thurner B, Lucas S, Thielemans K, Schuler G, Coulie PG. Functions of anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res. 68: 3931-3940 (2008). *

• Conney AH. Tailoring cancer chemoprevention regimens to the individual. J. Cell. Biochem. 91: 277-286 (2004). *

• Connolly SF, Kusner DJ. The regulation of dendritic cell function by calcium-signaling and its inhibition by microbial pathogens. Immunol. Res. 39: 115-127 (2007).

• Conti F, Rezai S, Valesini G. Vaccination and autoimmune rheumatic diseases. Autoimmun. Rev. 8: 124-128 (2008).

• Cooke GS, Hill AV. Genetics of susceptibility to human infectious disease. Nat. Rev. Genet. 2: 967-977 (2001). *

• Cools N, Ponsaerts P, Van Tendeloo VF, Berneman ZN. Regulatory T cells and human disease. Clin. Dev. Immunol. 2007: 89195 (2007). *

• Cooper AM. Cell-mediated immune responses in tuberculosis. Annu. Rev. Immunol. 27: 393-422 (2009). *

• Cooper AM. T cells in mycobacterial infection and disease. Curr. Opin. Immunol. 21: 378-384 (2009).

• Cooper AM, Khader SA. The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunol. Rev. 226: 191-204 (2008). *

• Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS. Risk factors for development of systemic lupus erythematosus: allergies, infections, and family history. J. Clin. Epidemiol. 55: 982-989 (2002).

• Cooper MD, Herrin BR. How did our complex immune system evolve? Nat. Rev. Immunol. 10: 2-3 (2010).

• Cooper PJ. Mucosal immunology of geohelminth infections in humans. Mucosal Immunol. 2: 288-299 (2009).

• Correale J, Farez M, Gilmore W. Vaccines for multiple sclerosis: progress to date. CNS Drugs 22: 175-198 (2008).

• Cortez-Gonzalez X, Pellicciotta I, Gerloni M, Wheeler MC, Castiglioni P, Lenert P, Zanetti M. TLR9-independent activation of B lymphocytes by bacterial DNA. DNA Cell Biol. 25: 253-261 (2006).

• Coutinho A, Caramalho I, Seixas E, Demengeot J. Thymic commitment of regulatory T cells is a pathway of TCR-dependent selection that isolates repertoires undergoing positive or negative selection. Curr. Top. Microbiol. Immunol. 293: 43-71 (2005).

• Cox FE. Concomitant infections, parasites and immune responses. Parasitology 122: S23-S38 (2001).

• Cranmer LD, Hersh E. The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest. 25: 613-631 (2007).

• Criado MT, Sanchez S, Ferreiros CM. Classic vaccinology and advances in vaccine design. Enferm. Infecc. Microbiol. Clin. 26: 564-572 (2008).

• Criado PR, de Oliveira Ramos R, Vasconcellos C, Jardim Criado RF, Valente NY. Two case reports of cutaneous adverse reactions following hepatitis B vaccine: lichen planus and granuloma annulare. J. Eur. Acad. Dermatol. Venereol. 18: 603-606 (2004).

• Crimeen-Irwin B, Scalzo K, Gloster S, Mottram PL, Plebanski M. Failure of immune homeostasis - the consequences of under and over reactivity. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5: 413-422 (2005).

• Crispe IN. Hepatic T cells and liver tolerance. Nat. Rev. Immunol. 3: 51-62 (2003). *

• Crispe IN, Giannandrea M, Klein I, John B, Sampson B, Wuensch S. Cellular and molecular mechanisms of liver tolerance. Immunol. Rev. 213: 101-118 (2006). *

• Crotty S, Johnston RJ, Schoenberger SP. Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation. Nat. Immunol. 11: 114-120 (2010). *

• Cui J, Han LY, Lin HH, Tang ZQ, Jiang L, Cao ZW, Chen YZ. MHC-BPS: MHC-binder prediction server for identifying peptides of flexible lengths from sequence-derived physicochemical properties. Immunogenetics 58: 607-613 (2006). *

• Culver EL, Travis SP. How to manage the infectious risk under anti-TNF in inflammatory bowel disease. Curr. Drug Targets Nov 17 [Epub ahead of print] (2009).

• Currie CG, McCallum K, Poxton IR. Mucosal and systemic antibody responses to the lipopolysaccharide of Escherichia coli O157 in health and disease. J. Med. Microbiol. 50: 345-354 (2001). *

• Cush JJ. Biological drug use: US perspectives on indications and monitoring. Ann. Rheum. Dis. 64 Suppl. 4: iv18-iv23 (2005). *

• Cusick MF, Wang S, Eckels DD. In vitro responses to avian influenza H5 by human CD4 T cells. J. Immunol. 183: 6432-6441 (2009).

• Czaja AJ. Autoimmune liver disease. Curr. Opin. Gastroenterol. 15: 240-248 (1999).

• Czaja AJ. Treatment of autoimmune hepatitis. Semin. Liver Dis. 22: 365-378 (2002). *

• Czaja AJ. Autoimmune liver disease. Curr. Opin. Gastroenterol. 23: 255-262 (2007).

• Czaja AJ. Emerging treatments for autoimmune hepatitis. Curr. Drug Targets Inflamm. Allergy 1: 317-326 (2002).

• Czaja AJ. Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol. Dietol. 51: 313-333 (2005).

• Czaja AJ. Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Dig. Dis. Sci. Jan 27 [Epub ahead of print] (2010). *

• Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, Nisenbaum H, Pasha T, Xu M, Fox KR, Weinstein S, Orel SG, Vonderheide R, Coukos G, Demichele A, Araujo L, Spitz FR, Rosen M, Levine BL, June C, Zhang PJ. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 67: 1842-1852 (2007). *

• D'Elios MM, Andersen LP. Inflammation, immunity, and vaccines for Helicobacter pylori. Helicobacter 14 Suppl. 1: 21-28 (2009). *

• Daftarian P, Song GY, Ali S, Faynsod M, Longmate J, Diamond DJ, Ellenhorn JD. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. Cancer Res. 64: 5407-5414 (2004). *

• Daley A, Randall R, Darsley M, Choudhry N, Thomas N, Sanderson IR, Croft N, Kelly P. Genetically modified enterotoxigenic Escherichia coli vaccines induce mucosal immune responses without inflammation. Gut 56: 1550-1556 (2007). *

• Dam-Tuxen R, Riise E. Antibodies against a class II HLA-peptide complex raised by active immunization of mice with antigen mimicking peptides. Scand. J. Immunol. 70: 93-100 (2009). *

• Dammeyer P, Mwakigonja AR, Rethi B, Chiodi F, Wolpert EZ. Vaccination with beta-microglobulin-deficient dendritic cells protects against growth of beta-microglobulin-deficient tumours. Scand. J. Immunol. 70: 44-52 (2009). *

• Danese S, Rutella S. The Janus face of CD4(+)CD25(+) regulatory T cells in cancer and autoimmunity. Curr. Med. Chem. 14: 649-666 (2007).

• Dang Y, Knutson KL, Goodell V, Dela Rosa C, Salazar LG, Higgins D, Childs J, Disis ML. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming. Clin. Cancer Res. 13: 1883-1891 (2007). *

• Dao T, Korontsvit T, Zakhaleva V, Haro K, Packin J, Scheinberg DA. Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells. PLoS One 4: e6730 (2009). *

• Das A, Chang D, Biankin AV, Merrett ND. Pancreatitis following human papillomavirus vaccination. Med. J. Aust. 189: 178 (2008).

• Dash BP, Mukherjee S, Suhas VL, Chandra N. Interaction profiling of T-cell epitopes with MHC-class I molecules. Protein Pept. Lett. 14: 557-564 (2007).

• Dass J FP, Deepika V. Implications from predictions of HLA-DRB1 binding peptides in the membrane proteins of Corynebacterium diphtheriae. Bioinformation 3: 111-113 (2008). *

• Daubenberger CA. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines. Curr. Opin. Mol. Ther. 9: 45-52 (2007).

• Dauer M, Lam V, Arnold H, Junkmann J, Kiefl R, Bauer C, Schnurr M, Endres S, Eigler A. Combined use of Toll-like receptor agonists and prostaglandin E(2) in the FastDC model: rapid generation of human monocyte-derived dendritic cells capable of migration and IL-12p70 production. J. Immunol. Methods 337: 97-105 (2008). *

• Davenport MP, Belz GT, Ribeiro RM. The race between infection and immunity: how do pathogens set the pace? Trends Immunol. 30: 61-66 (2009). *

• Davies SL, Moral MA, Bozzo J. Chronicles in drug discovery. Drug News Perspect. 20: 133-137 (2007).

• Davis AN, Haque R, Petri WA. Update on protozoan parasites of the intestine. Curr. Opin. Gastroenterol. 18: 10-14 (2002).

• Davis RL, Bohlke K. Measles vaccination and inflammatory bowel disease: controversy laid to rest? Drug Saf. 24: 939-946 (2001).

• Davis RL, Kramarz P, Bohlke K, Benson P, Thompson RS, Mullooly J, Black S, Shinefield H, Lewis E, Ward J, Marcy SM, Eriksen E, Destefano F, Chen R; Vaccine Safety Datalink Team. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project. Arch. Pediatr. Adolesc. Med. 155: 354-359 (2001). *

• Davoodi-Semiromi A, Samson N, Daniell H. The green vaccine: a global strategy to combat infectious and autoimmune diseases. Hum. Vaccin. 5: 488-493 (2009).

• Davoodi-Semiromi A, Schreiber M, Nalapalli S, Verma D, Singh ND, Banks RK, Chakrabarti D, Daniell H. Chloroplast-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery. Plant Biotechnol. J. Dec 28 [Epub ahead of print] (2009).

• Day MJ. Immune system development in the dog and cat. J. Comp. Pathol. 137: S10-S15 (2007).

• Day SL, Ramsland PA, Apostolopoulos V. Non-canonical peptides bound to MHC. Curr. Pharm. Des. 15: 3274-3282 (2009).

• de Alencar BC, Persechini PM, Haolla FA, de Oliveira G, Silverio JC, Lannes-Vieira J, Machado AV, Gazzinelli RT, Bruna-Romero O, Rodrigues MM. Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination. Infect. Immun. 77: 4383-4395 (2009). *

• de Boer T, van Dissel JT, Kuijpers TW, Rimmelzwaan GF, Kroon FP, Ottenhoff TH. Influenza vaccination induces interleukin-12/23 receptor beta1-independent production of interferon-gamma: cellular and humoral immune response to influenza vaccine in patients with genetic deficiency in IL-12/23Rbeta1 or IFN-gammaRI. Clin. Vaccine Immunol. 15: 1171-1175 (2008).

• de Carvalho JF, Shoenfeld Y. Status epilepticus and lymphocytic pneumonitis following hepatitis B vaccination. Eur. J. Intern. Med. 19: 383-385 (2008).

• De Gregorio E, Tritto E, Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur. J. Immunol. 38: 2068-2071 (2008). *

• De Koker S, Naessens T, De Geest BG, Bogaert P, Demeester J, De Smedt S, Grooten J. Biodegradable polyelectrolyte microcapsules: antigen delivery tools with Th17 skewing activity after pulmonary delivery. J. Immunol. 184: 203-211 (2010).

• de la Barrera S, Aleman M, Sasiain Mdel C. Toll-like receptors in human infectious diseases. Curr. Pharm. Des. 12: 4173-4184 (2006).

• De Libero G, Mori L. Recognition of lipid antigens by T cells. Nat. Rev. Immunol. 5: 485-496 (2005). *

• De Libero G, Mori L. How T cells get grip on lipid antigens. Curr. Opin. Immunol. 20: 96-104 (2008). *

• de Lisle GW. Johne's disease in New Zealand: the past, present and a glimpse into the future. N. Z. Vet. J. 50: S53-S56 (2002).

• de Silva S, Devlin S, Panaccione R. Optimizing the safety of biologic therapy for IBD. Nat. Rev. Gastroenterol. Hepatol. 7: 93-101 (2010). *

• De Simone C, Caldarola G, D'agostino M, Zampetti A, Amerio P, Feliciani C. Exacerbation of pemphigus after influenza vaccination. Clin. Exp. Dermatol. 33: 718-720 (2008).

• De Sousa EA, Hays AP, Chin RL, Sander HW, Brannagan TH 3rd. Characteristics of patients with sensory neuropathy diagnosed with abnormal small nerve fibres on skin biopsy. J. Neurol. Neurosurg. Psychiatry 77: 983-985 (2006).

• de Witte MA, Jorritsma A, Swart E, Straathof KC, de Punder K, Haanen JB, Rooney CM, Schumacher TN. An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease. J. Immunol. 180: 6365-6373 (2008). *

• Debard N, Py P, Kraehenbuhl JP, Fuchs J. The influence of the Internet on immunology education. Nat. Rev. Immunol. 5: 736-740 (2005). *

• Debat Zoguereh D, Ruiz JM. Immunosuppression and vaccinations. Sante 10: 211-219 (2000).

• Decker WK, Li S, Xing D, Robinson SN, Yang H, Steiner D, Komanduri KV, Bollard CM, Shpall EJ. Deficient T(H)-1 responses from TNF-alpha-matured and alpha-CD40-matured dendritic cells. J. Immunother. 31: 157-165 (2008).

• Decker WK, Xing D, Shpall EJ. Dendritic cell immunotherapy for the treatment of neoplastic disease. Biol. Blood Marrow Transplant. 12: 113-125 (2006).

• Deering RP, Orange JS. Development of a clinical assay to evaluate Toll-like receptor function. Clin. Vaccine Immunol. 13: 68-76 (2006). *

• Dekker CL, Arvin AM. One step closer to a CMV vaccine. N. Engl. J. Med. 360: 1250-1252 (2009). *

• Del Campo AB, Aptsiauri N, Mendez R, Zinchenko S, Vales A, Paschen A, Ward S, Ruiz-Cabello F, Gonzalez-Aseguinolaza G, Garrido F. Efficient recovery of HLA class I expression in human tumor cells after beta2-microglobulin gene transfer using adenoviral vector: implications for cancer immunotherapy. Scand. J. Immunol. 70: 125-135 (2009). *

• Del Giudice G, Michetti P. Inflammation, immunity and vaccines for Helicobacter pylori. Helicobacter 9 Suppl. 1: 23-28 (2004).

• Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A. Interleukin-12: biological properties and clinical application. Clin. Cancer Res. 13: 4677-4685 (2007). *

• Delavallee L, Assier E, Denys A, Falgarone G, Zagury JF, Muller S, Bessis N, Boissier MC. Vaccination with cytokines in autoimmune diseases. Ann. Med. 40: 343-351 (2008).

• Delavallee L, Assier E, Semerano L, Bessis N, Boissier MC. Emerging applications of anticytokine vaccines. Expert Rev. Vaccines 7: 1507-1517 (2008).

• Delavallee L, Le Buanec H, Bessis N, Assier E, Denys A, Bizzini B, Zagury D, Boissier MC. Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha. Ann. Rheum. Dis. 67: 1332-1338 (2008).

• Deleo FR, Otto M. An antidote for Staphylococcus aureus pneumonia? J. Exp. Med. 205: 271-274 (2008). *

• Deluca DS, Blasczyk R. The immunoinformatics of cancer immunotherapy. Tissue Antigens 70: 265-271 (2007). *

• Delyria ES, Redline RW, Blanchard TG. Vaccination of mice against H. pylori induces a strong Th-17 response and immunity that is neutrophil dependent. Gastroenterology 136: 247-256 (2009). *

• Demento SL, Eisenbarth SC, Foellmer HG, Platt C, Caplan MJ, Mark Saltzman W, Mellman I, Ledizet M, Fikrig E, Flavell RA, Fahmy TM. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 27: 3013-3021 (2009).

• Demicheli V, Jefferson T, Rivetti A, Price D, Demicheli V. Vaccines for measles, mumps and rubella in children. Cochrane Database Syst. Rev. 4: CD004407 (2005). *

• den Brok MH, Sutmuller RP, Nierkens S, Bennink EJ, Frielink C, Toonen LW, Boerman OC, Figdor CG, Ruers TJ, Adema GJ. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br. J. Cancer 95: 896-905 (2006). *

• Deniz G, Oral HB, Zouali M. Frontiers in clinical immunology 2008. Scand. J. Immunol. 70: 163-171 (2009). *

• Denman CJ, McCracken J, Hariharan V, Klarquist J, Oyarbide-Valencia K, Guevara-Patino JA, Caroline Le Poole I. HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo. J. Invest. Dermatol. 128: 2041-2048 (2008). *

• Denning TL, Wang YC, Patel SR, Williams IR, Pulendran B. Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat. Immunol. 8: 1086-1094 (2007). *

• Depil S, Morales O, Castelli FA, Delhem N, Francois V, Georges B, Dufosse F, Morschhauser F, Hammer J, Maillere B, Auriault C, Pancre V. Determination of a HLA II promiscuous peptide cocktail as potential vaccine against EBV latency II malignancies. J. Immunother. 30: 215-226 (2007).

• Depla E, Van der Aa A, Livingston BD, Crimi C, Allosery K, De Brabandere V, Krakover J, Murthy S, Huang M, Power S, Babe L, Dahlberg C, McKinney D, Sette A, Southwood S, Philip R, Newman MJ, Meheus L. Rational design of a multi-epitope vaccine encoding T-lymphocyte epitopes for treatment of chronic HBV infections. J. Virol. 82: 435-450 (2008). *

• Derhovanessian E, Adams V, Hahnel K, Groeger A, Pandha H, Ward S, Pawelec G. Pretreatment frequency of circulating IL-17(+)CD4(+) T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int. J. Cancer 125: 1372-1379 (2009). *

• Derre L, Rivals JP, Jandus C, Pastor S, Rimoldi D, Romero P, Michielin O, Olive D, Speiser DE. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J. Clin. Invest. pii: 40070 (2009). *

• Desar IM, Weemaes CM, van Deuren M, van der Meer JW. Reversible hypogammaglobulinaemia. Neth. J. Med. 65: 381-385 (2007). *

• Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, Dubin G. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum. Vaccin. 5: 332-340 (2009).

• Descamps V, Mahe E, Houhou N, Abramowitz L, Rozenberg F, Ranger-Rogez S, Crickx B. Drug-induced hypersensitivity syndrome associated with Epstein-Barr virus infection. Br. J. Dermatol. 148: 1032-1034 (2003). *

• Desombere I, Hauser P, Rossau R, Paradijs J, Leroux-Roels G. Nonresponders to hepatitis B vaccine can present envelope particles to T lymphocytes. J. Immunol. 154: 520-529 (1995).

• Desombere I, Willems A, Leroux-Roels G. Response to hepatitis B vaccine: multiple HLA genes are involved. Tissue Antigens 51: 593-604 (1998).

• DeStefano F, Mullooly JP, Okoro CA, Chen RT, Marcy SM, Ward JI, Vadheim CM, Black SB, Shinefield HR, Davis RL, Bohlke K; Vaccine Safety Datalink Team. Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus. Pediatrics 108: e112 (2001). *

• DeStefano F, Verstraeten T, Chen RT. Hepatitis B vaccine and risk of multiple sclerosis. Expert Rev. Vaccines 1: 461-466 (2002).

• DeStefano F, Verstraeten T, Jackson LA, Okoro CA, Benson P, Black SB, Shinefield HR, Mullooly JP, Likosky W, Chen RT; Vaccine Safety Datalink Research Group, National Immunization Program, Centers for Disease Control and Prevention. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch. Neurol. 60: 504-509 (2003). *

• Destefano F, Weintraub ES, Chen RT. Hepatitis B vaccine and risk of multiple sclerosis. Pharmacoepidemiol. Drug Saf. 16: 705-707 (2007).

• Deviren G, Gupta K, Paulaitis ME, Schneck JP. Detection of antigen-specific T cells on p/MHC microarrays. J. Mol. Recognit. 20: 32-38 (2007). *

• Dharmaraj P, Smyth RL. Vaccines for preventing influenza in people with cystic fibrosis. Cochrane Database Syst. Rev. 4: CD001753 (2009).

• Dhiman N, Ovsyannikova IG, Vierkant RA, Ryan JE, Shane Pankratz V, Jacobson RM, Poland GA. Associations between SNPs in Toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine 26: 1731-1736 (2008). *

• Dhodapkar MV. Immunity to stemness genes in human cancer. Curr. Opin. Immunol. Feb 8 [Epub ahead of print] (2010).

• Di Bisceglie AM. Hepatitis B and hepatocellular carcinoma. Hepatology 49: S56-S60 (2009).

• Di Bisceglie MB, Lucchese A, Crincoli V. Pemphigus: the promises of peptide immunotherapy. Immunopharmacol. Immunotoxicol. 31: 509-515 (2009).

• Di Pierro M, Lu R, Uzzau S, Wang W, Margaretten K, Pazzani C, Maimone F, Fasano A. Zonula occludens toxin structure-function analysis. Identification of the fragment biologically active on tight junctions and of the zonulin receptor binding domain. J. Biol. Chem. 276: 19160-19165 (2001). *

• Di Rosa F, Pabst R. The bone marrow: a nest for migratory memory T cells. Trends Immunol. 26: 360-366 (2005). *

• Dickhaut K, Hoepner S, Eckhard J, Wiesmueller KH, Schindler L, Jung G, Falk K, Roetzschke O. Enhancement of tumour-specific immune responses in vivo by 'MHC loading-enhancer' (MLE). PLoS One 4: e6811 (2009). *

• Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, Larocque D, Van Mechelen M, Garcon N. AS04, an aluminum salt- and TLR-4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 183: 6186-6197 (2009).

• Diebold SS. Determination of T-cell fate by dendritic cells. Immunol. Cell Biol. 86: 389-397 (2008). *

• Dikopoulos N, Wegenka U, Kroger A, Hauser H, Schirmbeck R, Reimann J. Recently primed CD8+ T cells entering the liver induce hepatocytes to interact with naive CD8+ T cells in the mouse. Hepatology 39: 1256-1266 (2004). *

• Dinarello CA. Historical insights into cytokines. Eur. J. Immunol. 37 Suppl. 1: 34-45 (2007). *

• Dinarello CA. Anti-cytokine therapeutics and infections. Vaccine 21 Suppl. 2: S24-S34 (2003). *

• Ding FX, Wang F, Lu YM, Li K, Wang KH, He XW, Sun SH. Multiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus-related hepatocellular carcinoma. Hepatology 49: 1492-1502 (2009).

• Ding H, Nedrud JG, Wershil B, Redline RW, Blanchard TG, Czinn SJ. Partial protection against Helicobacter pylori in the absence of mast cells in mice. Infect. Immun. 77: 5543-5550 (2009). *

• Ding Y, Seow SV, Huang CH, Liew LM, Lim YC, Kuo IC, Chua KY. Coadministration of the fungal immunomodulatory protein FIP-Fve and a tumour-associated antigen enhanced antitumour immunity. Immunology 128: e881-e894 (2009).

• Dinges WL, Richardt J, Friedrich D, Jalbert E, Liu Y, Stevens CE, Maenza J, Collier AC, Geraghty DE, Smith J, Moodie Z, Mullins JI, McElrath MJ, Horton H. Virus specific CD8+ T cell responses better define HIV disease progression than HLA genotype. J. Virol. Feb 10 [Epub ahead of print] (2010).

• Dispirito JR, Shen H. Quick to remember, slow to forget: rapid recall responses of memory CD8(+) T cells. Cell Res. Dec 22 [Epub ahead of print] (2009).

• Dodd JS, Lum E, Goulding J, Muir R, Van Snick J, Openshaw PJ. IL-9 regulates pathology during primary and memory responses to respiratory syncytial virus infection. J. Immunol. 183: 7006-7013 (2009).

• Dohi T, Fujihashi K. Type 1 and 2 T helper cell-mediated colitis. Curr. Opin. Gastroenterol. 22: 651-657 (2006).

• Dohi T, Fujihashi K, Kiyono H, Elson CO, McGhee JR. Mice deficient in Th1- and Th2-type cytokines develop distinct forms of hapten-induced colitis. Gastroenterology 119: 724-733 (2000). *

• Dohnal AM, Luger R, Paul P, Fuchs D, Felzmann T. CD40 ligation restores type 1 polarizing capacity in TLR4 activated dendritic cells that have ceased interleukin-12 expression. J. Cell. Mol. Med. 13: 1741-1750 (2009). *

• Dohnal AM, Luger R, Paul P, Fuchs D, Felzmann T. CD40 ligation restores type 1 polarizing capacity in TLR4-activated dendritic cells that have ceased interleukin-12 expression. J. Cell. Mol. Med. 13: 1741-1750 (2009).

• Doll DC, List AF, Yarbro JW. Functional hyposplenism. South. Med. J. 80: 999-1006 (1987).

• Dominguez AL, Lustgarten J. Implications of aging and self-tolerance on the generation of immune and antitumor immune responses. Cancer Res. 68: 5423-5431 (2008). *

• Donaldson DS, Williams NA. Bacterial toxins as immunomodulators. Adv. Exp. Med. Biol. 666: 1-18 (2009).

• Donaldson EF, Yount B, Sims AC, Burkett S, Pickles RJ, Baric RS. Systematic assembly of a full-length infectious clone of human coronavirus NL63. J. Virol. 82: 11948-11957 (2008). *

• Dong J, Gao Y, Liu Y, Shi J, Feng J, Li Z, Pan H, Xue Y, Liu C, Shen B, Shao N, Yang G. The protective antibodies induced by a novel epitope of human TNF-alpha could suppress the development of collagen-induced arthritis. PLoS One 5: e8920 (2010). *

• Dong Y, Denny TN. HLA-A2-restricted human CD8+ cytotoxic T lymphocyte responses to a novel epitope in vaccinia virus that is conserved among orthopox viruses. J. Infect. Dis. 194: 168-175 (2006). *

• Donohue KB, Grant JM, Tewalt EF, Palmer DC, Theoret MR, Restifo NP, Norbury CC. Cross-priming utilizes antigen not available to the direct presentation pathway. Immunology 119: 63-73 (2006). *

• Doring G, Meisner C, Stern M; for the Flagella Vaccine Trial Study Group. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc. Natl. Acad. Sci. U.S.A. 104: 11020-11025 (2007). *

• Dos Santos Jr RR, Sartori A, Deperon Bonato VL, Coelho Castelo AA, Vilella CA, Zollner RL, Lopes Silva C. Immune modulation induced by tuberculosis DNA vaccine protects non-obese diabetic mice from diabetes progression. Clin. Exp. Immunol. 149: 570-578 (2007). *

• Dosenovic P, Chakrabarti B, Soldemo M, Douagi I, Forsell MN, Li Y, Phogat A, Paulie S, Hoxie J, Wyatt RT, Hedestam GB. Selective expansion of HIV-1 envelope glycoprotein-specific B cell subsets recognizing distinct structural elements following immunization. J. Immunol. 183: 3373-3382 (2009).

• Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Annu. Rev. Med. 60: 471-484 (2009). *

• Dougan M, Dranoff G. Immune therapy for cancer. Annu. Rev. Immunol. 27: 83-117 (2009). *

• Dow S. Liposome-nucleic acid immunotherapeutics. Expert Opin. Drug Deliv. 5: 11-24 (2008).

• Doytchinova IA, Flower DR. In silico identification of supertypes for class II MHCs. J. Immunol. 174: 7085-7095 (2005). *

• Doytchinova IA, Flower DR. Predicting class I major histocompatibility complex (MHC) binders using multivariate statistics: comparison of discriminant analysis and multiple linear regression. J. Chem. Inf. Model. 47: 234-238 (2007). *

• Draghia-Akli R, Khan AS. In vivo electroporation of gene sequences for therapeutic and vaccination applications. Recent. Pat. DNA Gene Seq. 1: 207-213 (2007).

• Droge W, Breitkreutz R. Glutathione and immune function. Proc. Nutr. Soc. 59: 595-600 (2000). *

• Du J, Liang X, Liu Y, Qu Z, Gao L, Han L, Liu S, Cui M, Shi Y, Zhang Z, Yu L, Cao L, Ma C, Zhang L, Chen Y, Sun W. Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression. Cell Death Differ. 16: 219-229 (2009).

• Duan J, Avci FY, Kasper DL. Microbial carbohydrate depolymerization by antigen-presenting cells: deamination prior to presentation by the MHCII pathway. Proc. Natl. Acad. Sci. U.S.A. 105: 5183-5188 (2008). *

• Dubaniewicz A. Mycobacterium tuberclosis heat shock proteins and autoimmunity in sarcoidosis. Autoimmun. Rev. Nov 18 [Epub ahead of print] (2009).

• Dubey AP, Banerjee S. Measles, mumps, rubella (MMR) vaccine. Indian J. Pediatr. 70: 579-584 (2003).

• Dubin PJ, Kolls JK. Th17 cytokines and mucosal immunity. Immunol. Rev. 226: 160-171 (2008). *

• Dubinsky MC, Fleshner PP. Treatment of Crohn's disease of inflammatory, stenotic, and fistulizing phenotypes. Curr. Treat. Options Gastroenterol. 6: 183-200 (2003).

• Dubois B, Goubier A, Joubert G, Kaiserlian D. Oral tolerance and regulation of mucosal immunity. Cell. Mol. Life Sci. 62: 1322-1332 (2005). *

• Dubus JC, Bosdure E, Bakuridze L, Andrieu V. Nebulized drugs: the evolution? Arch. Pediatr. 14: 504-506 (2007).

• Duchet-Niedziolka P, Hanslik T, Aouba A, Le Guern V, Guillevin L, Launay O; pour le groupe GEVACCIM. Pneumococcal infections and vaccination in patients with systemic autoimmune and/or inflammatory diseases. Presse. Med. 38: 243-250 (2009).

• Duchini A, Hendry RM, Nyberg LM, Viernes ME, Pockros PJ. Immune response to influenza vaccine in adult liver transplant recipients. Liver Transpl. 7: 311-313 (2001). *

• Duchini A, Hendry RM, Redfield DC, Pockros PJ. Influenza infection in patients before and after liver transplantation. Liver Transpl. 6: 531-542 (2000). *

• Duclos P. Safety of immunisation and adverse events following vaccination against hepatitis B. Expert Opin. Drug Saf. 2: 225-231 (2003).

• Duda A, Turner L, Fox J, Robinson N, Dustan S, Kaye S, Fryer H, Carrington M, McClure M, McLean AR, Fidler S, Weber J, Phillips RE, Frater AJ; the SPARTAC Trial Investigators. HLA-associated clinical progression correlates with epitope reversion rates in early HIV infection. J. Virol. 83: 1228-1239 (2009). *

• Dudeja V, Vickers SM, Saluja AK. The role of heat shock proteins in gastrointestinal diseases. Gut 58: 1000-1009 (2009).

• Duenas AI, Aceves M, Orduna A, Diaz R, Sanchez Crespo M, Garcia-Rodriguez C. Francisella tularensis LPS induces the production of cytokines in human monocytes and signals via Toll-like receptor 4 with much lower potency than E. coli LPS. Int. Immunol. 18: 785-795 (2006). *

• Dullaers M, Li D, Xue Y, Ni L, Gayet I, Morita R, Ueno H, Palucka KA, Banchereau J, Oh S. A T cell-dependent mechanism for the induction of human mucosal homing immunoglobulin A-secreting plasmablasts. Immunity 30: 120-129 (2009). *

• Dunne C, Shanahan F. Role of probiotics in the treatment of intestinal infections and inflammation. Curr. Opin. Gastroenterol. 18: 40-45 (2002).

• DuPont HL. Travellers' diarrhoea: contemporary approaches to therapy and prevention. Drugs 66: 303-314 (2006).

• DuPont HL, Garey K, Caeiro JP, Jiang ZD. New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control. Curr. Opin. Infect. Dis. 21: 500-507 (2008).

• Durantez M, Lopez-Vazquez AB, de Cerio AL, Huarte E, Casares N, Prieto J, Borras-Cuesta F, Lasarte JJ, Sarobe P. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes. Scand. J. Immunol. 69: 80-89 (2009). *

• Durova OM, Vorobiev II, Smirnov IV, Reshetnyak AV, Telegin GB, Shamborant OG, Orlova NA, Genkin DD, Bacon A, Ponomarenko NA, Friboulet A, Gabibov AG. Strategies for induction of catalytic antibodies toward HIV-1 glycoprotein gp120 in autoimmune prone mice. Mol. Immunol. 47: 87-95 (2009). *

• Durupinar B, Okten G. HLA tissue types in nonresponders to hepatitis B vaccine. Indian J. Pediatr. 63: 369-373 (1996).

• Dzhambazov B, Nandakumar KS, Kihlberg J, Fugger L, Holmdahl R, Vestberg M. Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules. J. Immunol. 176: 1525-1533 (2006). *

• Ebert EC, Hagspiel KD, Nagar M, Schlesinger N. Gastrointestinal involvement in polyarteritis nodosa. Clin. Gastroenterol. Hepatol. 6: 960-966 (2008).

• Ebringer A, Rashid T, Jawad N, Wilson C, Thompson EJ, Ettelaie C. From rabies to transmissible spongiform encephalopathies: an immune-mediated microbial trigger involving molecular mimicry could be the answer. Med. Hypotheses 68: 113-124 (2007).

• Edwards E, Razvi S, Cunningham-Rundles C. IgA deficiency: clinical correlates and responses to pneumococcal vaccine. Clin. Immunol. 111: 93-97 (2004). *

• Eichler H, Nguyen XD, Roelen D, Celluzzi CM, McKenna D, Pamphilon D, Blair A, Read EJ, Takahashi TA, Szczepiorkowski ZM; Biomedical Excellence for Safer Transfusion Collaborative. Multicenter study on in vitro characterization of dendritic cells. Cytotherapy 10: 21-19 (2008).

• El Arifeen S. Child health and mortality. J. Health Popul. Nutr. 26: 273-279 (2008).

• El Asmar R, Panigrahi P, Bamford P, Berti I, Not T, Coppa GV, Catassi C, Fasano A. Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure. Gastroenterology 123: 1607-1615 (2002). *

• El-Hagrassy N, El-Chennawi F, Zaki ME, Fawzy H, Zaki A, Joseph N. HLA class I and class II HLA DRB profiles in Egyptian children with rheumatic valvular disease. Pediatr. Cardiol. Feb 10 [Epub ahead of print] (2010).

• El-Karaksy HM, El-Hawary MI, El-Koofy NM, El-Sayed R, El-Raziky MA, Mansour SA, Taha GM, El-Mougy F. Safety and efficacy of hepatitis A vaccine in children with chronic liver disease. World J. Gastroenterol. 12: 7337-7340 (2006). *

• Elamanchili P, Lutsiak CM, Hamdy S, Diwan M, Samuel J. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells. J. Immunother. 30: 378-395 (2007).

• Eldor R, Cohen IR, Raz I. Innovative immune-based therapeutic approaches for the treatment of type 1 diabetes mellitus. Int. Rev. Immunol. 24: 327-339 (2005).

• Elkayam O. Safety and efficacy of vaccination against influenza in patients with rheumatoid arthritis. Clin. Dev. Immunol. 13: 349-351 (2006). *

• Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin. Arthritis Rheum. 33: 283-288 (2004). *

• Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann. Rheum. Dis. 61: 623-625 (2002). *

• Elkord E, Burt DJ, Drijfhout JW, Hawkins RE, Stern PL. CD4(+) T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25(+) T cells. Cancer Immunol. Immunother. 57: 833-847 (2008). *

• Elkord E, Dangoor A, Burt DJ, Southgate TD, Daayana S, Harrop R, Drijfhout JW, Sherlock D, Hawkins RE, Stern PL. Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4). Cancer Immunol. Immunother. 58: 1657-1667 (2009). *

• Elliman DA, Bedford HE. Measles, mumps and rubella vaccine, autism and inflammatory bowel disease: advising concerned parents. Paediatr. Drugs 4: 631-635 (2002).

• Elliott SL, Suhrbier A, Miles JJ, Lawrence G, Pye SJ, Le TT, Rosenstengel A, Nguyen T, Allworth A, Burrows SR, Cox J, Pye D, Moss DJ, Bharadwaj M. A phase I trial of a CD8+ T cell peptide epitope-based vaccine for infectious mononucleosis. J. Virol. 82: 1448-1457 (2008). *

• Elson CO. In defense of mucosal surfaces. Regulation and manipulation of the mucosal immune system. Adv. Exp. Med. Biol. 412: 373-385 (1997).

• Elvang T, Christensen JP, Billeskov R, Thi Kim Thanh Hoang T, Holst P, Thomsen AR, Andersen P, Dietrich J. CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination. PLoS ONE 4: e5139 (2009). *

• Emens LA, Reilly RT, Jaffee EM. Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. Endocr. Relat. Cancer 12: 1-17 (2005). *

• Emini EA, Koff WC. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope. Science 304: 1913-1914 (2004). *

• Enarsson K, Johnsson E, Lindholm C, Lundgren A, Pan-Hammarstrom Q, Stromberg E, Bergin P, Baunge EL, Svennerholm AM, Quiding-Jarbrink M. Differential mechanisms for T lymphocyte recruitment in normal and neoplastic human gastric mucosa. Clin. Immunol. 118: 24-34 (2006). *

• Enioutina EY, Bareyan D, Daynes RA. TLR-induced local metabolism of vitamin D3 plays an important role in the diversification of adaptive immune responses. J. Immunol. 182: 4296-4305 (2009).

• Erdmann M, Schuler-Thurner B. Dendritic cell vaccines in metastasized malignant melanoma. G. Ital. Dermatol. Venereol. 143: 235-250 (2008).

• Erol A. PPARalpha activators may be good candidates as antiaging agents. Med. Hypotheses 65: 35-38 (2005).

• Ertem D, Gonen I, Tanidir C, Ugras M, Yildiz A, Pehlivanoglu E, Eksioglu-Demiralp E. The response to hepatitis B vaccine: does it differ in celiac disease? Eur. J. Gastroenterol. Hepatol. Jul 4 [Epub ahead of print] (2009).

• Escobar D, Pons J, Clemente A, Iglesias J, Regueiro V, Bengoechea JA, Matamoros N, Ferrer JM. Defective B cell response to TLR9 ligand (CpG-ODN), Streptococcus pneumoniae and Haemophilus influenzae extracts in common variable immunodeficiency patients. Cell. Immunol. Jan 25 [Epub ahead of print] (2010).

• Essakalli M, Atouf O, Bennani N, Benseffaj N, Ouadghiri S, Brick C. Toll-like receptors. Pathol. Biol. (Paris) 57: 430-438 (2009).

• Esteve Comas M, Loras Alastruey C, Fernandez-Banares F. How do we manage vaccinations in patients with inflammatory bowel disease? Dig. Dis. 27: 370-374 (2009).

• Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 53: 1363-1365 (2004). *

• Evdokimova VN, Liu Y, Potter DM, Butterfield LH. AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients. J. Immunother. 30: 425-437 (2007).

• Evel-Kabler K, Chen SY. Dendritic cell-based tumor vaccines and antigen presentation attenuators. Mol. Ther. 13: 850-858 (2006).

• Ewer K, Cockle P, Gordon S, Mansoor H, Govaerts M, Walravens K, Marche S, Hewinson G, Vordermeier M. Antigen mining with iterative genome screens identifies novel diagnostics for the Mycobacterium tuberculosis complex. Clin. Vaccine Immunol. 13: 90-97 (2006). *

• Exley C, Swarbrick L, Gherardi RK, Authier FJ. A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome. Med. Hypotheses 72: 135-139 (2009).

• Ezernitchi AV, Vaknin I, Cohen-Daniel L, Levy O, Manaster E, Halabi A, Pikarsky E, Shapira L, Baniyash M. TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J. Immunol. 177: 4763-4772 (2006). *

• Facci MR, Auray G, Buchanan R, van Kessel J, Thompson DR, Mackenzie-Dyck S, Babiuk LA, Gerdts V. A comparison between isolated blood dendritic cells and monocyte-derived dendritic cells in pigs. Immunology 129: 396-405 (2010). *

• Fahlen-Yrlid L, Gustafsson T, Westlund J, Holmberg A, Strombeck A, Blomquist M, Macpherson GG, Holmgren J, Yrlid U. CD11chigh dendritic cells are essential for activation of CD4+ T cells and generation of specific antibodies following mucosal immunization. J. Immunol. 183: 5032-5041 (2009).

• Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am. J. Pathol. 173: 600-609 (2008). *

• Fallarino F, Puccetti P. Toll-like receptor 9-mediated induction of the immunosuppressive pathway of tryptophan catabolism. Eur. J. Immunol. 36: 8-11 (2005). *

• Farjadian S, Ghaderi A. HLA class II genetic diversity in Arabs and Jews of Iran. Iran J. Immunol. 4: 85-93 (2007).

• Fasano A. Surprises from celiac disease. Sci. Am. 301: 54-61 (2009).

• Fasano A. Physiological, pathological, and therapeutic implications of zonulin-mediated intestinal barrier modulation: living life on the edge of the wall. Am. J. Pathol. 173: 1243-1252 (2008). *

• Faure E. Multiple sclerosis and hepatitis B vaccination: could minute contamination of the vaccine by partial Hepatitis B virus polymerase play a role through molecular mimicry? Med. Hypotheses 65: 509-520 (2005).

• Fazilleau N, Eisenbraun MD, Malherbe L, Ebright JN, Pogue-Caley RR, McHeyzer-Williams LJ, McHeyzer-Williams MG. Lymphoid reservoirs of antigen-specific memory T helper cells. Nat. Immunol. 8: 753-761 (2007). *

• Fazilleau N, Mark L, McHeyzer-Williams LJ, McHeyzer-Williams MG. Follicular helper T cells: lineage and location. Immunity 30: 324-335 (2009). *

• Fazilleau N, McHeyzer-Williams LJ, Rosen H, McHeyzer-Williams MG. The function of follicular helper T cells is regulated by the strength of T cell antigen receptor binding. Nat. Immunol. 10: 375-384 (2009). *

• Fedele G, Celestino I, Spensieri F, Frasca L, Nasso M, Watanabe M, Remoli ME, Coccia EM, Altieri F, Ausiello CM. Lipooligosaccharide from Bordetella pertussis induces mature human monocyte-derived dendritic cells and drives a Th2 biased response. Microbes Infect. 9: 855-863 (2007). *

• Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm. Bowel Dis. 10: 286-299 (2004). *

• Feeney M, Ciegg A, Winwood P, Snook J. A case-control study of measles vaccination and inflammatory bowel disease. The East Dorset Gastroenterology Group. Lancet 350: 764-766 (1997). *

• Feillet H, Bach JF. Increased incidence of inflammatory bowel disease: the price of the decline of infectious burden? Curr. Opin. Gastroenterol. 20: 560-564 (2004).

• Feldmann H, Jones S, Klenk HD, Schnittler HJ. Ebola virus: from discovery to vaccine. Nat. Rev. Immunol. 3: 677-685 (2003).

• Ferreira DM, Darrieux M, Silva DA, Leite LC, Ferreira JM Jr, Ho PL, Miyaji EN, Oliveira ML. Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface proteins PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice. Clin. Vaccine Immunol. 16: 636-645 (2009). *

• Ferrera F, Cava AL, Rizzi M, Hahn BH, Indiveri F, Filaci G. Gene vaccination for the induction of immune tolerance. Ann. N. Y. Acad. Sci. 1110: 99-111 (2007). *

• Ferrera F, Hahn BH, Rizzi M, Anderson M, Fitzgerald J, Millo E, Indiveri F, Shi FD, Filaci G, La Cava A. Protection against renal disease in (NZB x NZW)F(1) lupus-prone mice after somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide. Arthritis Rheum. 56: 1945-1953 (2007). *

• Ferris I Tortajada J, Ortega Garcia JA, Garcia I Castell J, Lopez Andreu JA, Ribes Koninckx C, Berbel Tornero O. Risks factors for pediatric malignant liver tumors. An. Pediatr. (Barc.) 68: 377-384 (2008).

• Fiala M. Re-balancing of inflammation and immunity as a therapeutic for Alzheimer's disease - view from the bedside. CNS Neurol. Disord. Drug Targets Oct 7 [Epub ahead of print] (2009).

• Fields SW, Baiocco PJ, Korelitz BI. Influenza vaccinations: should they really be encouraged for IBD patients being treated with immunosuppressives? Inflamm. Bowel Dis. 15: 649-651 (2009).

• Filippi C, von Herrath M. IL-10 and the resolution of infections. J. Pathol. 214: 224-230 (2008). *

• Filippi C, von Herrath M. How viral infections affect the autoimmune process leading to type 1 diabetes. Cell. Immunol. 233: 125-132 (2005). *

• Finetti F, Pellegrini M, Ulivieri C, Savino MT, Paccagnini E, Ginanneschi C, Lanfrancone L, Pelicci PG, Baldari CT. The proapoptotic and antimitogenic protein p66SHC acts as a negative regulator of lymphocyte activation and autoimmunity. Blood 111: 5017-5027 (2008). *

• Finkelstein SE, Heimann DM, Klebanoff CA, Antony PA, Gattinoni L, Hinrichs CS, Hwang LN, Palmer DC, Spiess PJ, Surman DR, Wrzesiniski C, Yu Z, Rosenberg SA, Restifo NP. Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. J. Leukoc. Biol. 76: 333-337 (2004). *

• Finn OJ. Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. 3: 630-641 (2003). *

• Finney OC, Riley EM, Walther M. Regulatory T cells in malaria - friend or foe? Trends Immunol. 31: 63-70 (2010). *

• Fisher MA, Eklund SA, James SA, Lin X. Adverse events associated with hepatitis B vaccine in U.S. children less than six years of age, 1993 and 1994. Ann. Epidemiol. 11: 13-21 (2001).

• Fitness J, Tosh K, Hill AV. Genetics of susceptibility to leprosy. Genes Immun. 3: 441-453 (2002). *

• Flaminio MJ, Tallmadge RL, Salles-Gomes CO, Matychak MB. Common variable immunodeficiency in horses is characterized by B cell depletion in primary and secondary lymphoid tissues. J. Clin. Immunol. 29: 107-116 (2009). *

• Flesch IE, Woo WP, Wang Y, Panchanathan V, Wong YC, La Gruta NL, Cukalac T, Tscharke DC. Altered CD8+ T cell immunodominance after vaccinia virus infection and the naive repertoire in inbred and F1 mice. J. Immunol. 184: 45-55 (2010).

• Fletcher HA. Correlates of immune protection from tuberculosis. Curr. Mol. Med. 7: 319-325 (2007).

• Fletcher HA, Keyser A, Bowmaker M, Sayles PC, Kaplan G, Hussey G, Hill AV, Hanekom WA. Transcriptional profiling of mycobacterial antigen-induced responses in infants vaccinated with BCG at birth. BMC Med. Genomics 2: 10 (2009). *

• Flohr C, Pascoe D, Williams HC. Atopic dermatitis and the 'hygiene hypothesis': too clean to be true? Br. J. Dermatol. 152: 202-216 (2005). *

• Florence WC, Bhat RK, Joyce S. CD1d-restricted glycolipid antigens: presentation principles, recognition logic and functional consequences. Expert Rev. Mol. Med. 10: e20 (2008).

• Flores J, Okhuysen PC. Enteroaggregative Escherichia coli infection. Curr. Opin. Gastroenterol. 25: 8-11 (2009).

• Flower DR. Receptor-binding sites: bioinformatic approaches. Methods Mol. Biol. 316: 291-358 (2006).

• Foell J, Hewes B, Mittler RS. T cell costimulatory and inhibitory receptors as therapeutic targets for inducing anti-tumor immunity. Curr. Cancer Drug Targets 7: 55-70 (2007).

• Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 18: 245-273 (2000). *

• Fonseca DM, Silva CL, Wowk PF, Paula MO, Ramos SG, Horn C, Marchal G, Bonato VL. Mycobacterium tuberculosis culture filtrate proteins plus CpG-ODN confer protection to BCG primed mice by inhibiting IL-4 secretion. Infect. Immun. 77: 5311-5321 (2009). *

• Forns X, Sanchez Tapias JM, Pares A, Llovet JM, Bruix J, Rodes J. Expected developments in hepatology. Best Pract. Res. Clin. Gastroenterol. 16: 957-970 (2002). *

• Forte GI, Scola L, Misiano G, Milano S, Mansueto P, Vitale G, Bellanca F, Sanacore M, Vaccarino L, Rini GB, Caruso C, Cillari E, Lio D, Mansueto S. Relevance of interferon-gamma, tumor necrosis factor-alpha and interleukin 10 gene polymorphisms for Mediterranean spotted fever susceptibility. Clin. Vaccine Immunol. 16: 811-815 (2009). *

• Foucaud P, de Truchis A, Tassin E, Allouch P, Pangon B. Pseudomonas aeruginosa and cystic fibrosis: non-antibiotic strategy. Arch. Pediatr. 13 Suppl. 1: S44-S47 (2006).

• Fourneau JM, Bach JM, van Endert PM, Bach JF. The elusive case for a role of mimicry in autoimmune diseases. Mol. Immunol. 40: 1095-1102 (2004). *

• Fowler KH, Chapkin RS, McMurray DN. Effects of purified dietary n-3 ethyl esters on murine T lymphocyte function. J. Immunol. 151: 5186-5197 (1993).

• Fox JG, Wang TC. Helicobacter pylori infection: pathogenesis. Curr. Opin. Gastroenterol. 18: 15-25 (2002).

• Frahm N, Yusim K, Suscovich TJ, Adams S, Sidney J, Hraber P, Hewitt HS, Linde CH, Kavanagh DG, Woodberry T, Henry LM, Faircloth K, Listgarten J, Kadie C, Jojic N, Sango K, Brown NV, Pae E, Zaman MT, Bihl F, Khatri A, John M, Mallal S, Marincola FM, et al. Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur. J. Immunol. 37: 2419-2433 (2007). *

• Frank DN. Mycobacterium avium subspecies paratuberculosis and Crohn's disease. Lancet Infect. Dis. 8: 345 (2008).

• Frasca D, Blomberg BB. Effects of aging on B cell function. Curr. Opin. Immunol. 21: 425-430 (2009).

• Frasca L, Nasso M, Spensieri F, Fedele G, Palazzo R, Malavasi F, Ausiello CM. IFN-gamma arms human dendritic cells to perform multiple effector functions. J. Immunol. 180: 1471-1481 (2008). *

• Fraser DA, Tenner AJ. Directing an appropriate immune response: the role of defense collagens and other soluble pattern recognition molecules. Curr. Drug Targets 9: 113-122 (2008).

• Fraszczak J, Trad M, Janikashvili N, Cathelin D, Lakomy D, Granci V, Morizot A, Audia S, Micheau O, Lagrost L, Katsanis E, Solary E, Larmonier N, Bonnotte B. Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells. J. Immunol. Jan 20 [Epub ahead of print] (2010).

• Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat. Rev. Immunol. 4: 46-54 (2004). *

• Fregonese L, Stolk J. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J. Rare Dis. 3: 16 (2008). *

• Freire de Carvalho J, Pereira RM, Shoenfeld Y. The mosaic of autoimmunity: the role of environmental factors. Front. Biosci. (Elite Ed.) 1: 501-509 (2009).

• Frey FJ. Polyarteritis nodosa, a vanishing vasculitis since its main cause has been identified. Ther. Umsch. 65: 247-251 (2008).

• Friedland RP, Tedesco JM, Wilson AC, Atwood CS, Smith MA, Perry G, Zagorski MG. Antibodies to potato virus Y bind the amyloid beta peptide: immunohistochemical and NMR studies. J. Biol. Chem. 283: 22550-22556 (2008). *

• Fry L, Baker BS, Powles AV. Psoriasis - a possible candidate for vaccination. Autoimmun. Rev. 6: 286-289 (2007).

• Fry L, Baker BS, Powles AV. Psoriasis - a possible candidate for vaccination. Clin. Dev. Immunol. 13: 361-367 (2006). *

• Fu N, Khan S, Quinten E, de Graaf N, Pemberton AJ, Rivett AJ, Melief CJ, Ossendorp F. Effective CD8(+) T cell priming and tumor protection by enterotoxin B subunit-conjugated peptides targeted to dendritic cells. Vaccine 27: 5252-5258 (2009). *

• Fuchs I, Avnon L, Freud T, Abu-Shakra M. Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors. Clin. Rheumatol. 28: 167-172 (2009). *

• Fujihashi K, Kiyono H. Mucosal immunosenescence: new developments and vaccines to control infectious diseases. Trends Immunol. 30: 334-343 (2009). *

• Fuleihan RL. The hyper IgM syndrome. Curr. Allergy Asthma Rep. 1: 445-450 (2001).

• Fuller MJ, Shoukry NH, Gushima T, Bowen DG, Callendret B, Campbell KJ, Hasselschwert DL, Hughes AL, Walker CM. Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. Hepatology 51: 378-387 (2010). *

• Fulop T, Larbi A, Wikby A, Mocchegiani E, Hirokawa K, Pawelec G. Dysregulation of T-cell function in the elderly: scientific basis and clinical implications. Drugs Aging 22: 589-603 (2005).

• Fulton A, Miller F, Weise A, Wei WZ. Prospects of controlling breast cancer metastasis by immune intervention. Breast Dis. 26: 115-127 (2007).

• Fung KT, Fung J, Lai CL, Yuen MF. Etiologies of chronic liver diseases in Hong Kong. Eur. J. Gastroenterol. Hepatol. 19: 659-664 (2007).

• Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin. Arthritis Rheum. Dec 29 [Epub ahead of print] (2008). *

• Furugaki K, Pokorna K, le Pogam C, Aoki M, Reboul M, Bajzik V, Krief P, Janin A, Noguera ME, West R, Charron D, Chomienne C, Pla M, Moins-Teisserenc H, Padua RA. DNA vaccination with all-trans retinoic acid treatment induces long term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse model. Blood Nov 19 [Epub ahead of print] (2009). *

• Gade JN. Clinical update on alefacept: consideration for use in patients with psoriasis. J. Manag. Care Pharm. 10 (3 Suppl. B): S33-S37 (2004).

• Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, Harlin H. Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 213: 131-145 (2006). *

• Galdeano CM, Perdigon G. The probiotic bacterium Lactobacillus casei induces activation of the gut mucosal immune system through innate immunity. Clin. Vaccine Immunol. 13: 219-226 (2006). *

• Gallagher KM, Lauder S, Rees IW, Gallimore AM, Godkin AJ. Type I interferon (IFNalpha) acts directly on human memory CD4+ T cells altering their response to antigen. J. Immunol. 183: 2915-2920 (2009).

• Ganley-Leal LM, Liu X, Wetzler LM. Toll-like receptor 2-mediated human B cell differentiation. Clin. Immunol. 120: 272-284 (2006). *

• Gao H, Leaver SK, Burke-Gaffney A, Finney SJ. Severe sepsis and Toll-like receptors. Semin. Immunopathol. 30: 29-40 (2008). *

• Garcia-Bates TM, Baglole CJ, Bernard MP, Murant TI, Simpson-Haidaris PJ, Phipps RP. Peroxisome proliferator-activated receptor gamma ligands enhance human B cell antibody production and differentiation. J. Immunol. 183: 6903-6912 (2009).

• Gardner MS, Rowland MD, Siu AY, Bundy JL, Wagener DK, Stephenson JL. Comprehensive defensin assay for saliva. Anal. Chem. 81: 557-566 (2009). *

• Gargano LM, Forrest JC, Speck SH. Signaling through Toll-like receptors induces murine gammaherpesvirus 68 reactivation in vivo. J. Virol. 83: 1474-1482 (2009). *

• Garin T, Rubinstein A, Grigoriadis N, Nedvetzki S, Abramsky O, Mizrachi-Koll R, Hand C, Naor D, Karussis D. CD44 variant DNA vaccination with virtual lymph node ameliorates experimental autoimmune encephalomyelitis through the induction of apoptosis. J. Neurol. Sci. 258: 17-26 (2007). *

• Garmory HS, Titball RW. ATP-binding cassette transporters are targets for the development of antibacterial vaccines and therapies. Infect. Immun. 72: 6757-6763 (2004). *

• Garren H. DNA vaccines for autoimmune diseases. Expert Rev. Vaccines 8: 1195-1203 (2009).

• Gaseitsiwe S, Valentini D, Mahdavifar S, Reilly M, Ehrnst A, Maeurer M. Peptide microarray-based identification of Mycobacterium tuberculosis epitope binding to HLA-DRB1*0101, DRB1*1501 and DRB1*0401. Clin. Vaccine Immunol. Oct 28 [Epub ahead of print] (2009). *

• Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6: 383-393 (2006). *

• Gavin AL, Hoebe K, Duong B, Ota T, Martin C, Beutler B, Nemazee D. Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science 314: 1936-1938 (2006). *

• Geier DA, Geier MR. Hepatitis B vaccination and adult associated gastrointestinal reactions: a follow-up analysis. Hepatogastroenterology 49: 1571-1575 (2002).

• Geier DA, Geier MR. A one year followup of chronic arthritis following rubella and hepatitis B vaccination based upon analysis of the Vaccine Adverse Events Reporting System (VAERS) database. Clin. Exp. Rheumatol. 20: 767-771 (2002).

• Geier DA, Geier MR. Anthrax vaccination and joint related adverse reactions in light of biological warfare scenarios. Clin. Exp. Rheumatol. 20: 217-220 (2002).

• Geier DA, Geier MR. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity 38: 295-301 (2005).

• Geier MR, Geier DA. Gastrointestinal adverse reactions following anthrax vaccination: an analysis of the Vaccine Adverse Events Reporting System (VAERS) database. Hepatogastroenterology 51: 762-767 (2004).

• Geier MR, Geier DA. Hepatitis B vaccination safety. Ann. Pharmacother. 36: 370-374 (2002).

• Geier MR, Geier DA. A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the Vaccine Adverse Event Reporting System (VAERS) database and literature review. Clin. Exp. Rheumatol. 22: 749-755 (2004).

• Geier MR, Geier DA, Zahalsky AC. A review of hepatitis B vaccination. Expert Opin. Drug Saf. 2: 113-122 (2003).

• Geijtenbeek TB, Gringhuis SI. Signalling through C-type lectin receptors: shaping immune responses. Nat. Rev. Immunol. 9: 465-479 (2009). *

• Geissler M. DNA-based immunotherapy. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 43. October 20 - 21 (2003). *

• Geldmacher C, Metzler IS, Tovanabutra S, Asher TE, Gostick E, Ambrozak DR, Petrovas C, Schuetz A, Ngwenyama N, Kijak G, Maboko L, Hoelscher M, McCutchan F, Price DA, Douek DC, Koup RA. Minor viral and host genetic polymorphisms can dramatically impact the biological outcome of an epitope-specific CD8 T cell response. Blood 114: 1553-1562 (2009). *

• Gelinas DS, DaSilva K, Fenili D, St George-Hyslop P, McLaurin J. Immunotherapy for Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 101: 14657-14662 (2004). *

• Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, Rimmelzwaan GF, Kroon FP. The effect of anti-tumor necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann. Rheum. Dis. 67: 713-716 (2008).

• Gelinck LB, van der Bijl AE, Visser LG, Huizinga TW, van Hogezand RA, Rijkers GT, Kroon FP. Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine. Vaccine 26: 3528-3533 (2008).

• Geluk A, van Meijgaarden KE, Franken KL, Drijfhout JW, D'Souza S, Necker A, Huygen K, Ottenhoff TH. Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans. J. Immunol. 165: 6463-6471 (2000). *

• Gennery AR, Khawaja K, Veys P, Bredius RG, Notarangelo LD, Mazzolari E, Fischer A, Landais P, Cavazzana-Calvo M, Friedrich W, Fasth A, Wulffraat NM, Matthes-Martin S, Bensoussan D, Bordigoni P, Lange A, Pagliuca A, Andolina M, Cant AJ, Davies EG. Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation: a survey of the European experience, 1993-2002. Blood 103: 1152-1157 (2004). *

• Gentry M, Taormina J, Pyles RB, Yeager L, Kirtley M, Popov VL, Klimpel G, Eaves-Pyles T. The role of primary human alveolar epithelial cells in host defense against Francisella tularensis infection. Infect. Immun. 75: 3969-3978 (2007). *

• Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin. Infect. Dis. 46 Suppl. 1: S32-S42 (2008).

• Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4(+)CD25 (+) regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56: 641-648 (2007). *

• Giannandrea M, Pierce RH, Crispe IN. Indirect action of tumor necrosis factor-alpha in liver injury during the CD8+ T cell response to an adeno-associated virus vector in mice. Hepatology 49: 2010-2020 (2009).

• Gibbons DL, Haque SF, Copestake SL, Wells JW, Noble A, Smith AL, Hayday AC. Suppression of airway inflammation by a natural acute infection of the intestinal epithelium. Mucosal Immunol. 2: 144-155 (2009). *

• Gibson RA, Barclay D, Marshall H, Moulin J, Maire JC, Makrides M. Safety of supplementing infant formula with long-chain polyunsaturated fatty acids and Bifidobacterium lactis in term infants: a randomised controlled trial. Br. J. Nutr. 101: 1706-1713 (2009). *

• Gilat T, Hacohen D, Lilos P, Langman MJ. Childhood factors in ulcerative colitis and Crohn's disease. An international cooperative study. Scand. J. Gastroenterol. 22: 1009-1024 (1987).

• Gilkeson GS. Vaccinations in patients with systemic lupus erythematosus - safe, but not always effective. Nat. Clin. Pract. Rheumatol. 2: 590-591 (2006). *

• Girard M. Autoimmune hazards of hepatitis B vaccine. Autoimmun. Rev. 4: 96-100 (2005).

• Glass EJ. Genetic variation and responses to vaccines. Anim. Health Res. Rev. 5: 197-208 (2004).

• Glaum MC, Narula S, Song D, Zheng Y, Anderson AL, Pletcher CH, Levinson AI. Toll-like receptor 7-induced naive human B-cell differentiation and immunoglobulin production. J. Allergy Clin. Immunol. 123: 224-230.e4 (2009). *

• Glinka Y, Chang Y, Prud'homme GJ. Protective regulatory T cell generation in autoimmune diabetes by DNA covaccination with islet antigens and a selective CTLA-4 ligand. Mol. Ther. 14: 578-587 (2006).

• Gluck T, Muller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin. Infect. Dis. 46: 1459-1465 (2008). *

• Glynn F, O'Sullivan P. Vocal fold deposits in macrophagic myofasciitis. Ear Nose Throat J. 86: 238-239 (2007).

• Godebu E, Summers-Torres D, Lin MM, Baaten BJ, Bradley LM. Polyclonal adaptive regulatory CD4 cells that can reverse type I diabetes become oligoclonal long-term protective memory cells. J. Immunol. 181: 1798-1805 (2008). *

• Godkin A, Davenport M, Hill AV. Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. Hepatology 41: 1383-1390 (2005). *

• Goldman M. Translational mini-review series on Toll-like receptors: Toll-like receptor ligands as novel pharmaceuticals for allergic disorders. Clin. Exp. Immunol. 147: 208-216 (2007). *

• Gomariz RP, Gutierrez-Canas I, Arranz A, Carrion M, Juarranz Y, Leceta J, Martinez C. Peptides targeting Toll-like receptor signalling pathways for novel immune therapeutics. Curr. Pharm. Des. Dec 23 [Epub ahead of print] (2009).

• Gomes MM, Herr AB. IgA and IgA-specific receptors in human disease: structural and functional insights into pathogenesis and therapeutic potential. Springer Semin. Immunopathol. 28: 383-395 (2006). *

• Gomollon F. Treatment safety in inflammatory bowel disease. Gastroenterol. Hepatol. 29 Suppl. 3: 45-51 (2006).

• Gong J, Zhang Y, Durfee J, Weng D, Liu C, Koido S, Song B, Apostolopoulos V, Calderwood SK. A heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use. J. Immunol. 184: 488-496 (2010).

• Gong J, Zhu B, Murshid A, Adachi H, Song B, Lee A, Liu C, Calderwood SK. T cell activation by heat shock protein 70 vaccine requires TLR signaling and scavenger receptor expressed by endothelial cells-1. J. Immunol. 183: 3092-3098 (2009).

• Gong Z, Jin Y, Zhang Y. Suppression of diabetes in non-obese diabetic (NOD) mice by oral administration of a cholera toxin B subunit-insulin B chain fusion protein vaccine produced in silkworm. Vaccine 25: 1444-1451 (2007). *

• Gong Z, Jin Y, Zhang Y. Oral administration of a cholera toxin B subunit-insulin fusion protein produced in silkworm protects against autoimmune diabetes. J. Biotechnol. 119: 93-105 (2005). *

• Gong Z, Long X, Pan L, Le Y, Liu Q, Wang S, Guo J, Xiao B, Zhou M, Mei D. Cloning, expression, purification and characterization of the cholera toxin B subunit and triple glutamic acid decarboxylase epitopes fusion protein in E. coli. Protein Expr. Purif. 66: 191-197 (2009). *

• Gong ZH, Jin HQ, Jin YF, Zhang YZ. Expression of cholera toxin B subunit and assembly as functional oligomers in silkworm. J. Biochem. Mol. Biol. 38: 717-724 (2005). *

• Gonzalez G, Lage A. Cancer vaccines for hormone/growth factor immune deprivation: a feasible approach for cancer treatment. Curr. Cancer Drug Targets 7: 229-241 (2007).

• Good MF. Towards a blood-stage vaccine for malaria: are we following all the leads? Nat. Rev. Immunol. 1: 117-125 (2001). *

• Good MF. Genetically modified Plasmodium highlights the potential of whole parasite vaccine strategies. Trends Immunol. 26: 295-297 (2005). *

• Goodchild A, Nopper N, Craddock A, Law T, King A, Fanning G, Rivory L, Passioura T. Primary leukocyte screens for innate immune agonists. J. Biomol. Screen. 14: 723-730 (2009).

• Gorbach SL. Probiotics in the third millennium. Dig. Liver Dis. 34 Suppl. 2: S2-S7 (2002).

• Goriely S, Goldman M. From tolerance to autoimmunity: is there a risk in early life vaccination? J. Comp. Pathol. 137 Suppl. 1: S57-S61 (2007). *

• Goudy KS, Wang B, Tisch R. Gene gun-mediated DNA vaccination enhances antigen-specific immunotherapy at a late preclinical stage of type 1 diabetes in nonobese diabetic mice. Clin. Immunol. 129: 49-57 (2008).

• Goulder PJ, Watkins DI. HIV and SIV CTL escape: implications for vaccine design. Nat. Rev. Immunol. 4: 630-640 (2004). *

• Goutagny N, Jiang Z, Tian J, Parroche P, Schickli J, Monks BG, Ulbrandt N, Ji H, Kiener PA, Coyle AJ, Fitzgerald KA. Cell type-specific recognition of human metapneumoviruses (HMPVs) by retinoic acid-inducible gene I (RIG-I) and TLR7 and viral interference of RIG-I ligand recognition by HMPV-B1 phosphoprotein. J. Immunol. Dec 30 [Epub ahead of print] (2009).

• Gowthaman U, Agrewala JN. In silico tools for predicting peptides binding to HLA-class II molecules: more confusion than conclusion. J. Proteome Res. 7: 154-163 (2008). *

• Gradman AH, Pinto R. Vaccination: a novel strategy for inhibiting the renin-angiotensin-aldosterone system. Curr. Hypertens. Rep. 10: 473-479 (2008).

• Gram GJ, Karlsson I, Agger EM, Andersen P, Fomsgaard A. A novel liposome-based adjuvant CAF01 for induction of CD8 cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice. PLoS One 4: e6950 (2009). *

• Grant JF, Iwasawa T, Sinn HW, Siemens DR, Griffith TS, Takacs EB, Ratliff TL. Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-IL-2/IL-12/TNF-alpha combination therapy. Int. J. Cancer 119: 2632-2641 (2006). *

• Grauer O, Poschl P, Lohmeier A, Adema GJ, Bogdahn U. Toll-like receptor triggered dendritic cell maturation and IL-12 secretion are necessary to overcome T-cell inhibition by glioma-associated TGF-beta2. J. Neurooncol. 82: 151-161 (2007). *

• Gravante G, Sconocchia G, Ong SL, Dennison AR, Lloyd DM. Immunoregulatory effects of liver ablation therapies for the treatment of primary and metastatic liver malignancies. Liver Int. 29: 18-24 (2009). *

• Grebely J, Thomas DL, Dore GJ. HCV reinfection studies and the door to vaccine development. J. Hepatol. 51: 628-631 (2009).

• Greenberg HB, Estes MK. Rotaviruses: from pathogenesis to vaccination. Gastroenterology 136: 1939-1951 (2009). *

• Gregor PD, Wolchok JD, Ferrone CR, Buchinshky H, Guevara-Patino JA, Perales MA, Mortazavi F, Bacich D, Heston W, Latouche JB, Sadelain M, Allison JP, Scher HI, Houghton AN. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 22: 1700-1708 (2004).

• Griffin A, Baraho-Hassan D, McSorley SJ. Successful treatment of bacterial infection hinders development of acquired immunity. J. Immunol. 183: 1263-1270 (2009).

• Grogan PM, Katz JS. Inflammatory myopathies. Curr. Treat. Options Neurol. 6: 155-161 (2004).

• Gross K, Combe C, Kruger K, Schattenkirchner M. Arthritis after hepatitis B vaccination. Report of three cases. Scand. J. Rheumatol. 24: 50-52 (1995).

• Gross S, Geldmacher A, Sharav T, Losch F, Walden P. Immunosuppressive mechanisms in cancer: consequences for the development of therapeutic vaccines. Vaccine 27: 3398-3400 (2009). *

• Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, Anders R, Netto G, Getnet D, Bruno TC, Goldberg MV, Pardoll DM, Drake CG. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J. Clin. Invest. 117: 3383-3392 (2007). *

• Grover A, Taylor J, Troudt J, Keyser A, Sommersted K, Schenkel A, Izzo AA. Mycobacterial infection induces the secretion of high-mobility group box 1 protein. Cell. Microbiol. 10: 1390-1404 (2008). *

• Grunebach F, Erndt S, Hantschel M, Heine A, Brossart P. Generation of antigen-specific CTL responses using RGS1 mRNA transfected dendritic cells. Cancer Immunol. Immunother. 57: 1483-1491 (2008). *

• Grunewald J, Tsao ML, Perera R, Dong L, Niessen F, Wen BG, Kubitz DM, Smider VV, Ruf W, Nasoff M, Lerner RA, Schultz PG. Immunochemical termination of self-tolerance. Proc. Natl. Acad. Sci. U.S.A. 105: 11276-11280 (2008). *

• Grygorczuk S, Zajkowska J, Kondrusik M, Pancewicz S, Hermanowska-Szpakowicz T. Guillain-Barre Syndrome and its association with infectious factors. Neurol. Neurochir. Pol. 39: 230-236 (2005).

• Guan Q, Ma Y, Hillman CL, Ma A, Zhou G, Qing G, Peng Z. Development of recombinant vaccines against IL-12/IL-23 p40 and in vivo evaluation of their effects in the downregulation of intestinal inflammation in murine colitis. Vaccine 27: 7096-7104 (2009). *

• Guarner F. Hygiene, microbial diversity and immune regulation. Curr. Opin. Gastroenterol. 23: 667-672 (2007).

• Guarner F, Bourdet-Sicard R, Brandtzaeg P, Gill HS, McGuirk P, van Eden W, Versalovic J, Weinstock JV, Rook GA. Mechanisms of disease: the hygiene hypothesis revisited. Nat. Clin. Pract. Gastroenterol. Hepatol. 3: 275-284 (2006). *

• Gudmundsdotter L, Bernasconi D, Hejdeman B, Sandstrom E, Alaeus A, Lidman K, Ensoli B, Wahren B, Butto S. Cross-clade immune responses to Gag p24 in patients infected with different HIV-1 subtypes and correlation with HLA class I and II alleles. Vaccine 26: 5182-5187 (2008).

• Guerra S, Najera JL, Gonzalez JM, Lopez L, Climent N, Gatell JM, Gallart T, Esteban M. Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J. Virol. 81: 8707-8721 (2007). *

• Guerrettaz LM, Johnson SA, Cambier JC. Acquired hematopoietic stem cell defects determine B-cell repertoire changes associated with aging. Proc. Natl. Acad. Sci. U.S.A. 105: 11898-11902 (2008). *

• Guilherme L, Fae KC, Higa F, Chaves L, Oshiro SE, Freschi de Barros S, Puschel C, Juliano MA, Tanaka AC, Spina G, Kalil J. Towards a vaccine against rheumatic fever. Clin. Dev. Immunol. 13: 125-132 (2006). *

• Guilherme L, Postol E, Barros SF, Higa F, Alencar R, Lastre M, Zayas C, R Puschel C, R Silva W, C Sa-Rocha L, M Sa-Rocha V, Perez O, Kalil J. A vaccine against S. pyogenes: design and experimental immune response. Methods 49: 316-321 (2009).

• Guillonneau C, Mintern JD, Hubert FX, Hurt AC, Besra GS, Porcelli S, Barr IG, Doherty PC, Godfrey DI, Turner SJ. Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc. Natl. Acad. Sci. U.S.A. 106: 3330-3335 (2009). *

• Guinn BA, Kasahara N, Farzaneh F, Habib NA, Norris JS, Deisseroth AB. Recent advances and current challenges in tumor immunology and immunotherapy. Mol. Ther. 15: 1065-1071 (2007).

• Gunther S, Hempel D, Dunkel M, Rother K, Preissner R. SuperHapten: a comprehensive database for small immunogenic compounds. Nucleic Acids Res. 35: D906-D910 (2007). *

• Guo JH, Fan MW, Jia R, Bian Z, Chen Z, Yu F. Expression pattern and level of cytotoxic T lymphocyte-associated antigen-4 targeted anti-caries plasmids in eukaryotic cells. Zhonghua Kou Qiang Yi Xue Za Zhi 41: 272-274 (2006).

• Guo P, Hirano M, Herrin BR, Li J, Yu C, Sadlonova A, Cooper MD. Dual nature of the adaptive immune system in lampreys. Nature 459: 796-801 (2009). *

• Guo X, Barroso L, Becker SM, Lyerly DM, Vedvick TS, Reed SG, Petri WA Jr, Houpt ER. Protection against intestinal amebiasis by a recombinant vaccine is transferable by T cells and mediated by IFN-gamma. Infect. Immun. 77: 3909-3918 (2009). *

• Gupta A, Macrae FA, Gibson PR. Vaccination and screening for infections in patients with inflammatory bowel disease: a survey of Australian gastroenterologists. Intern. Med. J. Oct 22 [Epub ahead of print] (2009). *

• Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 4: 1483-1490 (2006).

• Gupta M, Subramanian V, Yadav J. Immunoproteomic identification of secretory and subcellular protein antigens and functional evaluation of the secretome fraction of Mycobacterium immunogenum, a newly recognized species of the M. chelonae-M. abscessus group. J. Proteome Res. 8: 2319-2330 (2009). *

• Gurfinkel E, Lernoud V. The role of infection and immunity in atherosclerosis. Expert Rev. Cardiovasc. Ther. 4: 131-137 (2006).

• Gurgel R, Bohland A, Vieira S, Oliveira D, Fontes P, Barros V, Ramos M, Dove W, Nakagomi T, Nakagomi O, Correia J, Cunliffe N, Cuevas L. Incidence of rotavirus and all-cause siarrhea in Northeast Brazil following the introduction of a national vaccination program. Gastroenterology 137: 1970-1975 (2009). *

• Gurr W, Shaw M, Li Y, Sherwin R. RegII is a beta-cell protein and autoantigen in diabetes of NOD mice. Diabetes 56: 34-40 (2007). *

• Gururajan M, Jacob J, Pulendran B. Toll-like receptor expression and responsiveness of distinct murine splenic and mucosal B-cell subsets. PLoS ONE 2: e863 (2007). *

• Gustafsson K, Ingelsten M, Bergqvist L, Nystrom J, Andersson B, Karlsson-Parra A. Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine. Cancer Res. 68: 5965-5971 (2008). *

• Guzylack-Piriou L, Piersma S, McCullough K, Summerfield A. Role of natural interferon-producing cells and T lymphocytes in porcine monocyte-derived dendritic cell maturation. Immunology 118: 78-87 (2006). *

• Gyongyosi A, Nagy L. Potential therapeutic use of PPARgamma-programed human monocyte-derived dendritic cells in cancer vaccination therapy. PPAR Res. 2008: 473804 (2008). *

• Haahr S, Hollsberg P. Multiple sclerosis is linked to Epstein-Barr virus infection. Rev. Med. Virol. 16: 297-310 (2006).

• Haase AT. Perils at mucosal front lines for HIV and SIV and their hosts. Nat. Rev. Immunol. 5: 783-792 (2005). *

• Haber P, DeStefano F, Angulo FJ, Iskander J, Shadomy SV, Weintraub E, Chen RT. Guillain-Barre syndrome following influenza vaccination. JAMA 292: 2478-2481 (2004). *

• Habib EE, Aziz M, Kotb M. Genetic polymorphism of folate and methionine metabolizing enzymes and their susceptibility to malignant lymphoma. J. Egypt. Natl. Canc. Inst. 17: 184-192 (2005).

• Hahn BH, Ebling F, Singh RR, Singh RP, Karpouzas G, La Cava A. Cellular and molecular mechanisms of regulation of autoantibody production in lupus. Ann. N. Y. Acad. Sci. 1051: 433-441 (2005). *

• Haining WN, Davies J, Kanzler H, Drury L, Brenn T, Evans J, Angelosanto J, Rivoli S, Russell K, George S, Sims P, Neuberg D, Li X, Kutok J, Morgan J, Wen P, Demetri G, Coffman RL, Nadler LM. CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin. Cancer Res. 14: 5626-5634 (2008). *

• Hall JA, Bouladoux N, Sun CM, Wohlfert EA, Blank RB, Zhu Q, Grigg ME, Berzofsky JA, Belkaid Y. Commensal DNA limits regulatory T cell conversion and is a natural adjuvant of intestinal immune responses. Immunity 29: 637-649 (2008). *

• Halling-Brown M, Sansom CE, Davies M, Titball RW, Moss DS. Are bacterial vaccine antigens T-cell epitope depleted? Trends Immunol. 29: 374-379 (2008). *

• Halsey J. Current and future treatment modalities for Clostridium difficile-associated disease. Am. J. Health Syst. Pharm. 65: 705-715 (2008).

• Halsey NA, Hyman SL; Conference Writing Panel. Measles-mumps-rubella vaccine and autistic spectrum disorder: report from the New Challenges in Childhood Immunizations Conference convened in Oak Brook, Illinois, June 12-13, 2000. Pediatrics 107: e84 (2001). *

• Halwani M, Yebio B, Suntres ZE, Alipour M, Azghani AO, Omri A. Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa. J. Antimicrob. Chemother. 62: 1291-1297 (2008).

• Hamdy S, Molavi O, Ma Z, Haddadi A, Alshamsan A, Gobti Z, Elhasi S, Samuel J, Lavasanifar A. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8(+) T cell-mediated anti-tumor immunity. Vaccine 26: 5046-5057 (2008).

• Han BC, Xia HF, Sun J, Yang Y, Peng JP. Retinoic acid-metabolizing enzyme cytochrome P450 26a1 (cyp26a1) is essential for implantation: functional study of its role in early pregnancy. J. Cell. Physiol. Jan 28 [Epub ahead of print] (2010).

• Han TH, Jin P, Ren J, Slezak S, Marincola FM, Stroncek DF. Evaluation of 3 clinical dendritic cell maturation protocols containing lipopolysaccharide and interferon-gamma. J. Immunother. 32: 399-407 (2009).

• Hance KW, Rogers CJ, Hursting SD, Greiner JW. Combination of physical activity, nutrition, or other metabolic factors and vaccine response. Front. Biosci. 12: 4997-5029 (2007).

• Hansen J, Jensen KT, Follmann F, Agger EM, Theisen M, Andersen P. Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital Chlamydial infection in a mouse model. J. Infect. Dis. 198: 758-767 (2008). *

• Hanslik T, Vaillant JN, Audrain L, Jubault V, Prinseau J, Baglin A, Flahault A. Systemic lupus erythematosus and risk of hepatitis B vaccination: from level of evidence to prescription. Rev. Med. Interne. 21: 785-790 (2000).

• Hanslik T, Valleron AJ, Flahault A. Risk-benefit assessment of hepatitis B vaccination in France, 2005. Rev. Med. Interne. 27: 40-45 (2006).

• Hanson LA, Silfverdal SA. Vaccination immunology. Scand. J. Infect. Dis. 40: 696-701 (2008).

• Hansson L, Abdalla AO, Moshfegh A, Choudhury A, Rabbani H, Nilsson B, Osterborg A, Mellstedt H. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin. Cancer Res. 13: 1503-1510 (2007). *

• Hao S, Bai O, Li F, Yuan J, Laferte S, Xiang J. Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity. Immunology 120: 90-102 (2007). *

• Harding A. Fine-tuning our defenses. The Scientist May, 2007 (http://www.the-scientist.com/2007/05/01/s56/1/) (2007).

• Harrington LE, Janowski KM, Oliver JR, Zajac AJ, Weaver CT. Memory CD4 T cells emerge from effector T-cell progenitors. Nature 452: 356-360 (2008). *

• Harrison LC. Vaccination against self to prevent autoimmune disease: the type 1 diabetes model. Immunol. Cell Biol. 86: 139-145 (2008). *

• Harrison LC. The prospect of vaccination to prevent type 1 diabetes. Hum. Vaccin. 1: 143-150 (2005).

• Hartoonian C, Ebtekar M, Soleimanjahi H, Karami A, Mahdavi M, Rastgoo N, Azadmanesh K. Effect of immunological adjuvants: GM-CSF (granulocyte-monocyte colony stimulating factor) and IL-23 (interleukin-23) on immune responses generated against hepatitis C virus core DNA vaccine. Cytokine 46: 43-50 (2009).

• Harty JT, Badovinac VP. Shaping and reshaping CD8+ T-cell memory. Nat. Rev. Immunol. 8: 107-119 (2008). *

• Hashizume T, Togawa A, Nochi T, Igarashi O, Kweon MN, Kiyono H, Yamamoto M. Peyer's patches are required for intestinal IgA responses to Salmonella. Infect. Immun. 76: 927-934 (2008). *

• Hasselberg A, Ekman L, Yrlid LF, Schon K, Lycke NY. ADP-ribosylation controls the outcome of tolerance or enhanced priming following mucosal immunization. J. Immunol. Feb 8 [Epub ahead of print] (2010).

• Hattotuwagama CK, Doytchinova IA, Flower DR. Toward the prediction of class I and II mouse major histocompatibility complex-peptide-binding affinity: in silico bioinformatic step-by-step guide using quantitative structure-activity relationships. Methods Mol. Biol. 409: 227-245 (2007).

• Havarinasab S, Hultman P. Alteration of the spontaneous systemic autoimmune disease in (NZB x NZW)F1 mice by treatment with thimerosal (ethyl mercury). Toxicol. Appl. Pharmacol. 214: 43-54 (2006). *

• Havrdova E, Horakova D, Kovarova I, Krasulova E. Future possibilities of the multiple sclerosis treatment. Cas. Lek. Cesk. 144: 663-665 (2005).

• Hayashi A, Wakita H, Yoshikawa T, Nakanishi T, Tsutsumi Y, Mayumi T, Mukai Y, Yoshioka Y, Okada N, Nakagawa S. A strategy for efficient cross-presentation of CTL-epitope peptides leading to enhanced induction of in vivo tumor immunity. J. Control Release 117: 11-19 (2007).

• Hayashi D, Takii T, Fujiwara N, Fujita Y, Yano I, Yamamoto S, Kondo M, Yasuda E, Inagaki E, Kanai K, Fujiwara A, Kawarazaki A, Chiba T, Onozaki K. Comparable studies of immunostimulating activities in vitro among Mycobacterium bovis bacillus Calmette-Guerin (BCG) substrains. FEMS Immunol. Med. Microbiol. 56: 116-128 (2009). *

• Hayashi T, Raz E. TLR9-based immunotherapy for allergic disease. Am. J. Med. 119: 897.e1-6 (2006). *

• Hayes CE, Nashold FE, Spach KM, Pedersen LB. The immunological functions of the vitamin D endocrine system. Cell. Mol. Biol. (Noisy-le-grand) 49: 277-300 (2003).

• Haynes L, Maue AC. Effects of aging on T cell function. Curr. Opin. Immunol. 21: 414-417 (2009).

• Hazebrouck S, Przybylski-Nicaise L, Ah-Leung S, Adel-Patient K, Corthier G, Langella P, Wal JM. Influence of the route of administration on immunomodulatory properties of bovine beta-lactoglobulin-producing Lactobacillus casei. Vaccine 27: 5800-5805 (2009).

• Hazeldine J, Arlt W, Lord JM. Dehydroepiandrosterone as a regulator of immune cell function. J. Steroid Biochem. Mol. Biol. Jan 7 [Epub ahead of print] (2010).

• He B, Xu W, Santini PA, Polydorides AD, Chiu A, Estrella J, Shan M, Chadburn A, Villanacci V, Plebani A, Knowles DM, Rescigno M, Cerutti A. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 26: 812-826 (2007). *

• He S, Cao Q, Yoneyama H, Ge H, Zhang Y, Zhang Y. MIP-3alpha and MIP-1alpha rapidly mobilize dendritic cell precursors into the peripheral blood. J. Leukoc. Biol. 84: 1549-1556 (2008).

• Heathcote EJ. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S294-S302 (2004). *

• Hegde GV, Meyers-Clark E, Joshi SS, Sanderson SD. A conformationally-biased, response-selective agonist of C5a acts as a molecular adjuvant by modulating antigen processing and presentation activities of human dendritic cells. Int. Immunopharmacol. 8: 819-827 (2008).

• Heijstek MW, Pileggi C, Zonneveld-Huijssoon E, Armbrust W, Hoppenreijs EP, Uiterwaal CS, Kuis W, Wulffraat NM. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann. Rheum. Dis. 66: 1384-1387 (2007). *

• Heiny AT, Miotto O, Srinivasan KN, Khan AM, Zhang GL, Brusic V, Tan TW, August JT. Evolutionarily conserved protein sequences of influenza A viruses, avian and human, as vaccine targets. PLoS ONE 2: e1190 (2007). *

• Hellings N, Raus J, Stinissen P. T-cell vaccination in multiple sclerosis: update on clinical application and mode of action. Autoimmun. Rev. 3: 267-275 (2004).

• Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745 (2000). *

• Herbst-Kralovetz M, Pyles R. Toll-like receptors, innate immunity and HSV pathogenesis. Herpes 13: 37-41 (2006). *

• Herd KA, Mahalingam S, Mackay IM, Nissen M, Sloots TP, Tindle RW. Cytotoxic T-lymphocyte epitope vaccination protects against human metapneumovirus infection and disease in mice. J. Virol. 80: 2034-2044 (2006). *

• Hermon-Taylor J. Mycobacterium avium subspecies paratuberculosis in the causation of Crohn's disease. World J. Gastroenterol. 6: 630-632 (2000). *

• Hermon-Taylor J, Bull TJ, Sheridan JM, Cheng J, Stellakis ML, Sumar N. Causation of Crohn's disease by Mycobacterium avium subspecies paratuberculosis. Can. J. Gastroenterol. 14: 521-539 (2000). *

• Hernan MA, Alonso A, Hernandez-Diaz S. Tetanus vaccination and risk of multiple sclerosis: a systematic review. Neurology 67: 212-215 (2006).

• Hernan MA, Jick SS. Rejoinder on "hepatitis B vaccination and multiple sclerosis the jury is still out". Pharmacoepidemiol. Drug Saf. 16: 707-708 (2007).

• Herrera JL, Fernandez-Montesinos R, Gonzalez-Rey E, Delgado M, Pozo D. Protective role for plasmid DNA-mediated VIP gene transfer in non-obese diabetic mice. Ann. N. Y. Acad. Sci. 1070: 337-341 (2006). *

• Herrington CS, Douek DC. Infection and disease: cause and cure. J. Pathol. 208: 131-133 (2006). *

• Hervas-Stubbs S, Majlessi L, Simsova M, Morova J, Rojas MJ, Nouze C, Brodin P, Sebo P, Leclerc C. High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection. Infect. Immun. 74: 3396-3407 (2006). *

• Heuking S, Iannitelli A, Di Stefano A, Borchard G. Toll-like receptor-2 agonist functionalized biopolymer for mucosal vaccination. Int. J. Pharm. 381: 97-105 (2009).

• Higgins PD, Fontana RJ. Liver transplantation in acute liver failure. Panminerva. Med. 45: 85-94 (2003).

• Higgins SC, Jarnicki AG, Lavelle EC, Mills KH. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J. Immunol. 177: 7980-7989 (2006). *

• Hill AV. Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat. Rev. Immunol. 6: 21-32 (2006). *

• Hiltunen M, Lonnrot M, Hyoty H. Immunisation and type 1 diabetes mellitus: is there a link? Drug Saf. 20: 207-212 (1999).

• Hiss JA, Bredenbeck A, Losch FO, Wrede P, Walden P, Schneider G. Design of MHC I stabilizing peptides by agent-based exploration of sequence space. Protein Eng. Des. Sel. 20: 99-108 (2007). *

• Ho PP, Fontoura P, Platten M, Sobel RA, Devoss JJ, Lee LY, Kidd BA, Tomooka BH, Capers J, Agrawal A, Gupta R, Zernik J, Yee MK, Lee BJ, Garren H, Robinson WH, Steinman L. A suppressive oligodeoxynucleotide enhances the efficacy of myelin cocktail/IL-4-tolerizing DNA vaccination and treats autoimmune disease. J. Immunol. 175: 6226-6234 (2005). *

• Ho PP, Higgins JP, Kidd BA, Tomooka B, Digennaro C, Lee LY, de Vegvar HE, Steinman L, Robinson WH. Tolerizing DNA vaccines for autoimmune arthritis. Autoimmunity 39: 675-682 (2006).

• Hodge JW, Chakraborty M, Kudo-Saito C, Garnett CT, Schlom J. Multiple costimulatory modalities enhance CTL avidity. J. Immunol. 174: 5994-6004 (2005). *

• Hodi FS. Cytotoxic T-lymphocyte associated antigen-4. Clin. Cancer Res. 13: 5238-5242 (2007). *

• Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl. Acad. Sci. U.S.A. 105: 3005-3010 (2008). *

• Hodi FS, Dranoff G. Combinatorial cancer immunotherapy. Adv. Immunol. 90C: 341-368 (2006).

• Hoehlig K, Lampropoulou V, Roch T, Neves P, Calderon-Gomez E, Anderton SM, Steinhoff U, Fillatreau S. Chapter 1. Immune regulation by B cells and antibodies a view towards the clinic. Adv. Immunol. 98: 1-38 (2008).

• Hofer J, Hofer S, Zlamy M, Jeller V, Koppelstaetter C, Brandstatter A, Kern H, Kohle J, Zimmerhackl LB, Prelog M. Elevated proportions of recent thymic emigrants in children and adolescents with type 1 diabetes. Rejuvenation Res. 12: 311-320 (2009).

• Hogg KG, Kumkate S, Mountford AP. IL-10 regulates early IL-12-mediated immune responses induced by the radiation-attenuated schistosome vaccine. Int. Immunol. 15: 1451-1459 (2003). *

• Hohler T, Stradmann-Bellinghausen B, Starke R, Sanger R, Victor A, Rittner C, Schneider PM. C4A deficiency and nonresponse to hepatitis B vaccination. J. Hepatol. 37: 387-392 (2002). *

• Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat. Rev. Immunol. 8: 218-230 (2008). *

• Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat. Med. 10 Suppl. 1: S45-S53 (2005). *

• Holtfreter S, Nguyen TT, Wertheim H, Steil L, Kusch H, Truong QP, Engelmann S, Hecker M, Volker U, van Belkum A, Broker BM. Human immune proteome in experimental colonization with Staphylococcus aureus. Clin. Vaccine Immunol. 16: 1607-1614 (2009).

• Holvast A, De Haan A, Van Assen S, Stegeman CA, Huitema MG, Huckriede A, Benne CA, Westra J, Palache A, Wilschut J, Kallenberg CG, Bijl M. Cell-mediated immune responses to influenza vaccination in Wegener's granulomatosis. Ann. Rheum. Dis. Jul 12 [Epub ahead of print] (2009).

• Holvast B, Huckriede A, Kallenberg CG, Bijl M. Influenza vaccination in systemic lupus erythematosus: safe and protective? Autoimmun. Rev. 6: 300-305 (2007).

• Homma S, Sagawa Y, Ito M, Ohno T, Toda G. Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses. Clin. Exp. Immunol. 144: 41-47 (2006). *

• Hong J, Zang YC, Nie H, Zhang JZ. CD4+ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 103: 5024-5029 (2006). *

• Hong R, Agrawal S, Gollapudi S, Gupta S. Impaired pneumovax-23-induced monocyte-derived cytokine production in patients with common variable immunodeficiency. J. Clin. Immunol. Feb 23 [Epub ahead of print] (2010).

• Hopkins RJ, Morris JG Jr. Helicobacter pylori: the missing link in perspective. Am. J. Med. 97: 265-277 (1994).

• Horlock C, Stott B, Dyson J, Ogg G, McPherson T, Jones L, Sewell A, Wooldridge L, Cole D, Stebbing J, Savage P. ELISPOT and functional T cell analyses using HLA mono-specific target cells. J. Immunol. Methods 350: 150-160 (2009). *

• Horowitz A, Li X, Poles MA, Tsuji M. Use of immobilized HLA-A2:Ig dimeric proteins to determine the level of epitope-specific, HLA-restricted CD8(+) T-cell response. Scand. J. Immunol. 70: 415-422 (2009). *

• Horspool JH, Perrin PJ, Woodcock JB, Cox JH, King CL, June CH, Harlan DM, St Louis DC, Lee KP. Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4. J. Immunol. 160: 2706-2714 (1998). *

• Houghton M. The long and winding road leading to the identification of the hepatitis C virus. J. Hepatol. 51: 939-948 (2009).

• Housley WJ, O'Conor CA, Nichols F, Puddington L, Lingenheld EG, Zhu L, Clark RB. PPARgamma regulates retinoic acid-mediated DC induction of Tregs. J. Leukoc. Biol. 86: 293-301 (2009). *

• Howard WA, Gibson KL, Dunn-Walters DK. Antibody quality in old age. Rejuvenation Res. 9: 117-125 (2006).

• Howel D, Fischbacher CM, Bhopal RS, Gray J, Metcalf JV, James OF. An exploratory population-based case-control study of primary biliary cirrhosis. Hepatology 31: 1055-1060 (2000). *

• Howitz M, Krause TG, Simonsen JB, Hoffmann S, Frisch M, Nielsen NM, Robbins J, Schneerson R, Molbak K, Miller MA. Lack of association between group B meningococcal disease and autoimmune disease. Clin. Infect. Dis. 45: 1327-1334 (2007). *

• Hryniewicz A, Boasso A, Edghill-Smith Y, Vaccari M, Fuchs D, Venzon D, Nacsa J, Betts MR, Tsai WP, Heraud JM, Beer B, Blanset D, Chougnet C, Lowy I, Shearer GM, Franchini G. CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood 108: 3834-3842 (2006). *

• Hsieh YF, Liu HW, Hsu TC, Wei JC, Shih CM, Krause PJ, Tsay GJ. Serum reactivity against Borrelia burgdorferi OspA in rheumatoid arthritis. Clin. Vaccine Immunol. 14: 1437-1441 (2007). *

• Hsu HY, Chang MH, Ho HN, Hsieh RP, Lee SD, Chen DS, Lee CY, Hsieh KH. Association of HLA-DR14-DR52 with low responsiveness to hepatitis B vaccine in Chinese residents in Taiwan. Vaccine 11: 1437-1440 (1993).

• Huan J, Culbertson N, Spencer L, Bartholomew R, Burrows GG, Chou YK, Bourdette D, Ziegler SF, Offner H, Vandenbark AA. Decreased FOXP3 levels in multiple sclerosis patients. J. Neurosci. Res. 81: 45-52 (2005). *

• Huang H, Ostroff GR, Lee CK, Wang JP, Specht CA, Levitz SM. Distinct patterns of dendritic cell cytokine release stimulated by fungal beta-glucans and Toll-like receptor agonists. Infect. Immun. 77: 1774-1781 (2009). *

• Hudecek M, Bartsch K, Tschiedel S, Niederwieser D. Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation. Dtsch. Med. Wochenschr. 133: 1511-1516 (2008).

• Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Tang J, McDonald W, Song L, Evans RK, Umlauf S, Tussey L, Powell TJ. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26: 201-214 (2008).

• Hull M, Berger M, Heneka M. Disease-modifying therapies in Alzheimer's disease: how far have we come? Drugs 66: 2075-2093 (2006).

• Hurtado P, Au Peh C. LL-37 promotes rapid sensing of CpG oligodeoxynucleotides by B lymphocytes and plasmacytoid dendritic cells. J. Immunol. Dec 30 [Epub ahead of print] (2009).

• Hutton DW, So SK, Brandeau ML. Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China. Hepatology 51: 405-414 (2010).

• Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Childhood vaccination and type 1 diabetes. N. Engl. J. Med. 350: 1398-1404 (2004). *

• Hwang SA, Actor JK. Lactoferrin modulation of BCG-infected dendritic cell functions. Int. Immunol. 21: 1185-1197 (2009).

• Hyser JM, Estes MK. Rotavirus vaccines and pathogenesis: 2008. Curr. Opin. Gastroenterol. 25: 36-43 (2009).

• Hyun YM, Lefort CT, Kim M. Leukocyte integrins and their ligand interactions. Immunol. Res. Jan 29 [Epub ahead of print] (2009). *

• Iacobelli-Martinez M, Nemerow GR. Preferential activation of Toll-like receptor nine (TLR9) by CD46-utilizing adenoviruses. J. Virol. 81: 1305-1312 (2007). *

• Ichinohe T, Iwasaki A, Hasegawa H. Innate sensors of influenza virus: clues to developing better intranasal vaccines. Expert Rev. Vaccines 7: 1435-1445 (2008).

• Iijima H, Takahashi I, Kiyono H. Mucosal immune network in the gut for the control of infectious diseases. Rev. Med. Virol. 11: 117-133 (2001).

• Ingale S, Wolfert MA, Buskas T, Boons GJ. Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors. Chembiochem. 10: 455-463 (2009). *

• Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, Fukase K, Inamura S, Kusumoto S, Hashimoto M, Foster SJ, Moran AP, Fernandez-Luna JL, Nunez G. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J. Biol. Chem. 278: 5509-5512 (2003). *

• Inoue J, Aramaki Y. Toll-like receptor-9 expression induced by tape-stripping triggers on effective immune response with CpG-oligodeoxynucleotides. Vaccine 25: 1007-1013 (2007). *

• Inoue K, Shiota S, Yamada K, Gotoh K, Suganuma M, Fujioka T, Ahmed K, Iha H, Nishizono A. Evaluation of a new tumor necrosis factor-alpha-inducing membrane protein of Helicobacter pylori as a prophylactic vaccine antigen. Helicobacter 14: 135-143 (2009). *

• Inoue Y. Immunological aspects of herpetic stromal keratitis. Semin. Ophthalmol. 23: 221-227 (2008).

• Ioannou Y, Isenberg DA. Immunisation of patients with systemic lupus erythematosus: the current state of play. Lupus 8: 497-501 (1999).

• Irie J, Wu Y, Kachapati K, Mittler RS, Ridgway WM. Modulating protective and pathogenic CD4+ subsets via CD137 in type 1 diabetes. Diabetes 56:186-196 (2007). *

• Irving PM, Gibson PR. Infections and IBD. Nat. Clin. Pract. Gastroenterol. Hepatol. 5: 18-27 (2008). *

• Ishii KJ, Akira S. Toll or Toll-free adjuvant path toward the optimal vaccine development. J. Clin. Immunol. 27: 363-371 (2007). *

• Isolauri E. Probiotics in human disease. Am. J. Clin. Nutr. 73: 1142S-1146S (2001). *

• Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Adjuvants and autoimmunity. Lupus 18: 1217-1225 (2009).

• Itoh K, Yamada A. Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci. 97: 970-976 (2006). *

• Itoh T, Celis E. Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice. J. Immunother. 28: 430-437 (2005).

• Iwami S, Takeuchi Y, Iwamoto K, Naruo Y, Yasukawa M. A mathematical design of vector vaccine against autoimmune disease. J. Theor. Biol. 256: 382-392 (2009). *

• Iweala OI, Smith DW, Matharu KS, Sada-Ovalle I, Nguyen DD, Dekruyff RH, Umetsu DT, Behar SM, Nagler CR. Vaccine-induced antibody isotypes are skewed by impaired CD4 T cell and invariant NKT cell effector responses in MyD88-deficient mice. J. Immunol. 183: 2252-2260 (2009).

• Jackson DC, Lau YF, Le T, Suhrbier A, Deliyannis G, Cheers C, Smith C, Zeng W, Brown LE. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc. Natl. Acad. Sci. U.S.A. 101: 15440-15445 (2004). *

• Jacob JB, Kong YC, Nalbantoglu I, Snower DP, Wei WZ. Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity. J. Immunol. 182: 5873-5881 (2009).

• Jacobi D, Maillot F, Hommet C, Arsene S, Cottier JP, Lamisse F, Guillevin L. P-ANCA cranial pachymeningitis: a case report. Clin. Rheumatol. 24: 174-177 (2005).

• Jacobson IG, Smith TC, Smith B, Wells TS, Reed RJ, Ryan MA. US military service members vaccinated against smallpox in 2003 and 2004 experience a slightly higher risk of hospitalization postvaccination. Vaccine 26: 4048-4056 (2008).

• Jadali Z, Sanati MH. The autoimmune diseases manifested by production of autoantibodies: the autoantigens identified by random peptide library. Iran. J. Allergy Asthma Immunol. 7: 115-131 (2008).

• Jager E, Karbach J, Gnjatic S, Jager D, Maeurer M, Atmaca A, Arand M, Skipper J, Stockert E, Chen YT, Old LJ, Knuth A. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. Cancer Immun. 2: 12 (2002). *

• Jahrsdorfer B, Vollmer A, Blackwell SE, Maier J, Sontheimer K, Beyer T, Mandel B, Lunov O, Tron K, Nienhaus GU, Simmet T, Debatin KM, Weiner GJ, Fabricius D. Granzyme B produced by human plasmacytoid dendritic cells suppresses T cell expansion. Blood Dec 3 [Epub ahead of print] (2009). *

• Jain M, Thomson AH. Palivizumab, pneumococcal and influenza vaccination in cystic fibrosis. J. R. Soc. Med. 102 Suppl. 1: 23-28 (2009).

• Jaiswal S, Pearson T, Friberg H, Shultz LD, Greiner DL, Rothman AL, Mathew A. Dengue virus infection and virus-specific HLA-A2 restricted immune responses in humanized NOD-scid IL2rgamma null mice. PLoS One. 4: e7251 (2009). *

• James CM, Bartlett EJ, Mansfield JP, Cull VS. Interferon subtype gene therapy for regulating cytomegalovirus disease. Methods Mol. Med. 116: 207-219 (2005).

• Jandus C, Bioley G, Dojcinovic D, Derre L, Baitsch L, Wieckowski S, Rufer N, Kwok WW, Tiercy JM, Luescher IF, Speiser DE, Romero P. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. Cancer Res. 69: 8085-8093 (2009). *

• Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ, Old LJ, Romero P, Hoos A, Davis MM. "MIATA" - minimal information about T cell assays. Immunity 31: 527-528 (2009). *

• Jang MH, Kweon MN, Iwatani K, Yamamoto M, Terahara K, Sasakawa C, Suzuki T, Nochi T, Yokota Y, Rennert PD, Hiroi T, Tamagawa H, Iijima H, Kunisawa J, Yuki Y, Kiyono H. Intestinal villous M cells: an antigen entry site in the mucosal epithelium. Proc. Natl. Acad. Sci. U.S.A. 101: 6110-6115 (2004). *

• Janovska L, Vetchy D, Rabiskova M. New systems for colonic drug targeting. Ceska. Slov. Farm. 55: 203-209 (2006).

• Jansen CA, van Baarle D, Miedema F. HIV-specific CD4(+) T cells and viremia: who's in control? Trends Immunol. 27: 119-124 (2006). *

• Jar AM, Osorio FA, Lopez OJ. Mouse x pig chimeric antibodies expressed in Baculovirus retain the same properties of their parent antibodies. Biotechnol. Prog. 25: 516-523 (2009).

• Jariwala SP, Fodeman J, Hudes G, Ahuja K, Rosenstreich D. Functional antibody deficiency in a patient with type I Gaucher disease. J. Inherit. Metab. Dis. Short Report #103 (2008). *

• Jarnicki AG, Conroy H, Brereton C, Donnelly G, Toomey D, Walsh K, Sweeney C, Leavy O, Fletcher J, Lavelle EC, Dunne P, Mills KH. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J. Immunol. 180: 3797-3806 (2008). *

• Jaskowski TD, Litwin CM, Hill HR. Analysis of serum antibodies in patients suspected of having inflammatory bowel disease. Clin. Vaccine Immunol. 13: 655-660 (2006). *

• Jason J, Archibald LK, Nwanyanwu OC, Sowell AL, Buchanan I, Larned J, Bell M, Kazembe PN, Dobbie H, Jarvis WR. Vitamin A levels and immunity in humans. Clin. Diagn. Lab. Immunol. 9: 616-621 (2002). *

• Javid B, MacAry PA, Lehner PJ. Structure and function: heat shock proteins and adaptive immunity. J. Immunol. 179: 2035-2040 (2007). *

• Jeevan A, Bonilla DL, McMurray DN. Expression of interferon-gamma and tumour necrosis factor-alpha messenger RNA does not correlate with protection in guinea pigs challenged with virulent Mycobacterium tuberculosis by the respiratory route. Immunology 128: e296-e305 (2009).

• Jelleyman T, Ure A. Attitudes to immunisation: a survey of health professionals in the Rotorua District. N. Z. Med. J. 117: U769 (2004).

• Jenkins MC. Present and future control of cryptosporidiosis in humans and animals. Expert Rev. Vaccines 3: 669-671 (2004).

• Jeong SH, Lee HS. Hepatitis A: clinical manifestations and management. Intervirology 53: 15-19 (2010).

• Jerala R, Porro M. Endotoxin neutralizing peptides. Curr. Top. Med. Chem. 4: 1173-1184 (2004).

• Jia J, Cui J, Liu X, Han J, Yang S, Wei Y, Chen Y. Genome-scale search of tumor-specific antigens by collective analysis of mutations, expressions and T-cell recognition. Mol. Immunol. 46: 1824-1829 (2009). *

• Jiang HQ, Thurnheer MC, Zuercher AW, Boiko NV, Bos NA, Cebra JJ. Interactions of commensal gut microbes with subsets of B- and T-cells in the murine host. Vaccine 22: 805-811 (2004). *

• Jin HT, Youn JI, Choi SY, Seo SH, Park SH, Song MY, Yang SH, Sung YC. Adenovirus-mediated gene transfer of interleukin-23 shows prophylactic but not therapeutic antitumor effects. Cancer Gene Ther. 15: 693-702 (2008).

• Jin L, Zhu A, Wang Y, Chen Q, Xiong Q, Li J, Sun Y, Li T, Cao R, Wu J, Liu J. A Th1-recognized peptide P277, when tandemly repeated, enhances a Th2 immune response toward effective vaccines against autoimmune diabetes in nonobese diabetic mice. J. Immunol. 180: 58-63 (2008). *

• Jinushi M, Hodi FS, Dranoff G. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc. Natl. Acad. Sci. U.S.A. 103: 9190-9195 (2007). *

• Jinushi M, Nakazaki Y, Dougan M, Carrasco DR, Mihm M, Dranoff G. MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. J. Clin. Invest. 117: 1902-1913 (2007). *

• Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J, Neuberg D, Anderson KC, Carrasco DR, Dranoff G. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc. Natl. Acad. Sci. U.S.A. 105: 1285-1290 (2008). *

• Johansen HK. Potential of preventing Pseudomonas aeruginosa lung infections in cystic fibrosis patients: experimental studies in animals. APMIS Suppl. 63: 5-42 (1996).

• Johansen HK, Gotzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst. Rev. 4: CD001399 (2008).

• Johansen P, Senti G, Martinez Gomez JM, Storni T, von Beust BR, Wuthrich B, Bot A, Kundig TM. Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clin. Exp. Allergy 35: 1591-1598 (2005). *

• Johansson C, Ahlstedt I, Furubacka S, Johnsson E, Agace WW, Quiding-Jarbrink M. Differential expression of chemokine receptors on human IgA+ and IgG+ B cells. Clin. Exp. Immunol. 141: 279-287 (2005). *

• Johansson C, Kelsall BL. Phenotype and function of intestinal dendritic cells. Semin. Immunol. 17: 284-294 (2005). *

• Johansson J, Hellman L. Modifications increasing the efficacy of recombinant vaccines; marked increase in antibody titers with moderately repetitive variants of a therapeutic allergy vaccine. Vaccine 25: 1676-1682 (2007). *

• John B, Klein I, Crispe IN. Immune role of hepatic TLR-4 revealed by orthotopic mouse liver transplantation. Hepatology 45: 178-186 (2007). *

• Johnson BD, Jing W, Orentas RJ. CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. J. Immunother. 30: 203-214 (2007).

• Johnson S, Bourges D, Wijburg O, Strugnell RA, Lew AM. Milk IgA responses are augmented by antigen delivery to the mucosal addressin cellular adhesion molecule 1. Vaccine 24: 5552-5558 (2006). *

• Johnston D, Zaidi B, Bystryn JC. TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines. Cancer Immunol. Immunother. 56: 1133-1141 (2007). *

• Johnston RJ, Poholek AC, Ditoro D, Yusuf I, Eto D, Barnett B, Dent AL, Craft J, Crotty S. Bcl6 and blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 325: 1006-1010 (2009). *

• Jones DE, Palmer JM, Burt AD, Walker C, Robe AJ, Kirby JA. Bacterial motif DNA as an adjuvant for the breakdown of immune self-tolerance to pyruvate dehydrogenase complex. Hepatology 36: 679-686 (2002). *

• Jonsson G, Oxelius VA, Truedsson L, Braconier JH, Sturfelt G, Sjoholm AG. Homozygosity for the IgG2 subclass allotype G2M(n) protects against severe infection in hereditary C2 deficiency. J. Immunol. 177: 722-728 (2006). *

• Jonville-Bera AP, Autret E, Galy-Eyraud C, Hessel L. Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French Regional Pharmacovigilance Centres and Pasteur-Merieux Serums et Vaccins. Pediatr. Infect. Dis. J. 15: 44-48 (1996).

• Jovanova-Nesic K, Koruga D, Kojic D, Kostic V, Rakic L, Shoenfeld Y. Choroid plexus connexin 43 expression and gap junction flexibility are associated with clinical features of acute EAE. Ann. N. Y. Acad. Sci. 1173: 75-82 (2009). *

• Joyee AG, Yang X. Role of Toll-like receptors in immune responses to chlamydial infections. Curr. Pharm. Des. 14: 593-600 (2008).

• Juji T, Tanaka S. RANKL vaccination. Nippon Rinsho 63: 1666-1670 (2005).

• Kaba SA, Brando C, Guo Q, Mittelholzer C, Raman S, Tropel D, Aebi U, Burkhard P, Lanar DE. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. J. Immunol. 183: 7268-7277 (2009).

• Kabir S. The current status of Helicobacter pylori vaccines: a review. Helicobacter 12: 89-102 (2007). *

• Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2: 251-262 (2002).

• Kalfa VC, Roberts RL, Stiehm ER. The syndrome of chronic mucocutaneous candidiasis with selective antibody deficiency. Ann. Allergy Asthma Immunol. 90: 259-264 (2003).

• Kalia V, Sarkar S, Subramaniam S, Haining WN, Smith KA, Ahmed R. Prolonged interleukin-2Ralpha expression on virus-specific CD8(+) T cells favors terminal-effector differentiation in vivo. Immunity Jan 20 [Epub ahead of print] (2010).

• Kalinski P, Vieira PL, Schuitemaker JH, de Jong EC, Kapsenberg ML. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 97: 3466-3469 (2001). *

• Kalli KR, Krco CJ, Hartmann LC, Goodman K, Maurer MJ, Yu C, Johnson EM, Erskine CL, Disis ML, Wettstein PJ, Fikes JD, Beebe M, Ishioka G, Knutson KL. An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer. Cancer Res. 68: 4893-4901 (2008). *

• Kalyuzhny AE. ELISPOT assay on membrane microplates. Methods Mol. Biol. 536: 355-365 (2009).

• Kamal SM, El Sayed Khalifa K. Immune modulation by helminthic infections: worms and viral infections. Parasite Immunol. 28: 483-496 (2006). *

• Kamath AT, Rochat AF, Christensen D, Agger EM, Andersen P, Lambert PH, Siegrist CA. A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells. PLoS ONE 4: e5771 (2009). *

• Kamath AT, Rochat AF, Valenti MP, Agger EM, Lingnau K, Andersen P, Lambert PH, Siegrist CA. Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant. PLoS ONE 3: e3683 (2008). *

• Kamath AT, Valenti MP, Rochat AF, Agger EM, Lingnau K, von Gabain A, Andersen P, Lambert PH, Siegrist CA. Protective anti-mycobacterial T cell responses through exquisite in vivo activation of vaccine-targeted dendritic cells. Eur. J. Immunol. 38: 1247-1256 (2008). *

• Kanai T, Nemoto Y, Tomita T, Totsuka T, Watanabe M, Hibi T. Persistent retention of colitogenic CD4+ memory T cells causes inflammatory bowel diseases to become intractable. Inflamm. Bowel Dis. 15: 926-934 (2009). *

• Kanduc D. Quantifying the possible cross-reactivity risk of an HPV16 vaccine. J. Exp. Ther. Oncol. 8: 65-76 (2009).

• Kang Y, Xu L, Wang B, Chen A, Zheng G. Cutting edge: immunosuppressant as adjuvant for tolerogenic immunization. J. Immunol. 180: 5172-5176 (2008). *

• Kang Y, Zhao J, Liu Y, Chen A, Zheng G, Yu Y, Mi J, Zou Q, Wang B. FK506 as an adjuvant of tolerogenic DNA vaccination for the prevention of experimental autoimmune encephalomyelitis. J. Gene Med. 11: 1064-1070 (2009).

• Kangueane P, Sakharkar MK. T-Epitope Designer: a HLA-peptide binding prediction server. Bioinformation 1: 21-24 (2005). *

• Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 13: 552-559 (2007). *

• Karbach J, Gnjatic S, Bender A, Neumann A, Weidmann E, Yuan J, Ferrara CA, Hoffmann E, Old LJ, Altorki NK, Jager E. Tumor-reactive CD8(+) T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and montanide(R) ISA-51: association with survival. Int. J. Cancer 126: 909-918 (2009). *

• Karlsson EA, Sheridan PA, Beck MA. Diet-induced obesity impairs the T cell memory response to influenza virus infection. J. Immunol. Feb 19 [Epub ahead of print] (2010).

• Karyampudi L, Formicola C, Erskine CL, Maurer MJ, Ingle JN, Krco CJ, Wettstein PJ, Kalli KR, Fikes JD, Beebe M, Hartmann LC, Disis ML, Ferrone S, Ishioka G, Knutson KL. A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102. Clin. Cancer Res. Jan 26 [Epub ahead of print] (2010). *

• Katano M, Morisaki T, Koga K, Nakamura M, Onishi H, Matsumoto K, Tasaki A, Nakashima H, Akiyoshi T, Nakamura M. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas. Anticancer Res. 25: 3771-3776 (2005).

• Kato T, Kiire A, Yamagata H, Yamanaka H, Kamatani N. Hypersensitivity reaction against influenza vaccine in a patient with rheumatoid arthritis after the initiation of etanercept injections. Mod. Rheumatol. 16: 327-329 (2006). *

• Katsara M, Matsoukas J, Deraos G, Apostolopoulos V. Towards immunotherapeutic drugs and vaccines against multiple sclerosis. Acta Biochim. Biophys. Sin. (Shanghai) 40: 636-642 (2008).

• Katsara M, Minigo G, Plebanski M, Apostolopoulos V. The good, the bad and the ugly: how altered peptide ligands modulate immunity. Expert Opin. Biol. Ther. 8: 1873-1884 (2008).

• Katsara M, Tselios T, Deraos S, Deraos G, Matsoukas MT, Lazoura E, Matsoukas J, Apostolopoulos V. Round and round we go: cyclic peptides in disease. Curr. Med. Chem. 13: 2221-2232 (2006).

• Katsara M, Yuriev E, Ramsland PA, Deraos G, Tselios T, Matsoukas J, Apostolopoulos V. Mannosylation of mutated MBP(83-99) peptides diverts immune responses from Th1 to Th2. Mol. Immunol. 45: 3661-3670 (2008). *

• Katsara M, Yuriev E, Ramsland PA, Tselios T, Deraos G, Lourbopoulos A, Grigoriadis N, Matsoukas J, Apostolopoulos V. Altered peptide ligands of myelin basic protein (MBP(87-89)) conjugated to reduced mannan modulate immune responses in mice. Immunology 128: 521-533 (2009). *

• Kaufmann SH. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol. 26: 660-667 (2005). *

• Kaufmann SH. How can immunology contribute to the control of tuberculosis? Nat. Rev. Immunol. 1: 20-30 (2001). *

• Kaufmann SH. Envisioning future strategies for vaccination against tuberculosis. Nat. Rev. Immunol. 6: 699-704 (2006). *

• Kaul MN, Misra RC, Agarwal SK, Saha K. Decreased gut-associated IgA levels in patients with typhoid fever. Scand. J. Immunol. 11: 623-628 (1980).

• Kaumaya PT, Foy KC, Garrett J, Rawale SV, Vicari D, Thurmond JM, Lamb T, Mani A, Kane Y, Balint CR, Chalupa D, Otterson GA, Shapiro CL, Fowler JM, Grever MR, Bekaii-Saab TS, Carson WE 3rd. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J. Clin. Oncol. 27: 5270-5277 (2009).

• Kaushik K, Khurana S, Wanchu A, Malla N. Lympho-proliferative and cytokine responses to Cryptosporidium parvum in Cryptosporidium-HIV co-infected patients. Clin. Vaccine Immunol. 16: 116-121 (2009). *

• Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Schilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J. Immunother. 30: 762-772 (2007).

• Kawada M, Igarashi H, Takeda A, Tsukamoto T, Yamamoto H, Dohki S, Takiguchi M, Matano T. Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques. J. Virol. 80: 1949-1958 (2006). *

• Kawakami Y, Tomimori Y, Yumoto K, Hasegawa S, Ando T, Tagaya Y, Crotty S, Kawakami T. Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum. J. Exp. Med. 206: 1219-1225 (2009). *

• Kawamoto S, Aki T, Yamashita M, Tategaki A, Fujimura T, Tsuboi S, Katsutani T, Suzuki O, Shigeta S, Murooka Y, Ono K. Toward elucidating the full spectrum of mite allergens - state of the art. J. Biosci. Bioeng. 94: 285-298 (2002). *

• Kawashima H, Mori T, Kashiwagi Y, Takekuma K, Hoshika A, Wakefield A. Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism. Dig. Dis. Sci. 45: 723-729 (2000). *

• Kawashti MI, Amin OR, Rowehy NG. Possible immunological disorders in autism: concomitant autoimmunity and immune tolerance. Egypt. J. Immunol. 13: 99-104 (2006).

• Kayamuro H, Abe Y, Yoshioka Y, Katayama K, Nomura T, Yoshida T, Yamashita K, Yoshikawa T, Kawai Y, Mayumi T, Hiroi T, Itoh N, Nagano K, Kamada H, Tsunoda SI, Tsutsumi Y. The use of a mutant TNF-alpha as a vaccine adjuvant for the induction of mucosal immune responses. Biomaterials 30: 5869-5876 (2009). *

• Kayamuro H, Yoshioka Y, Abe Y, Katayama K, Yoshida T, Yamashita K, Yoshikawa T, Hiroi T, Itoh N, Kawai Y, Kamada H, Tsunoda SI, Tsutsumi Y. TNF superfamily member, TL1A, is a potential mucosal vaccine adjuvant. Biochem. Biophys. Res. Commun. 384: 296-300 (2009). *

• Kearney M, Maldarelli F, Shao W, Margolick JB, Daar ES, Mellors JW, Rao V, Coffin JM, Palmer S. Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J. Virol. 83: 2715-2727 (2009). *

• Kedzierska K, Guillonneau C, Gras S, Hatton LA, Webby R, Purcell AW, Rossjohn J, Doherty PC, Turner SJ. Complete modification of TCR specificity and repertoire selection does not perturb a CD8+ T cell immunodominance hierarchy. Proc. Natl. Acad. Sci. U.S.A. 105: 19408-19413 (2008). *

• Keita AV, Stertman L, Sun YQ, Larhed A, Sjoholm I, Soderholm JD. Effects of chronic stress on the immune response to oral human serum albumin-conjugated starch microparticles in rats. J. Neuroimmunol. 183: 33-42 (2007).

• Keler T, He L, Graziano RF. Development of antibody-targeted vaccines. Curr. Opin. Mol. Ther. 7: 157-163 (2005).

• Keler T, Ramakrishna V, Fanger MW. Mannose receptor-targeted vaccines. Expert Opin. Biol. Ther. 4: 1953-1962 (2004).

• Kelly DF, Snape MD, Perrett KP, Clutterbuck EA, Lewis S, Rohner GB, Jones M, Yu LM, Pollard AJ. Plasma and memory B-cell kinetics in infants following a primary schedule of CRM-conjugated serogroup C meningococcal polysaccharide vaccine. Immunology 127: 134-143 (2009). *

• Kemeny ME, Schedlowski M. Understanding the interaction between psychosocial stress and immune-related diseases: a stepwise progression. Brain Behav. Immun. 21: 1009-1018 (2007).

• Kennedy RB, Ovsyannikova IG, Jacobson RM, Poland GA. The immunology of smallpox vaccines. Curr. Opin. Immunol. 21: 314-320 (2009).

• Kensler TW, Egner PA, Wang JB, Zhu YR, Zhang BC, Lu PX, Chen JG, Qian GS, Kuang SY, Jackson PE, Gange SJ, Jacobson LP, Munoz A, Groopman JD. Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology 127 (5 Suppl. 2): S310-S318 (2004). *

• Kessler JH, Melief CJ. Identification of T-cell epitopes for cancer immunotherapy. Leukemia 21: 1859-1874 (2007).

• Ketloy C, Engering A, Srichairatanakul U, Limsalakpetch A, Yongvanitchit K, Pichyangkul S, Ruxrungtham K. Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates. Vet. Immunol. Immunopathol. 125: 18-30 (2008).

• Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, Shen F, Eaton SM, Gaffen SL, Swain SL, Locksley RM, Haynes L, Randall TD, Cooper AM. IL-23 and IL-17 in the establishment of protective pulmonary CD4(+) T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol. 8: 369-377 (2007). *

• Khaliq S, Khaliq SA, Zahur M, Jahan S, Ijaz B, Riazuddin SH. RNAi as a new therapeutic strategy against HCV. Biotechnol. Adv. 28: 27-34 (2010).

• Khan MA, Bass DM. Viral infections: new and emerging. Curr. Opin. Gastroenterol. 26: 26-30 (2010).

• Khan S, Bijker MS, Weterings JJ, Tanke HJ, Adema GJ, van Hall T, Drijfhout JW, Melief CJ, Overkleeft HS, van der Marel GA, Filippov DV, van der Burg SH, Ossendorp FA. Distinct uptake mechanisms but similar intracellular processing of two different Toll-like receptor ligand-peptide conjugates in dendritic cells. J. Biol. Chem. 282: 21145-21159 (2007). *

• Khemiri M, Labessi A, Zouari S, Borgi A, Ben Mansour F, Oubich F, Khaldi F, Barsaoui S. Tuberculosis in childhood: clinical features and problems in diagnosis. Report of 30 cases. Tunis. Med. 87: 61-67 (2009).

• Khoury SJ, Sayegh MH. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity 20: 529-538 (2004). *

• Khurana A, Kronenberg M. A method for production of recombinant mCD1d protein in insect cells. J. Vis. Exp. 10: 556 (2007). *

• Kiewe P, Mansmann V, Scheibenbogen C, Buhr HJ, Thiel E, Nagorsen D. HLA-A2 expression, stage, and survival in colorectal cancer. Int. J. Colorectal Dis. 23: 767-772 (2008). *

• Kiewe P, Wojtke S, Thiel E, Nagorsen D. Antiviral cellular immunity in colorectal cancer patients. Hum. Immunol. 70: 85-88 (2009).

• Kijanka G, Murphy D. Protein arrays as tools for serum autoantibody marker discovery in cancer. J. Proteomics 72: 936-944 (2009). *

• Kilhamn J, Brevinge H, Quiding-Jarbrink M, Svennerholm AM, Jertborn M. Induction and distribution of intestinal immune responses after administration of recombinant cholera toxin B subunit in the ileal pouches of colectomized patients. Infect. Immun. 69: 3466-3471 (2001). *

• Kim BE, Leung DY, Streib JE, Boguniewicz M, Hamid QA, Howell MD. Macrophage inflammatory protein 3alpha deficiency in atopic dermatitis skin and role in innate immune response to vaccinia virus. J. Allergy Clin. Immunol. 119: 457-463 (2007). *

• Kim DJ, Youn JI, Seo SH, Jin HT, Sung YC. Differential regulation of antigen-specific CD8+ T cell responses by IL-12p40 in a dose-dependent manner. J. Immunol. 180: 7167-7174 (2008). *

• Kim EY, Teh SJ, Yang J, Chow MT, Teh HS. TNFR2-deficient memory CD8 T cells provide superior protection against tumor cell growth. J. Immunol. 183: 6051-6057 (2009).

• Kim S, Kim HO, Kim HJ, Lee K, Kim HS. Generation of functionally mature dendritic cells from elutriated monocytes using polyinosinic:polycytidylic acid and soluble CD40 ligand for clinical application. Clin. Exp. Immunol. 154: 365-374 (2008). *

• Kim WR. Epidemiology of hepatitis B in the United States. Hepatology 49: S28-S34 (2009).

• Kimman TG, Banus S, Reijmerink N, Reimerink J, Stelma FF, Koppelman GH, Thijs C, Postma DS, Kerkhof M. Association of interacting genes in the Toll-like receptor signaling pathway and the antibody response to pertussis vaccination. PLoS ONE 3: e3665 (2008). *

• Kindlund B, Sjoling A, Hansson M, Edebo A, Hansson LE, Sjovall H, Svennerholm AM, Lundin BS. FOXP3-expressing CD4(+) T-cell numbers increase in areas of duodenal gastric metaplasia and are associated to CD4(+) T-cell aggregates in the duodenum of Helicobacter pylori-infected duodenal ulcer patients. Helicobacter 14: 192-201 (2009). *

• Kindrachuk J, Potter JE, Brownlie R, Ficzycz AD, Griebel PJ, Mookherjee N, Mutwiri GK, Babiuk LA, Napper S. Nucleic acids exert a sequence-independent cooperative effect on sequence-dependent activation of Toll-like receptor 9. J. Biol. Chem. 282: 13944-13953 (2007). *

• King JW, Thomas S, Corsi F, Gao L, Dina R, Gillmore R, Pigott K, Kaisary A, Stauss HJ, Waxman J. IL15 can reverse the unresponsiveness of Wilms' tumor antigen-specific CTL in patients with prostate cancer. Clin. Cancer Res. 15: 1145-1154 (2009). *

• Kirjavainen PV, Pautler S, Baroja ML, Anukam K, Crowley K, Carter K, Reid G. Abnormal immunological profile and vaginal microbiota in women prone to urinary tract infections. Clin. Vaccine Immunol. 16: 29-36 (2009). *

• Kirschner DE, Chang ST, Riggs TW, Perry N, Linderman JJ. Toward a multiscale model of antigen presentation in immunity. Immunol. Rev. 216: 93-118 (2007). *

• Kiyono H, Fukuyama S. NALT- versus Peyer's-patch-mediated mucosal immunity. Nat. Rev. Immunol. 4: 699-710 (2004). *

• Klein I, Gassel HJ, Crispe IN. Cytotoxic T-cell response following mouse liver transplantation is independent of the initial site of T-cell priming. Transplant. Proc. 38: 3241-3243 (2006). *

• Klein NP, Ray P, Carpenter D, Hansen J, Lewis E, Fireman B, Black S, Galindo C, Schmidt J, Baxter R. Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine 28: 1062-1068 (2010). *

• Kline JN, Krieg AM. Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. Drug News Perspect. 21: 434-439 (2008).

• Kling C, Steinmann J, Westphal E, Magez J, Kabelitz D. Adverse effects of intradermal allogeneic lymphocyte immunotherapy: acute reactions and role of autoimmunity. Hum. Reprod. 21: 429-435 (2006).

• Klippstein R, Pozo D. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine Jan 16 [Epub ahead of print] (2010).

• Klote MM, Engler RJ. Response to sex differences in autoimmune disease. Lupus 16: 457 (2007).

• Klucar P, Barnes PF, Kong Y, Howard ST, Pang X, Huang FF, Tvinnereim AR, Samten B, Shams H. Vaccination strategies to enhance local immunity and protection against Mycobacteriun tuberculosis. Vaccine 27: 1816-1824 (2009).

• Klug F, Miller M, Schmidt HH, Stevanovic S. Characterization of MHC ligands for peptide based tumor vaccination. Curr. Pharm. Des. 15: 3221-3236 (2009).

• Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 54: 721-728 (2005). *

• Kobayashi T, Yoshimura A. Keeping DCs awake by putting SOCS1 to sleep. Trends Immunol. 26: 177-179 (2005). *

• Kochetkova I, Trunkle T, Callis G, Pascual DW. Vaccination without autoantigen protects against collagen II-induced arthritis via immune deviation and regulatory T cells. J. Immunol. 181: 2741-2752 (2008). *

• Koesters SA, Matu L, Kiama P, Anzala O, Embree J, Plummer FA, Kimani J, Fowke KR. Elevation of immune activation in Kenyan women is associated with alterations in immune function: implications for vaccine development. J. Clin. Immunol. 24: 702-709 (2004). *

• Kohlmeyer J, Cron M, Landsberg J, Bald T, Renn M, Mikus S, Bondong S, Wikasari D, Gaffal E, Hartmann G, Tuting T. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy. Cancer Res. 69: 6265-6274 (2009). *

• Kokhaei P, Palma M, Hansson L, Osterborg A, Mellstedt H, Choudhury A. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. Exp. Hematol. 35: 297-304 (2007). *

• Kolls JK. Th17 cells in mucosal immunity and tissue inflammation. Semin. Immunopathol. Feb 25 [Epub ahead of print] (2010).

• Koloski NA, Bret L, Radford-Smith G. Hygiene hypothesis in inflammatory bowel disease: a critical review of the literature. World J. Gastroenterol. 14: 165-173 (2008). *

• Komohara Y, Harada M, Ishihara Y, Suekane S, Noguchi M, Yamada A, Matsuoka K, Itoh K. HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma. Oncol. Rep. 18: 1463-1468 (2007). *

• Kondratieva TK, Rubakova EI, Linge IA, Evstifeev VV, Majorov KB, Apt AS. B cells delay neutrophil migration toward the site of stimulus: tardiness critical for effective Bacillus Calmette-Guerin vaccination against tuberculosis infection in mice. J. Immunol. Dec 18 [Epub ahead of print] (2009).

• Kong YC, Jacob JB, Flynn JC, Elliott BE, Wei WZ. Autoimmune thyroiditis as an indicator of autoimmune sequelae during cancer immunotherapy. Autoimmun. Rev. 9: 28-33 (2009).

• Koo HC, Park YH, Hamilton MJ, Barrington GM, Davies CJ, Kim JB, Dahl JL, Waters WR, Davis WC. Analysis of the immune response to Mycobacterium avium subsp. paratuberculosis in experimentally infected calves. Infect. Immun. 72: 6870-6883 (2004). *

• Kool M, Petrilli V, De Smedt T, Rolaz A, Hammad H, van Nimwegen M, Bergen IM, Castillo R, Lambrecht BN, Tschopp J. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J. Immunol. 181: 3755-3759 (2008). *

• Koppang EO, Bjerkas I, Haugarvoll E, Chan EK, Szabo NJ, Ono N, Akikusa B, Jirillo E, Poppe TT, Sveier H, Torud B, Satoh M. Vaccination-induced systemic autoimmunity in farmed atlantic salmon. J. Immunol. 181: 4807-4814 (2008). *

• Koppen S, de Groot R, Neijens HJ, Nagelkerke N, van Eden W, Rumke HC. No epidemiological evidence for infant vaccinations to cause allergic disease. Vaccine 22: 3375-3385 (2004). *

• Korbel DS, Schneider B, Schaible UE. Innate immunity in tuberculosis: myths and truth. Microbes Infect. 10: 995-1004 (2008). *

• Korber B, LaBute M, Yusim K. Immunoinformatics comes of age. PLoS Comput. Biol. 2: e71 (2006). *

• Kornbluth RS, Stone GW. Immunostimulatory combinations: designing the next generation of vaccine adjuvants. J. Leukoc. Biol. 80: 1084-1102 (2006). *

• Korthals M, Safaian N, Kronenwett R, Maihofer D, Schott M, Papewalis C, Diaz Blanco E, Winter M, Czibere A, Haas R, Kobbe G, Fenk R. Monocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis. J. Transl. Med. 5: 46 (2007). *

• Korzeniowska-Kowal A, Witkowska D, Gamian A. Molecular mimicry of bacterial polysaccharides and their role in etiology of infectious and autoimmune diseases. Postepy. Hig. Med. Dosw. 55: 211-232 (2001).

• Kosor E, Gagro A, Drazenovic V, Kuzman I, Jeren T, Rakusic S, Rabatic S, Markotic A, Gotovac K, Sabioncello A, Cecuk E, Kerhin-Brkljacic V, Gjenero-Margan I, Kaic B, Mlinaric-Galinovic G, Kastelan A, Dekaris D. MHC tetramers: tracking specific immunity. Acta Med. Croatica 57: 255-259 (2003).

• Kostinov MP, Skochilova TV, Vorob'eva VA, Tarasova AA, Korovkina TI, Lukachev IV, Iushkova IIu, Vaneeva NP. Autoantibodies after vaccination against pneumococcal and influenza infections in children and adolescents with type I diabetes mellitus. Zh. Mikrobiol. Epidemiol. Immunobiol. 2: 53-57 (2009).

• Kotloski NJ, Nardelli DT, Peterson SH, Torrealba JR, Warner TF, Callister SM, Schell RF. Interleukin-23 is required for the development of arthritis in Borrelia-vaccinated and -challenged mice. Clin. Vaccine Immunol. 15: 1199-1207 (2008). *

• Kotturi MF, Assarsson E, Peters B, Grey H, Oseroff C, Pasquetto V, Sette A. Of mice and humans: how good are HLA transgenic mice as a model of human immune responses? Immunome Res. 5: 3 (2009). *

• Kovacs T. Therapy of Alzheimer disease. Neuropsychopharmacol. Hung. 11: 27-33 (2009).

• Koyama S, Coban C, Aoshi T, Horii T, Akira S, Ishii KJ. Innate immune control of nucleic acid-based vaccine immunogenicity. Expert Rev. Vaccines 8: 1099-1107 (2009).

• Koyama S, Ishii KJ, Kumar H, Tanimoto T, Coban C, Uematsu S, Kawai T, Akira S. Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination. J. Immunol. 179: 4711-4720 (2007). *

• Kramer DR, Sutherland RM, Bao S, Husband AJ. Cytokine mediated effects in mucosal immunity. Immunol. Cell Biol. 73: 389-396 (1995). *

• Krebs P, Barnes MJ, Lampe K, Whitley K, Bahjat KS, Beutler B, Janssen E, Hoebe K. NK cell-mediated killing of target cells triggers robust antigen-specific T cell-mediated and humoral responses. Blood 113: 6593-6602 (2009). *

• Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5: 471-484 (2006). *

• Krishnan A, Wang Z, Srivastava T, Rawal R, Manchanda P, Diamond DJ, La Rosa C. A novel approach to evaluate the immunogenicity of viral antigens of clinical importance in HLA transgenic murine models. Immunol. Lett. 120: 108-116 (2008).

• Krishnan J, Lee G, Choi S. Drugs targeting Toll-like receptors. Arch. Pharm. Res. 32: 1485-1502 (2009).

• Krucken J, Delic D, Pauen H, Woytalla A, El-Khadragy M, Dkhil MA, Mossmann H, Wunderlich F. Augmented particle trapping and attenuated inflammation in the liver by protective vaccination against Plasmodium chabaudi malaria. Malar. J. 8: 54 (2009).

• Krueger JG, Ochs HD, Patel P, Gilkerson E, Guttman-Yassky E, Dummer W. Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study. J. Invest. Dermatol. 128: 2615-2624 (2008). *

• Kruger A, Adams P, Hammer J, Bocher WO, Schneider PM, Rittner C, Hoehler T. Hepatitis B surface antigen presentation and HLA-DRB1* - lessons from twins and peptide binding studies. Clin. Exp. Immunol. 140: 325-332 (2005). *

• Krumbiegel D, Zepp F, Meyer CU. Combined Toll-like receptor agonists synergistically increase production of inflammatory cytokines in human neonatal dendritic cells. Hum. Immunol. 68: 813-822 (2007).

• Kruskall MS, Alper CA, Awdeh Z, Yunis EJ, Marcus-Bagley D. The immune response to hepatitis B vaccine in humans: inheritance patterns in families. J. Exp. Med. 175: 495-502 (1992). *

• Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, Beaumont T, Tedder TF, van Noesel CJ, Eldering E, van Lier RA. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J. Clin. Invest. pii: 40231 (2009). *

• Kullavanijaya P, Tangkijvanich P, Poovorawan Y. Current status of infection-related gastrointestinal and hepatobiliary diseases in Thailand. Southeast Asian J. Trop. Med. Public Health 30: 96-105 (1999).

• Kullberg MC. Immunology: soothing intestinal sugars. Nature 453: 602-604 (2008). *

• Kumar M, Sundaramurthi JC, Mehra NK, Kaur G, Raja A. Cellular immune response to Mycobacterium tuberculosis-specific antigen culture filtrate protein-10 in south India. Med. Microbiol. Immunol. Nov 10 [Epub ahead of print] (2009). *

• Kumar RS, Sarmila M, Prasad MS, Pankaj M, Satish K. An epidemiological study on incidence, symptoms and complications of measles in bordering districts of West Bengal. J. Commun. Dis. 40: 59-64 (2008).

• Kunisawa J, Fukuyama S, Kiyono H. Mucosa-associated lymphoid tissues in the aerodigestive tract: their shared and divergent traits and their importance to the orchestration of the mucosal immune system. Curr. Mol. Med. 5: 557-572 (2005).

• Kunisawa J, Nochi T, Kiyono H. Immunological commonalities and distinctions between airway and digestive immunity. Trends Immunol. 29: 505-513 (2008). *

• Kunkel EJ, Kim CH, Lazarus NH, Vierra MA, Soler D, Bowman EP, Butcher EC. CCR10 expression is a common feature of circulating and mucosal epithelial tissue IgA Ab-secreting cells. J. Clin. Invest. 111: 1001-1010 (2003). *

• Kuo E, Maruyama T, Fernandez F, Mohanakumar T. Molecular mechanisms of chronic rejection following transplantation. Immunol. Res. 32: 179-186 (2005). *

• Kuroda Y, Nacionales DC, Akaogi J, Reeves WH, Satoh M. Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomed. Pharmacother. 58: 325-337 (2004).

• Kuruma KA, Borba EF, Lopes MH, de Carvalho JF, Bonfa E. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus 16: 350-354 (2007).

• Kutukculer N, Gulez N. The outcome of patients with unclassified hypogammaglobulinemia in early childhood. Pediatr. Allergy Immunol. 20: 693-698 (2009).

• Kvistborg P, Hadrup SR, Svane IM, Andersen MH, Straten PT. Characterization of a single peptide derived from cytochrome P450 1B1 that elicits spontaneous human leukocyte antigen (HLA)-A1 as well as HLA-B35 restricted CD8 T-cell responses in cancer patients. Hum. Immunol. 69: 266-272 (2008).

• Kwon OS, Park YS, Choi JH, Kim SH, Song MH, Lee HH, Jeon DW, Kim NI. A case of ulcerative colitis relapsed by influenza vaccination. Korean J. Gastroenterol. 49: 327-330 (2007).

• Kwon SS, Kim N, Yoo TJ. The effects of intradermal vaccination with DNA encoding for the T-cell receptor on the induction of experimental autoimmune encephalomyelitis in B10.PL mice. J. Korean Med. Sci. 20: 1039-1045 (2005). *

• Kyte JA, Trachsel S, Risberg B, Thor Straten P, Lislerud K, Gaudernack G. Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. Cancer Immunol. Immunother. 58: 1609-1626 (2009). *

• La Rosa C, Krishnan A, Longmate J, Martinez J, Manchanda P, Lacey SF, Limaye AP, Diamond DJ. Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease. J. Infect. Dis. 197: 25-33 (2008).

• Laffitte E, Janssens JP, Roux-Lombard P, Thielen AM, Barde C, Marazza G, Panizzon RG, Saurat JH. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. Br. J. Dermatol. 161: 797-800 (2009). *

• Lahiri A, Das P, Chakravortty D. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine 26: 6777-6783 (2008). *

• Lal P, Ramachandran VG, Goyal R, Sharma R. Edible vaccines: current status and future. Indian J. Med. Microbiol. 25: 93-102 (2007).

• Lalor MK, Smith SG, Floyd S, Gorak-Stolinska P, Weir RE, Blitz R, Branson K, Fine PE, Dockrell HM. Complex cytokine profiles induced by BCG vaccination in UK infants. Vaccine Nov 23 [Epub ahead of print] (2009).

• Lamb DJ, El-Sankary W, Ferns GA. Molecular mimicry in atherosclerosis: a role for heat shock proteins in immunisation. Atherosclerosis 167: 177-185 (2003).

• Lamm ME. Interaction of antigens and antibodies at mucosal surfaces. Annu. Rev. Microbiol. 51: 311-340 (1997). *

• Lang GA, Exley MA, Lang ML. The CD1d-binding glycolipid alpha-galactosylceramide enhances humoral immunity to T-dependent and T-independent antigen in a CD1d-dependent manner. Immunology 119: 116-125 (2006). *

• Lang L. Vaccine against rotavirus lowers hospitalizations and emergency visits. Gastroenterology 136: 373 (2009). *

• Lang L. Rotavirus vaccines prove powerful against diarrhea. Gastroenterology Feb 19 [Epub ahead of print] (2010).

• Lang T, Prina E, Sibthorpe D, Blackwell JM. Nramp1 transfection transfers Ity/Lsh/Bcg-related pleiotropic effects on macrophage activation: influence on antigen processing and presentation. Infect. Immun. 65: 380-386 (1997). *

• Lann MA, Lovell MA, Kleinschmidt-Demasters BK. Acute hemorrhagic leukoencephalitis: a critical entity for forensic pathologists to recognize. Am. J. Forensic Med. Pathol. Dec 14 [Epub ahead of print] (2009).

• Lanzavecchia A, Sallusto F. Toll-like receptors and innate immunity in B-cell activation and antibody responses. Curr. Opin. Immunol. 19: 268-274 (2007).

• Lanzavecchia A, Sallusto F. Human B cell memory. Curr. Opin. Immunol. 21: 298-304 (2009).

• Lapierre P, Beland K, Martin C, Alvarez F Jr, Alvarez F. FOXP3+ regulatory T cell underlies male resistance to experimental type 2 autoimmune hepatitis. Hepatology [In Press] (2010). *

• Lapteva N, Seethammagari MR, Hanks BA, Jiang J, Levitt JM, Slawin KM, Spencer DM. Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. Cancer Res. 67: 10528-10537 (2007). *

• Larche M. Determining MHC restriction of T-cell responses. Methods Mol. Med. 138: 57-72 (2008). *

• Larche M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat. Med. 10 Suppl. 1: S69-S76 (2005). *

• Larkin EA, Carman RJ, Krakauer T, Stiles BG. Staphylococcus aureus: the toxic presence of a pathogen extraordinaire. Curr. Med. Chem. 16: 4003-4019 (2009).

• Larrieu P, Renaud V, Godet Y, Jotereau F, Fonteneau JF. A HLA-Cw*0701 restricted Melan-A/MART1 epitope presented by melanoma tumor cells to CD8+ tumor infiltrating lymphocytes. Cancer Immunol. Immunother. 57: 745-752 (2008). *

• Larsen MD, Griesenbach U, Goussard S, Gruenert DC, Geddes DM, Scheule RK, Cheng SH, Courvalin P, Grillot-Courvalin C, Alton EW. Bactofection of lung epithelial cells in vitro and in vivo using a genetically modified Escherichia coli. Gene Ther. 15: 434-442 (2008).

• Larsen MV, Lundegaard C, Lamberth K, Buus S, Lund O, Nielsen M. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics 8: 424 (2007). *

• Lau YF, Deliyannis G, Zeng W, Mansell A, Jackson DC, Brown LE. Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines. Int. Immunol. 18: 1801-1813 (2006). *

• Laughlin EM, Miller JD, James E, Fillos D, Ibegbu CC, Mittler RS, Akondy R, Kwok W, Ahmed R, Nepom G. Antigen-specific CD4+ T cells recognize epitopes of protective antigen following AVA vaccination. Infect. Immun. 75: 1852-1860 (2007). *

• Laurans M, Arion A, Fines-Guyon M, Regeasse A, Brouard J, Leclercq R, Duhamel JF. Pseudomonas aeruginosa and cystic fibrosis: first colonization to chronic infection. Arch. Pediatr. 13 Suppl. 1: S22-S29 (2006).

• Lavy A, Broide E, Reif S, Keter D, Niv Y, Odes S, Eliakim R, Halak A, Ron Y, Patz J, Fich A, Villa Y, Arber N, Gilat T. Measles is more prevalent in Crohn's disease patients. A multicentre Israeli study. Dig. Liver Dis. 33: 472-476 (2001).

• Lawal A, Basler C, Branch A, Gutierrez J, Schwartz M, Schiano TD. Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation. Am. J. Transplant. 4: 1805-1809 (2004).

• Lazarski CA, Chaves FA, Jenks SA, Wu S, Richards KA, Weaver JM, Sant AJ. The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. Immunity 23: 29-40 (2005). *

• Lazarski CA, Chaves FA, Sant AJ. The impact of DM on MHC class II-restricted antigen presentation can be altered by manipulation of MHC-peptide kinetic stability. J. Exp. Med. 203: 1319-1328 (2006). *

• Lazoura E, Lodding J, Farrugia W, Ramsland PA, Stevens J, Wilson IA, Pietersz GA, Apostolopoulos V. Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non-canonical tumour-associated mucin 1-8 peptide. Immunology 119: 306-316 (2006). *

• Le Buanec H, Delavallee L, Bessis N, Paturance S, Bizzini B, Gallo R, Zagury D, Boissier MC. TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc. Natl. Acad. Sci. U.S.A. 103: 19442-19447 (2006). *

• Le Gall S, Stamegna P, Walker BD. Portable flanking sequences modulate CTL epitope processing. J. Clin. Invest. 117: 3563-3575 (2007). *

• Le Gros G, Erb K, Harris N, Holloway J, McCoy K, Ronchese F. Immunoregulatory networks in asthma. Clin. Exp. Allergy 28 Suppl. 5: 92-96 (1998).

• Leadbetter EA, Brigl M, Illarionov P, Cohen N, Luteran MC, Pillai S, Besra GS, Brenner MB. NK T cells provide lipid antigen-specific cognate help for B cells. Proc. Natl. Acad. Sci. U.S.A. 105: 8339-8344 (2008). *

• Leandro AC, Rocha MA, Cardoso CS, Bonecini-Almeida MG. Genetic polymorphisms in vitamin D receptor, vitamin D-binding protein, Toll-like receptor 2, nitric oxide synthase 2, and interferon-gamma genes and its association with susceptibility to tuberculosis. Braz. J. Med. Biol. Res. 42: 312-322 (2009). *

• Lebwohl M, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, Kalb RE, Kimball AB, Korman NJ, Krueger GG, Mease P, Morison WL, Paller A, Pariser DM, Ritchlin C, Strober B, Van Voorhees A, Weinstein GD, Young M, Horn L. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J. Am. Acad. Dermatol. 58: 94-105 (2008).

• Lecollinet S, Gavard F, Havenga MJ, Spiller OB, Lemckert A, Goudsmit J, Eloit M, Richardson J. Improved gene delivery to intestinal mucosa by adenoviral vectors bearing subgroup B and D fibers. J. Virol. 80: 2747-2759 (2006). *

• Lederman MM, Offord RE, Hartley O. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat. Rev. Immunol. 6: 371-382 (2006). *

• Ledue TB, Collins MF, Young J, Schriefer ME. Evaluation of the LIAISON(R) Borrelia burgdorferi test, a recombinant VlsE-based chemiluminescence immunoassay for the diagnosis of Lyme disease. Clin. Vaccine Immunol. 15: 1796-1804 (2008).

• Lee BO, Tucker A, Frelin L, Sallberg M, Jones J, Peters C, Hughes J, Whitacre D, Darsow B, Peterson DL, Milich DR. Interaction of the hepatitis B core antigen and the innate immune system. J. Immunol. 182: 6670-6681 (2009).

• Lee J, Reinke EK, Zozulya AL, Sandor M, Fabry Z. Mycobacterium bovis Bacille Calmette-Guerin infection in the CNS suppresses experimental autoimmune encephalomyelitis and Th17 responses in an IFN-gamma-independent manner. J. Immunol. 181: 6201-6212 (2008). *

• Lee JB, Jang JE, Song MK, Chang J. Intranasal delivery of cholera toxin induces Th17-dominated T-cell response to bystander antigens. PLoS ONE 4: e5190 (2009). *

• Lee JL, Naguwa SM, Cheema GS, Gershwin ME. Acute rheumatic fever and its consequences: a persistent threat to developing nations in the 21st century. Autoimmun. Rev. 9: 117-123 (2009).

• Lee LN, Burke S, Montoya M, Borrow P. Multiple mechanisms contribute to impairment of type 1 interferon production during chronic lymphocytic choriomeningitis virus infection of mice. J. Immunol. 182: 7178-7189 (2009).

• Lee SW, Croft M. 4-1BB as a therapeutic target for human disease. Adv. Exp. Med. Biol. 647: 120-129 (2009). *

• Lee WI, Liang FC, Huang JL, Jaing TH, Wang CH, Lin TY, Huang YC, Huang WL, Jou R, Hsieh MY, Chia JH, Wu TL. Immunologic analysis of HIV-uninfected Taiwanese children with BCG-induced disease. J. Clin. Immunol. 29: 319-329 (2009). *

• Leech MD, Grencis RK. Induction of enhanced immunity to intestinal nematodes using IL-9-producing dendritic cells. J. Immunol. 176: 2505-2511 (2006). *

• Lees CW, Critchley J, Chee N, Beez T, Gailer RE, Williams AR, Shand AG, Arnott ID, Satsangi J. Lack of association between cervical dysplasia and IBD: a large case-control study. Inflamm. Bowel Dis. 15: 1621-1629 (2009).

• Lefort A, Dachary D, Vergier B, Boiron G. Lichen planus and vaccination against hepatitis B. Ann. Dermatol. Venereol. 122: 701-703 (1995).

• Lefort CT, Hyun YM, Schultz JB, Law FY, Waugh RE, Knauf PA, Kim M. Outside-in signal transmission by conformational changes in integrin Mac-1. J. Immunol. 183: 6460-6468 (2009).

• Lefrancois L, Puddington L. Intestinal and pulmonary mucosal T cells: local heroes fight to maintain the status quo. Annu. Rev. Immunol. 24: 681-704 (2006). *

• Lehe C, Ghebeh H, Al-Sulaiman A, Al Qudaihi G, Al-Hussein K, Almohareb F, Chaudhri N, Alsharif F, Al-Zahrani H, Tbakhi A, Aljurf M, Dermime S. The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy. Cancer Res. 68: 6350-6359 (2008). *

• Lehner M, Stilper A, Morhart P, Holter W. Plasticity of dendritic cell function in response to prostaglandin E2 (PGE2) and interferon-gamma (IFN-gamma). J. Leukoc. Biol. 83: 883-893 (2008). *

• Lehours P. Helicobacter pylori and the others. Gastroenterol. Clin. Biol. 27: 367-373 (2003).

• Lehrer SB, Ayuso R, Reese G. Seafood allergy and allergens: a review. Mar. Biotechnol. (N.Y.) 5: 339-348 (2003). *

• Leibundgut-Landmann S, Osorio F, Brown GD, Reis E Sousa C. Stimulation of dendritic cells via the Dectin-1/Syk pathway allows priming of cytotoxic T cell responses. Blood 112: 4971-4980 (2008). *

• Lekka E, Gritzapis AD, Perez SA, Tsavaris N, Missitzis I, Mamalaki A, Papamichail M, Baxevanis CN. Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy. Cancer Immunol. Immunother. Nov 11 [Epub ahead of print] (2009). *

• Lemere CA. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. Prog. Brain Res. 175: 83-93 (2009).

• Leonardi S, Spina M, Spicuzza L, Rotolo N, La Rosa M. Hepatitis B vaccination failure in celiac disease: is there a need to reassess current immunization strategies? Vaccine 27: 6030-6033 (2009).

• Leonis MA, Balistreri WF. Evaluation and management of end-stage liver disease in children. Gastroenterology 134: 1741-1751 (2008). *

• Lerner A. New therapeutic strategies for celiac disease. Autoimmun. Rev. May 7 [Epub ahead of print] (2009).

• Leslie S, Donnelly P, McVean G. A statistical method for predicting classical HLA alleles from SNP data. Am. J. Hum. Genet. 82: 48-56 (2008). *

• Letsch A, Keilholz U, Kern F, Asemissen AM, Thiel E, Scheibenbogen C. Specific central memory T cells in the bone marrow of patients immunized against tyrosinase peptides. J. Immunother. 29: 201-207 (2006).

• Letvin NL. Progress and obstacles in the development of an AIDS vaccine. Nat. Rev. Immunol. 6: 930-939 (2006). *

• Levy C, Lindor KD. Treatment options for primary biliary cirrhosis and primary sclerosing cholangitis. Curr. Treat. Options Gastroenterol. 6: 93-103 (2003).

• Levy C, Lindor KD. Management of primary biliary cirrhosis. Curr. Treat. Options Gastroenterol. 6: 493-498 (2003).

• Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat. Rev. Immunol. 7: 379-390 (2007). *

• Li CK, Wu H, Yan H, Ma S, Wang L, Zhang M, Tang X, Temperton NJ, Weiss RA, Brenchley JM, Douek DC, Mongkolsapaya J, Tran BH, Lin CL, Screaton GR, Hou JL, McMichael AJ, Xu XN. T cell responses to whole SARS coronavirus in humans. J. Immunol. 181: 5490-5500 (2008). *

• Li H, Willingham SB, Ting JP, Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J. Immunol. 181: 17-21 (2008). *

• Li J, Jin H, Zhang F, Du X, Zhao G, Yu Y, Wang B. Treatment of autoimmune ovarian disease by co-administration with mouse zona pellucida protein 3 and DNA vaccine through induction of adaptive regulatory T cells. J. Gene Med. 10: 810-820 (2008).

• Li L, Bouvier M. Biochemical and structural impact of natural polymorphism in the HLA-A3 superfamily. Mol. Immunol. 42: 1331-1344 (2005). *

• Li L, Yi Z, Wang B, Tisch R. Suppression of ongoing T cell-mediated autoimmunity by peptide-MHC class II dimer vaccination. J. Immunol. 183: 4809-4816 (2009).

• Li M, Yan Z, Han W, Zhang Y. Mimotope vaccination for epitope-specific induction of anti-CD20 antibodies. Cell. Immunol. 239: 136-143 (2006). *

• Li S, Yao X, Liu H, Li J, Fan B. Prediction of T-cell epitopes based on least squares support vector machines and amino acid properties. Anal. Chim. Acta 584: 37-42 (2007).

• Li X, Shiratsuchi T, Chen G, Dellabona P, Casorati G, Franck RW, Tsuji M. Invariant TCR rather than CD1d shapes the preferential activities of C-glycoside analogues against human versus murine invariant NKT cells. J. Immunol. 183: 4415-4421 (2009).

• Li X, Yang A, Huang H, Zhang X, Town J, Davis B, Cockcroft DW, Gordon JR. Induction of Th2 cell allergen tolerance by IL-10-differentiated regulatory dendritic cells. Am. J. Respir. Cell. Mol. Biol. Apr 16 [Epub ahead of print] (2009). *

• Li Y, Ni R, Song W, Shao W, Shrestha S, Ahmad S, Cunningham CK, Flynn PM, Kapogiannis BG, Wilson CM, Tang J. Clear and independent associations of several HLA-DRB1 alleles with differential antibody responses to hepatitis B vaccination in youth. Hum. Genet. 126: 685-696 (2009). *

• Li ZG, Mu R, Dai ZP, Gao XM. T cell vaccination in systemic lupus erythematosus with autologous activated T cells. Lupus 14: 884-889 (2005).

• Liang S, Hajishengallis G. Heat-labile enterotoxins as adjuvants or anti-inflammatory agents. Immunol. Invest. 39: 186-204 (2010). *

• Liangpunsakul S, Chalasani N. Treatment of nonalcoholic fatty liver disease. Curr. Treat. Options Gastroenterol. 6: 455-463 (2003).

• Liao YC, Lee JY. Psoriasis in a 3-month-old infant with Kawasaki disease. Dermatol. Online J. 15: 10 (2009).

• Lien E, Zipris D. The role of Toll-like receptor pathways in the mechanism of type 1 diabetes. Curr. Mol. Med. 9: 52-68 (2009).

• Limas C, Limas CJ. Lichen planus in children: a possible complication of hepatitis B vaccines. Pediatr. Dermatol. 19: 204-209 (2002).

• Limou S, Le Clerc S, Coulonges C, Carpentier W, Dina C, Delaneau O, Labib T, Taing L, Sladek R; ANRS Genomic Group, Deveau C, Ratsimandresy R, Montes M, Spadoni JL, Lelievre JD, Levy Y, Therwath A, Schachter F, Matsuda F, Gut I, Froguel P, et al. Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS genomewide association study 02). J. Infect. Dis. 199: 419-426 (2009). *

• Lin CC, Tu CF, Yen MC, Chen MC, Hsieh WJ, Chang WC, Chang WT, Lai MD. Inhibitor of heat-shock protein 90 enhances the antitumor effect of DNA vaccine targeting clients of heat-shock protein. Mol. Ther. 15: 404-410 (2007). *

• Lin HH, Liao HW, Lin SK, Wang LY. HLA and response to booster hepatitis B vaccination in anti-HBs-seronegative adolescents who had received primary infantile vaccination. Vaccine 26: 3414-3420 (2008).

• Lin HH, Ray S, Tongchusak S, Reinherz EL, Brusic V. Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research. BMC Immunol. 9: 8 (2008). *

• Lin HH, Zhang GL, Tongchusak S, Reinherz EL, Brusic V. Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. BMC Bioinformatics 9 Suppl. 12: S22 (2008). *

• Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baquir B, Fu Y, French SW, Edwards JE, Spellberg B. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog. 5: e1000703 (2009). *

• Lin Y, Gallardo HF, Ku GY, Li H, Manukian G, Rasalan TS, Xu Y, Terzulli SL, Old LJ, Allison JP, Houghton AN, Wolchok JD, Yuan J. Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy Aug 11 [Epub ahead of print] (2009).

• Lin Y, Gallardo HF, Ku GY, Li H, Manukian G, Rasalan TS, Xu Y, Terzulli SL, Old LJ, Allison JP, Houghton AN, Wolchok JD, Yuan J. Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy 11: 912-922 (2009).

• Lin Y, Ritchea S, Logar A, Slight S, Messmer M, Rangel-Moreno J, Guglani L, Alcorn JF, Strawbridge H, Park SM, Onishi R, Nyugen N, Walter MJ, Pociask D, Randall TD, Gaffen SL, Iwakura Y, Kolls JK, Khader SA. Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 31: 799-810 (2009). *

• Lin Y, Slight SR, Khader SA. Th17 cytokines and vaccine-induced immunity. Semin. Immunopathol. Jan 30 [Epub ahead of print] (2010). *

• Linchevski I, Klmenet E, Nir-Paz R. Mycoplasma pneumoniae vaccine protective efficacy and adverse reactions: systematic review and meta-analysis. Vaccine 27: 2437-2446 (2009).

• Lindholm C, Naylor A, Johansson EL, Quiding-Jarbrink M. Mucosal vaccination increases endothelial expression of mucosal addressin cell adhesion molecule 1 in the human gastrointestinal tract. Infect. Immun. 72: 1004-1009 (2004). *

• Lipscomb MW, Chen L, Taylor JL, Goldbach C, Watkins SC, Kalinski P, Butterfield LH, Wesa AK, Storkus WJ. Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro. J. Immunol. 183: 7250-7258 (2009). *

• Listgarten J, Brumme Z, Kadie C, Xiaojiang G, Walker B, Carrington M, Goulder P, Heckerman D. Statistical resolution of ambiguous HLA typing data. PLoS Comput. Biol. 4: e1000016 (2008). *

• Littrell J. The mind-body connection: not just a theory anymore. Soc. Work Health Care 46: 17-37 (2008).

• Liu G, Zhang L, Zhao Y. Modulation of immune responses through direct activation of Toll-like receptors to T cells. Clin. Exp. Immunol. Jan 29 [Epub ahead of print] (2010). *

• Liu LN, Shivakumar R, Allen C, Fratantoni JC. Delivery of whole tumor lysate into dendritic cells for cancer vaccination. Methods Mol. Biol. 423: 139-153 (2008). *

• Liu MA. Gene-based vaccines: recent developments. Curr. Opin. Mol. Ther. 12: 86 (2010).

• Liu QJ, Gao B. Manipulation of MHC-I/TCR interaction for immune therapy. Cell. Mol. Immunol. 5: 171-182 (2008). *

• Liu SJ, Tsai JP, Shen CR, Sher YP, Hsieh CL, Yeh YC, Chou AH, Chang SR, Hsiao KN, Yu FW, Chen HW. Induction of a distinct CD8 Tnc17 subset by transforming growth factor-beta and interleukin-6. J. Leukoc. Biol. 82: 354-360 (2007). *

• Lockshin MD. Sex differences in autoimmune disease. Lupus 15: 753-756 (2006). *

• Lodato F, Mazzella G, Festi D, Azzaroli F, Colecchia A, Roda E. Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J. Gastroenterol. 12: 7239-7249 (2006). *

• Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S303-S309 (2004). *

• Looney RJ, Diamond B, Holers VM, Levesque MC, Moreland L, Nahm MH, St Clair EW. Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. Clin. Immunol. 123: 235-243 (2007). *

• Lopez MJ, Lee YM. Primary sclerosing cholangitis and primary biliary cirrhosis. The American College of Gastroenterology (http://www.acg.gi.org/patients/gihealth/pdf/sclerosing.pdf) (2005). *

• Loras C, Saro C, Gonzalez-Huix F, Mínguez M, Merino O, Gisbert JP, Barrio J, Bernal A, Gutierrez A, Piqueras M, Calvet X, Andreu M, Abad A, Ginard D, Bujanda L, Panes J, Torres M, Fernandez-Banares F, Viver JM, Esteve M. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am. J. Gastroenterol. 104: 57-63 (2009). *

• Lorenz P, Kreutzer M, Zerweck J, Schutkowski M, Thiesen HJ. Probing the epitope signatures of IgG antibodies in human serum from patients with autoimmune disease. Methods Mol. Biol. 524: 247-258 (2009). *

• Lotem M, Zhao Y, Riley J, Hwu P, Morgan RA, Rosenberg SA, Parkhurst MR. Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors. J. Immunother. 29: 616-627 (2006).

• Louagie H, Delanghe J, Desombere I, De Buyzere M, Hauser P, Leroux-Roels G. Haptoglobin polymorphism and the immune response after hepatitis B vaccination. Vaccine 11: 1188-1190 (1993).

• Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, Pietersz GA, Apostolopoulos V, Vaughan H, Karanikas V, Kyriakou P, McKenzie IF, Mitchell PL. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin. Cancer Res. 12: 869-877 (2006). *

• Lu JX, Qian SY, Shu X, Li G. The significance of antimitochondrial IgA and IgG in the diagnosis of primary biliary cirrhosis. Zhonghua Gan Zang Bing Za Zhi 17: 905-909 (2009).

• Lu S. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 21: 346-351 (2009).

• Lu Y, Jacobson D, Bousvaros A. Immunizations in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 15: 1417-1423 (2009). *

• Lu Y, Jacobson DL, Ashworth LA, Grand RJ, Meyer AL, McNeal MM, Gregas MC, Burchett SK, Bousvaros A. Immune response to influenza vaccine in children with inflammatory bowel disease. Am. J. Gastroenterol. 104: 444-453 (2009).

• Lu YJ, Forte S, Thompson CM, Anderson PW, Malley R. Protection against pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide. Infect. Immun. 77: 2076-2083 (2009). *

• Lucchese A, Mittelman A, Lin MS, Kanduc D, Sinha AA. Epitope definition by proteomic similarity analysis: identification of the linear determinant of the anti-Dsg3 MAb 5H10. J. Transl. Med. 2: 43 (2004). *

• Lucchese G, Stufano A, Kanduc D. Proteome-guided search for influenza A B-cell epitopes. FEMS Immunol. Med. Microbiol. 57: 88-92 (2009). *

• Ludvigsson J. Therapy with GAD in diabetes. Diabetes Metab. Res. Rev. 25: 307-315 (2009).

• Lukaszewski RA, Yates AM, Jackson MC, Swingler K, Scherer JM, Simpson AJ, Sadler P, McQuillan P, Titball RW, Brooks TJ, Pearce MJ. The pre-symptomatic prediction of sepsis in intensive care unit patients: a pilot study. Clin. Vaccine Immunol. 15: 1089-1094 (2008). *

• Lundberg A, Wikberg LA, Ilonen J, Vaarala O, Fageras Bottcher M. Lipopolysaccharide induced immune responses in relation to TLR4 Asp299Gly gene polymorphism. Clin. Vaccine Immunol. 15: 1878-1883 (2008). *

• Lundberg K, Roos AK, Pavlenko M, Leder C, Wehrum D, Guevara-Patino J, Andersen RS, Pisa P. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols. Vaccine 27: 1557-1565 (2009).

• Lunde E, Lauvrak V, Rasmussen IB, Schjetne KW, Thompson KM, Michaelsen TE, Brekke OH, Sollid LM, Bogen B, Sandlie I. Troybodies and pepbodies. Biochem. Soc. Trans. 30: 500-506 (2002). *

• Luther J, Kao JY. Considering global vaccination against Helicobacter pylori. South. Med. J. Feb 3 [Epub ahead of print] (2010).

• Lynch HE, Goldberg GL, Chidgey A, Van den Brink MR, Boyd R, Sempowski GD. Thymic involution and immune reconstitution. Trends Immunol. 30: 366-373 (2009). *

• Ma X, Qiu DK, Li EL, Peng YS, Chen XY. Effect of T-cell vaccination in murine experimental autoimmune hepatitis. Zhonghua Gan Zang Bing Za Zhi 12: 44-45 (2004).

• Ma Y, Chen Q, Ross AC. Retinoic acid and polyriboinosinic:polyribocytidylic acid stimulate robust anti-tetanus antibody production while differentially regulating type 1/type 2 cytokines and lymphocyte populations. J. Immunol. 174: 7961-7969 (2005). *

• Ma Y, Guan Q, Bai A, Weiss CR, Hillman CL, Ma A, Zhou G, Qing G, Peng Z. Targeting TGF-beta1 by employing a vaccine ameliorates fibrosis in a mouse model of chronic colitis. Inflamm. Bowel Dis. Nov 18 [Epub ahead of print] (2009). *

• Ma Y, Ma AG, Peng Z. A potential immunotherapy approach: mucosal immunization with an IL-13 peptide-based virus-like particle vaccine in a mouse asthma model. Vaccine 25: 8091-8099 (2007). *

• Ma Y, Ross AC. TLR3 ligand and retinoic acid enhance germinal center formation and increase the tetanus toxoid vaccine response. Clin. Vaccine Immunol. 16: 1476-1484 (2009). *

• Maassen CB, Claassen E. Strain-dependent effects of probiotic lactobacilli on EAE autoimmunity. Vaccine 26: 2056-2057 (2008).

• Macal M, Sankaran S, Chun TW, Reay E, Flamm J, Prindiville TJ, Dandekar S. Effective CD4+ T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses. Mucosal Immunol. 1: 475-488 (2008).

• Machado NO, Grant CS, Alkindi S, Daar S, Al-Kindy N, Al Lamki Z, Ganguly S. Splenectomy for haematological disorders: a single center study in 150 patients from Oman. Int. J. Surg. 7: 476-481 (2009).

• Macintyre CR. New developments in BCG vaccine: implications for tuberculosis control. Epidemiol. Infect. 135: 177-180 (2007).

• MacIntyre CR, McIntyre PB. MMR, autism and inflammatory bowel disease: responding to patient concerns using an evidence-based framework. Med. J. Aust. 175: 127-128 (2001).

• Mackay IR, Leskovsek NV, Rose NR. Cell damage and autoimmunity: a critical appraisal. J. Autoimmun. 30: 5-11 (2008). *

• Mackay IR, Rowley MJ. Autoimmune epitopes: autoepitopes. Autoimmun. Rev. 3: 487-492 (2004).

• Mackowiak PA, Wasserman SS, Levine MM. A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. JAMA 268: 1578-1580 (1992).

• Maehlen J, Heger B, Rostrup M. Splenic atrophy and fatal pneumococcal infection in inflammatory bowel disease. Tidsskr. Nor. Laegeforen. 117: 1900-1901 (1997).

• Magnani C. SV40, genetic polymorphism and mesothelioma. Pathological and epidemiological evidence. Med. Lav. 96: 347-353 (2006).

• Mahad D, Callahan MK, Williams KA, Ubogu EE, Kivisakk P, Tucky B, Kidd G, Kingsbury GA, Chang A, Fox RJ, Mack M, Sniderman MB, Ravid R, Staugaitis SM, Stins MF, Ransohoff RM. Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain 129: 212-223 (2006).

• Mahdi N, Al-Ola K, Al-Subaie AM, Ali ME, Al-Irhayim Z, Al-Irhayim AQ, Almawi WY. Distinct HLA class II associations with vaso-occlusion in children with sickle cell disease. Clin. Vaccine Immunol. 15: 729-731 (2008). *

• Maillefert JF, Sibilia J, Toussirot E, Vignon E, Eschard JP, Lorcerie B, Juvin R, Parchin-Geneste N, Piroth C, Wendling D, Kuntz JL, Tavernier C, Gaudin P. Rheumatic disorders developed after hepatitis B vaccination. Rheumatology (Oxford) 38: 978-983 (1999). *

• Majlessi L, Simsova M, Jarvis Z, Brodin P, Rojas MJ, Bauche C, Nouze C, Ladant D, Cole ST, Sebo P, Leclerc C. An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. Infect. Immun. 74: 2128-2137 (2006). *

• Mak TW. 'Order from disorder sprung': recognition and regulation in the immune system. Philos. Transact. A. Math. Phys. Eng. Sci. 361: 1235-50 (2003). *

• Makkouk A, Abdelnoor AM. The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents. Immunopharmacol. Immunotoxicol. 31: 331-338 (2009).

• Maksimow M, Alam C, Hanninen A. Incomplete killing and enhanced activation of islet-reactive CD8+ T cells by FasL-expressing dendritic cells limits protection from diabetes. Rev. Diabet. Stud. 5: 144-153 (2008). *

• Malaitsev VV, Bogdanova IM, Makarova OV. Heat shock proteins and their role in the development of pathological processes. Arkh. Patol. 70: 31-38 (2008).

• Malamud A, Wilson KT. Treatment of gastrointestinal infections. Curr. Opin. Gastroenterol. 16: 51-55 (2000).

• Mamori S, Amano K, Kijima H, Takagi I, Tajiri H. Thrombocytopenic purpura after the administration of an influenza vaccine in a patient with autoimmune liver disease. Digestion 77: 159-160 (2008). *

• Mamula P, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 5: 851-856 (2007).

• Manches O, Munn D, Fallahi A, Lifson J, Chaperot L, Plumas J, Bhardwaj N. HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. J. Clin. Invest. 118: 3431-3439 (2008). *

• Mandic D, Curcic R, Radosavljevic G, Damjanov N, Stefanovic D, Mitic I, Dimic A. Recommendations for tuberculosis screening before and during treatment with tumour necrosis factor inhibitors. Srp. Arh. Celok. Lek. 137: 211-216 (2009).

• Maness NJ, Wilson NA, Reed JS, Piaskowski SM, Sacha JB, Walsh AD, Thoryk E, Heidecker GJ, Citron MP, Liang X, Bett AJ, Casimiro DR, Watkins DI. Robust, vaccine-induced CD8+ T lymphocyte response against an out-of-frame epitope. J. Immunol. 184: 67-72 (2010).

• Manicassamy S. Sotrastaurin, a protein kinase C inhibitor for the prevention of transplant rejection and treatment of psoriasis. Curr. Opin. Investig. Drugs 10: 1225-1235 (2009).

• Manicassamy S, Pulendran B. Modulation of adaptive immunity with Toll-like receptors. Semin. Immunol. 21: 185-193 (2009). *

• Manicassamy S, Pulendran B. Retinoic acid-dependent regulation of immune responses by dendritic cells and macrophages. Semin. Immunol. 21: 22-27 (2009). *

• Manicassamy S, Ravindran R, Deng J, Oluoch H, Denning TL, Kasturi SP, Rosenthal KM, Evavold BD, Pulendran B. Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity. Nat. Med. 15: 401-409 (2009). *

• Manigold T, Mori A, Graumann R, Llop E, Simon V, Ferres M, Valdivieso F, Castillo C, Hjelle B, Vial P. Highly differentiated, resting gn-specific memory CD8 T cells persist years after infection by Andes hantavirus. PLoS Pathog. 6: e1000779 (2010). *

• Mannie MD, Abbott DJ. A fusion protein consisting of IL-16 and the encephalitogenic peptide of myelin basic protein constitutes an antigen-specific tolerogenic vaccine that inhibits experimental autoimmune encephalomyelitis. J. Immunol. 179: 1458-1465 (2007). *

• Mannie MD, Abbott DJ, Blanchfield JL. Experimental autoimmune encephalomyelitis in Lewis rats: IFN-beta acts as a tolerogenic adjuvant for induction of neuroantigen-dependent tolerance. J. Immunol. 182: 5331-5341 (2009).

• Mannie MD, Devine JL, Clayson BA, Lewis LT, Abbott DJ. Cytokine-neuroantigen fusion proteins: new tools for modulation of myelin basic protein (MBP)-specific T cell responses in experimental autoimmune encephalomyelitis. J. Immunol. Methods 319: 118-132 (2007). *

• Mansilla C, Gorraiz M, Martinez M, Casares N, Arribillaga L, Rudilla F, Echeverria I, Riezu-Boj JI, Sarobe P, Borras-Cuesta F, Prieto J, Lasarte JJ. Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein. J. Hepatol. 51: 520-527 (2009).

• Marchioni E, Tavazzi E, Minoli L, Del Bue S, Ferrante P, Piccolo G, Bastianello S, Ravaglia S. Acute disseminated encephalomyelitis. Neurol. Sci. 29 Suppl. 2: S286-S288 (2008).

• Margalit M, Israeli E, Shibolet O, Zigmond E, Klein A, Hemed N, Donegan JJ, Rabbani E, Goldin, E, Ilan Y. A double-blind clinical trial for treatment of Crohn's disease by oral administration of Alequel™, a mixture of autologous colon-extracted proteins: a patient-tailored approach. Am. J. Gastroenterol. 101: 561-568 (2006). *

• Mari A. Is there a causative role for tetanus toxoid vaccination in the development of allergy-like symptoms and in the increasing prevalence of atopic diseases? Med. Hypotheses 63: 875-886 (2004).

• Marietta EV, Rashtak S, Murray JA. Correlation analysis of celiac sprue tissue transglutaminase and deamidated gliadin IgG/IgA. World J. Gastroenterol. 15: 845-848 (2009). *

• Marinaro M, Fasano A, De Magistris MT. Zonula occludens toxin acts as an adjuvant through different mucosal routes and induces protective immune responses. Infect. Immun. 71: 1897-1902 (2003). *

• Markova T, Chuvirov D. Frequently ill children. Adv. Exp. Med. Biol. 601: 301-306 (2007).

• Markovic-Plese S, Hemmer B, Zhao Y, Simon R, Pinilla C, Martin R. High level of cross-reactivity in influenza virus hemagglutinin-specific CD4+ T-cell response: implications for the initiation of autoimmune response in multiple sclerosis. J. Neuroimmunol. 169: 31-38 (2005).

• Marks DJ, Mitchison NA, Segal AW, Sieper J. Can unresolved infection precipitate autoimmune disease? Curr. Top. Microbiol. Immunol. 305: 105-125 (2006).

• Marks MA, Gravitt PE, Burk RR, Studentsov Y, Farzadegan H, Klein SL. Progesterone and 17beta-estradiol enhance regulatory responses to HPV 16 VLP in peripheral blood mononuclear cells from healthy women. Clin. Vaccine Immunol. Feb 3 [Epub ahead of print] (2010). *

• Marmon S, Strober BE. Balancing immunity and immunosuppression: vaccinating patients receiving treatment with efalizumab. J. Invest. Dermatol. 128: 2567-2569 (2008). *

• Marmor M, Sheppard HW, Donnell D, Bozeman S, Celum C, Buchbinder S, Koblin B, Seage GR 3rd; HIV Network for Prevention Trials Vaccine Preparedness Protocol Team. Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection. J. Acquir. Immune Defic. Syndr. 27: 472-481 (2001).

• Marra F, Cox VC, FitzGerald JM, Moadebi S, Elwood RK. Successful treatment of multidrug-resistant tuberculosis following drug-induced hepatic necrosis requiring liver transplant. Int. J. Tuberc. Lung Dis. 8: 905-909 (2004).

• Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9: 287-293 (2009). *

• Marrero R, Schiff E. Viral hepatitis. Curr. Opin. Gastroenterol. 18: 330-333 (2002).

• Martin A, Lemon SM. Hepatitis A virus: from discovery to vaccines. Hepatology 43: S164-S172 (2006). *

• Martin DA, Zhang K, Kenkel J, Hughes G, Clark E, Davidson A, Elkon KB. Autoimmunity stimulated by adoptively transferred dendritic cells is initiated by both alphabeta and gammadelta T cells but does not require MyD88 signaling. J. Immunol. 179: 5819-5828 (2007). *

• Martin P. Key consultations in hepatology. Preface. Clin. Liver Dis. 13: xi-xii (2009). *

• Martinelli Natzke A, Shaw JL, McKeller MR, Lambert Emo K, Mullen CA. Hematopoietic stem cell recipients do not develop post-transplantation immune tolerance to antigens present on minimal residual disease. Biol. Blood Marrow Transplant. 13: 34-45 (2007).

• Martinet L, Poupot R, Fournie JJ. Pitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies. Immunol. Lett. 124: 1-8 (2009).

• Martinez JP, Gil ML, Lopez-Ribot JL, Chaffin WL. Serologic response to cell wall mannoproteins and proteins of Candida albicans. Clin. Microbiol. Rev. 11: 121-141 (1998). *

• Martino A, Badell E, Abadie V, Balloy V, Chignard M, Mistou MY, Combadiere B, Combadiere C, Winter N. Mycobacterium bovis Bacillus Calmette-Guerin vaccination mobilizes innate myeloid-derived suppressor cells restraining in vivo T cell priming via IL-1R-dependent nitric oxide production. J. Immunol. Jan 18 [Epub ahead of print] (2010).

• Martinuc Porobic J, Avcin T, Bozic B, Kuhar M, Cucnik S, Zupancic M, Prosenc K, Kveder T, Rozman B. Anti-phospholipid antibodies following vaccination with recombinant hepatitis B vaccine. Clin. Exp. Immunol. 142: 377-380 (2005). *

• Mastroeni P, Menager N. Development of acquired immunity to Salmonella. J. Med. Microbiol. 52: 453-459 (2003). *

• Matsoukas J, Apostolopoulos V, Kalbacher H, Papini AM, Tselios T, Chatzantoni K, Biagioli T, Lolli F, Deraos S, Papathanassopoulos P, Troganis A, Mantzourani E, Mavromoustakos T, Mouzaki A. Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators. J. Med. Chem. 48: 1470-1480 (2005). *

• Matsumoto Y. New approach to immunotherapy against organ-specific autoimmune diseases with T cell receptor and chemokine receptor DNA vaccines. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5: 73-77 (2005).

• Matsuzaki J, Qian F, Luescher I, Lele S, Ritter G, Shrikant PA, Gnjatic S, Old LJ, Odunsi K. Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1. Cancer Immunol. Immunother. 57: 1185-1195 (2008). *

• Matthews PC, Prendergast A, Leslie A, Crawford H, Payne R, Rousseau C, Rolland M, Honeyborne I, Carlson J, Kadie C, Brander C, Bishop K, Mlotshwa N, Mullins JD, Coovadia H, Ndung'u T, Walker BD, Heckerman D, Goulder PJ. Central role of reverting mutations in HLA associations with human immunodeficiency virus setpoint. J. Virol. 82: 8548-8559 (2008). *

• Matulis G, Juni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases - performance of a Mycobacterium tuberculosis antigen specific IFN-gamma assay. Ann. Rheum. Dis. 67: 84-90 (2008).

• Maue AC, Eaton SM, Lanthier PA, Sweet KB, Blumerman SL, Haynes L. Proinflammatory adjuvants enhance the cognate helper activity of aged CD4 T cells. J. Immunol. 182: 6129-6135 (2009).

• Maue AC, Yager EJ, Swain SL, Woodland DL, Blackman MA, Haynes L. T-cell immunosenescence: lessons learned from mouse models of aging. Trends Immunol. 30: 301-305 (2009). *

• Maxmen A. IL-17 propels infection. J. Exp. Med. 206: 1210 (2009).

• Mayer L. Review article: local and systemic regulation of mucosal immunity. Aliment. Pharmacol. Ther. 11 Suppl. 3: 81-85 (1997).

• Mayer ML, Phillips CM, Townsend RA, Halperin SA, Lee SF. Differential activation of dendritic cells by Toll-like receptor agonists isolated from the Gram-positive vaccine vector Streptococcus gordonii. Scand. J. Immunol. 69: 351-356 (2009). *

• Mayerl C, Prelog M. Immunosenescence and juvenile idiopathic arthritis. Autoimmun. Rev. Feb 18 [Epub ahead of print] (2010).

• Mazzola TN, Da Silva MT, Moreno YM, Lima SC, Carniel EF, Morcillo AM, Antonio MA, Zanolli ML, Netto AA, Blotta MH, Raw I, Vilela MM. Robust gammadelta+ T cell expansion in infants immunized at birth with BCG vaccine. Vaccine 25: 6313-6320 (2007). *

• Mbawuike IN, Pacheco S, Acuna CL, Switzer KC, Zhang Y, Harriman GR. Mucosal immunity to influenza without IgA: an IgA knockout mouse model. J. Immunol. 162: 2530-2537 (1999). *

• McAdam SN, Fleckenstein B, Rasmussen IB, Schmid DG, Sandlie I, Bogen B, Viner NJ, Sollid LM. T cell recognition of the dominant I-A(k)-restricted hen egg lysozyme epitope: critical role for asparagine deamidation. J. Exp. Med. 193: 1239-1246 (2001). *

• McAleer JP, Liu B, Li Z, Ngoi SM, Dai J, Oft M, Vella AT. Potent intestinal Th17 priming through peripheral lipopolysaccharide-based immunization. J. Leukoc. Biol. Feb 3 [Epub ahead of print] (2010). *

• McAleer JP, Rossi RJ, Vella AT. Lipopolysaccharide potentiates effector T cell accumulation into nonlymphoid tissues through TRIF. J. Immunol. 182: 5322-5330 (2009).

• McArdle S. Cancer vaccines: uses of HLA transgenic mice compared to genetically modified mice. Front. Biosci. 14: 4640-4651 (2009).

• McCarron M, Reen DJ. Activated human neonatal CD8+ T cells are subject to immunomodulation by direct TLR2 or TLR5 stimulation. J. Immunol. 182: 55-62 (2009). *

• McCluskie MJ, Krieg AM. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr. Top. Microbiol. Immunol. 311: 155-178 (2006).

• McDermott AB, Cohen SB, Zuckerman JN, Madrigal JA. Human leukocyte antigens influence the immune response to a pre-S/S hepatitis B vaccine. Vaccine 17: 330-339 (1999).

• McDermott AB, Zuckerman JN, Sabin CA, Marsh SG, Madrigal JA. Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination. Tissue Antigens 50: 8-14 (1997).

• McDevitt H. Specific antigen vaccination to treat autoimmune disease. Proc. Natl. Acad. Sci. U.S.A. 101: 14627-14630 (2004). *

• McDonald WF, Huleatt JW, Foellmer HG, Hewitt D, Tang J, Desai P, Price A, Jacobs A, Takahashi VN, Huang Y, Nakaar V, Alexopoulou L, Fikrig E, Powell TJ. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J. Infect. Dis. 195: 1607-1617 (2007). *

• McElhaney JE, Effros RB. Immunosenescence: what does it mean to health outcomes in older adults? Curr. Opin. Immunol. 21: 418-424 (2009).

• McFarlane AA, Orriss GL, Stetefeld J. The use of coiled-coil proteins in drug delivery systems. Eur. J. Pharmacol. 625: 101-107 (2009). *

• McGhee JR, Kiyono H, Michalek SM, Mestecky J. Enteric immunization reveals a T cell network for IgA responses and suggests that humans possess a common mucosal immune system. Antonie Van Leeuwenhoek. 53: 537-543 (1987).

• McGowen AL, Hale LP, Shelburne CP, Abraham SN, Staats HF. The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen. Vaccine 27: 3544-3552 (2009). *

• McKenzie BS, Corbett AJ, Brady JL, Boyle JS, Rockman SP, Lew AM. Targeting lymphocyte Peyer's patch adhesion molecule-1: a relay approach to gut immunization. Vaccine 23: 3668-3678 (2005). *

• McKenzie BS, Corbett AJ, Johnson S, Brady JL, Pleasance J, Kramer DR, Boyle JS, Jackson DC, Strugnell RA, Lew AM. Bypassing luminal barriers, delivery to a gut addressin by parenteral targeting elicits local IgA responses. Int. Immunol. 16: 1613-1622 (2004). *

• McKinnon LR, Capina R, Peters H, Mendoza M, Kimani J, Wachihi C, Kariri A, Kimani M, Richmond M, Kiazyk SK, Fowke KR, Jaoko W, Luo M, Ball TB, Plummer FA. Clade-specific evolution mediated by HLA-B*57/5801 in human immunodeficiency virus type 1 clade A1 p24. J. Virol. 83: 12636-12642 (2009). *

• McMahon BJ, Helminiak C, Wainwright RB, Bulkow L, Trimble BA, Wainwright K. Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. Am. J. Med. 92: 254-256 (1992).

• McMichael A, Hanke T. The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? Nat. Rev. Immunol. 2: 283-291 (2002).

• McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 10: 11-23 (2010). *

• McNamara C, Zinkernagel AS, Macheboeuf P, Cunningham MW, Nizet V, Ghosh P. Coiled-coil irregularities and instabilities in group A Streptococcus M1 are required for virulence. Science 319: 1405-1408 (2008). *

• McWilliams JA, Sanchez PJ, Haluszczak C, Gapin L, Kedl RM. Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity. Vaccine Dec 5 [Epub ahead of print] (2009). *

• Mega J, Fujihashi K, Kiyono H. Regulation of mucosal immune responses by T lymphocytes: the effect of chronic CD4+ T cell deficiency on IgA synthesis. Reg. Immunol. 4: 70-78 (1992).

• Mehra NK, Kaur G. MHC-based vaccination approaches: progress and perspectives. Expert Rev. Mol. Med. 5: 1-17 (2003).

• Mehra NK, Kaur G, Jaini R. Genetic diversity in the human major histocompatibility complex: lessons for vaccination approaches to HIV infection. Community Genet. 5: 162-166 (2002).

• Mei Y, Wang Y, Xu L. Suppression of immune-mediated liver injury after vaccination with attenuated pathogenic cells. Immunol. Lett. 110: 29-35 (2007).

• Meiring HD, Soethout EC, de Jong AP, van Els CA. Targeted identification of infection-related HLA class I-presented epitopes by stable isotope tagging of epitopes (SITE). Curr. Protoc. Immunol. Chapter 16: Unit 16.3 (2007).

• Meissonnier GM, Pinton P, Laffitte J, Cossalter AM, Gong YY, Wild CP, Bertin G, Galtier P, Oswald IP. Immunotoxicity of aflatoxin B1: impairment of the cell-mediated response to vaccine antigen and modulation of cytokine expression. Toxicol. Appl. Pharmacol. 231: 142-149 (2008). *

• Melchjorsen J. Cellular recognition of herpes simplex virus infection and virus-induced cytokine production. Dan. Med. Bull. 52: 257 (2005).

• Melles DC, de Marie S. Prevention of infections in hyposplenic and asplenic patients: an update. Neth. J. Med. 62: 45-52 (2004). *

• Melmed GY. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm. Bowel Dis. 15: 1410-1416 (2009). *

• Melmed GY, Agarwal N, Frenck RW, Ippoliti AF, Ibanez P, Papadakis KA, Simpson P, Barolet-Garcia C, Ward J, Targan SR, Vasiliauskas EA. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am. J. Gastroenterol. 105: 148-154 (2010). *

• Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, Frenck RW, Targan SR, Vasiliauskas EA. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am. J. Gastroenterol. 101: 1834-1840 (2006). *

• Mendez-Samperio P. Role of interleukin-12 family cytokines in the cellular response to mycobacterial disease. Int. J. Infect. Dis. Sep 15 [Epub ahead of print] (2009).

• Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, van Eldere J, Glupczynski Y, van Laethem Y, Jacobs F, Lebecque P, Malfroot A, Tulkens PM, van Bambeke F. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin. Microbiol. Infect. 13: 560-578 (2007). *

• Meshcheryakova E, Makarov E, Philpott D, Andronova T, Ivanov V. Evidence for correlation between the intensities of adjuvant effects and NOD2 activation by monomeric, dimeric and lipophylic derivatives of N-acetylglucosaminyl-N-acetylmuramyl peptides. Vaccine 25: 4515-4520 (2007). *

• Mestecky J, Moldoveanu Z, Elson CO. Immune response versus mucosal tolerance to mucosally administered antigens. Vaccine 23: 1800-1803 (2005).

• Mestecky J, Nguyen H, Czerkinsky C, Kiyono H. Oral immunization: an update. Curr. Opin. Gastroenterol. 24: 713-719 (2008).

• Mestecky J, Russell MW, Elson CO. Perspectives on mucosal vaccines: is mucosal tolerance a barrier? J. Immunol. 179: 5633-5638 (2007). *

• Met O, Wang M, Pedersen AE, Nissen MH, Buus S, Claesson MH. The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling. Cancer Lett. 231: 247-256 (2006). *

• Meurens F, Berri M, Whale J, Dybvig T, Strom S, Thompson D, Brownlie R, Townsend HG, Salmon H, Gerdts V. Expression of TECK/CCL25 and MEC/CCL28 chemokines and their respective receptors CCR9 and CCR10 in porcine mucosal tissues. Vet. Immunol. Immunopathol. 113: 313-327 (2006). *

• Meurens F, Whale J, Brownlie R, Dybvig T, Thompson DR, Gerdts V. Expression of mucosal chemokines TECK/CCL25 and MEC/CCL28 during fetal development of the ovine mucosal immune system. Immunology 120: 544-555 (2007). *

• Meyer T, Stockfleth E. Clinical investigations of Toll-like receptor agonists. Expert Opin. Investig. Drugs 17: 1051-1065 (2008).

• Meyer VS, Kastenmuller W, Gasteiger G, Franz-Wachtel M, Lamkemeyer T, Rammensee HG, Stevanovic S, Sigurdardottir D, Drexler I. Long-term immunity against actual poxviral HLA ligands as identified by differential stable isotope labeling. J. Immunol. 181: 6371-6383 (2008). *

• Mikaeloff Y, Caridade G, Assi S, Tardieu M, Suissa S. Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS inflammatory demyelination. Brain 130: 1105-1110 (2007).

• Mikula C. Measles vaccination a risk factor for inflammatory bowel disease? Gastroenterol. Nurs. 23: 168-171 (2000).

• Miles DJ, Gadama L, Gumbi A, Nyalo F, Makanani B, Heyderman RS. Human immunodeficiency virus (HIV) infection during pregnancy induces CD4 T-cell differentiation and modulates responses to Bacille Calmette-Guerin (BCG) vaccine in HIV-uninfected infants. Immunology 129: 446-454 (2010). *

• Milich DR. Influence of C4A deficiency on nonresponse to HBsAg vaccination: a new immune response gene. J. Hepatol. 37: 396-399 (2002). *

• Miller E, Waight P, Farrington CP, Andrews N, Stowe J, Taylor B. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch. Dis. Child. 84: 227-229 (2001). *

• Miller F, Jones RF, Jacob J, Kong YC, Wei WZ. From breast cancer immunobiology to Her-2 DNA vaccine and autoimmune sequelae. Breast Dis. 20: 43-51 (2009).

• Miller JD, Whitehair LH. Concurrent HLA-related response factors mediate recombinant hepatitis B vaccine major adverse events. Autoimmunity 38: 181-194 (2005).

• Mimran A, Cohen IR. Regulatory T cells in autoimmune diseases: anti-ergotypic T cells. Int. Rev. Immunol. 24: 159-179 (2005).

• Minden K, Niewerth M, Borte M, Singendonk W, Haas JP. Immunization in children and adolescents with rheumatic diseases. Z. Rheumatol. 66: 111-120 (2007).

• Mir MA, Battiwalla M. Immune deficits in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Mycopathologia 168: 271-282 (2009). *

• Miron D, Fink D, Hashkes PJ. Kawasaki disease in an infant following immunisation with hepatitis B vaccine. Clin. Rheumatol. 22: 461-463 (2003). *

• Misharin AV, Rapoport B, McLachlan SM. Thyroid antigens, not central tolerance, control responses to immmunization in BALB/C versus C57BL/6 mice. Thyroid 19: 503-509 (2009).

• Mishra A, Mishra S, Jain P, Bhadoriya RS, Mishra R, Lahariya C. Measles related complications and the role of vitamin A supplementation: findings from an outbreak investigation in Shivpuri, India. Indian J. Pediatr. 75: 887-890 (2008).

• Mitchell AE, Colvin HM, Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology Feb 22 [Epub ahead of print] (2010).

• Mitra-Kaushik S, Cruz J, Stern LJ, Ennis FA, Terajima M. Human cytotoxic CD4+ T cells recognize HLA-DR1-restricted epitopes on vaccinia virus proteins A24R and D1R conserved among poxviruses. J. Immunol. 179: 1303-1312 (2007). *

• Mitragotri S. Immunization without needles. Nat. Rev. Immunol. 5: 905-916 (2005). *

• Mittler RS, Foell J, McCausland M, Strahotin S, Niu L, Bapat A, Hewes LB. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer. Immunol. Res. 29: 197-208 (2004). *

• Miyasaka N, Takeuchi T, Eguchi K. Official Japanese guidelines for the use of infliximab for rheumatoid arthritis. Mod. Rheumatol. 15: 4-8 (2005).

• Mizrahi M, Lalazar G, Ben Ya'acov A, Livovsky DM, Horowitz Y, Zolotarov L, Adler R, Shouval D, Ilan Y. Beta-glycoglycosphingolipid-induced augmentation of the anti-HBV immune response is associated with altered CD8 and NKT lymphocyte distribution: a novel adjuvant for HBV vaccination. Vaccine 26: 2589-2595 (2008).

• Mocellin S, Rossi CR, Lise M, Nitti D. Colorectal cancer vaccines: principles, results, and perspectives. Gastroenterology 127: 1821-1837 (2004). *

• Moe GR, Bhandari TS, Flitter BA. Vaccines containing de-N-acetyl sialic acid elicit antibodies protective against neisseria meningitidis groups B and C. J. Immunol. 182: 6610-6617 (2009).

• Mohamadzadeh M, Olson S, Kalina WV, Ruthel G, Demmin GL, Warfield KL, Bavari S, Klaenhammer TR. Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc. Natl. Acad. Sci. U.S.A. 102: 2880-2885 (2005). *

• Mohamed ER, Naito M, Terasaki Y, Niu Y, Gohara S, Komatsu N, Shichijo S, Itoh K, Noguchi M. Capability of SART3109-118 peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles. Int. J. Oncol. 34: 529-536 (2009).

• Mohapatra SK, Cole LE, Evans C, Sobral BW, Bassaganya-Riera J, Hontecillas R, Vogel SN, Crasta OR. Modulation of hepatic PPAR expression during Ft LVS LPS-induced protection from Francisella tularensis LVS infection. BMC Infect. Dis. 10: 10 (2010). *

• Moingeon P. Clinical trials with allergen products: in search of biological markers of efficacy. Arb. Paul Ehrlich Inst. Bundesamt. Sera. Impfstoffe Frankf. A. M. 95: 182-187 (2006).

• Moir S, Fauci AS. B cells in HIV infection and disease. Nat. Rev. Immunol. 9: 235-245 (2009). *

• Moise L, McMurry JA, Buus S, Frey S, Martin WD, De Groot AS. In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes. Vaccine 27: 6471-6479 (2009). *

• Molina V, Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 38: 235-245 (2005).

• Moller M, de Wit E, Hoal EG. Past, present and future directions in human genetic susceptibility to tuberculosis. FEMS Immunol. Med. Microbiol. Aug 19 [Epub ahead of print] (2009). *

• Molnar E, Dopfer EP, Deswal S, Schamel WW. Models of antigen receptor activation in the design of vaccines. Curr. Pharm. Des. 15: 3237-3248 (2009).

• Monath TP, Frey SE. Possible autoimmune reactions following smallpox vaccination: the biologic false positive test for syphilis. Vaccine 27: 1645-1650 (2009). *

• Montano Loza AJ, Czaja AJ. Current therapy for autoimmune hepatitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 4: 202-214 (2007). *

• Montero Vega MT, de Andres Martín A. The significance of Toll-like receptors in human diseases. Allergol. Immunopathol. (Madr.) 37: 252-263 (2009).

• Montgomery SM, Ehlin AG, Ekbom A, Wakefield AJ. Pertussis infection in childhood and subsequent type 1 diabetes mellitus. Diabet. Med. 19: 986-993 (2002).

• Montor WR, Huang J, Hu Y, Hainsworth E, Lynch S, Kronish JW, Ordonez CL, Logvinenko T, Lory S, Labaer J. A genome-wide study of Pseudomonas aeruginosa outer membrane protein immunogenicity using self-assembling protein microarrays. Infect. Immun. 77: 4877-4886 (2009). *

• Mor F, Cohen IR. Vaccines to prevent and treat autoimmune diseases. Int. Arch. Allergy Immunol. 108: 345-349 (1995).

• Moreira LO, Smith AM, Defreitas AA, Qualls JE, El Kasmi KC, Murray PJ. Modulation of adaptive immunity by different adjuvant-antigen combinations in mice lacking Nod2. Vaccine 26: 5808-5813 (2008). *

• Morfín Maciel BM, Castillo Morfín BM. Scleroderma related to specific immunotherapy. A report of a case. Rev. Alerg. Mex. 56: 136-145 (2009).

• Moriwaki H, Shimizu M, Okuno M, Nishiwaki-Matsushima R. Chemoprevention of liver carcinogenesis with retinoids: basic and clinical aspects. Hepatol. Res. 37 Suppl. 2: S299-S302 (2007). *

• Morris DL, Montgomery SM, Thompson NP, Ebrahim S, Pounder RE, Wakefield AJ. Measles vaccination and inflammatory bowel disease: a national British Cohort Study. Am. J. Gastroenterol. 95: 3507-3512 (2000). *

• Morse M, Langer L, Starodub A, Hobeika A, Clay T, Lyerly HK. Current immunotherapeutic strategies in colon cancer. Surg. Oncol. Clin. N. Am. 16: 873-900 (2007).

• Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD. Inflamm. Bowel Dis. 15: 1399-1409 (2009). *

• Moser JM, Sassano ER, Leistritz DC, Eatrides JM, Phogat S, Koff W, Drake DR 3rd. Optimization of a dendritic cell-based assay for the in vitro priming of naive human CD4(+) T cells. J. Immunol. Methods Nov 16 [Epub ahead of print] (2009). *

• Moser K, Muehlinghaus G, Manz R, Mei H, Voigt C, Yoshida T, Dorner T, Hiepe F, Radbruch A. Long-lived plasma cells in immunity and immunopathology. Immunol. Lett. 103: 83-85 (2006).

• Mostbock S, Catalfamo M, Tagaya Y, Schlom J, Sabzevari H. Acquisition of antigen presentasomes (APS), an MHC/costimulatory complex, is a check-point of memory T cell homeostasis. Blood 109: 2488-2495 (2007). *

• Mouries J, Moron G, Schlecht G, Escriou N, Dadaglio G, Leclerc C. Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation. Blood 112: 3713-3722 (2008). *

• Moustakas AK, Papadopoulos GK. Use of MHC II structural features in the design of vaccines for organ-specific autoimmune diseases. Curr. Pharm. Des. 15: 3262-3273 (2009).

• Mouzaki A, Tselios T, Papathanassopoulos P, Matsoukas I, Chatzantoni K. Immunotherapy for multiple sclerosis: basic insights for new clinical strategies. Curr. Neurovasc. Res. 1: 325-340 (2004).

• Movsesyan N, Ghochikyan A, Mkrtichyan M, Petrushina I, Davtyan H, Olkhanud PB, Head E, Biragyn A, Cribbs DH, Agadjanyan MG. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS ONE 3: e2124 (2008). *

• Mowat AM, Donachie AM, Parker LA, Robson NC, Beacock-Sharp H, McIntyre LJ, Millington O, Chirdo F. The role of dendritic cells in regulating mucosal immunity and tolerance. Novartis Found. Symp. 252: 291-302 (2003).

• Muellenhoff M, Cukrowski T, Morgan M, Dorton D. Oral pemphigus vulgaris after anthrax vaccine administration: association or coincidence? J. Am. Acad. Dermatol. 50: 136-139 (2004).

• Mueller A, Sayi A, Hitzler I. Protective and pathogenic functions of T-cells are inseparable during the Helicobacter-host interaction. Discov. Med. 8: 68-73 (2009).

• Mueller SN, Hosiawa-Meagher KA, Konieczny BT, Sullivan BM, Bachmann MF, Locksley RM, Ahmed R, Matloubian M. Regulation of homeostatic chemokine expression and cell trafficking during immune responses. Science 317: 670-674 (2007). *

• Mueller YM, Do DH, Boyer JD, Kader M, Mattapallil JJ, Lewis MG, Weiner DB, Katsikis PD. CD8+ cell depletion of SHIV89.6P-infected macaques induces CD4+ T cell proliferation that contributes to increased viral loads. J. Immunol. 183: 5006-5012 (2009).

• Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics 113: e472-e486 (2004). *

• Mulcahy G, O'Neill S, Donnelly S, Dalton JP. Helminths at mucosal barriers - interaction with the immune system. Adv. Drug Deliv. Rev. 56: 853-868 (2003). *

• Munroe ME. Functional roles for T cell CD40 in infection and autoimmune disease: the role of CD40 in lymphocyte homeostasis. Semin. Immunol. 21: 283-288 (2009). *

• Murris-Espin M, Aubert M, Bosdure E, Dubus JC. Influenza vaccination coverage in patients with cystic fibrosis followed at 12 care centers in the Greater South Region of France for the season 2005/2006. Vaccine 26: 5612-5618 (2008). *

• Musicki K, Briscoe H, Britton WJ, Saunders BM. LIGHT contributes to early but not late control of Mycobacterium tuberculosis infection. Int. Immunol. Feb 25 [Epub ahead of print] (2010).

• Musselli C, Daverio-Zanetti S, Zanetti M. Antigenized antibodies expressing Vb8.2 TCR peptides immunize against rat experimental allergic encephalomyelitis. J. Immune Based Ther. Vaccines 2: 9 (2004). *

• Mustafa AS. HLA-promiscuous Th1-cell reactivity of MPT64 (Rv1980c), a major secreted antigen of Mycobacterium tuberculosis, in healthy subjects. Med. Princ. Pract. 18: 385-392 (2009).

• Mustafa AS. Th1 cell reactivity and HLA-DR binding prediction for promiscuous recognition of MPT63 (Rv1926c), a major secreted protein of Mycobacterium tuberculosis. Scand. J. Immunol. 69: 213-222 (2009). *

• Mustafa AS, Al-Attiyah R, Hanif SN, Shaban FA. Efficient testing of large pools of Mycobacterium tuberculosis RD1 peptides and identification of major antigens and immunodominant peptides recognized by human Th1 cells. Clin. Vaccine Immunol. 15: 916-924 (2008). *

• Muthumani G, Laddy DJ, Sundaram SG, Fagone P, Shedlock DJ, Kannan S, Wu L, Chung CW, Lankaraman KM, Burns J, Muthumani K, Weiner DB. Co-immunization with an optimized plasmid-encoded immune stimulatory interleukin, high-mobility group box 1 protein, results in enhanced interferon-gamma secretion by antigen-specific CD8 T cells. Immunology 128: e612-e620 (2009).

• Muthuswamy R, Urban J, Lee JJ, Reinhart TA, Bartlett D, Kalinski P. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res. 68: 5972-5978 (2008). *

• Mutter J, Naumann J, Schneider R, Walach H, Haley B. Mercury and autism: accelerating evidence? Neuro. Endocrinol. Lett. 26: 439-446 (2005).

• Mutwiri G, van Drunen Little-van den Hurk S, Babiuk LA. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides. Adv. Drug Deliv. Rev. 61: 226-232 (2009).

• Myllyluoma E, Ahonen AM, Korpela R, Vapaatalo H, Kankuri E. Effects of multispecies probiotic combination on Helicobacter pylori infection in vitro. Clin. Vaccine Immunol. 15: 1472-1482 (2008). *

• Nady S, Ignatz-Hoover J, Shata MT. IL-12 is the optimum cytokine to expand human Th17 cells in vitro. Clin. Vaccine Immunol. 16: 798-805 (2009).

• Nagayama Y. Graves' animal models of Graves' hyperthyroidism. Thyroid 17: 981-988 (2007).

• Nahmias AJ, Nahmias SB, Danielsson D. The possible role of transplacentally-acquired antibodies to infectious agents, with molecular mimicry to nervous system sialic acid epitopes, as causes of neuromental disorders: prevention and vaccine implications. Clin. Dev. Immunol. 13: 167-183 (2006). *

• Nakano T, Goto S, Lai CY, Hsu LW, Ono K, Kawamoto S, Lin YC, Kao YH, Chiang KC, Ohmori N, Goto T, Sato S, Tu CH, Jawan B, Cheng YF, Chen CL. Impact of vaccine therapy using nuclear histone H1 on allograft survival in experimental organ transplantation. Transpl. Immunol. 17: 147-152 (2007).

• Nakano T, Ono K, Goto S, Lai CY, Hsu LW, Kawamoto S, Lin YC, Kao YH, Chiang KC, Ohmori N, Goto T, Sato S, Jawan B, Cheng YF, Chen CL. Histone H1 vaccine therapy for overcoming acute rejection in experimental organ transplantation. Transplant. Proc. 38: 3247-3248 (2006). *

• Nakatsuji T, Liu YT, Huang CP, Gallo RL, Huang CM. Antibodies elicited by inactivated Propionibacterium acnes-based vaccines exert protective immunity and attenuate the IL-8 production in human sebocytes: relevance to therapy for acne vulgaris. J. Invest. Dermatol. 128: 2451-2457 (2008). *

• Nancey S, Holvoet S, Graber I, Joubert G, Philippe D, Martin S, Nicolas JF, Desreumaux P, Flourie B, Kaiserlian D. CD8(+) cytotoxic T cells induce relapsing colitis in normal mice. Gastroenterology 131: 485-496 (2006). *

• Nancy AL, Yehuda S. Chronic fatigue syndrome with autoantibodies - the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant. Autoimmun. Rev. 8: 52-55 (2008).

• Naor D, Nedvetzki S, Walmsley M, Yayon A, Turley EA, Golan I, Caspi D, Sebban LE, Zick Y, Garin T, Karussis D, Assayag-Asherie N, Raz I, Weiss L, Slavin S, Golan I. CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout mice. Ann. N. Y. Acad. Sci. 1110: 233-247 (2007). *

• Nardelli DT, Burchill MA, England DM, Torrealba J, Callister SM, Schell RF. Association of CD4+ CD25+ T cells with prevention of severe destructive arthritis in Borrelia burgdorferi-vaccinated and challenged gamma interferon-deficient mice treated with anti-interleukin-17 antibody. Clin. Diagn. Lab. Immunol. 11: 1075-1084 (2004). *

• Nardelli DT, Cloute JP, Luk KH, Torrealba J, Warner TF, Callister SM, Schell RF. CD4(+) CD25(+) T cells prevent arthritis associated with Borrelia vaccination and infection. Clin. Diagn. Lab. Immunol. 12: 786-792 (2005). *

• Nardelli DT, Warner TF, Callister SM, Schell RF. Anti-CD25 antibody treatment of mice vaccinated and challenged with Borrelia spp. does not exacerbate arthritis but inhibits Borreliacidal antibody production. Clin. Vaccine Immunol. 13: 884-891 (2006). *

• Narula N, Yamamura DL, Marshall JK. Should my patient with inflammatory bowel disease on immunosuppressive therapy be vaccinated against influenza virus? Can. J. Gastroenterol. 24: 121-125 (2010).

• Naser S, Shafran I, El-Zaatari F. Mycobacterium avium subsp. paratuberculosis in Crohn's disease is serologically positive. Clin. Diagn. Lab. Immunol. 6: 282 (1999). *

• Nasso M, Fedele G, Spensieri F, Palazzo R, Costantino P, Rappuoli R, Ausiello CM. Genetically detoxified pertussis toxin induces Th1/Th17 immune response through MAPKs and IL-10-dependent mechanisms. J. Immunol. 183: 1892-1899 (2009).

• Neau D, Bonnet F, Michaud M, Perel Y, Longy-Boursier M, Ragnaud JM, Guillard JM. Immune thrombocytopenic purpura after recombinant hepatitis B vaccine: retrospective study of seven cases. Scand. J. Infect. Dis. 30: 115-118 (1998).

• Neethling FA, Ramakrishna V, Keler T, Buchli R, Weidanz JA. Assessing vaccine potency using TCRmimic antibodies. Vaccine 26: 3092-3102 (2008).

• Nemazee D, Gavin A, Hoebe K, Beutler B. Immunology: Toll-like receptors and antibody responses. Nature 441: E4 (2006). *

• Nemes E, Lefler E, Szegedi L, Kapitany A, Kovacs JB, Balogh M, Szabados K, Tumpek J, Sipka S, Korponay-Szabo IR. Gluten intake interferes with the humoral immune response to recombinant hepatitis B vaccine in patients with celiac disease. Pediatrics 121: e1570-e1576 (2008). *

• Nesburn AB, Bettahi I, Dasgupta G, Chentoufi AA, Zhang X, You S, Morishige N, Wahlert AJ, Brown DJ, Jester JV, Wechsler SL, Benmohamed L. Functional Foxp3+ CD4+CD25(Bright+) "natural" regulatory T cells are abundant in rabbit conjunctiva and suppress virus-specific CD4+ and CD8+ effector T cells during ocular herpes infection. J. Virol. 81: 7647-7661 (2007). *

• Netto EM, Takahashi D, de Fatima Paim de Oliveira M, Barbosa P, Ferraz N, Paixao A, Oyafuso LK, Bortoletto C, Matos D, Paixao M, da Silva AO, Badaro R. Phase II randomized, placebo-controlled trial of M. vaccae-derived protein (PVAC((R))) for the treatment of psoriasis. Vaccine 24: 5056-5063 (2006). *

• Neumann D, Tschernig T, Boraschi D. Development of biologicals for the therapy of lupus erythematosus. Expert Rev. Vaccines 6: 1001-1011 (2007).

• Neumann-Haefelin C, Thimme R. Impact of the genetic restriction of virus-specific T-cell responses in hepatitis C virus infection. Genes Immun. 8: 181-192 (2007). *

• Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6: 148-158 (2006). *

• Newberry RD. Intestinal lymphoid tissues: is variety an asset or a liability? Curr. Opin. Gastroenterol. 24: 121-128 (2008). *

• Newell MK, Villalobos-Menuey E, Schweitzer SC, Harper ME, Camley RE. Cellular metabolism as a basis for immune privilege. J. Immune Based Ther. Vaccines 4:1 (2006). *

• Newport MJ, Goetghebuer T, Weiss HA, Whittle H, Siegrist CA, Marchant A; MRC Gambia Twin Study Group. Genetic regulation of immune responses to vaccines in early life. Genes Immun. 5: 122-129 (2004). *

• Newton S, Owusu-Agyei S, Filteau S, Gyan T, Kirkwood BR. Vitamin A supplements are well tolerated with the pentavalent vaccine. Vaccine 26: 6608-6613 (2008). *

• Newton SM, Mackie SL, Martineau AR, Wilkinson KA, Kampmann B, Fisher C, Dutta S, Levin M, Wilkinson RJ, Pasvol G. Reduction of chemokine secretion in response to mycobacteria in infliximab-treated patients. Clin. Vaccine Immunol. 15: 506-512 (2008). *

• Ney JT, Schmidt T, Kurts C, Zhou Q, Eckert D, Felsher DW, Schorle H, Knolle P, Tuting T, Barchet W, Buttner R, Limmer A, Gutgemann I. Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down-modulation. Hepatology 49: 471-481 (2009). *

• Ng N, Lam D, Paulus P, Batzer G, Horner AA. House dust extracts have both T(H)2 adjuvant and tolerogenic activities. J. Allergy Clin. Immunol. 117: 1074-1081 (2006). *

• Ngoi SM, Tovey MG, Vella AT. Targeting poly(I:C) to the TLR3-independent pathway boosts effector CD8 T cell differentiation through IFN-alpha/beta. J. Immunol. 181: 7670-7680 (2008). *

• Nguyen CT, Tran TT. Hepatitis vaccination and prophylaxis. Clin. Liver Dis. 13: 317-329 (2009).

• Nguyen XD, Muller-Berghaus J, Kalsch T, Schadendorf D, Borggrefe M, Kluter H. Differentiation of monocyte-derived dendritic cells under the influence of platelets. Cytotherapy 10: 720-729 (2008).

• Niazi KR, Ochoa MT, Sieling PA, Rooke NE, Peter AK, Mollahan P, Dickey M, Rabizadeh S, Rea TH, Modlin RL. Activation of human CD4(+) T cells by targeting MHC class II epitopes to endosomal compartments using human CD1 tail sequences. Immunology 122: 522-531 (2007). *

• Nicolas A, Cathelin D, Larmonier N, Fraszczak J, Puig PE, Bouchot A, Bateman A, Solary E, Bonnotte B. Dendritic cells trigger tumor cell death by a nitric oxide-dependent mechanism. J. Immunol. 179: 812-818 (2007). *

• Nie DY, Xu G, Ahmed S, Xiao ZC. DNA vaccine and the CNS axonal regeneration. Curr. Pharm. Des. 13: 2500-2506 (2007).

• Nielsen M, Lundegaard C, Blicher T, Lamberth K, Harndahl M, Justesen S, Roder G, Peters B, Sette A, Lund O, Buus S. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS ONE 2: e796 (2007). *

• Nielsen M, Lundegaard C, Lund O. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics 8: 238 (2007). *

• Niess JH, Reinecker HC. Dendritic cells in the recognition of intestinal microbiota. Cell. Microbiol. 8: 558-564 (2006). *

• Nigam P, Velu V, Kannanganat S, Chennareddi L, Kwa S, Siddiqui M, Amara RR. Expansion of FOXP3+ CD8 T cells with suppressive potential in colorectal mucosa following a pathogenic simian immunodeficiency virus infection correlates with diminished antiviral T cell response and viral control. J. Immunol. Jan 6 [Epub ahead of print] (2010).

• Nigro EA, Brini AT, Soprana E, Ambrosi A, Dombrowicz D, Siccardi AG, Vangelista L. Antitumor IgE adjuvanticity: key role of FcvarepsilonRI. J. Immunol. 183: 4530-4536 (2009).

• Nijhuis MM, van Keulen JK, Pasterkamp G, Quax PH, de Kleijn DP. Activation of the innate immune system in atherosclerotic disease. Curr. Pharm. Des. 13: 983-994 (2007).

• Nikolich-Zugich J. High specificity, not degeneracy, allows T cell alloresponses. Nat. Immunol. 8: 335-337 (2007). *

• Nikolich-Zugich J, Fremont DH, Miley MJ, Messaoudi I. The role of MHC polymorphism in anti-microbial resistance. Microbes Infect. 6: 501-512 (2004). *

• Nikolich-Zugich J, Slifka MK, Messaoudi I. The many important facets of T-cell repertoire diversity. Nat. Rev. Immunol. 4: 123-132 (2004). *

• Nilssen DE, Friman V, Theman K, Bjorkander J, Kilander A, Holmgren J, Hanson LA, Brandtzaeg P. B-cell activation in duodenal mucosa after oral cholera vaccination in IgA deficient subjects with or without IgG subclass deficiency. Scand. J. Immunol. 38: 201-208 (1993).

• Nilsson J, Bengtsson E, Fredrikson GN, Bjorkbacka H. Inflammation and immunity in diabetic vascular complications. Curr. Opin. Lipidol. 19: 519-524 (2008).

• Nilsson J, Fredrikson GN, Bjorkbacka H, Chyu KY, Shah PK. Vaccines modulating lipoprotein autoimmunity as a possible future therapy for cardiovascular disease. J. Intern. Med. 266: 221-231 (2009). *

• Nilsson J, Hansson GK. Autoimmunity in atherosclerosis: a protective response losing control? J. Intern. Med. 263: 464-478 (2008). *

• Ninkovic T, Kinarsky L, Engelmann K, Pisarev V, Sherman S, Finn OJ, Hanisch FG. Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes. Mol. Immunol. 47: 131-140 (2009). *

• Nishikawa H, Tsuji T, Jager E, Briones G, Ritter G, Old LJ, Galan JE, Shiku H, Gnjatic S. Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. Blood 111: 1404-1412 (2008). *

• Nishimura Y, Nakatsura T, Senju S. Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma. Nihon Rinsho Meneki Gakkai Kaishi 31: 383-391 (2008).

• Nitcheu-Tefit J, Dai MS, Critchley-Thorne RJ, Ramirez-Jimenez F, Xu M, Conchon S, Ferry N, Stauss HJ, Vassaux G. Listeriolysin O expressed in a bacterial vaccine suppresses CD4+CD25high regulatory T cell function in vivo. J. Immunol. 179: 1532-1541 (2007). *

• Niu L, Strahotin S, Hewes B, Zhang B, Zhang Y, Archer D, Spencer T, Dillehay D, Kwon B, Chen L, Vella AT, Mittler RS. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J. Immunol. 178: 4194-4213 (2007). *

• Niu MT, Davis DM, Ellenberg S. Recombinant hepatitis B vaccination of neonates and infants: emerging safety data from the Vaccine Adverse Event Reporting System. Pediatr. Infect. Dis. J. 15: 771-776 (1996).

• Niu MT, Rhodes P, Salive M, Lively T, Davis DM, Black S, Shinefield H, Chen RT, Ellenberg SS. Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD). J. Clin. Epidemiol. 51: 503-510 (1998).

• Niu MT, Salive ME, Ellenberg SS. Neonatal deaths after hepatitis B vaccine: the vaccine adverse event reporting system, 1991-1998. Arch. Pediatr. Adolesc. Med. 153: 1279-1282 (1999).

• Niu Y, Terasaki Y, Komatsu N, Noguchi M, Shichijo S, Itoh K. Identification of peptides applicable as vaccines for HLA-A26-positive cancer patients. Cancer Sci. 100: 2167-2174 (2009). *

• Njoku DB, Mellerson JL, Talor MV, Kerr DR, Faraday NR, Outschoorn I, Rose NR. Role of CYP2E1 immunoglobulin G4 subclass antibodies and complement in pathogenesis of idiosyncratic drug-induced hepatitis. Clin. Vaccine Immunol. 13: 258-265 (2006). *

• No authors listed. Don't exaggerate the systemic adverse effects of hepatitis B vaccination: the vaccine benefits people at risk. Prescrire. Int. 9: 59-63 (2000).

• No authors listed. Systemic adverse effects of hepatitis B vaccines are rare. Prescrire. Int. 13: 218-223 (2004).

• No authors listed. Global Advisory Committee on Vaccine Safety, 1-2 December 2005. Wkly. Epidemiol. Rec. 81: 15-19 (2006).

• No authors listed. In this issue. Eur. J. Immunol. 38: 895-896 (2008).

• No authors listed. In this issue. Eur. J. Immunol. 39: 1690-1691 (2009).

• No authors listed. In this issue. Eur. J. Immunol. 39: 628-629 (2009). *

• No authors listed. In this issue. Eur. J. Immunol. 38: 1179-1180 (2008). *

• No authors listed. Global Advisory Committee on Vaccine Safety, 12-13 June 2007. Wkly. Epidemiol. Rec. 82: 252-259 (2007).

• No authors listed. In this issue. Eur. J. Immunol. 38: 605-606 (2008).

• No authors listed. In this issue. Eur. J. Immunol. 38: 9-10 (2008). *

• No authors listed. In this issue. Eur. J. Immunol. 40: 6-7 (2009). *

• No authors listed. In this issue. Eur. J. Immunol. 40: 310-311 (2010). *

• Nochi T, Kiyono H. Innate immunity in the mucosal immune system. Curr. Pharm. Des. 12: 4203-4213 (2006).

• Noh KW, Poland GA, Murray JA. Hepatitis B vaccine nonresponse and celiac disease. Am. J. Gastroenterol. 98: 2289-2292 (2003). *

• Nokleby H, Feiring B. The Norwegian vaccination program. Tidsskr. Nor. Laegeforen. 126: 2538-2540 (2006).

• Nolte MA, van Olffen RW, van Gisbergen KP, van Lier RA. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol. Rev. 229: 216-231 (2009). *

• Nomura Y, Abe Y, Ishida Y, Kobayashi H, Harabuchi Y. Promiscuous peptides on the nontypeable Haemophilus influenzae P6 outer membrane protein. J. Clin. Immunol. 28: 361-369 (2008). *

• Norval M. The mechanisms and consequences of ultraviolet-induced immunosuppression. Prog. Biophys. Mol. Biol. 92: 108-118 (2006). *

• Norval M, Cullen AP, de Gruijl FR, Longstreth J, Takizawa Y, Lucas RM, Noonan FP, van der Leun JC. The effects on human health from stratospheric ozone depletion and its interactions with climate change. Photochem. Photobiol. Sci. 6: 232-251 (2007). *

• Nunn FG, Pirie RS, McGorum B, Wernery U, Poxton IR. Preliminary study of mucosal IgA in the equine small intestine: specific IgA in cases of acute grass sickness and controls. Equine Vet. J. 39: 457-460 (2007).

• Nussbaum G, Zanin-Zhorov A, Quintana F, Lider O, Cohen IR. Peptide p277 of HSP60 signals T cells: inhibition of inflammatory chemotaxis. Int. Immunol. 18: 1413-1419 (2006). *

• O'Brien C, Flower DR, Feighery C. Peptide length significantly influences in vitro affinity for MHC class II molecules. Immunome Res. 4: 6 (2008). *

• O'Daly JA, Lezama R, Gleason J. Isolation of Leishmania amastigote protein fractions which induced lymphocyte stimulation and remission of psoriasis. Arch. Dermatol. Res. 301: 411-427 (2009). *

• O'Daly JA, Lezama R, Rodriguez PJ, Silva E, Indriago NR, Pena G, Colorado I, Gleason J, Rodriguez B, Acuna L, Ovalles T. Antigens from Leishmania amastigotes induced clinical remission of psoriasis. Arch. Dermatol. Res. 301: 1-13 (2009). *

• O'Daly JA, Rodriguez B, Ovalles T, Pelaez C. Lymphocyte subsets in peripheral blood of patients with psoriasis before and after treatment with leishmania antigens. Arch. Dermatol. Res. Aug 26 [Epub ahead of print] (2009). *

• O'Leary S, Lloyd ML, Shellam GR, Robertson SA. Immunization with recombinant murine cytomegalovirus expressing murine zona pellucida 3 causes permanent infertility in BALB/c mice due to follicle depletion and ovulation failure. Biol. Reprod. 79: 849-860 (2008). *

• O'Mahony D, Morris JC, Quinn C, Gao W, Wilson WH, Gause B, Pittaluga S, Neelapu S, Brown M, Fleisher TA, Gulley JL, Schlom J, Nussenblatt R, Albert P, Davis TA, Lowy I, Petrus M, Waldmann TA, Janik JE. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin. Cancer Res. 13: 958-964 (2007). *

• O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104: 2235-2246 (2004). *

• O'Neill SG, Isenberg DA. Immunizing patients with systemic lupus erythematosus: a review of effectiveness and safety. Lupus 15: 778-783 (2006).

• Obar JJ, Lefrancois L. Memory CD8 T cell differentiation. Ann. N. Y. Acad. Sci. 1183: 251-266 (2010). *

• Ochoa-Reparaz J, Riccardi C, Rynda A, Jun S, Callis G, Pascual DW. Regulatory T cell vaccination without autoantigen protects against experimental autoimmune encephalomyelitis. J. Immunol. 178: 1791-1799 (2007). *

• Ochoa-Reparaz J, Rynda A, Ascon MA, Yang X, Kochetkova I, Riccardi C, Callis G, Trunkle T, Pascual DW. IL-13 production by regulatory T cells protects against experimental autoimmune encephalomyelitis independently of autoantigen. J. Immunol. 181: 954-968 (2008). *

• Odey F, Okomo U, Oyo-Ita A. Vaccines for preventing invasive salmonella infections in people with sickle cell disease. Cochrane Database Syst. Rev. 4: CD006975 (2009).

• Odunsi K, Lele S, Savalgi R. Vaccine therapy for cancer: fact or fiction? Surg. Technol. Int. 13: 39-47 (2004).

• Offit PA. Vaccines and autism revisited - the Hannah Poling case. N. Engl. J. Med. 358: 2089-2091 (2008). *

• Offit PA, Hackett CJ. Addressing parents' concerns: do vaccines cause allergic or autoimmune diseases? Pediatrics 111: 653-659 (2003). *

• Offringa R. Antigen choice in adoptive T-cell therapy of cancer. Curr. Opin. Immunol. 21: 190-199 (2009).

• Oh DY, Baumann K, Hamouda O, Eckert JK, Neumann K, Kucherer C, Bartmeyer B, Poggensee G, Oh N, Pruss A, Jessen H, Schumann RR. A frequent functional Toll-like receptor 7 polymorphism is associated with accelerated HIV-1 disease progression. AIDS 23: 297-307 (2009).

• Ohman L, Willen R, Hultgren OH, Hultgren Hornquist E. Acellular Bordetella pertussis vaccine enhances mucosal interleukin-10 production, induces apoptosis of activated Th1 cells and attenuates colitis in Galphai2-deficient mice. Clin. Exp. Immunol. 141: 37-46 (2005). *

• Ohta S, Bahrun U, Shimazu R, Matsushita H, Fukudome K, Kimoto M. Induction of long-term lipopolysaccharide tolerance by an agonistic monoclonal antibody to the Toll-like receptor 4/MD-2 complex. Clin. Vaccine Immunol. 13: 1131-1136 (2006). *

• Okada M, Shirakawa T. Frontier of Mycobacterium research - host vs. Mycobacterium. Kekkaku 80: 613-629 (2005).

• Okochi M, Hayashi H, Ito A, Kato R, Tamura Y, Sato N, Honda H. Identification of HLA-A24-restricted epitopes with high affinities to Hsp70 using peptide arrays. J. Biosci. Bioeng. 105: 198-203 (2008). *

• Okoli AS, Menard A, Mendz GL. Helicobacter spp. other than Helicobacter pylori. Helicobacter 14 Suppl. 1: 69-74 (2009). *

• Olafsdottir TA, Lingnau K, Nagy E, Jonsdottir I. IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice. Scand. J. Immunol. 69: 194-202 (2009). *

• Olah I, Nagy N, Magyar A, Palya V. Esophageal tonsil: a novel gut-associated lymphoid organ. Poult. Sci. 82: 767-770 (2003). *

• Onodera S, Ohshima S, Tohyama H, Yasuda K, Nishihira J, Iwakura Y, Matsuda I, Minami A, Koyama Y. A novel DNA vaccine targeting macrophage migration inhibitory factor protects joints from inflammation and destruction in murine models of arthritis. Arthritis Rheum. 56: 521-530 (2007). *

• Orban EC, Pallos JP, Kocsar LT. Production and properties of antiserum for radioimmunoassay of serum conjugated chenodeoxycholic acid and its preliminary application. Acta Med. Hung. 42: 77-84 (1985).

• Oren S, Mendelboim M, Braun-Moscovici Y, Paran D Dr, Ablin J, Litinsky I, Levartovsky D, Comaneshter D, Mendelson E, Azar R, Wigler I, Balbir-Gurman A, Caspi D, Elkayam O. Vaccination against influenza in rheumatoid arthritis patients: the effect of rituximab on the humoral response. Ann. Rheum. Dis. 67: 937-941 (2008).

• Ortega-Cava CF, Ishihara S, Rumi MA, Aziz MM, Kazumori H, Yuki T, Mishima Y, Moriyama I, Kadota C, Oshima N, Amano Y, Kadowaki Y, Ishimura N, Kinoshita Y. Epithelial Toll-like receptor 5 is constitutively localized in the mouse cecum and exhibits distinctive down-regulation during experimental colitis. Clin. Vaccine Immunol. 13: 132-138 (2006). *

• Ortega-Hernandez OD, Shoenfeld Y. Infection, vaccination, and autoantibodies in chronic fatigue syndrome, cause or coincidence? Ann. N. Y. Acad. Sci. 1173: 600-609 (2009). *

• Oshima M, Deitiker P, Atassi M. Targeting the antigen-binding site of HLA-restricting alleles in treatment of autoimmune disease. Crit. Rev. Immunol. 27: 271-288 (2007).

• Ottenhoff TH, Verreck FA, Hoeve MA, van de Vosse E. Control of human host immunity to mycobacteria. Tuberculosis (Edinb.) 85: 53-64 (2005).

• Ou-Yang HF, Hu XB, Ti XY, Shi JR, Li SJ, Qi HW, Wu CG. Suppression of allergic airway inflammation in a mouse model by Der p2 recombined BCG. Immunology 128: e343-e352 (2009). *

• Overbeck S, Rink L, Haase H. Modulating the immune response by oral zinc supplementation: a single approach for multiple diseases. Arch. Immunol. Ther. Exp. (Warsz.) 56: 15-30 (2008).

• Overstreet MG, Freyberger H, Cockburn IA, Chen YC, Tse SW, Zavala F. CpG-enhanced CD8+ T cell responses to peptide immunization are severely inhibited by B cells. Eur. J. Immunol. Oct 14 [Epub ahead of print] (2009). *

• Overwijk WW, de Visser KE, Tirion FH, de Jong LA, Pols TW, van der Velden YU, van den Boorn JG, Keller AM, Buurman WA, Theoret MR, Blom B, Restifo NP, Kruisbeek AM, Kastelein RA, Haanen JB. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J. Immunol. 176: 5213-5222 (2006). *

• Ovetchkine P. Secondary effects of vaccinations. Arch. Pediatr. 8: 316-320 (2001).

• Ovsyannikova IG, Dhiman N, Haralambieva IH, Vierkant RA, O'Byrne MM, Jacobson RM, Poland GA. Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes. Hum. Genet. Nov 10 [Epub ahead of print] (2009).

• Ovsyannikova IG, Haralambieva IH, Dhiman N, O'Byrne MM, Pankratz VS, Jacobson RM, Poland GA. Polymorphisms in the vitamin A receptor and innate immunity genes influence the antibody response to rubella vaccination. J. Infect. Dis. 201: 207-213 (2010). *

• Ovsyannikova IG, Jacobson RM, Poland GA. Variation in vaccine response in normal populations. Pharmacogenomics 5: 417-427 (2004).

• Ovsyannikova IG, Jacobson RM, Vierkant RA, O'Byrne MM, Poland GA. Replication of Rubella vaccine population genetic studies: validation of HLA genotype and humoral response associations. Vaccine 27: 6926-6931 (2009). *

• Ovsyannikova IG, Jacobson RM, Vierkant RA, Shane Pankratz V, Jacobsen SJ, Poland GA. Associations between human leukocyte antigen (HLA) alleles and very high levels of measles antibody following vaccination. Vaccine 22: 1914-1920 (2004). *

• Ovsyannikova IG, Johnson KL, Bergen HR 3rd, Poland GA. Mass spectrometry and peptide-based vaccine development. Clin. Pharmacol. Ther. 82: 644-652 (2007). *

• Oyoshi MK, Elkhal A, Kumar L, Scott JE, Koduru S, He R, Leung DY, Howell MD, Oettgen HC, Murphy GF, Geha RS. Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response. Proc. Natl. Acad. Sci. U.S.A. 106: 14954-14959 (2009). *

• Ozakbas S, Idiman E, Yulug B, Pakoz B, Bahar H, Gulay Z. Development of multiple sclerosis after vaccination against hepatitis B: a study based on human leucocyte antigen haplotypes. Tissue Antigens 68: 235-238 (2006). *

• Ozbay Hosnut F, Ozcay F, Selda Bayrakci U, Avci Z, Ozbek N. Etiology of hemolysis in two patients with hepatitis A infection: glucose-6-phosphate dehydrogenase deficiency or autoimmune hemolytic anemia. Eur. J. Pediatr. 167: 1435-1439 (2008).

• Pacheco AG, Cardoso CC, Moraes MO. IFNG +874T/A, IL10 -1082G/A and TNF -308G/A polymorphisms in association with tuberculosis susceptibility: a meta-analysis study. Hum. Genet. 123: 477-484 (2008). *

• Pahl MV, Gollapudi S, Sepassi L, Gollapudi P, Elahimehr R, Vaziri ND. Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol. Dial. Transplant. 25: 205-212 (2010).

• Paine P, Hobday C, Keating JJ, Brown CM, Morris JA. Ulcerative pan-colitis and primary sclerosing cholangitis with hyposplenism complicated by fatal pneumococcal meningitis. CME Gastroenterology 4: 95-96 (2001). *

• Pajtasz-Piasecka E, Rossowska J, Szyda A, Krawczenko A, Dus D. Generation of anti-tumor response by JAWS II mouse dendritic cells transduced with murine interleukin 12 genes. Oncol. Rep. 17: 1249-1257 (2007). *

• Pala P, Gomez-Roman VR, Gilmour J, Kaleebu P. An African perspective on mucosal immunity and HIV-1. Mucosal Immunol. 2: 300-314 (2009). *

• Palikhe A, Lokki ML, Saikku P, Leinonen M, Paldanius M, Seppänen M, Valtonen V, Nieminen MS, Sinisalo J. Chlamydia pneumoniae infection is associated with HLA-B*35 in patients with coronary artery disease. Clin. Vaccine Immunol. 15: 55-59 (2008). *

• Panda A, Arjona A, Sapey E, Bai F, Fikrig E, Montgomery RR, Lord JM, Shaw AC. Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol. 30: 325-333 (2009). *

• Panoutsakopoulou V, Huster KM, McCarty N, Feinberg E, Wang R, Wucherpfennig KW, Cantor H. Suppression of autoimmune disease after vaccination with autoreactive T cells that express Qa-1 peptide complexes. J. Clin. Invest. 113: 1218-1224 (2004). *

• Panter G, Kuznik A, Jerala R. Therapeutic applications of nucleic acids as ligands for Toll-like receptors. Curr. Opin. Mol. Ther. 11: 133-145 (2009).

• Papp M, Altorjay I, Lakos G, Tumpek J, Sipka S, Dinya T, Palatka K, Veres G, Udvardy M, Lakatos PL. Evaluation of the combined application of ethanol-fixed and formaldehyde-fixed neutrophil substrates for identifying atypical p-ANCA in inflammatory bowel disease. Clin. Vaccine Immunol. 16: 464-470 (2009). *

• Paranavitana C, Pittman P, Velauthapillai M, Dasilva L. Temporal cytokine profiling of Francisella tularensis-infected human peripheral blood mononuclear cells. J. Microbiol. Immunol. Infect. 41: 192-199 (2008). *

• Parekh VV, Lalani S, Van Kaer L. The in vivo response of invariant natural killer T cells to glycolipid antigens. Int. Rev. Immunol. 26: 31-48 (2007).

• Parez N, Fourgeux C, Mohamed A, Dubuquoy C, Pillot M, Dehee A, Charpilienne A, Poncet D, Schwartz-Cornil I, Garbarg-Chenon A. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection. J. Virol. 80: 1752-1761 (2006). *

• Park JS, Koh YS, Bang JY, Jeong YI, Lee JJ. Antitumor effect of all-trans retinoic acid-encapsulated nanoparticles of methoxy poly(ethylene glycol)-conjugated chitosan against CT-26 colon carcinoma in vitro. J. Pharm. Sci. 97: 4011-4019 (2008). *

• Park JY, Yoon SH, Kim EK, Yun SO, Park MY, Sohn HJ, Kim TG. A membrane-bound form of IL-4 enhances proliferation and antigen presentation of CD40-activated human B cells. Immunol. Lett. 116: 33-40 (2008).

• Park SD, Markowitz J, Pettei M, Weinstein T, Sison CP, Swiss SR, Levine J. Failure to respond to hepatitis B vaccine in children with celiac disease. J. Pediatr. Gastroenterol. Nutr. 44: 431-435 (2007). *

• Park SJ, Nakagawa T, Kitamura H, Atsumi T, Kamon H, Sawa S, Kamimura D, Ueda N, Iwakura Y, Ishihara K, Murakami M, Hirano T. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J. Immunol. 173: 3844-3854 (2004). *

• Parkinson T. The future of Toll-like receptor therapeutics. Curr. Opin. Mol. Ther. 10: 21-31 (2008).

• Pascolo S. Vaccination with messenger RNA (mRNA). Handb. Exp. Pharmacol. 183: 221-235 (2008).

• Pascual DW, Ochoa-Reparaz J, Rynda A, Yang X. Tolerance in the absence of autoantigen. Endocr. Metab. Immune Disord. Drug Targets 7: 203-210 (2007).

• Pascual DW, Riccardi C, Csencsits-Smith K. Distal IgA immunity can be sustained by E7+ B cells in L-selectin-/- mice following oral immunization. Mucosal Immunol. 1: 68-77 (2008).

• Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, Corey L, Hill J, Davis E, Flanigan C, Cloud G. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med. 360: 1191-1199 (2009). *

• Patel P, Barone F, Nunes C, Boursier L, Odell E, Escudier M, Challacombe S, Brostoff J, Spencer J, Sanderson J. Subepithelial dendritic B cells in orofacial granulomatosis. Inflamm. Bowel Dis. Nov 18 [Epub ahead of print] (2009).

• Patja A, Paunio M, Kinnunen E, Junttila O, Hovi T, Peltola H. Risk of Guillain-Barre syndrome after measles-mumps-rubella vaccination. J. Pediatr. 138: 250-254 (2001). *

• Pattison EJ, Harrison BJ, Griffiths CE, Silman AJ, Bruce IN. Environmental risk factors for the development of psoriatic arthritis: results from a case control study. Ann. Rheum. Dis. 67: 672-676 (2008).

• Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. Hepatology 43: S207-S220 (2006). *

• Pearce EL, Shen H. Generation of CD8 T cell memory is regulated by IL-12. J. Immunol. 179: 2074-2081 (2007). *

• Pechine S, Janoir C, Collignon A. Variability of Clostridium difficile surface proteins and specific serum antibody response in patients with Clostridium difficile-associated disease. J. Clin. Microbiol. 43: 5018-5025 (2005). *

• Pedraza-Sanchez S, Herrera-Barrios MT, Aldana-Vergara R, Neumann-Ordonez M, Gonzalez-Hernandez Y, Sada-Diaz E, de Beaucoudrey L, Casanova JL, Torres-Rojas M. Bacille Calmette-Guerin infection and disease with fatal outcome associated with a point mutation in the interleukin-12/interleukin-23 receptor beta-1 chain in two Mexican families. Int. J. Infect. Dis. Feb 18 [Epub ahead of print] (2010).

• Pegu A, Qin S, Fallert Junecko BA, Nisato RE, Pepper MS, Reinhart TA. Human lymphatic endothelial cells express multiple functional TLRs. J. Immunol. 180: 3399-3405 (2008). *

• Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 27: 6959-6965 (2009).

• Pemberton MN, Sloan P, Thakker NS. Oral lichenoid lesions after hepatitis B vaccination. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 89: 717-719 (2000).

• Penaloza-MacMaster P, Masopust D, Ahmed R. T-cell reconstitution without T-cell immunopathology in two models of T-cell-mediated tissue destruction. Immunology 128: 164-171 (2009). *

• Pender MP. Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection. Autoimmun. Rev. 8: 563-568 (2009).

• Peng SL. Signaling in B cells via Toll-like receptors. Curr. Opin. Immunol. 17: 230-236 (2005).

• Peng Y, Lin FC, Verardi PH, Jones LA, McChesney MB, Yilma TD. Pseudotyped single-cycle SIVs expressing gamma interferon augment T cell priming responses in vitro. J. Virol. 81: 2187-2195 (2007). *

• Perdigon G, Fuller R, Raya R. Lactic acid bacteria and their effect on the immune system. Curr. Issues Intest. Microbiol. 2: 27-42 (2001).

• Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, Baker B, Trocha A, Rosenberg R, Mackey E, Ueda P, Lu Z, Cohen D, Wrin T, Petropoulos CJ, Rosenberg ES, Walker BD. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 197: 563-571 (2008). *

• Perfetto SP, Chattopadhyay PK, Roederer M. Seventeen-colour flow cytometry: unravelling the immune system. Nat. Rev. Immunol. 4: 648-655 (2004).

• Perumalswami P, Peng L, Odin JA. Vaccination as a triggering event for autoimmune hepatitis. Semin. Liver Dis. 29: 331-334 (2009).

• Peruzzi D, Mori F, Conforti A, Lazzaro D, De Rinaldis E, Ciliberto G, La Monica N, Aurisicchio L. MMP11: a novel target antigen for cancer immunotherapy. Clin. Cancer Res. 15: 4104-4113 (2009). *

• Peters B, Sette A. Integrating epitope data into the emerging web of biomedical knowledge resources. Nat. Rev. Immunol. 7: 485-490 (2007). *

• Peters B, Sidney J, Bourne P, Bui HH, Buus S, Doh G, Fleri W, Kronenberg M, Kubo R, Lund O, Nemazee D, Ponomarenko JV, Sathiamurthy M, Schoenberger SP, Stewart S, Surko P, Way S, Wilson S, Sette A. The design and implementation of the immune epitope database and analysis resource. Immunogenetics 57: 326-336 (2005). *

• Peterson SH, Nardelli DT, Warner TF, Callister SM, Torrealba JR, Schell RF. Anti-p19 antibody treatment exacerbates lyme arthritis and enhances borreliacidal activity. Clin. Vaccine Immunol. 14: 510-517 (2007).

• Petrakova N, Gudmundsdotter L, Yermalovich M, Belikov S, Eriksson L, Pyakurel P, Johansson O, Biberfeld P, Andersson S, Isaguliants M. Autoimmunogenicity of the helix-loop-helix DNA-binding domain. Mol. Immunol. 46: 1467-1480 (2009). *

• Petrausch U, Jensen SM, Twitty C, Poehlein CH, Haley DP, Walker EB, Fox BA. Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity. J. Immunol. 183: 3682-3689 (2009).

• Petrovsky N. Immunomodulation with microbial vaccines to prevent type 1 diabetes mellitus. Nat. Rev. Endocrinol. 6: 131-138 (2010).

• Pfender NA, Grosch S, Roussel G, Koch M, Trifilieff E, Greer JM. Route of uptake of palmitoylated encephalitogenic peptides of myelin proteolipid protein by antigen-presenting cells: importance of the type of bond between lipid chain and peptide and relevance to autoimmunity. J. Immunol. 180: 1398-1404 (2008). *

• Pfister G, Herndler-Brandstetter D, Grubeck-Loebenstein B. Results from biomedical aging research. Trends and current examples from immunology. Bundesgesundheitsblatt. Gesundheitsforschung. Gesundheitsschutz. 49: 506-512 (2006).

• Phalipon A, Sansonetti PJ. Shigellosis: innate mechanisms of inflammatory destruction of the intestinal epithelium, adaptive immune response, and vaccine development. Crit. Rev. Immunol. 23: 371-401 (2003).

• Pham NL, Badovinac VP, Harty JT. A default pathway of memory CD8 T cell differentiation after dendritic cell immunization is deflected by encounter with inflammatory cytokines during antigen-driven proliferation. J. Immunol. 183: 2337-2348 (2009).

• Pham T, Claudepierre P, Constantin A, Fautrel B, Gossec L, Gottenberg JE, Goupille P, Hachulla E, Masson C, Morel J, Saraux A, Schaeverbeke T, Wendling D, Mariette X, Sibilia J. Abatacept therapy and safety management. Joint Bone Spine 76 Suppl. 1: S3-S55 (2009). *

• Phatsara C, Jonas E, Yammuen-art S, Buschbell H, Tesfaye D, Ponsuksili S, Tholen E, Juengst H, Schellander K, Wimmers K. Physiological interactions between the endocrine and immune systems shown in gene analysis in pigs. Dev. Biol. (Basel) 132: 161-167 (2008).

• Phillipps KS, Wykes MN, Liu XQ, Brown M, Blanchfield J, Toth I. A novel synthetic adjuvant enhances dendritic cell function. Immunology 128: e582-e588 (2009).

• Phillips B, Nylander K, Harnaha J, Machen J, Lakomy R, Styche A, Gillis K, Brown L, Gallo M, Knox J, Hogeland K, Trucco M, Giannoukakis N. A microsphere-based vaccine prevents and reverses new-onset autoimmune diabetes. Diabetes 57: 1544-1555 (2008). *

• Phipps S, Lam CE, Foster PS, Matthaei KI. The contribution of Toll-like receptors to the pathogenesis of asthma. Immunol. Cell Biol. 85: 463-470 (2007). *

• Piao J, Kamimura Y, Iwai H, Cao Y, Kikuchi K, Hashiguchi M, Masunaga T, Jiang H, Tamura K, Sakaguchi S, Azuma M. Enhancement of T-cell-mediated anti-tumour immunity via the ectopically expressed glucocorticoid-induced tumour necrosis factor receptor-related receptor ligand (GITRL) on tumours. Immunology 127: 489-499 (2009). *

• Pichurin P, Pham N, David CS, Rapoport B, McLachlan SM. HLA-DR3 transgenic mice immunized with adenovirus encoding the thyrotropin receptor: T Cell epitopes and functional analysis of the CD40 Graves' polymorphism. Thyroid 16: 1221-1227 (2006).

• Pichurin PN, Chazenbalk GD, Aliesky H, Pichurina O, Rapoport B, McLachlan SM. "Hijacking" the thyrotropin receptor: a chimeric receptor-lysosome associated membrane protein enhances deoxyribonucleic acid vaccination and induces Graves' hyperthyroidism. Endocrinology 145: 5504-5514 (2004). *

• Pickard KM, Bremner AR, Gordon JN, MacDonald TT. Microbial-gut interactions in health and disease. Immune responses. Best Pract. Res. Clin. Gastroenterol. 18: 271-285 (2004).

• Pier GB. Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity. Int. J. Med. Microbiol. 297: 277-295 (2007).

• Pierce SK. Understanding B cell activation: from single molecule tracking, through Tolls, to stalking memory in malaria. Immunol. Res. 43: 85-97 (2009). *

• Piercy J, Petrova S, Tchilian EZ, Beverley PC. CD45 negatively regulates tumour necrosis factor and interleukin-6 production in dendritic cells. Immunology 118: 250-256 (2006). *

• Piesche M, Hildebrandt Y, Chapuy B, Wulf GG, Trumper L, Schroers R. Characterization of HLA DR-restricted T-cell epitopes derived from human proteinase 3. Vaccine 27: 4718-4723 (2009). *

• Piesche M, Hildebrandt Y, Zettl F, Chapuy B, Schmitz M, Wulf G, Trumper L, Schroers R. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin. Hum. Immunol. 68: 572-576 (2007).

• Pietersz GA. Enhanced immune responses to an adenovirus CEA vaccine in CD4(+)CD25(+) regulatory T-cell inactivated mice. Expert Rev. Vaccines 6: 21-23 (2007).

• Pietrella D, Bistoni G, Corbucci C, Perito S, Vecchiarelli A. Candida albicans mannoprotein influences the biological function of dendritic cells. Cell. Microbiol. 8: 602-612 (2006). *

• Pietrella D, Lupo P, Rachini A, Sandini S, Ciervo A, Perito S, Bistoni F, Vecchiarelli A. A Candida albicans mannoprotein deprived of its mannan moiety is efficiently taken up, processed by human dendritic cells and induces T cell activation without stimulating proinflammatory cytokine production. Infect. Immun. 76: 4359-4367 (2008). *

• Pine SO, McElrath MJ, Bochud PY. Polymorphisms in Toll-like receptor 4 and Toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals. AIDS 23: 2387-2395 (2009).

• Pinilla-Ibarz J, May RJ, Korontsvit T, Gomez M, Kappel B, Zakhaleva V, Zhang RH, Scheinberg DA. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein. Leukemia 20: 2025-2033 (2006).

• Pizza G, Amadori M, Ablashi D, De Vinci C, Viza D. Cell mediated immunity to meet the avian influenza A (H5N1) challenge. Med. Hypotheses 67: 601-608 (2006).

• Placzkiewicz-Jankowska E, Szybinski Z, Huszno B. Environmental factors in the development of type 1 diabetes - a new insight. Przegl. Lek. 64: 175-179 (2007).

• Pleass RJ. Fc-receptors and immunity to malaria: from models to vaccines. Parasite Immunol. 31: 529-538 (2009). *

• Plebani A, Lougaris V, Soresina A, Meini A, Zunino F, Losi CG, Gatta R, Cattaneo G, Nespoli L, Marinoni M, Capolunghi F, Vivarelli M, Quinti I, Carsetti R. A novel immunodeficiency characterized by the exclusive presence of transitional B cells unresponsive to CpG. Immunology 121: 183-188 (2007). *

• Pless RP. Recent differing expert opinions regarding the safety profile of hepatitis B vaccines: is there really a controversy? Expert Opin. Drug Saf. 2: 451-455 (2003).

• Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457: 882-996 (2009). *

• Pluchino S, Zanotti L, Brambilla E, Rovere-Querini P, Capobianco A, Alfaro-Cervello C, Salani G, Cossetti C, Borsellino G, Battistini L, Ponzoni M, Doglioni C, Garcia-Verdugo JM, Comi G, Manfredi AA, Martino G. Immune regulatory neural stem/precursor cells protect from central nervous system autoimmunity by restraining dendritic cell function. PLoS One 4: e5959 (2009). *

• Poland G, Barrett A. The old and the new: successful vaccines of the 20th century and approaches to making vaccines for the important diseases of the 21st century. Curr. Opin. Immunol. 21: 305-307 (2009).

• Poland GA, Ovsyannikova IG, Jacobson RM. Vaccine immunogenetics: bedside to bench to population. Vaccine 26: 6183-6188 (2008).

• Poland GA, Ovsyannikova IG, Jacobson RM, Smith DI. Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin. Pharmacol. Ther. 82: 653-664 (2007). *

• Poland GA, Poterucha JJ. Hepatitis B immunization after liver transplantation: what is the answer? Liver Transpl. 11: 1181-1183 (2005). *

• Politi M, Papanagiotou P, Grunwald IQ, Roth C, Reith W. Acute disseminated encephalomyelitis. Radiologe 48: 553-559 (2008).

• Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat. Rev. Immunol. 9: 213-220 (2009). *

• Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, Perich R, Sanchez-Torres A, Pastor C, Sanchez-Schwartz C, Medina M, Gamboa R, Ugarte M. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J. Rheumatol. 35: 776-781 (2008).

• Poodt AE, Driessen GJ, de Klein A, van Dongen JJ, van der Burg M, de Vries E. TACI mutations and disease susceptibility in patients with common variable immunodeficiency. Clin. Exp. Immunol. 156: 35-39 (2009). *

• Pop SM, Wong CP, He Q, Wang Y, Wallet MA, Goudy KS, Tisch R. The type and frequency of immunoregulatory CD4+ T cells govern the efficacy of antigen-specific immunotherapy in diabetic NOD mice. Diabetes 56: 1395-1402 (2007). *

• Pope JE, Stevens A, Howson W, Bell DA. The development of rheumatoid arthritis after recombinant hepatitis B vaccination. J. Rheumatol. 25: 1687-1693 (1998).

• Popkov M, Gonzalez B, Sinha SC, Barbas CF 3rd. Instant immunity through chemically programmable vaccination and covalent self-assembly. Proc. Natl. Acad. Sci. U.S.A. 106: 4378-4383 (2009). *

• Popov I, Li M, Zheng X, Sun H, Zhang X, Feng B, Vladau C, Zhong R, Garcia B, Strejan G, Inman RD, Min WP, Ichim TE, Suzuki M. Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Res. Ther. 8: R141 (2006). *

• Poser CM. The multiple sclerosis trait and the development of multiple sclerosis: genetic vulnerability and environmental effect. Clin. Neurol. Neurosurg. 108: 227-233 (2006).

• Potzl J, Botteron C, Tausch E, Pedre X, Mueller AM, Mannel DN, Lechner A. Tracing functional antigen-specific CCR6 Th17 cells after vaccination. PLoS ONE 3: e2951 (2008). *

• Pou MA, Diaz-Torne C, Vidal S, Corchero C, Narvaez J, Nolla JM, Diaz-Lopez C. Development of autoimmune diseases after vaccination. J. Clin. Rheumatol. 14: 243-244 (2008).

• Prakken B, Albani S. Exploiting T cell crosstalk as a vaccination strategy for rheumatoid arthritis. Arthritis Rheum. 56: 389-392 (2007). *

• Prakken BJ, Albani S. Using biology of disease to understand and guide therapy of JIA. Best Pract. Res. Clin. Rheumatol. 23: 599-608 (2009).

• Precopio ML, Butterfield TR, Casazza JP, Little SJ, Richman DD, Koup RA, Roederer M. Optimizing peptide matrices for identifying T-cell antigens. Cytometry A. 73A: 1071-1078 (2008).

• Prelog M, Wilk C, Keller M, Karall T, Orth D, Geiger R, Walder G, Laufer G, Cottogni M, Zimmerhackl Lothar B, Stein J, Grubeck-Loebenstein B, Wuerzner R. Diminished response to tick-borne encephalitis vaccination in thymectomized children. Vaccine 26: 595-600 (2008). *

• Presicce P, Taddeo A, Conti A, Villa ML, Bella SD. Keyhole limpet hemocyanin induces the activation and maturation of human dendritic cells through the involvement of mannose receptor. Mol. Immunol. 45: 1136-1145 (2008). *

• Priebe GP, Walsh RL, Cederroth TA, Kamei A, Coutinho-Sledge YS, Goldberg JB, Pier GB. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. J. Immunol. 181: 4965-4975 (2008). *

• Prince A. Flagellar activation of epithelial signaling. Am. J. Respir. Cell. Mol. Biol. 34: 548-551 (2006). *

• Prince HE. Evaluation of the INOVA diagnostics enzyme-linked immunosorbent assay kits for measuring serum immunoglobulin G (IgG) and IgA to deamidated gliadin peptides. Clin. Vaccine Immunol. 13: 150-151 (2006). *

• Prioult G, Nagler-Anderson C. Mucosal immunity and allergic responses: lack of regulation and/or lack of microbial stimulation? Immunol. Rev. 206: 204-218 (2005). *

• Prud'homme GJ. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab. Invest. 87: 1077-1091 (2007). *

• Prud'homme GJ, Draghia-Akli R, Wang Q. Plasmid-based gene therapy of diabetes mellitus. Gene Ther. 14: 553-564 (2007). *

• Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat. Rev. Immunol. 9: 741-747 (2009). *

• Pulendran B, Cao W. 2008: A MyD88 O, DC. Immunity 29: 173-175 (2008). *

• Pulendran B, Tang H, Denning TL. Division of labor, plasticity, and crosstalk between dendritic cell subsets. Curr. Opin. Immunol. 20: 61-7 (2008). *

• Pulickal AS, Hambleton S, Callaghan MJ, Moore CE, Goulding J, Goodsall A, Baretto R, Lammas DA, Anderson ST, Levin M, Pollard AJ. Biliary cirrhosis in a child with inherited interleukin-12 deficiency. J. Trop. Pediatr. 54: 269-271 (2008).

• Pulko V, Liu X, Krco CJ, Harris KJ, Frigola X, Kwon ED, Dong H. TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. J. Immunol. 183: 3634-3641 (2009).

• Qadri F, Bhuiyan TR, Dutta KK, Raqib R, Alam MS, Alam NH, Svennerholm AM, Mathan MM. Acute dehydrating disease caused by Vibrio cholerae serogroups O1 and O139 induce increases in innate cells and inflammatory mediators at the mucosal surface of the gut. Gut 53: 62-69 (2004). *

• Qazi KR, Oehlmann W, Singh M, Lopez MC, Fernandez C. Microbial heat shock protein 70 stimulatory properties have different TLR requirements. Vaccine 25: 1096-1103 (2007). *

• Qie YQ, Wang JL, Liu W, Shen H, Chen JZ, Zhu BD, Xu Y, Zhang XL, Wang HH. More vaccine efficacy studies on the recombinant Bacille Calmette-Guerin co-expressing Ag85B, Mpt64 and Mtb8.4. Scand. J. Immunol. 69: 342-350 (2009). *

• Qin H, Cha SC, Neelapu SS, Lou Y, Wei J, Liu YJ, Kwak LW. Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T-cell, and not B-cell, dependent anti-lymphoma immunity. Blood 114: 4142-4149 (2009). *

• Qin H, Zhou C, Wang D, Ma W, Liang X, Lin C, Zhang Y, Zhang S. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens. Immunology 117: 419-430 (2006). *

• Qiu L, Huang D, Chen CY, Wang R, Shen L, Shen Y, Hunt R, Estep J, Haynes BF, Jacobs Jr WR, Letvin NL, Du G, Chen ZW. Severe tuberculosis induces unbalanced up-regulation of gene networks and overexpression of IL-22, MIP-1alpha, CCL27, IP-10, CCR4, CCR5, CXCR3, PD1, PDL2, IL-3, IFN-beta, TIM1, and TLR2 but low antigen-specific cellular responses. J. Infect. Dis. 198: 1514-1519 (2008). *

• Queirolo P, Acquati M. Targeted therapies in melanoma. Cancer Treat. Rev. 32: 524-531 (2006). *

• Quiding-Jarbrink M, Ahlstedt I, Lindholm C, Johansson EL, Lonroth H. Homing commitment of lymphocytes activated in the human gastric and intestinal mucosa. Gut 49: 519-525 (2001). *

• Quintana FJ, Cohen IR. Anti-ergotypic immunoregulation. Scand. J. Immunol. 64: 205-210 (2006). *

• Quintana FJ, Solomon A, Cohen IR, Nussbaum G. Induction of IgG3 to LPS via Toll-like receptor 4 co-stimulation. PLoS ONE 3: e3509 (2008). *

• Rachinsky A, Guerrero FD, Scoles GA. Proteomic profiling of Rhipicephalus (Boophilus) microplus midgut responses to infection with Babesia bovis. Vet. Parasitol. 152: 294-313 (2008).

• Rachman H, Kaufmann SH. Exploring functional genomics for the development of novel intervention strategies against tuberculosis. Int. J. Med. Microbiol. 297: 559-567 (2007).

• Rad R, Ballhorn W, Voland P, Eisenacher K, Mages J, Rad L, Ferstl R, Lang R, Wagner H, Schmid RM, Bauer S, Prinz C, Kirschning CJ, Krug A. Extracellular and intracellular pattern recognition receptors cooperate in the recognition of Helicobacter pylori. Gastroenterology 136: 2247-2257 (2009). *

• Radfar S, Wang Y, Khong HT. Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo. J. Immunol. 183: 6800-6807 (2009).

• Radhakrishnan S, Cabrera R, Bruns KM, Van Keulen VP, Hansen MJ, Felts SJ, Pease LR. Indirect recruitment of a CD40 signaling pathway in dendritic cells by B7-DC cross-linking antibody modulates T cell functions. PLoS ONE 4: e5373 (2009). *

• Radhakrishnan S, Cabrera R, Schenk EL, Nava-Parada P, Bell MP, Van Keulen VP, Marler RJ, Felts SJ, Pease LR. Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo. J. Immunol. 181: 3137-3147 (2008). *

• Raetz CR, Reynolds CM, Trent MS, Bishop RE. Lipid A modification systems in Gram-negative bacteria. Annu. Rev. Biochem. 76: 295-329 (2007). *

• Raghavan S, Holmgren J. CD4(+)CD25(+) suppressor T cells regulate pathogen induced inflammation and disease. FEMS Immunol. Med. Microbiol. 44: 121-127 (2005). *

• Rahier JF, Yazdanpanah Y, Viget N, Travis S, Colombel JF. Systematic review: influenza A (H1N1) virus in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 31: 5-10 (2010). *

• Raimondi G, Turner MS, Thomson AW, Morel PA. Naturally occurring regulatory T cells: recent insights in health and disease. Crit. Rev. Immunol. 27: 61-95 (2007).

• Rajapakse M, Schmidt B, Feng L, Brusic V. Predicting peptides binding to MHC class II molecules using multi-objective evolutionary algorithms. BMC Bioinformatics 8: 459 (2007). *

• Rajasalu T, Barth C, Spyrantis A, Durinovic-Bello I, Uibo R, Schirmbeck R, Boehm BO, Karges W. Experimental autoimmune diabetes: a new tool to study mechanisms and consequences of insulin-specific autoimmunity. Ann. N. Y. Acad. Sci. 1037: 208-215 (2004). *

• Rall GF. Measles virus 1998-2002: progress and controversy. Annu. Rev. Microbiol. 57: 343-367 (2003). *

• Rallabhandi P, Awomoyi A, Thomas KE, Phalipon A, Fujimoto Y, Fukase K, Kusumoto S, Qureshi N, Sztein MB, Vogel SN. Differential activation of human TLR4 by Escherichia coli and Shigella flexneri 2a lipopolysaccharide: combined effects of lipid A acylation state and TLR4 polymorphisms on signaling. J. Immunol. 180: 1139-1147 (2008). *

• Ram M, Shoenfeld Y. Hepatitis B: infection, vaccination and autoimmunity. Isr. Med. Assoc. J. 10: 61-64 (2008). *

• Ramachandran J, Eapen C, Kang G, Abraham P, Hubert DD, Kurian G, Hephzibah J, Mukhopadhya A, Chandy GM. Hepatitis E superinfection produces severe decompensation in patients with chronic liver disease. J. Gastroenterol. Hepatol. 19: 134-138 (2004). *

• Raman K, Bhat AG, Chandra N. A systems perspective of host-pathogen interactions: predicting disease outcome in tuberculosis. Mol. Biosyst. 6: 516-530 (2010).

• Raman VS, Lind EF, Benson MJ, Noelle RJ. Strategies for selective priming of memory B cells. Immunol. Lett. 109: 93-100 (2007).

• Ramasawmy R, Spina GS, Fae KC, Perreira AC, Nisihara R, Messias Reason IJ, Grinberg M, Tarasoutchi F, Kalil J, Guilherme L. Association of mannose-binding lectin gene polymorphism but not of mannose-binding serine protease-2 with chronic severe aortic regurgitation of rheumatic etiology. Clin. Vaccine Immunol. 15: 932-936 (2008). *

• Ramoner R, Putz T, Gander H, Rahm A, Bartsch G, Schaber C, Thurnher M. Dendritic cell activation by secretory phospholipase A2. Blood 105: 3583-3587 (2005). *

• Ramsey CD, Celedon JC. The hygiene hypothesis and asthma. Curr. Opin. Pulm. Med. 11: 14-20 (2005).

• Ranieri E. Role of immunity and tolerance in renal diseases. G. Ital. Nefrol. 22: 140-151 (2005).

• Rao VK, Price S, Perkins K, Aldridge P, Tretler J, Davis J, Dale JK, Gill F, Hartman KR, Stork LC, Gnarra DJ, Krishnamurti L, Newburger PE, Puck J, Fleisher T. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatr. Blood Cancer 52: 847-852 (2009). *

• Raska M, Weigl E. Heat shock proteins in autoimmune diseases. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech. Repub. 149: 243-249 (2005).

• Rauch A, James I, Pfafferott K, Nolan D, Klenerman P, Cheng W, Mollison L, McCaughan G, Shackel N, Jeffrey GP, Baker R, Freitas E, Humphreys I, Furrer H, Gunthard HF, Hirschel B, Mallal S, John M, Lucas M, Barnes E, Gaudieri S. Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology 50: 1017-1029 (2009).

• Raue HP, Slifka MK. Pivotal advance: CTLA-4+ T cells exhibit normal antiviral functions during acute viral infection. J. Leukoc. Biol. 81: 1165-1175 (2007). *

• Ravel G, Christ M, Horand F, Descotes J. Autoimmunity, environmental exposure and vaccination: is there a link? Toxicology 196: 211-216 (2004). *

• Ravikumar R, Anolik J, Looney RJ. Vaccine responses in patients with rheumatoid arthritis. Curr. Rheumatol. Rep. 9: 407-415 (2007).

• Ravkov EV, Williams MA. The magnitude of CD4+ T cell recall responses is controlled by the duration of the secondary stimulus. J. Immunol. 183: 2382-2389 (2009).

• Reche PA, Reinherz EL. Definition of MHC supertypes through clustering of MHC peptide-binding repertoires. Methods Mol. Biol. 409: 163-173 (2007).

• Redchenko I, Harrop R, Ryan MG, Hawkins RE, Carroll MW. Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4. Immunology 118: 50-57 (2006). *

• Reddehase MJ. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat. Rev. Immunol. 2: 831-844 (2002).

• Regner M, Pavlinovic L, Koskinen A, Young N, Trapani JA, Mullbacher A. Cutting edge: rapid and efficient in vivo cytotoxicity by cytotoxic T cells is independent of granzymes A and B. J. Immunol. 183: 37-40 (2009).

• Rehm KE, Connor RF, Jones GJ, Yimbu K, Mannie MD, Roper RL. Vaccinia virus decreases major histocompatibility complex (MHC) class II antigen presentation, T-cell priming, and peptide association with MHC class II. Immunology 128: 381-392 (2009). *

• Reif S, Lerner A. Tissue transglutaminase - the key player in celiac disease: a review. Autoimmun. Rev. 3: 40-45 (2004). *

• Reinhardt RL, Liang HE, Locksley RM. Cytokine-secreting follicular T cells shape the antibody repertoire. Nat. Immunol. 10: 385-393 (2009). *

• Remondo C, Cereda V, Mostbock S, Sabzevari H, Franzusoff A, Schlom J, Tsang KY. Human dendritic cell maturation and activation by a heat-killed recombinant yeast (Saccharomyces cerevisiae) vector encoding carcinoembryonic antigen. Vaccine 27: 987-994 (2009). *

• Ren D, Guo Y, He X, Wang F, Jiang L, Song S, He Y, Sun S. A novel mouse model for immunogenic evaluation of human HBV vaccines. Vaccine 27: 5692-5699 (2009).

• Ren SX, Ren ZJ, Zhao MY, Wang XB, Zuo SG, Yu F. Antitumor activity of endogenous mFlt4 displayed on a T4 phage nanoparticle surface. Acta Pharmacol. Sin. 30: 637-645 (2009).

• Rezaei N. Therapeutic targeting of pattern-recognition receptors. Int. Immunopharmacol. 6: 863-869 (2006).

• Rezaei N, Aghamohammadi A, Siadat SD, Moin M, Pourpak Z, Nejati M, Ahmadi H, Kamali S, Norouzian D, Tabaraei B, Read RC. Serum bactericidal antibody responses to meningococcal polysaccharide vaccination as a basis for clinical classification of common variable immunodeficiency. Clin. Vaccine Immunol. 15: 607-611 (2008). *

• Ribas A. Update on immunotherapy for melanoma. J. Natl. Compr. Canc. Netw. 4: 687-694 (2006).

• Rice J, Dossett ML, Ohlen C, Buchan SL, Kendall TJ, Dunn SN, Stevenson FK, Greenberg PD. DNA fusion gene vaccination mobilizes effective anti-leukemic cytotoxic T lymphocytes from a tolerized repertoire. Eur. J. Immunol. 38: 2118-2130 (2008). *

• Richmond P, Goldblatt D. Autism, inflammatory bowel disease, and MMR vaccine. Lancet 351: 1355-1356 (1998). *

• Riedl P, Reimann J, Schirmbeck R. Complexes of DNA vaccines with cationic, antigenic peptides are potent, polyvalent CD8+ T-cell-stimulating immunogens. Methods Mol. Med. 127: 159-170 (2006).

• Rist M, Smith C, Bell MJ, Burrows SR, Khanna R. Cross-recognition of HLA DR4 alloantigen by virus-specific CD8+ T cells: a new paradigm for self/non-self recognition. Blood 114: 2244-2253 (2009). *

• Rivera DS, McMurry JA, Buus S, Martin W, De Groot AS. Identification of immunogenic HLA-B7 "Achilles' heel" epitopes within highly conserved regions of HIV. Vaccine 26: 3059-3071 (2008).

• Robberecht E, Van Biervliet S, Vanrentergem K, Kerremans I. Outcome of total splenectomy with portosystemic shunt for massive splenomegaly and variceal bleeding in cystic fibrosis. J. Pediatr. Surg. 41: 1561-1565 (2006).

• Roberts L. Vaccines. Rotavirus vaccines' second chance. Science 305: 1890-1893 (2004). *

• Robertson DJ, Sandler RS. Measles virus and Crohn's disease: a critical appraisal of the current literature. Inflamm. Bowel Dis. 7: 51-57 (2001). *

• Robinson HL. New hope for an AIDS vaccine. Nat. Rev. Immunol. 2: 239-250 (2002).

• Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN, Csaky KG, Rosenberg SA. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J. Immunother. 27: 478-479 (2004).

• Robinson WH, Garren H, Utz PJ, Steinman L. Millennium Award. Proteomics for the development of DNA tolerizing vaccines to treat autoimmune disease. Clin. Immunol. 103: 7-12 (2002). *

• Robson NC, Hoves S, Maraskovsky E, Schnurr M. Presentation of tumour antigens by dendritic cells and challenges faced. Curr. Opin. Immunol. Jan 28 [Epub ahead of print] (2010).

• Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl. 10: S74-S85 (2004). *

• Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat. Rev. Immunol. 9: 480-490 (2009). *

• Roddis M, Carter RW, Sun MY, Weissensteiner T, McMichael AJ, Bowness P, Bodmer HC. Fully functional HLA B27-restricted CD4+ as well as CD8+ T cell responses in TCR transgenic mice. J. Immunol. 172: 155-161 (2004). *

• Rodeberg DA, Nuss RA, Elsawa SF, Erskine CL, Celis E. Generation of tumoricidal PAX3 peptide antigen specific cytotoxic T lymphocytes. Int. J. Cancer 119: 126-132 (2006). *

• Rodrigo Mora J, Von Andrian UH. Specificity and plasticity of memory lymphocyte migration. Curr. Top. Microbiol. Immunol. 308: 83-116 (2006).

• Rodriguez-Garcia M, Oliva H, Climent N, Escribese MM, Garcia F, Moran TM, Gatell JM, Gallart T. Impact of alpha-defensins1-3 on the maturation and differentiation of human monocyte-derived DCs. Concentration-dependent opposite dual effects. Clin. Immunol. 131: 374-384 (2009). *

• Rodriguez-Garcia M, Oliva H, Climent N, Garcia F, Gatell JM, Gallart T. Human immature monocyte-derived dendritic cells produce and secrete alpha-definsins 1-3. J. Leukoc. Biol. 82: 1143-1146 (2007). *

• Rodriguez-Pinto D. B cells as antigen presenting cells. Cell. Immunol. 238: 67-75 (2005). *

• Rogers JT, Lahiri DK. Metal and inflammatory targets for Alzheimer's disease. Curr. Drug Targets 5: 535-551 (2004).

• Rohn TA, Jennings GT, Hernandez M, Grest P, Beck M, Zou Y, Kopf M, Bachmann MF. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur. J. Immunol. 36: 2857-2867 (2006). *

• Romagnani S. Th1/Th2 cells. Inflamm. Bowel Dis. 5: 285-294 (1999). *

• Romagnani S. T-cell subsets (Th1 versus Th2). Ann. Allergy Asthma Immunol. 85: 9-18 (2000).

• Romagne F. Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors. Drug Discov. Today 12: 80-87 (2007).

• Romani L. Immunity to fungal infections. Nat. Rev. Immunol. 4: 1-23 (2004). *

• Romero-Adrian TB, Leal-Montiel J, Monsalve-Castillo F, Mengual-Moreno E, McGregor EG, Perini L, Antunez A. Helicobacter pylori: bacterial factors and the role of cytokines in the immune response. Curr. Microbiol. Oct 22 [Epub ahead of print] (2009).

• Romero-Mate A, Garcia-Donoso C, Cordoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am. J. Clin. Dermatol. 8: 143-155 (2007).

• Ronchi F, Cecchi P, Falcioni F, Marsciani A, Minak G, Muratori G, Tazzari PL, Beverini S. Thrombocytopenic purpura as adverse reaction to recombinant hepatitis B vaccine. Arch. Dis. Child. 78: 273-274 (1998). *

• Roner S, Zinser E, Menges M, Wiethe C, Littmann L, Hanig J, Steinkasserer A, Lutz MB. Minor role of bystander tolerance to fetal calf serum in a peptide-specific dendritic cell vaccine model against autoimmunity: comparison with serum-free cultures. J. Immunother. 31: 656-664 (2008).

• Rook GA. Th2 cytokines in susceptibility to tuberculosis. Curr. Mol. Med. 7: 327-337 (2007).

• Rook GA, Dheda K, Zumla A. Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat. Rev. Immunol. 5: 661-667 (2005). *

• Roozendaal R, Mempel TR, Pitcher LA, Gonzalez SF, Verschoor A, Mebius RE, von Andrian UH, Carroll MC. Conduits mediate transport of low-molecular-weight antigen to lymph node follicles. Immunity 30: 264-276 (2009). *

• Rose WA 2nd, McGowin CL, Pyles RB. FSL-1, a bacterial-derived Toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection. Virol. J. 6: 195 (2009).

• Rosenberg SA, Sherry RM, Morton KE, Yang JC, Topalian SL, Royal RE, Kammula US, Restifo NP, Hughes MS, Schwarz SL, Ngo LT, Mavroukakis SA, White DE. Altered CD8+ T-cell responses when immunizing with multiepitope peptide vaccines. J. Immunother. 29: 224-231 (2006). *

• Rosenthal KL. Tweaking innate immunity: the promise of innate immunologicals as anti-infectives. Can. J. Infect. Dis. Med. Microbiol. 17: 307-314 (2006).

• Ross AC, Chen Q, Ma Y. Augmentation of antibody responses by retinoic acid and costimulatory molecules. Semin. Immunol. 21: 42-50 (2009). *

• Rossi M, Piovesan P, Ghirardi O, Mastroianni D, Bombardi V, Battistini L, Cencioni MT, Capobianco D, Borsini F, Colombo M, Verdoliva A. Immunogenic, antigenic, fibrillogenic and inflammatory properties of new simplified beta-amyloid peptides. Mol. Immunol. 46: 2524-2532 (2009). *

• Rothman AL, Morishima C, Bonkovsky HL, Polyak SJ, Ray R, Di Bisceglie AM, Lindsay KL, Malet PF, Chang M, Gretch DR, Sullivan DG, Bhan AK, Wright EC, Koziel MJ. Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology 41: 617-625 (2005). *

• Roti M, Yang J, Berger D, Huston L, James EA, Kwok WW. Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus. J. Immunol. 180: 1758-1768 (2008). *

• Rott LS, Rose JR, Bass D, Williams MB, Greenberg HB, Butcher EC. Expression of mucosal homing receptor alpha4beta7 by circulating CD4+ cells with memory for intestinal rotavirus. J. Clin. Invest. 100: 1204-1208 (1997). *

• Rottem M, Shoenfeld Y. Vaccination and allergy. Curr. Opin. Otolaryngol. Head Neck Surg. 12: 223-231 (2004).

• Rousseau MC, Parent ME, St-Pierre Y. Potential health effects from non-specific stimulation of the immune function in early age: the example of BCG vaccination. Pediatr. Allergy Immunol. 19: 438-448 (2008). *

• Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, Dumitriu IE, Muller S, Iannacone M, Traversari C, Bianchi ME, Manfredi AA. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 5: 825-830 (2004). *

• Rowe HM, Lopes L, Brown N, Efklidou S, Smallie T, Karrar S, Kaye PM, Collins MK. Expression of vFLIP in a lentiviral vaccine vector activates NF-kappaB, matures dendritic cells and increases CD8+ T cell responses. J. Virol. 83: 1555-1562 (2009). *

• Rowe JH, Johanns TM, Ertelt JM, Lai JC, Way SS. Cytotoxic T-lymphocyte antigen 4 blockade augments the T-cell response primed by attenuated Listeria monocytogenes resulting in more rapid clearance of virulent bacterial challenge. Immunology 128: e471-e478 (2009). *

• Roy-Chowdhury N, Lu Y, Jiang J, Lee SW, Guha C, Roy-Chowdhury J. Comparison of gene therapy strategies for treatment of liver diseases. J. Gastroenterol. Hepatol. 19: S295-S301 (2004). *

• Rozis G, Benlahrech A, Duraisingham S, Gotch F, Patterson S. Human Langerhans' cells and dermal-type dendritic cells generated from CD34 stem cells express different Toll-like receptors and secrete different cytokines in response to Toll-like receptor ligands. Immunology 124: 329-338 (2008). *

• Rucker RP, Day NK, Good RA, Kamchaisatian W, Emmanuel P, Sleasman JW, Mayeski C, Dinglasan E, Haraguchi S, Tangsinmankong N. Effect of influenza virus vaccine on the expression of human immunodeficiency virus co-receptor CCR5. Ann. Allergy Asthma Immunol. 93: 272-276 (2004).

• Rudd BD, Brien JD, Davenport MP, Nikolich-Zugich J. Cutting edge: TLR ligands increase TCR triggering by slowing peptide-MHC class I decay rates. J. Immunol. 181: 5199-5203 (2008). *

• Rumke HC, Visser HK. Childhood vaccinations anno 2004. II. The real and presumed side effects of vaccination. Ned. Tijdschr. Geneeskd. 148: 364-371 (2004).

• Rupnow MF, Chang AH, Shachter RD, Owens DK, Parsonnet J. Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States. J. Infect. Dis. 200: 1311-1317 (2009). *

• Rutella S, De Cristofaro R, Ferraccioli G. Function and dysfunction of dendritic cells in autoimmune rheumatic diseases. Hum. Immunol. 70: 360-373 (2009).

• Rutherford ME, Dockerty JD, Jasseh M, Howie SR, Herbison P, Jeffries DJ, Mulholland K, Adegbola RA, Hill PC. Preventive measures in infancy to reduce under-five mortality: a case-control study in The Gambia. Trop. Med. Int. Health 14: 149-155 (2009).

• Rutschmann OT, McCrory DC, Matchar DB; Immunization Panel of the Multiple Sclerosis Council for Clinical Practice Guidelines. Immunization and MS: a summary of published evidence and recommendations. Neurology 59: 1837-1843 (2002). *

• Rutz S, Janke M, Kassner N, Hohnstein T, Krueger M, Scheffold A. Notch regulates IL-10 production by T helper 1 cells. Proc. Natl. Acad. Sci. U.S.A. 105: 3497-3502 (2008). *

• Sabbagh L, Snell LM, Watts TH. TNF family ligands define niches for T cell memory. Trends Immunol. 28: 333-339 (2007). *

• Sabbah A, Bose S. Retinoic acid inducible gene I activates innate antiviral response against human parainfluenza virus type 3. Virol. J. 6: 200 (2009).

• Sachdeva S, Datta U. Vitamin A-first dose supplement coverage evaluation amongst children aged 12-23 months residing in slums of Delhi, India. Indian J. Ophthalmol. 57: 299-303 (2009).

• Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2: 845-858 (2002).

• Saeki C, Nakano M, Takahashi H, Saito S, Homma S, Tajiri H, Zeniya M. Accumulation of functional regulatory T cells in actively inflamed liver in mouse dendritic cell-based autoimmune hepatic inflammation. Clin. Immunol. Jan 14 [Epub ahead of print] (2010). *

• Saha A, Bhattacharya-Chatterjee M, Foon KA, Celis E, Chatterjee SK. Stimulatory effects of CpG oligodeoxynucleotide on dendritic cell-based immunotherapy of colon cancer in CEA/HLA-A2 transgenic mice. Int. J. Cancer 124: 877-888 (2009). *

• Saha A, Chatterjee SK, Foon KA, Bhattacharya-Chatterjee M. Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen. Immunology 118: 483-496 (2006). *

• Sakakura K, Chikamatsu K, Furuya N, Appella E, Whiteside TL, Deleo AB. Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides. Clin. Immunol. 125: 43-51 (2007). *

• Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P. Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin. Cancer Res. 13: 4565-4574 (2007). *

• Salazar LM, Bermudez A, Patarroyo ME. HLA-DR allele reading register shifting is associated with immunity induced by SERA peptide analogues. Biochem. Biophys. Res. Commun. 372: 114-120 (2008). *

• Salem ML, Diaz-Montero CM, El-Naggar SA, Chen Y, Moussa O, Cole DJ. The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into naive recipient mice. Vaccine 27: 549-557 (2009). *

• Salem ML, El-Naggar SA, Kadima A, Gillanders WE, Cole DJ. The adjuvant effects of the Toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine 24: 5119-5132 (2006). *

• Salemi S, Picchianti-Diamanti A, Germano V, Donatelli I, Di Martino A, Facchini M, Nisini R, Biselli R, Ferlito C, Podesta E, Cappella A, Milanetti F, Rossi F, Amodeo R, Tabacco F, Di Rosa R, Lagana B, D Amelio R. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity. Clin. Immunol. Oct 20 [Epub ahead of print] (2009). *

• Salmi M, Jalkanen S. Lymphocyte homing to the gut: attraction, adhesion, and commitment. Immunol. Rev. 206: 100-113 (2005). *

• Salmond RJ, Luross JA, Williams NA. Immune modulation by the cholera-like enterotoxins. Expert Rev. Mol. Med. 4: 1-16 (2002).

• Samile N, Hassan T. Acute disseminated encephalomyelitis in children. A descriptive study in Tehran, Iran. Saudi Med. J. 28: 396-399 (2007).

• Samten B, Wang X, Barnes PF. Mycobacterium tuberculosis ESX-1 system-secreted protein ESAT-6 but not CFP10 inhibits human T-cell immune responses. Tuberculosis (Edinb.) 89 Suppl. 1: S74-S76 (2009).

• Sanchez J, Holmgren J. Cholera toxin structure, gene regulation and pathophysiological and immunological aspects. Cell. Mol. Life Sci. 65: 1347-1360 (2008). *

• Sander DM, Wolfsheimer K, Gallaher WR, Fermin CD, Haislip AM, Garry RF. Seroreactivity to A-type retrovirus proteins in a subset of cats with hyperthyroidism. Microsc. Res. Tech. 68: 235-238 (2005).

• Sanders CJ, Franchi L, Yarovinsky F, Uematsu S, Akira S, Nunez G, Gewirtz AT. Induction of adaptive immunity by flagellin does not require robust activation of innate immunity. Eur. J. Immunol. 39: 359-371 (2009). *

• Sanders CJ, Moore DA 3rd, Williams IR, Gewirtz AT. Both radioresistant and hemopoietic cells promote innate and adaptive immune responses to flagellin. J. Immunol. 180: 7184-7192 (2008). *

• Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Keler T, Yellin M, Weber J. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. 23: 741-750 (2005). *

• Sands BE, Cuffari C, Katz J, Kugathasan S, Onken J, Vitek C, Orenstein W. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 10: 677-692 (2004). *

• Sanjabi S, Mosaheb MM, Flavell RA. Opposing effects of TGF-beta and IL-15 cytokines control the number of short-lived effector CD8+ T cells. Immunity 31: 131-144 (2009). *

• Santegoets SJ, Bontkes HJ, Stam AG, Bhoelan F, Ruizendaal JJ, van den Eertwegh AJ, Hooijberg E, Scheper RJ, de Gruijl TD. Inducing antitumor T cell immunity: comparative functional analysis of interstitial versus Langerhans dendritic cells in a human cell line model. J. Immunol. 180: 4540-4509 (2008). *

• Santoro D, Stella M, Montalto G, Castellino S. Lupus nephritis after hepatitis B vaccination: an uncommon complication. Clin. Nephrol. 67: 61-63 (2007).

• Santos-Junior RR, Sartori A, Franco MD, Filho OG, Coelho-Castelo AA, Bonato VL, Cabrera WH, Ibanez OM, Silva CL. Immunomodulation and protection induced by DNA-hsp65 vaccination in an animal model of arthritis. Hum. Gene Ther. 16: 1338-1345 (2005).

• Santos-Junior RR, Sartori A, Lima DS, Souza PR, Coelho-Castelo AA, Bonato VL, Silva CL. DNA vaccine containing the mycobacterial hsp65 gene prevented insulitis in MLD-STZ diabetes. J. Immune Based Ther. Vaccines 7: 4 (2009).

• Sanz I, Wei C, Lee FE, Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin. Immunol. 20: 67-82 (2008). *

• Sarnaik AA, Weber JS. Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer J. 15: 169-173 (2009).

• Sartorius R, Pisu P, D'Apice L, Pizzella L, Romano C, Cortese G, Giorgini A, Santoni A, Velotti F, De Berardinis P. The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses. J. Immunol. 180: 3719-3728 (2008). *

• Sasakawa A, Tatsumi T, Takehara T, Yamaguchi S, Yamamoto M, Ohkawa K, Miyagi T, Hayashi N. Activated liver dendritic cells generate strong acquired immunity in alpha-galactosylceramide treatment. J. Hepatol. 50: 1155-1162 (2009).

• Sauermann U, Siddiqui R, Suh YS, Platzer M, Leuchte N, Meyer H, Matz-Rensing K, Stoiber H, Nurnberg P, Hunsmann G, Stahl-Hennig C, Krawczak M. MHC class I haplotypes associated with survival time in simian immunodeficiency virus (SIV)-infected rhesus macaques. Genes Immun. 9: 69-80 (2008). *

• Saurer L, McCullough KC, Summerfield A. In vitro induction of mucosa-type dendritic cells by all-trans retinoic acid. J. Immunol. 179: 3504-3514 (2007). *

• Savage P, Dyson J, Milrain M, Mathews D, King B, Chan HT, Barber L, Epenetos A, Ogg G, McMichael A, Glennie MJ, French RR. Immunotherapy with antibody-targeted HLA class I complexes: results of in vivo tumour cell killing and therapeutic vaccination. Tumour Biol. 28: 205-211 (2007).

• Savoy F, Nicolle DM, Rivier D, Chiavaroli C, Ryffel B, Quesniaux VF. Synthetic triacylated lipid a derivative activates antigen presenting cells via the TLR4 pathway and promotes antigen-specific responses in vivo. Immunobiology 211: 767-777 (2006).

• Savy M, Edmond K, Fine PE, Hall A, Hennig BJ, Moore SE, Mulholland K, Schaible U, Prentice AM. Landscape analysis of interactions between nutrition and vaccine responses in children. J. Nutr. 139: 2154S-2218S (2009). *

• Sawa Y, Arima Y, Ogura H, Kitabayashi C, Jiang JJ, Fukushima T, Kamimura D, Hirano T, Murakami M. Hepatic interleukin-7 expression regulates T cell responses. Immunity 30: 447-457 (2009). *

• Sawada S, Takei M, Ishiwata T. SAP discovery : the sword edges - beneficial and harmful. Autoimmun. Rev. 6: 444-449 (2007).

• Sawada S, Takei M, Ishiwata T, Shiraiwa H, Inomata H, Nozaki T. SLAM-associated protein solves a mystery of autoimmunity. Ann. N. Y. Acad. Sci. 1109: 19-30 (2007). *

• Saywell CA, Wittal RA, Kossard S. Lichenoid reaction to hepatitis B vaccination. Australas. J. Dermatol. 38: 152-154 (1997).

• Scagnolari C, Midulla F, Pierangeli A, Moretti C, Bonci E, Berardi R, De Angelis D, Selvaggi C, Di Marco P, Girardi E, Antonelli G. Gene expression of nucleic acid sensing pattern-recognition receptors in children hospitalized for respiratory syncytial virus-associated acute bronchiolitis. Clin. Vaccine Immunol. 16: 816-823 (2009). *

• Schalich J, Vytvytska O, Zauner W, Fischer MB, Buschle M, Aichinger G, Klade CS. Analysis of the human cytomegalovirus pp65-directed T cell response in healthy, HLA-A2 positive individuals. Biol. Chem. 389: 551-559 (2008). *

• Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 23: 3876-3886 (2005). *

• Schettini J, Mukherjee P. Physiological role of plasmacytoid dendritic cells and their potential use in cancer immunity. Clin. Dev. Immunol. 2008: 106321 (2008). *

• Schif-Zuck S, Wildbaum G, Karin N. Coadministration of plasmid DNA constructs encoding an encephalitogenic determinant and IL-10 elicits regulatory T cell-mediated protective immunity in the central nervous system. J. Immunol. 177: 8241-8247 (2006). *

• Schjetne KW, Thompson KM, Aarvak T, Fleckenstein B, Sollid LM, Bogen B. A mouse C kappa-specific T cell clone indicates that DC-SIGN is an efficient target for antibody-mediated delivery of T cell epitopes for MHC class II presentation. Int. Immunol. 14: 1423-1430 (2002). *

• Schleiss MR, Bernstein DI, Passo M, Parker S, Meric C, Verdier F, Newkirk MM. Lack of induction of autoantibody responses following immunization with cytomegalovirus (CMV) glycoprotein B (gB) in healthy CMV-seronegative subjects. Vaccine 23: 687-692 (2004). *

• Schlosser E, Mueller M, Fischer S, Basta S, Busch DH, Gander B, Groettrup M. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 26: 1626-1637 (2008). *

• Schmid D, Munz C. Immune surveillance via self digestion. Autophagy 3: 133-135 (2007). *

• Schmitt N, Morita R, Bourdery L, Bentebibel SE, Zurawski SM, Banchereau J, Ueno H. Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12. Immunity 31: 158-169 (2009). *

• Schnarr S, Franz JK, Krause A, Zeidler H. Lyme borreliosis. Best Pract. Res. Clin. Rheumatol. 20: 1099-1118 (2006).

• Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, Le Gall S, Rinaldo CR, Craggs SL, Allgaier RL, Power KA, Kuntzen T, Tung CS, Labute MX, Mueller SM, Harrer T, McMichael AJ, Goulder PJ, Aiken C, Brander C, Kelleher AD, Allen TM. Escape from the dominant HLA-B27 restricted CTL response in Gag is associated with a dramatic reduction in HIV-1 replication. J. Virol. 81: 12382-12393 (2007). *

• Schoenen H, Bodendorfer B, Hitchens K, Manzanero S, Werninghaus K, Nimmerjahn F, Agger EM, Stenger S, Andersen P, Ruland J, Brown GD, Wells C, Lang R. Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J. Immunol. Feb 17 [Epub ahead of print] (2010).

• Schoepfer AM, Flogerzi B, Fallegger S, Schaffer T, Mueller S, Nicod L, Seibold F. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am. J. Gastroenterol. 103: 2799-2806 (2008). *

• Schofield L, Grau GE. Immunological processes in malaria pathogenesis. Nat. Rev. Immunol. 5: 722-735 (2005). *

• Schonbach C, Koh JL, Flower DR, Brusic V. An update on the Functional Molecular Immunology (FIMM) database. Appl. Bioinformatics 4: 25-31 (2005).

• Schreiber TH, Deyev VV, Rosenblatt JD, Podack ER. Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination. Cancer Res. 69: 2026-2033 (2009). *

• Schuenke KW, Cook RG, Rich RR. Binding specificity of a class II-restricted hepatitis B epitope by DR molecules from responder and nonresponder vaccine recipients. Hum. Immunol. 59: 783-793 (1998).

• Schuh T, Rocken M, Schmoeckel C, Degitz K. Lichen ruber planus after hepatitis B vaccination. Hautarzt. 53: 650-651 (2002).

• Schulz KH, Gold S. Psychoneuroimmunology. The relationship between stress, immune system and health. Bundesgesundheitsblatt. Gesundheitsforschung. Gesundheitsschutz. 49: 759-772 (2006).

• Schunk MK, Macallum GE. Applications and optimization of immunization procedures. ILAR J. 46: 241-257 (2005). *

• Schuurhuis DH, Lesterhuis WJ, Kramer M, Looman MG, van Hout-Kuijer M, Schreibelt G, Boullart AC, Aarntzen EH, Benitez-Ribas D, Figdor CG, Punt CJ, de Vries IJ, Adema GJ. Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells. Cancer Immunol. Immunother. 58: 1109-1115 (2009). *

• Schwabe M, Lubbert M. Epigenetic lesions in malignant melanoma. Curr. Pharm. Biotechnol. 8: 382-387 (2007).

• Schwartz M, Kipnis J. Therapeutic T cell-based vaccination for neurodegenerative disorders: the role of CD4+CD25+ regulatory T cells. Ann. N. Y. Acad. Sci. 1051: 701-708 (2005). *

• Schwartz M, Kipnis J. A common vaccine for fighting neurodegenerative disorders: recharging immunity for homeostasis. Trends Pharmacol. Sci. 25: 407-412 (2004). *

• Schwendener RA, Ludewig B, Cerny A, Engler O. Liposome-based vaccines. Methods Mol. Biol. 605: 163-175 (2010). *

• Scott-Moncrieff JC, Glickman NW, Glickman LT, HogenEsch H. Lack of association between repeated vaccination and thyroiditis in laboratory Beagles. J. Vet. Intern. Med. 20: 818-821 (2006).

• Scriba TJ, Kalsdorf B, Abrahams DA, Isaacs F, Hofmeister J, Black G, Hassan HY, Wilkinson RJ, Walzl G, Gelderbloem SJ, Mahomed H, Hussey GD, Hanekom WA. Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J. Immunol. 180: 1962-1970 (2008). *

• Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Isaacs F, Keyser A, Moyo S, Brittain N, Lawrie A, Gelderbloem S, Veldsman A, Hatherill M, Hawkridge A, Hill AV, Hussey GD, Mahomed H, McShane H, Hanekom WA. Modified vaccinia ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4(+) T cells. Eur. J. Immunol. Dec 16 [Epub ahead of print] (2009). *

• Seagroatt V. MMR vaccine and Crohn's disease: ecological study of hospital admissions in England, 1991 to 2002. BMJ 330: 1120-1121 (2005). *

• Seagroatt V, Goldacre MJ. Crohn's disease, ulcerative colitis, and measles vaccine in an English population, 1979-1998. J. Epidemiol. Community Health 57: 883-887 (2003).

• Sechi LA, Ahmed N, Felis GE, Dupre I, Cannas S, Fadda G, Bua A, Zanetti S. Immunogenicity and cytoadherence of recombinant heparin binding haemagglutinin (HBHA) of Mycobacterium avium subsp. paratuberculosis: functional promiscuity or a role in virulence? Vaccine 24: 236-243 (2006). *

• Sechi LA, Rosu V, Pacifico A, Fadda G, Ahmed N, Zanetti S. Humoral immune responses of type 1 diabetes patients to Mycobacterium avium subsp. paratuberculosis lend support to the infectious trigger hypothesis. Clin. Vaccine Immunol. 15: 320-326 (2008).

• Sedegah M, Charoenvit Y, Aguiar J, Sacci J, Hedstrom R, Kumar S, Belmonte A, Lanar DE, Jones TR, Abot E, Druilhe P, Corradin G, Epstein JE, Richie TL, Carucci DJ, Hoffman SL. Effect on antibody and T-cell responses of mixing five GMP-produced DNA plasmids and administration with plasmid expressing GM-CSF. Genes Immun. 5: 553-561 (2004). *

• Segal BH, Wang XY, Dennis CG, Youn R, Repasky EA, Manjili MH, Subjeck JR. Heat shock proteins as vaccine adjuvants in infections and cancer. Drug Discov. Today 11: 534-540 (2006).

• Segura E, Albiston AL, Wicks IP, Chai SY, Villadangos JA. Different cross-presentation pathways in steady-state and inflammatory dendritic cells. Proc. Natl. Acad. Sci. U.S.A. 106: 20377-20381 (2009). *

• Sejvar JJ. Acute disseminated encephalomyelitis. Curr. Infect. Dis. Rep. 10: 307-314 (2008).

• Sejvar JJ, Labutta RJ, Chapman LE, Grabenstein JD, Iskander J, Lane JM. Neurologic adverse events associated with smallpox vaccination in the United States, 2002-2004. JAMA 294: 2744-2750 (2005). *

• Sela M. Immunomodulatory vaccines against autoimmune diseases. Rejuvenation Res. 9: 126-133 (2006).

• Sela M, Mozes E. Therapeutic vaccines in autoimmunity. Proc. Natl. Acad. Sci. U.S.A. 101: 14586-14592 (2004). *

• Selleri S, Deola S, Pos Z, Jin P, Worschech A, Slezak SL, Rumio C, Panelli MC, Maric D, Stroncek DF, Wang E, Marincola FM. GM-CSF/IL-3/IL-5 receptor common beta chain (CD131) expression as a biomarker of antigen-stimulated CD8+ T cells. J. Transl. Med. 6: 17 (2008). *

• Selmi C, Battezzati PM, Gershwin ME, Tishler M, Shoenfeld Y. Vaccines in the 21st century: the genetic response and the innocent bystander. Autoimmun. Rev. 4: 79-81 (2005).

• Semeniuk CA, Capina RE, Mendoza MG, Kimani J, Ball TB, Luo M, Plummer FA. Identification and characterization of HLA-A*0301 epitopes in HIV-1 gag proteins using a novel approach. J. Immunol. Methods Nov 7 [Epub ahead of print] (2009). *

• Semeniuk CA, McKinnon L, Peters HO, Gubbins M, Mao X, Ball TB, Luo M, Plummer FA. Multiple T-cell epitopes overlap positively-selected residues in the p1 spacer protein of HIV-1 gag. AIDS 27: 771-777 (2009).

• Sen G, Chen Q, Snapper CM. Immunization of aged mice with a pneumococcal conjugate vaccine combined with an unmethylated CpG-containing oligodeoxynucleotide restores defective immunoglobulin G antipolysaccharide responses and specific CD4+-T-cell priming to young adult levels. Infect. Immun. 74: 2177-2186 (2006). *

• Sender LY, Gibbert K, Suezer Y, Radeke HH, Kalinke U, Waibler Z. CD40 ligand-triggered human dendritic cells mount interleukin-23 responses that are further enhanced by danger signals. Mol. Immunol. Jan 11 [Epub ahead of print] (2010). *

• Sendid B, Dotan N, Nseir S, Savaux C, Vandewalle P, Standaert A, Zerimech F, Guery BP, Dukler A, Colombel JF, Poulain D. Antibodies against glucan, chitin, and Saccharomyces cerevisiae mannan as new biomarkers of Candida albicans infection that complement tests based on C. albicans mannan. Clin. Vaccine Immunol. 15: 1868-1877 (2008). *

• Senju S, Hirata S, Motomura Y, Fukuma D, Matsunaga Y, Fukushima S, Matsuyoshi H, Nishimura Y. Pluripotent stem cells as source of dendritic cells for immune therapy. Int. J. Hematol. Feb 13 [Epub ahead of print] (2010).

• Seow CH, de Silva S, Kaplan GG, Devlin SM, Ghosh S, Panaccione R. Managing the risks of IBD therapy. Curr. Gastroenterol. Rep. 11: 509-517 (2009).

• Serra A, Nuti S, Tavarini S, Sammicheli C, Rosa D, Saletti G, Soldaini E, Abrignani S, Wack A. Coligation of the hepatitis C virus receptor CD81 with CD28 primes naive T lymphocytes to acquire type 2 effector function. J. Immunol. 181: 174-185 (2008). *

• Serwanga J, Shafer LA, Pimego E, Auma B, Watera C, Rowland S, Yirrell D, Pala P, Grosskurth H, Whitworth J, Gotch F, Kaleebu P. Host HLA B*allele-associated multi-clade Gag T-cell recognition correlates with slow HIV-1 disease progression in antiretroviral therapy-naive Ugandans. PLoS ONE 4: e4188 (2009). *

• Setti M, Fenoglio D, Ansaldi F, Filaci G, Bacilieri S, Sticchi L, Ferrera A, Indiveri F, Ghio M. Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. Vaccine 27: 3367-3372 (2009). *

• Sever JL, Brenner AI, Gale AD, Lyle JM, Moulton LH, West DJ; Anthrax Vaccine Export Committee. Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiol. Drug Saf. 11: 189-202 (2002).

• Seya T, Akazawa T, Tsujita T, Matsumoto M. Role of Toll-like receptors in adjuvant-augmented immune therapies. Evid. Based Complement. Alternat. Med. 3: 31-38 (2006). *

• Shackleton M, Davis ID, Hopkins W, Jackson H, Dimopoulos N, Tai T, Chen Q, Parente P, Jefford M, Masterman KA, Caron D, Chen W, Maraskovsky E, Cebon J. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun. 4: 9 (2004). *

• Shacklett BL. Mucosal immunity to HIV: a review of recent literature. Curr. Opin. HIV AIDS 3: 541-547 (2008).

• Shale MJ. The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease. Br. Med. Bull. 92: 61-77 (2009).

• Shao C, Qu J, He L, Zhang Y, Wang J, Zhou H, Wang Y, Liu X. Dendritic cells transduced with an adenovirus vector encoding interleukin-12 are a potent vaccine for invasive pulmonary aspergillosis. Genes Immun. 6: 103-114 (2005). *

• Sharma D, Balamurali MM, Chakraborty K, Kumaran S, Jeganathan S, Rashid U, Ingallinella P, Varadarajan R. Protein minimization of the gp120 binding region of human CD4. Biochemistry 44: 16192-16202 (2005). *

• Sharma MD, Hou DY, Liu Y, Koni PA, Metz R, Chandler P, Mellor AL, He Y, Munn DH. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 113: 6102-6111 (2009). *

• Sharp FA, Ruane D, Claass B, Creagh E, Harris J, Malyala P, Singh M, O'Hagan DT, Petrilli V, Tschopp J, O'Neill LA, Lavelle EC. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc. Natl. Acad. Sci. U.S.A. 106: 870-875 (2009). *

• Shaw MH, Freeman GJ, Scott MF, Fox BA, Bzik DJ, Belkaid Y, Yap GS. Tyk2 negatively regulates adaptive Th1 immunity by mediating IL-10 signaling and promoting IFN-gamma-dependent IL-10 reactivation. J. Immunol. 176: 7263-7271 (2006). *

• Shedlock DJ, Silvestri G, Weiner DB. Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nat. Rev. Immunol. 9: 717-728 (2009). *

• Sheikh KA, Nachamkin I, Ho TW, Willison HJ, Veitch J, Ung H, Nicholson M, Li CY, Wu HS, Shen BQ, Cornblath DR, Asbury AK, McKhann GM, Griffin JW. Campylobacter jejuni lipopolysaccharides in Guillain-Barre syndrome: molecular mimicry and host susceptibility. Neurology 51: 371-378 (1998).

• Shen Y, Chen J, Zhang X, Wu X, Xu Q. Human TNF-alpha gene vaccination prevents collagen-induced arthritis in mice. Int. Immunopharmacol. 7: 1140-1149 (2007).

• Sheng KC, Pietersz GA, Tang CK, Ramsland PA, Apostolopoulos V. Reactive oxygen species level defines two functionally distinctive stages of inflammatory dendritic cell development from mouse bone marrow. J. Immunol. Feb 22 [Epub ahead of print] (2010).

• Sheng XL, Zhang H. In-vitro activation of cytotoxic T lymphocytes by fusion of mouse hepatocellular carcinoma cells and lymphotactin gene-modified dendritic cells. World J. Gastroenterol. 13: 5944-5950 (2007). *

• Sherlock S. Biotechnologies and liver diseases. Forum (Genova) 9 (3 Suppl. 3): 63-66 (1999).

• Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2: 389-400 (2002). *

• Shi C, Zhang H, Zhang T, Wang X, Bai B, Zhao Y, Zhang C, Xu Z. New alternative vaccine component against Mycobacterium tuberculosis - heat shock protein 16.3 or its T-cell epitope. Scand. J. Immunol. 70: 465-474 (2009). *

• Shi M, Ye Z, Umeshappa KS, Moyana T, Xiang J. Alpha tumor necrosis factor contributes to CD8(+) T cell survival in the transition phase. Biochem. Biophys. Res. Commun. 360: 702-707 (2007). *

• Shigihara T, Shimada A, Oikawa Y, Yoneyama H, Kanazawa Y, Okubo Y, Matsushima K, Yamato E, Miyazaki JI, Kasuga A, Saruta T, Narumi S. CXCL10 DNA vaccination prevents spontaneous diabetes through enhanced beta cell proliferation in NOD mice. J. Immunol. 175: 8401-8408 (2005). *

• Shilyansky J, Jacobs P, Doffek K, Sugg SL. Induction of cytolytic T lymphocytes against pediatric solid tumors in vitro using autologous dendritic cells pulsed with necrotic primary tumor. J. Pediatr. Surg. 42: 54-61 (2007).

• Shim HK, Musson JA, Harper HM, McNeill HV, Walker N, Flick-Smith H, von Delwig A, Williamson ED, Robinson JH. Mechanisms of major histocompatibility complex class II-restricted processing and presentation of the V antigen of Yersinia pestis. Immunology 119: 385-392 (2006). *

• Shim M, Durazo F. Multinodular fatty liver after herpes-zoster vaccine: case report and review of the literature. Ann. Hepatol. 7: 382-385 (2008).

• Shin H, Blackburn SD, Intlekofer AM, Kao C, Angelosanto JM, Reiner SL, Wherry EJ. A role for the transcriptional repressor Blimp-1 in CD8+ T cell exhaustion during chronic viral infection. Immunity 31: 309-320 (2009).

• Shin SJ, Wu CW, Steinberg H, Talaat AM. Identification of novel virulence determinants in Mycobacterium paratuberculosis by screening a library of insertional mutants. Infect. Immun. 74: 3825-3833 (2006). *

• Shingler WH, Chikoti P, Kingsman SM, Harrop R. Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4. Int. Immunol. 20: 1057-1066 (2008).

• Shiratsuchi T, Schneck J, Kawamura A, Tsuji M. Human CD1 dimeric proteins as indispensable tools for research on CD1-binding lipids and CD1-restricted T cells. J. Immunol. Methods 345: 49-59 (2009). *

• Shoenfeld Y, Aron-Maor A. Vaccination and autoimmunity-'vaccinosis': a dangerous liaison? J. Autoimmun. 14: 1-10 (2000). *

• Shofner JD, Vasquez JG, Berger CL, Edelson RL. Improved generation of anti-tumor immunity by antigen dose limitation. J. Immune Based Ther. Vaccines 5: 2 (2007).

• Shurin GV, Tourkova IL, Kaneno R. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J. Immunol. 183: 137-144 (2009).

• Shurin MR, Shurin GV, Chatta GS. Aging and the dendritic cell system: implications for cancer. Crit. Rev. Oncol. Hematol. 64: 90-105 (2007).

• Sibilia J. Treatment of systemic lupus erythematosus in 2006. Joint Bone Spine 73: 591-598 (2006). *

• Sibilia J, Maillefert JF. Vaccination and rheumatoid arthritis. Ann. Rheum. Dis. 61: 575-576 (2002). *

• Sibilia J, Westhovens R. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 25: S46-S56 (2007).

• Sidhu M, Griffiths MM, Bradley DS. Vaccination with collagen-pulsed dendritic cells prevents the onset and reduces the disease severity in the mouse model of spontaneous polychondritis. Clin. Exp. Immunol. 157: 350-358 (2009). *

• Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol. 9: 1 (2008). *

• Siegel AM, Herskowitz JH, Speck SH. The MHV68 M2 protein drives IL-10 dependent B cell proliferation and differentiation. PLoS Pathog. 4: e1000039 (2008). *

• Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat. Rev. Immunol. 9: 185-194 (2009). *

• Siegrist CA, Lewis EM, Eskola J, Evans SJ, Black SB. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr. Infect. Dis. J. 26: 979-984 (2007).

• Sievers EJ, Heyneman CA. Relationship between vaccinations and multiple sclerosis. Ann. Pharmacother. 36: 160-162 (2002).

• Silva CL, Bonato VL, dos Santos-Junior RR, Zarate-Blades CR, Sartori A. Recent advances in DNA vaccines for autoimmune diseases. Expert Rev. Vaccines 8: 239-252 (2009).

• Silva ML, Espírito-Santo LR, Martins MA, Silveira-Lemos D, Peruhype-Magalhaes V, Caminha RC, de Andrade Maranhao-Filho P, Martins MA, de Menezes Martins R, Galler R, Freire MD, Marcovistz R, Homma A, Teuwen DE, Eloi-Santos SM, Andrade MC, et al. Clinical and immunological insights on severe adverse neurotropic/viscerotropic disease following 17D yellow fever vaccination. Clin. Vaccine Immunol. Nov 11 [Epub ahead of print] (2009). *

• Silver PB, Agarwal RK, Su SB, Suffia I, Grajewski RS, Luger D, Chan CC, Mahdi RM, Nickerson JM, Caspi RR. Hydrodynamic vaccination with DNA encoding an immunologically privileged retinal antigen protects from autoimmunity through induction of regulatory T cells. J. Immunol. 179: 5146-5158 (2007). *

• Simon AK, Jones E, Richards H, Wright K, Betts G, Godkin A, Screaton G, Gallimore A. Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity. Eur. J. Immunol. 37: 758-767 (2007). *

• Simon GG, Hu Y, Khan AM, Zhou J, Salmon J, Chikhlikar PR, Jung KO, Marques ET, August JT. Dendritic cell mediated delivery of plasmid DNA encoding LAMP/HIV-1 Gag fusion immunogen enhances T cell epitope responses in HLA DR4 transgenic mice. PLoS One 5: e8574 (2010). *

• Simon J, Kotloff K. New and candidate vaccines for gastrointestinal infections. Curr. Opin. Gastroenterol. 26: 12-16 (2010).

• Símova J, Indrova M, Bieblova J, Mikyskova R, Bubenik J, Reinis M. Therapy of minimal residual tumour disease: beta-galactosylceramide inhibits growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy. Int. J. Cancer Sep 8 [Epub ahead of print] (2009). *

• Sin JI. Suppression of antitumour protective cytotoxic T lymphocyte responses to a human papillomavirus 16 E7 DNA vaccine by coinjection of interleukin-12 complementary DNA: involvement of nitric oxide in immune suppression. Immunology 128: e707-e717 (2009).

• Sinclair L. Autism, inflammatory bowel disease, and MMR vaccine. Lancet 351: 1355 (1998). *

• Singh P, Kaur G, Sharma G, Mehra NK. Immunogenetic basis of HIV-1 infection, transmission and disease progression. Vaccine 26: 2966-2980 (2008). *

• Singh SK, Girschick HJ. Lyme borreliosis: from infection to autoimmunity. Clin. Microbiol. Infect. 10: 598-614 (2004). *

• Singh VK. Phenotypic expression of autoimmune autistic disorder (AAD): a major subset of autism. Ann. Clin. Psychiatry 21: 148-161 (2009).

• Sinha P, Snyder JA, Kim EY, Moudgil KD. The major histocompatibility complex haplotypes dictate and the background genes fine-tune the dominant versus the cryptic response profile of a T-cell determinant within a native antigen: relevance to disease susceptibility and vaccination. Scand. J. Immunol. 65: 158-265 (2007). *

• Sinistro A, Almerighi C, Ciaprini C, Natoli S, Sussarello E, Di Fino S, Calo-Carducci F, Rocchi G, Bergamini A. Downregulation of CD40L response in monocytes from septic patients. Clin. Vaccine Immunol. 15: 1851-1858 (2008). *

• Sioud M. Does our current understanding of immune tolerance, autoimmunity, and immunosuppressive mechanisms facilitate the design of efficient cancer vaccines? Scand. J. Immunol. 70: 516-525 (2009). *

• Sioud M, Floisand Y. TLR agonists induce the differentiation of human bone marrow CD34(+) progenitors into CD11c(+) CD80/86(+) DC capable of inducing a Th1-type response. Eur. J. Immunol. 37: 2834-2846 (2007). *

• Sitkovsky MV. T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol. 30: 102-108 (2009). *

• Skerka C, Zipfel PF. Complement factor H related proteins in immune diseases. Vaccine 26 Suppl. 8: I9-I14 (2008).

• Skountzou I, Kang SM. Transcutaneous immunization with influenza vaccines. Curr. Top. Microbiol. Immunol. 333: 347-368 (2009).

• Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun MM, Markowitz LE, Iskander J. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 302: 750-757 (2009). *

• Slatter MA, Brigham K, Dickinson AM, Harvey HL, Barge D, Jackson A, Bown N, Flood TJ, Cant AJ, Abinun M, Gennery AR. Long-term immune reconstitution after anti-CD52-treated or anti-CD34-treated hematopoietic stem cell transplantation for severe T-lymphocyte immunodeficiency. J. Allergy Clin. Immunol. 121: 361-367 (2008).

• Sleijffers A, Garssen J, Vos JG, Loveren H. Ultraviolet light and resistance to infectious diseases. J. Immunotoxicol. 1: 3-14 (2004).

• Slingluff CL Jr, Chianese-Bullock KA, Bullock TN, Grosh WW, Mullins DW, Nichols L, Olson W, Petroni G, Smolkin M, Engelhard VH. Immunity to melanoma antigens: from self-tolerance to immunotherapy. Adv. Immunol. 90C: 243-295 (2006).

• Smit JJ, Folkerts G, Nijkamp FP. Mycobacteria, genes and the 'hygiene hypothesis'. Curr. Opin. Allergy Clin. Immunol. 4: 57-62 (2004).

• Smith P, Mangan NE, Fallon PG. Generation of parasite antigens for use in Toll-like receptor research. Methods Mol. Biol. 517: 1-13 (2009).

• Smithson A, Perello R, Aibar J, Espinosa G, Tassies D, Freire C, Castro P, Suarez B, Lozano F, Nicolas JM. Genotypes coding for low serum levels of mannose-binding lectin are underrepresented among individuals suffering of non-infectious systemic inflammatory response syndrome. Clin. Vaccine Immunol. Dec 30 [Epub ahead of print] (2009). *

• Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 13: 859-875 (2008). *

• Snapper CM. Differential regulation of protein- and polysaccharide-specific Ig isotype production in vivo in response to intact Streptococcus pneumoniae. Curr. Protein Pept. Sci. 7: 295-305 (2006).

• Soam SS, Khan F, Bhasker B, Mishra BN. Prediction of MHC class I binding peptides using probability distribution functions. Bioinformation 3: 403-408 (2009). *

• Soares AP, Scriba TJ, Joseph S, Harbacheuski R, Murray RA, Gelderbloem SJ, Hawkridge A, Hussey GD, Maecker H, Kaplan G, Hanekom WA. Bacillus Calmette-Guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J. Immunol. 180: 3569-3577 (2008). *

• Soderlin M, Blomkvist C, Dahl P, Forsberg P, Fohlman J. Increased risk of infection with biological immunomodifying antirheumatic agents. Clear guidelines are necessary as shown by case reports. Lakartidningen 102: 3794-3796, 3799-3800 (2005).

• Soeda A, Morita-Hoshi Y, Makiyama H, Morizane C, Ueno H, Ikeda M, Okusaka T, Yamagata S, Takahashi N, Hyodo I, Takaue Y, Heike Y. Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. Jpn. J. Clin. Oncol. 39: 797-806 (2009).

• Sohal JS, Singh SV, Singh PK, Singh AV. On the evolution of 'Indian Bison type' strains of Mycobacterium avium subspecies paratuberculosis. Microbiol. Res. May 11 [Epub ahead of print] (2009).

• Sojka DK, Lazarski CA, Huang YH, Bromberg I, Hughson A, Fowell DJ. Regulation of immunity at tissue sites of inflammation. Immunol. Res. Jan 31 [Epub ahead of print] (2009). *

• Soleimani A, Berntsen A, Svane IM, Pedersen AE. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate. Scand. J. Immunol. 70: 481-489 (2009). *

• Solvason N, Lou YP, Peters W, Evans E, Martinez J, Ramirez U, Ocampo A, Yun R, Ahmad S, Liu E, Yu L, Eisenbarth G, Leviten M, Steinman L, Garren H. Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites. J. Immunol. 181: 8298-8307 (2008). *

• Sonderegger I, Rohn TA, Kurrer MO, Iezzi G, Zou Y, Kastelein RA, Bachmann MF, Kopf M. Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur. J. Immunol. 36: 2849-2856 (2006). *

• Song J, Abraham SN. Innate and adaptive immune responses in the urinary tract. Eur. J. Clin. Invest. 38 Suppl. 2: 21-28 (2008).

• Song X, Ye D, Liu B, Cui J, Zhao X, Yi L, Liang J, Song J, Zhang Z, Zhao Q. Combination of all-trans retinoic acid and a human papillomavirus therapeutic vaccine suppresses the number and function of immature myeloid cells and enhances antitumor immunity. Cancer Sci. 100: 334-340 (2009). *

• Song XT, Kabler KE, Shen L, Rollins L, Huang XF, Chen SY. A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat. Med. 14: 258-265 (2008). *

• Sood AK. PDEF and PDEF-induced proteins as candidate tumor antigens for T cell and antibody-mediated immunotherapy of breast cancer. Immunol. Res. Sep 10 [Epub ahead of print] (2009). *

• Sookoian S. Liver disease during pregnancy: acute viral hepatitis. Ann. Hepatol. 5: 231-236 (2006). *

• Sorichter S, Baumann U, Baumgart A, Walterspacher S, von Specht BU. Immune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung disease. Vaccine 27: 2755-2759 (2009). *

• Sosman JA, Carrillo C, Urba WJ, Flaherty L, Atkins MB, Clark JI, Dutcher J, Margolin KA, Mier J, Gollob J, Kirkwood JM, Panka DJ, Crosby NA, O'Boyle K, LaFleur B, Ernstoff MS. Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J. Clin. Oncol. 26: 2292-2298 (2008). *

• Sospedra M, Martin R. Molecular mimicry in multiple sclerosis. Autoimmunity 39: 3-8 (2006).

• Sougioultzis S Pothoulakis C. Bacterial infections: small intestine and colon. Curr. Opin. Gastroenterol. 19: 23-30 (2003).

• Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C, Giannasca PJ, Lee CK, Warny M, Monath TP, Kelly CP. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 128: 764-770 (2005). *

• Speiser DE, Baumgaertner P, Voelter V, Devevre E, Barbey C, Rufer N, Romero P. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc. Natl. Acad. Sci. U.S.A. 105: 3849-3854 (2008). *

• Spencer CT, Abate G, Blazevic A, Hoft DF. Only a subset of phosphoantigen-responsive gamma9delta2 T cells mediate protective tuberculosis immunity. J. Immunol. 181: 4471-4484 (2008). *

• Spickler AR. Paratuberculosis (Johne’s disease) and Crohn’s disease. OIE; Institute for International Cooperation in Animal Biologics; An OIE Collaborating Center, Iowa State University, College of Veterinary Medicine, p 1-8 (2004). *

• Spisek R, Brazova J, Rozkova D, Zapletalova K, Sediva A, Bartunkova J. Maturation of dendritic cells by bacterial immunomodulators. Vaccine 22: 2761-2768 (2004). *

• Spohn G, Bachmann MF. Exploiting viral properties for the rational design of modern vaccines. Expert Rev. Vaccines 7: 43-54 (2008).

• Spohn G, Guler R, Johansen P, Keller I, Jacobs M, Beck M, Rohner F, Bauer M, Dietmeier K, Kundig TM, Jennings GT, Brombacher F, Bachmann MF. A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J. Immunol. 178: 7450-7457 (2007). *

• Spohn G, Keller I, Beck M, Grest P, Jennings GT, Bachmann MF. Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur. J. Immunol. 38: 877-887 (2008). *

• Spohn R, Buwitt-Beckmann U, Brock R, Jung G, Ulmer AJ, Wiesmuller KH. Synthetic lipopeptide adjuvants and Toll-like receptor 2 - structure-activity relationships. Vaccine 22: 2494-2499 (2004).

• Spratt A, Key T, Vivian AJ. Chronic anterior uveitis following Bacille Calmette-Guerin vaccination: molecular mimicry in action? J. Pediatr. Ophthalmol. Strabismus 45: 252-253 (2008).

• Srinivasan KN, Zhang GL, Khan AM, August JT, Brusic V. Prediction of class I T-cell epitopes: evidence of presence of immunological hot spots inside antigens. Bioinformatics 20 Suppl. 1: i297-i302 (2004). *

• Starodubova ES, Boberg A, Litvina M, Morozov A, Petrakova NV, Timofeev A, Latyshev O, Tunitskaya V, Wahren B, Isaguliants MG, Karpov VL. HIV-1 reverse transcriptase artificially targeted for proteasomal degradation induces a mixed Th1/Th2-type immune response. Vaccine 26: 5170-5176 (2008). *

• Stayoussef M, Al-Jenaidi FA, Al-Abbasi A, Al-Ola K, Khayyat H, Mahjoub T, Almawi WY. Modulation of type 1 diabetes susceptibility by tumor necrosis factor alpha -308 G/A and lymphotoxin alpha +249 A/G haplotypes and lack of linkage disequilibrium with predisposing DQB1-DRB1 haplotypes in Bahraini patients. Clin. Vaccine Immunol. 15: 379-381 (2008). *

• Stayoussef M, Benmansour J, Al-Irhayim AQ, Said HB, Rayana CB, Mahjoub T, Almawi WY. Autoimmune type 1 diabetes genetic susceptibility encoded by HLA-DRB1 and -DQB1 genes in Tunisia. Clin. Vaccine Immunol. 16: 1146-1150 (2009). *

• Stayoussef M, Jatta J, Al-Jenaidi FA, Nemr R, Ali ME, Mahjoub T, Almawi WY. Common and specific HLA-DRB1/DQB1 haplotypes influence the genetic susceptibility to type 1 diabetes in three distinct Arab populations. Clin. Vaccine Immunol. 16: 136-138 (2009). *

• Steerenberg P, van Amelsvoort L, Colosio C, Corsini E, Fustinoni S, Vergieva T, Zaikov C, Pennanen S, Liesivuori J, Van Loveren H. Toxicological evaluation of the immune function of pesticide workers, a European wide assessment. Hum. Exp. Toxicol. 27: 701-707 (2008).

• Steinman L, Zamvil SS. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol. 26: 565-571 (2005). *

• Steinman RM. Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation. Mt. Sinai J. Med. 68: 106-166 (2001). *

• Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 449: 419-426 (2007). *

• Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol. 311: 17-58 (2006).

• Stern LJ, Calvo-Calle JM. HLA-DR: molecular insights and vaccine design. Curr. Pharm. Des. 15: 3249-3261 (2009).

• Stevceva L, Abimiku AG, Franchini G. Targeting the mucosa: genetically engineered vaccines and mucosal immune responses. Genes Immun. 1: 308-315 (2000). *

• Stevens DA. Th1/Th2 in aspergillosis. Med. Mycol. 44: S229-S235 (2006). *

• Stevenson FK, Ottensmeier CH, Rice J. DNA vaccines against cancer come of age. Curr. Opin. Immunol. Feb 19 [Epub ahead of print] (2010).

• Stock I. Measles. Med. Monatsschr. Pharm. 32: 118-126 (2009).

• Stojanovic M, Zivkovic I, Inic-Kanada A, Petrusic V, Micic M, Dimitrijevic L. The context of tetanus toxoid application influences the outcome of antigen-specific and self-directed humoral immune response. Microbiol. Immunol. 53: 89-100 (2009). *

• Stojanovich L. Influenza vaccination of patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Clin. Dev. Immunol. 13: 373-375 (2006). *

• Stoll LL, Denning GM, Weintraub NL. Endotoxin, TLR4 signaling and vascular inflammation: potential therapeutic targets in cardiovascular disease. Curr. Pharm. Des. 12: 4229-4245 (2006).

• Stoloff GA, Caparros-Wanderley W. Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes. Eur. J. Immunol. 37: 2441-2449 (2007). *

• Stordeur P. Monitoring the immune response using real-time PCR. Methods Mol. Biol. 496: 323-338 (2009).

• Story CM, Papa E, Hu CC, Ronan JL, Herlihy K, Ploegh HL, Love JC. Profiling antibody responses by multiparametric analysis of primary B cells. Proc. Natl. Acad. Sci. U.S.A. 105: 17902-17907 (2008). *

• Straatsma BR, Nusinowitz S, Young TA, Gordon LK, Chun MW, Rosen C, Seja E, Economou JS, Glaspy JA, Bozon V, Gomez-Navarro J, Ribas A. Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. Am. J. Ophthalmol. 143: 958-969 (2007). *

• Stratta P, Cremona R, Lazzarich E, Quaglia M, Fenoglio R, Canavese C. Letter to the editor: life-threatening systemic flare-up of systemic lupus erythematosus following influenza vaccination. Lupus 17: 67-68 (2008). *

• Stratton KR, Howe CJ, Johnston RB Jr. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. JAMA 271: 1602-1605 (1994).

• Strid J, Callard R, Strobel S. Epicutaneous immunization converts subsequent and established antigen-specific T helper type 1 (Th1) to Th2-type responses. Immunology 119: 27-35 (2006). *

• Stuve O, Cravens PD, Eagar TN. DNA-based vaccines: the future of multiple sclerosis therapy? Expert Rev. Neurother. 8: 351-360 (2008).

• Subbarao K, Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat. Rev. Immunol. 7: 267-278 (2007). *

• Subramanian S, Divya Shree AN. Enhanced Th2 immunity after DNA prime-protein boost immunization with amyloid beta (1-42) plus CpG oligodeoxynucleotides in aged rats. Neurosci. Lett. 436: 219-222 (2008).

• Suckow MA, Wolter WR, Sailes VT. Inhibition of prostate cancer metastasis by administration of a tissue vaccine. Clin. Exp. Metastasis 25: 913-918 (2008).

• Sudowe S, Dominitzki S, Montermann E, Bros M, Grabbe S, Reske-Kunz AB. Uptake and presentation of exogenous antigen and presentation of endogenously produced antigen by skin dendritic cells represent equivalent pathways for the priming of cellular immune responses following biolistic DNA immunization. Immunology 128: e193-e205 (2009). *

• Sukhumavasi W, Egan CE, Warren AL, Taylor GA, Fox BA, Bzik DJ, Denkers EY. TLR adaptor MyD88 is essential for pathogen control during oral toxoplasma gondii infection but not adaptive immunity induced by a vaccine strain of the parasite. J. Immunol. 181: 3464-3473 (2008). *

• Sun JB, Czerkinsky C, Holmgren J. Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit. Scand. J. Immunol. 71: 1-11 (2010). *

• Sun JB, Raghavan S, Sjoling A, Lundin S, Holmgren J. Oral tolerance induction with antigen conjugated to cholera toxin B subunit generates both Foxp3+CD25+ and Foxp3-CD25- CD4+ regulatory T cells. J. Immunol. 177: 7634-7644 (2006). *

• Sun Y, Song M, Jager E, Schwer C, Stevanovic S, Flindt S, Karbach J, Nguyen XD, Schadendorf D, Cichutek K. Human CD4+ T lymphocytes recognize a vascular endothelial growth factor receptor-2-derived epitope in association with HLA-DR. Clin. Cancer Res. 14: 4306-4315 (2008). *

• Sundstrom P, Lundin SB, Nilsson LA, Quiding-Jarbrink M. Human IgA-secreting cells induced by intestinal, but not systemic, immunization respond to CCL25 (TECK) and CCL28 (MEC). Eur. J. Immunol. 38: 3327-3338 (2008). *

• Surawicz CM. Treatment of recurrent Clostridium difficile-associated disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 32-38 (2004). *

• Surowiec D, Kuyumjian AG, Wynd MA, Cicogna CE. Past, present, and future therapies for Clostridium difficile-associated disease. Ann. Pharmacother. 40: 2155-2163 (2006).

• Sutherland JS, Adetifa IM, Hill PC, Adegbola RA, Ota MO. Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur. J. Immunol. 39: 723-729 (2009). *

• Sutmuller R, Garritsen A, Adema GJ. Regulatory T cells and Toll-like receptors: regulating the regulators. Ann. Rheum. Dis. 66 Suppl. 3: iii91-iii95 (2007).

• Svensson M. Isolation and culture of human hematopoietic progenitors for studies of dendritic cell biology. Methods Mol. Biol. 531: 187-202 (2009).

• Swanson PA 2nd, Pack CD, Hadley A, Wang CR, Stroynowski I, Jensen PE, Lukacher AE. An MHC class Ib-restricted CD8 T cell response confers antiviral immunity. J. Exp. Med. 205: 1647-1657 (2008). *

• Szajewska H, Dziechciarz P. Gastrointestinal infections in the pediatric population. Curr. Opin. Gastroenterol. 26: 36-44 (2010).

• Szalai K, Jensen-Jarolim E, Pali-Scholl I. Vaccination strategies based on the mimotope concept. G. Ital. Dermatol. Venereol. 143: 95-104 (2008).

• Szebeni A, Prohaszka Z, Buzas E, Falus A, Kecskemeti V. Effects of vaccination with heat shock proteins on streptozotocin induced diabetes in histidine decarboxylase knockout mice. Inflamm. Res. 57: 178-182 (2008). *

• Szenborn L, Czajka H, Wysocki J. Controversies around vaccinations. Przegl. Lek. 66: 65-71 (2009).

• Szenborn L, Kacprzak-Bergman I, Zaleska I, Gruszka J. Measles antibodies concentration in vaccinated children and adolescents with autoimmune hepatitis. Pol. Merkuriusz. Lek. 17: 326-330 (2004).

• Tabatabaie P, Aghamohammadi A, Mamishi S, Isaeian A, Heidari G, Abdollahzade S, Pirouzi P, Rezaei N, Heidarnazhad H, Mirsaeid Ghazi B, Yeganeh M, Cheraghi T, Abolhasani H, Saghafi S, Alizadeh H, Anaraki MR. Evaluation of humoral immune function in patients with bronchiectasis. Iran. J. Allergy Asthma Immunol. 7: 69-77 (2008).

• Tabira T. Alzheimer vaccine. Nippon Rinsho 66: 2008-2012 (2008).

• Tabira T. Vaccination therapy for Alzheimer's disease. Rinsho Shinkeigaku 49: 848-850 (2009).

• Tabira T. Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. Tohoku J. Exp. Med. 220: 95-106 (2010). *

• Takahashi Y, Matsuda K, Kubota Y, Shimomura J, Yamasaki E, Kudo T, Fukushima K, Osaka H, Akasaka N, Imamura A, Yamada S, Kondo N, Fujiwara T. Vaccination and infection as causative factors in Japanese patients with Rasmussen syndrome: molecular mimicry and HLA class I. Clin. Dev. Immunol. 13: 381-387 (2006). *

• Takei M, Umeyama A, Shoji N, Hashimoto T. Diterpenes drive Th1 polarization depending on IL-12. Int. Immunopharmacol. 8: 1602-1608 (2008).

• Tallima H, Salah M, Guirguis FR, El Ridi R. Transforming growth factor-beta and Th17 responses in resistance to primary murine Schistosomiasis mansoni. Cytokine 48: 239-245 (2009).

• Tan MP, Kaparakis M, Galic M, Pedersen J, Pearse M, Wijburg OL, Janssen PH, Strugnell RA. Chronic Helicobacter pylori infection does not significantly alter the microbiota of the murine stomach. Appl. Environ. Microbiol. 73: 1010-1013 (2007). *

• Tanaka F, Haraguchi N, Isikawa K, Inoue H, Mori M. Potential role of dendritic cell vaccination with MAGE peptides in gastrointestinal carcinomas. Oncol. Rep. 20: 1111-1116 (2008). *

• Taneja V, David CS. HLA class II transgenic mice as models of human diseases. Immunol. Rev. 169: 67-79 (1999).

• Tang ST, Wang M, Lamberth K, Harndahl M, Dziegiel MH, Claesson MH, Buus S, Lund O. MHC-I-restricted epitopes conserved among variola and other related orthopoxviruses are recognized by T cells 30 years after vaccination. Arch. Virol. 153: 1833-1844 (2008).

• Targonski PV, Jacobson RM, Poland GA. Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine 25: 3066-3069 (2007). *

• Tarkowski A. Infectious arthritis. Best Pract. Res. Clin. Rheumatol. 20: 1029-1044 (2006).

• Tartz S, Kamanova J, Simsova M, Sebo P, Bolte S, Heussler V, Fleischer B, Jacobs T. Immunization with a circumsporozoite epitope fused to Bordetella pertussis adenylate cyclase in conjunction with cytotoxic T-lymphocyte-associated antigen 4 blockade confers protection against Plasmodium berghei liver-stage malaria. Infect. Immun. 74: 2277-2285 (2006). *

• Tarzi M, Klunker S, Texier C, Verhoef A, Stapel SO, Akdis CA, Maillere B, Kay AB, Larche M. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin. Exp. Allergy 36: 465-474 (2006). *

• Tatsis N, Lasaro MO, Lin SW, Xiang ZQ, Zhou D, Dimenna L, Li H, Bian A, Abdulla S, Li Y, Giles-Davis W, Engram J, Ratcliffe SJ, Silvestri G, Ertl HC, Betts MR. Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens. J. Immunol. 182: 6587-6599 (2009).

• Tatsumi T, Takehara T, Yamaguchi S, Sasakawa A, Sakamori R, Ohkawa K, Kohga K, Uemura A, Hayashi N. Intrahepatic delivery of alpha-galactosylceramide-pulsed dendritic cells suppresses liver tumor. Hepatology 45: 22-30 (2007). *

• Taubman MA, Nash DA. The scientific and public-health imperative for a vaccine against dental caries. Nat. Rev. Immunol. 6: 555-563 (2006). *

• Taylor JM, Ziman ME, Huff JL, Moroski NM, Vajdy M, Solnick JV. Helicobacter pylori lipopolysaccharide promotes a Th1 type immune response in immunized mice. Vaccine 24: 4987-4994 (2006). *

• Tchilian EZ, Beverley PC. Altered CD45 expression and disease. Trends Immunol. 27: 146-153 (2006). *

• Tchilian EZ, Gil J, Navarro ML, Fernandez-Cruz E, Chapel H, Misbah S, Ferry B, Renz H, Schwinzer R, Beverley PC. Unusual case presentations associated with the CD45 C77G polymorphism. Clin. Exp. Immunol. 146: 448-454 (2006). *

• Telford JL, Covacci A, Rappuoli R, Chiara P. Immunobiology of Helicobacter pylori infection. Curr. Opin. Immunol. 9: 498-503 (1997).

• Tellam J, Fogg MH, Rist M, Connolly G, Tscharke D, Webb N, Heslop L, Wang F, Khanna R. Influence of translation efficiency of homologous viral proteins on the endogenous presentation of CD8+ T cell epitopes. J. Exp. Med. 204: 525-532 (2007). *

• Tellam J, Smith C, Rist M, Webb N, Cooper L, Vuocolo T, Connolly G, Tscharke DC, Devoy MP, Khanna R. Regulation of protein translation through mRNA structure influences MHC class I loading and T cell recognition. Proc. Natl. Acad. Sci. U.S.A. 105: 9319-9324 (2008). *

• Telyatnikova N, Hill Gaston JS. Prior exposure to infection with Chlamydia pneumoniae can influence the T-cell-mediated response to Chlamydia trachomatis. FEMS Immunol. Med. Microbiol. 47: 190-198 (2006). *

• Tenembaum S, Chitnis T, Ness J, Hahn JS. Acute disseminated encephalomyelitis. Neurology 68: S23-S36 (2007).

• Tenzer S, Wee E, Burgevin A, Stewart-Jones G, Friis L, Lamberth K, Chang CH, Harndahl M, Weimershaus M, Gerstoft J, Akkad N, Klenerman P, Fugger L, Jones EY, McMichael AJ, Buus S, Schild H, van Endert P, Iversen AK. Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat. Immunol. 10: 636-646 (2009). *

• Terabe M, Ambrosino E, Takaku S, O'Konek JJ, Venzon D, Lonning S, McPherson JM, Berzofsky JA. Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody. Clin. Cancer Res. 15: 6560-6569 (2009).

• Terabe M, Berzofsky JA. The contrasting roles of NKT cells in tumor immunity. Curr. Mol. Med. 9: 667-672 (2009).

• Terajima M, Orphin L, Leporati AM, Pazoles P, Cruz J, Rothman AL, Ennis FA. Vaccinia virus-specific CD8(+) T-cell responses target a group of epitopes without a strong immunodominance hierarchy in humans. Hum. Immunol. 69: 815-825 (2008).

• Terness P, Oelert T, Ehser S, Chuang JJ, Lahdou I, Kleist C, Velten F, Hammerling GJ, Arnold B, Opelz G. Mitomycin C-treated dendritic cells inactivate autoreactive T cells: toward the development of a tolerogenic vaccine in autoimmune diseases. Proc. Natl. Acad. Sci. U.S.A. 105: 18442-18447 (2008). *

• Terney D, Beniczky S, Barsi P, Kondakor I, Perenyi J, Faludi B, Szapper M, Vecsei L. Multiple sclerosis after hepatitis B vaccination in a 16-year-old patient. Chin. Med. J. (Engl.) 119: 77-79 (2006). *

• Texereau J, Chiche JD, Taylor W, Choukroun G, Comba B, Mira JP. The importance of Toll-like receptor 2 polymorphisms in severe infections. Clin. Infect. Dis. 41 Suppl. 7: S408-S415 (2005). *

• Teyton L. The saga of MHC-bound peptides: a renaissance for antigen presentation? J. Clin. Invest. 117: 3164-3166 (2007). *

• Thacker TC, Palmer MV, Waters WR. T-cell mRNA expression in response to Mycobacterium bovis BCG vaccination and Mycobacterium bovis infection of white-tailed deer. Clin. Vaccine Immunol. 16: 1139-1145 (2009).

• Theeler BJ, Simper NB, Ney JP. Polyglandular autoimmunity with macrophagic myofasciitis. Clin. Rheumatol. 27: 667-669 (2008). *

• Theil DJ, Libbey JE, Rodriguez F, Whitton JL, Tsunoda I, Derfuss TJ, Fujinami RS. Targeting myelin proteolipid protein to the MHC class I pathway by ubiquitination modulates the course of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 204: 92-100 (2008).

• Thibault VC, Grayon M, Boschiroli ML, Hubbans C, Overduin P, Stevenson K, Gutierrez MC, Supply P, Biet F. New variable-number tandem-repeat markers for typing Mycobacterium avium subsp. paratuberculosis and M. avium strains: comparison with IS900 and IS1245 restriction fragment length polymorphism typing. J. Clin. Microbiol. 45: 2404-2410 (2007). *

• Thimme R, Blum HE. Genetics in viral hepatitis. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 19 (2006). *

• Thimme R, Chang KM, Pemberton J, Sette A, Chisari FV. Degenerate immunogenicity of an HLA-A2-restricted hepatitis B virus nucleocapsid cytotoxic T-lymphocyte epitope that is also presented by HLA-B51. J. Virol. 75: 3984-3987 (2001). *

• Thirdborough SM, Roddick JS, Radcliffe JN, Howarth M, Stevenson FK, Elliott T. Tapasin shapes immunodominance hierarchies according to the kinetic stability of peptide - MHC class I complexes. Eur. J. Immunol. 38: 364-369 (2008). *

• Thomas HJ, Wotton CJ, Yeates D, Ahmad T, Jewell DP, Goldacre MJ. Pneumococcal infection in patients with coeliac disease. Eur. J. Gastroenterol. Hepatol. 20: 624-628 (2008).

• Thompson NP, Montgomery SM, Pounder RE, Wakefield AJ. Is measles vaccination a risk factor for inflammatory bowel disease? Lancet 345: 1071-1074 (1995).

• Thummler K, Ramming A, Schulze-Koops H, Skapenko A. Cellular therapy in autoimmune disease. Z. Rheumatol. 68: 337-339 (2009).

• Thurm CW, Halsey JF. Measurement of cytokine production using whole blood. Curr. Protoc. Immunol. Chapter 7: Unit 7.18B (2005).

• Tian FQ, Zhang LS, Wang CY, Tao WG. Induction of dendritic cells derived from acute promyelocytic leukemia cells by all trans retinoic acid. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16: 1140-1145 (2008).

• Tian S, Liu Z, Donahue C, Noh HS, Falo LD Jr, You Z. Transcriptional IL-15-directed in vivo DC targeting DNA vaccine. Gene Ther. 16: 1260-1270 (2009).

• Tiao MM, Lu L, Huang LT, Liang CD, Chen CL, Tao R, Fung JJ, Qian S. Cross-tolerance of recipient-derived transforming growth factor-beta dendritic cells. Transplant. Proc. 39: 281-282 (2007). *

• Tierney BC, Martin SW, Franzke LH, Marano N, Reissman DB, Louchart RD, Goff JA, Rosenstein NE, Sever JL, McNeil MM; Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program. Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax. Clin. Infect. Dis. 37: 905-911 (2003). *

• Tigno-Aranjuez JT, Lehmann PV, Tary-Lehmann M. Dissociated induction of cytotoxicity and DTH by CFA and CpG. J. Immunother. 32: 389-398 (2009).

• Tirlapur UK, Mulholland WJ, Bellhouse BJ, Kendall M, Cornhill JF, Cui Z. Femtosecond two-photon high-resolution 3D imaging, spatial-volume rendering and microspectral characterization of immunolocalized MHC-II and mLangerin/CD207 antigens in the mouse epidermis. Microsc. Res. Tech. 69: 767-775 (2006). *

• Tishon A, LaFace DM, Lewicki H, van Binnendijk RS, Osterhaus A, Oldstone MB. Transgenic mice expressing human HLA and CD8 molecules generate HLA-restricted measles virus cytotoxic T lymphocytes of the same specificity as humans with natural measles virus infection. Virology 275: 286-293 (2000). *

• Titball RW, Naylor CE, Basak AK. The Clostridium perfringens alpha-toxin. Anaerobe 5: 51-64 (1999).

• Todryk SM, Pathan AA, Keating S, Porter DW, Berthoud T, Thompson F, Klenerman P, Hill AV. The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming. Immunology 128: 83-91 (2009). *

• Toedter G, Hayden K, Wagner C, Brodmerkel C. Simultaneous detection of eight analytes in human serum by two commercially available platforms for multiplex cytokine analysis. Clin. Vaccine Immunol. 15: 42-48 (2008). *

• Tohyama S, Onodera S, Tohyama H, Yasuda K, Nishihira J, Mizue Y, Hamasaka A, Abe R, Koyama Y. A novel DNA vaccine-targeting macrophage migration inhibitory factor improves the survival of mice with sepsis. Gene Ther. 15: 1513-1522 (2008).

• Toller IM, Hitzler I, Sayi A, Mueller A. Prostaglandin E2 prevents Helicobacter-induced gastric preneoplasia and facilitates persistent infection in a mouse model. Gastroenterology Dec 16 [Epub ahead of print] (2009). *

• Tomillero A, Moral MA. Gateways to clinical trials. Methods Find. Exp. Clin. Pharmacol. 31: 263-298 (2009).

• Toplak N, Avcin T. Influenza and autoimmunity. Ann. N. Y. Acad. Sci. 1173: 619-626 (2009). *

• Toplak N, Avcin T. Vaccination of healthy subjects and autoantibodies: from mice through dogs to humans. Lupus 18: 1186-1191 (2009).

• Toplak N, Kveder T, Trampus-Bakija A, Subelj V, Cucnik S, Avcin T. Autoimmune response following annual influenza vaccination in 92 apparently healthy adults. Autoimmun. Rev. 8: 134-138 (2008).

• Tormo D, Ferrer A, Bosch P, Gaffal E, Basner-Tschakarjan E, Wenzel J, Tuting T. Therapeutic efficacy of antigen-specific vaccination and Toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res. 66: 5427-5435 (2006). *

• Toseland CP, Clayton DJ, McSparron H, Hemsley SL, Blythe MJ, Paine K, Doytchinova IA, Guan P, Hattotuwagama CK, Flower DR. AntiJen: a quantitative immunology database integrating functional, thermodynamic, kinetic, biophysical, and cellular data. Immunome Res. 1: 4 (2005). *

• Toussirot E, Lohse A, Wendling D, Mougin C. Sjogren's syndrome occurring after hepatitis B vaccination. Arthritis Rheum. 43: 2139-2140 (2000). *

• Trimnell A, Takagi A, Gupta M, Richie TL, Kappe SH, Wang R. Genetically attenuated parasite vaccines induce contact-dependent CD8+ T cell killing of Plasmodium yoelii liver stage-infected hepatocytes. J. Immunol. 183: 5870-5878 (2009).

• Trnka YM, Lamont JT. Clostridium difficile colitis. Adv. Intern. Med. 29: 85-107 (1984).

• Truscott SM, Wang X, Lybarger L, Biddison WE, McBerry C, Martinko JM, Connolly JM, Linette GP, Fremont DH, Hansen TH, Carreno BM. Human MHC class I molecules with disulfide traps secure disease-related antigenic peptides and exclude competitor peptides. J. Biol. Chem. 283: 7480-7490 (2008). *

• Tsai BY, Lin YL, Chiang BL. Autoimmune response induced by dendritic cells exerts anti-tumor effect in murine model of leukemia. J. Autoimmun. Oct 7 [Epub ahead of print] (2009).

• Tsai S, Shameli A, Santamaria P. Chapter 4. CD8+ T cells in type 1 diabetes. Adv. Immunol. 100: 79-124 (2008).

• Tsang RS, Valdivieso-Garcia A. Pathogenesis of Guillain-Barre syndrome. Expert Rev. Anti. Infect. Ther. 1: 597-608 (2003).

• Tsuji M. Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands. Cell. Mol. Life Sci. 63: 1889-1898 (2006). *

• Tsuji T, Altorki NK, Ritter G, Old LJ, Gnjatic S. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination. J. Immunol. 183: 4800-4808 (2009).

• Tu Z, Bozorgzadeh A, Pierce RH, Kurtis J, Crispe IN, Orloff MS. TLR-dependent cross talk between human Kupffer cells and NK cells. J. Exp. Med. 205: 233-244 (2008). *

• Tuettenberg A, Schmitt E, Knop J, Jonuleit H. Dendritic cell-based immunotherapy of malignant melanoma: success and limitations. J. Dtsch. Dermatol. Ges. 5: 190-196 (2007).

• Tummler B, Bosshammer J, Breitenstein S, Brockhausen I, Gudowius P, Herrmann C, Herrmann S, Heuer T, Kubesch P, Mekus F, Romling U, Schmidt KD, Spangenberg C, Walter S. Infections with Pseudomonas aeruginosa in patients with cystic fibrosis. Behring Inst. Mitt. 98: 249-255 (1997).

• Tundup S, Pathak N, Ramanadham M, Mukhopadhyay S, Murthy KJ, Ehtesham NZ, Hasnain SE. The co-operonic PE25/PPE41 protein complex of Mycobacterium tuberculosis elicits increased humoral and cell mediated immune response. PLoS ONE 3: e3586 (2008). *

• Tunheim G, Schjetne KW, Rasmussen IB, Sollid LM, Sandlie I, Bogen B. Recombinant antibodies for delivery of antigen: a single loop between beta-strands in the constant region can accommodate long, complex and tandem T cell epitopes. Int. Immunol. 20: 295-306 (2008). *

• Turcanu V, Winterbotham M, Kelleher P, Lack G. Peanut-specific B and T cell responses are correlated in peanut-allergic but not in non-allergic individuals. Clin. Exp. Allergy 38: 1132-1139 (2008). *

• Turlej E. Novel methods of cytokine detection: real-time PCR, ELISPOT, and intracellular cytokine staining. Postepy. Hig. Med. Dosw. (Online) 63: 213-224 (2009).

• Turner MS, Cohen PA, Finn OJ. Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells. J. Immunol. 178: 2787-2793 (2007). *

• Turner SJ, Doherty PC, McCluskey J, Rossjohn J. Structural determinants of T-cell receptor bias in immunity. Nat. Rev. Immunol. 6: 883-894 (2006). *

• Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, Thomson AW. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J. Immunol. 178: 7018-7031 (2007). *

• Ubeda JV. Comparative features of the epidemiology of multiple sclerosis and Parkinson's disease: environmental factors of potential etiological importance. J. Neurol. Sci. 262: 54-59 (2007).

• Ueda R, Ohkusu-Tsukada K, Fusaki N, Soeda A, Kawase T, Kawakami Y, Toda M. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy. Int. J. Cancer 126: 919-929 (2009). *

• Uehara A, Hirabayashi Y, Takada H. Antibodies to proteinase 3 (PR3-ANCA) prime human oral, lung, and kidney epithelial cells through protease-activated receptor-2 to secrete proinflammatory cytokines upon stimulation with agonists to various Toll-like receptors, NOD1 and NOD2. Clin. Vaccine Immunol. 15: 1060-1066 (2008). *

• Ugel S, Scarselli E, Iezzi M, Mennuni C, Pannellini T, Calvaruso F, Cipriani B, De Palma R, Ricci-Vitiani L, Peranzoni E, Musiani P, Zanovello P, Bronte V. Autoimmune B cell lymphopenia following successful adoptive therapy with telomerase-specific T lymphocytes. Blood Nov 10 [Epub ahead of print] (2009). *

• Ulevitch RJ, Mathison JC, Correia Jda S. Innate immune responses during infection. Vaccine 22 Suppl. 1: S25-S30 (2004).

• Ulmer JB, Liu MA. Ethical issues for vaccines and immunization. Nat. Rev. Immunol. 2: 291-296 (2002). *

• Ulmer JB, Wahren B, Liu MA. DNA vaccines: recent technological and clinical advances. Discov. Med. 6: 109-112 (2006).

• Ulmer JB, Wahren B, Liu MA. Gene-based vaccines: recent technical and clinical advances. Trends Mol. Med. 12: 216-222 (2006). *

• Unger WW, Laban S, Kleijwegt FS, van der Slik AR, Roep BO. Induction of regulatory T cells by monocyte-derived dendritic cells modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur. J. Immunol. 39: 3147-3159 (2009). *

• Uren TK, Johansen FE, Wijburg OL, Koentgen F, Brandtzaeg P, Strugnell RA. Role of the polymeric Ig receptor in mucosal B cell homeostasis. J. Immunol. 170: 2531-2539 (2003). *

• Uriondo San Juan B, Naval Valle D, Moreno Izcob F. Guillain-Barre syndrome after immunization with hepatitis A and typhoid vaccines. Aten. Primaria 34: 379 (2004).

• Urry Z, Xystrakis E, Richards DF, McDonald J, Sattar Z, Cousins DJ, Corrigan CJ, Hickman E, Brown Z, Hawrylowicz CM. Ligation of TLR9 induced on human IL-10-secreting Tregs by 1alpha,25-dihydroxyvitamin D3 abrogates regulatory function. J. Clin. Invest. 119: 387-398 (2009). *

• Urschel S, Kayikci L, Wintergerst U, Notheis G, Jansson A, Belohradsky BH. Common variable immunodeficiency disorders in children: delayed diagnosis despite typical clinical presentation. J. Pediatr. 154: 888-894 (2009). *

• Usman A, Kimyai-Asadi A, Stiller MJ, Alam M. Lichenoid eruption following hepatitis B vaccination: first North American case report. Pediatr. Dermatol. 18: 123-126 (2001).

• Uyttenhove C, Arendse B, Stroobant V, Brombacher F, Van Snick J. Development of an anti-IL-12 p40 auto-vaccine: protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection. Eur. J. Immunol. 34: 3572-3581 (2004). *

• Uyttenhove C, Sommereyns C, Theate I, Michiels T, Van Snick J. Anti-IL-17A autovaccination prevents clinical and histological manifestations of experimental autoimmune encephalomyelitis. Ann. N. Y. Acad. Sci. 1110: 330-336 (2007). *

• Uyttenhove C, Van Snick J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur. J. Immunol. 36: 2868-2874 (2006). *

• Vahedi H, Merat S, Momtahen S, Olfati G, Kazzazi AS, Tabrizian T, Rashtak S, Khaleghnejad R, Khademi H, Malekzadeh F, Nasseri-Moghaddam S, Malekzadeh R. Epidemiologic characteristics of 500 patients with inflammatory bowel disease in Iran studied from 2004 through 2007. Arch. Iran. Med. 12: 454-460 (2009).

• Valenta R. The future of antigen-specific immunotherapy of allergy. Nat. Rev. Immunol. 2: 446-453 (2002). *

• van de Berg PJ, van Leeuwen EM, Ten Berge IJ, van Lier R. Cytotoxic human CD4(+) T cells. Curr. Opin. Immunol. 20: 339-343 (2008).

• van de Laar TJ, Molenkamp R, van den Berg C, Schinkel J, Beld MG, Prins M, Coutinho RA, Bruisten SM. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J. Hepatol. 51: 667-674 (2009).

• van den Brink MR, Alpdogan O, Boyd RL. Strategies to enhance T-cell reconstitution in immunocompromised patients. Nat. Rev. Immunol. 4: 856-867 (2004). *

• van der Graaf CA, Netea MG, Franke B, Girardin SE, van der Meer JW, Kullberg BJ. Nucleotide oligomerization domain 2 (Nod2) is not involved in the pattern recognition of Candida albicans. Clin. Vaccine Immunol. 13: 423-425 (2006). *

• van Duin D, Allore HG, Mohanty S, Ginter S, Newman FK, Belshe RB, Medzhitov R, Shaw AC. Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine responses in young and older adults. J. Infect. Dis. 195: 1590-1597 (2007). *

• van Duin D, Medzhitov R, Shaw AC. Triggering TLR signaling in vaccination. Trends Immunol. 27: 49-55 (2006). *

• van Duin D, Shaw AC. Toll-like receptors in older adults. J. Am. Geriatr. Soc. 55: 1438-1444 (2007).

• van Duivenvoorde LM, Han WG, Bakker AM, Louis-Plence P, Charbonnier LM, Apparailly F, van der Voort EI, Jorgensen C, Huizinga TW, Toes RE. Immunomodulatory dendritic cells inhibit Th1 responses and arthritis via different mechanisms. J. Immunol. 179: 1506-1515 (2007). *

• van Duivenvoorde LM, van Mierlo GJ, Boonman ZF, Toes RE. Dendritic cells: vehicles for tolerance induction and prevention of autoimmune diseases. Immunobiology 211: 627-632 (2006).

• van Eden W, Koets A, van Kooten P, Prakken B, van der Zee R. Immunopotentiating heat shock proteins: negotiators between innate danger and control of autoimmunity. Vaccine 21: 897-901 (2003). *

• Van Endert P, Hassainya Y, Lindo V, Bach JM, Blancou P, Lemonnier F, Mallone R. HLA class I epitope discovery in type 1 diabetes. Ann. N. Y. Acad. Sci. 1079: 190-197 (2006). *

• van Ginkel FW, Iwamoto T, Schultz BD, Tomich JM. Immunity to a self-derived, channel-forming peptide in the respiratory tract. Clin. Vaccine Immunol. 15: 260-266 (2008). *

• van Hall T, Wolpert EZ, van Veelen P, Laban S, van der Veer M, Roseboom M, Bres S, Grufman P, de Ru A, Meiring H, de Jong A, Franken K, Teixeira A, Valentijn R, Drijfhout JW, Koning F, Camps M, Ossendorp F, Karre K, Ljunggren HG, Melief CJ, Offringa R. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat. Med. 12: 417-424 (2006). *

• Van Kessel DA, Horikx PE, Van Houte AJ, De Graaff CS, Van Velzen-Blad H, Rijkers GT. Clinical and immunological evaluation of patients with mild IgG1 deficiency. Clin. Exp. Immunol. 118: 102-107 (1999). *

• Van Kruiningen HJ, Joossens M, Vermeire S, Joossens S, Debeugny S, Gower-Rousseau C, Cortot A, Colombel JF, Rutgeerts P, Vlietinck R. Environmental factors in familial Crohn's disease in Belgium. Inflamm. Bowel Dis. 11: 360-365 (2005). *

• van Miert AS. Pro-inflammatory cytokines in a ruminant model: pathophysiological, pharmacological, and therapeutic aspects. Vet. Q. 17: 41-50 (1995).

• van Riet E, Hartgers FC, Yazdanbakhsh M. Chronic helminth infections induce immunomodulation: consequences and mechanisms. Immunobiology 212: 475-490 (2007).

• van Zelm MC, Reisli I, van der Burg M, Castano D, van Noesel CJ, van Tol MJ, Woellner C, Grimbacher B, Patino PJ, van Dongen JJ, Franco JL. An antibody-deficiency syndrome due to mutations in the CD19 gene. N. Engl. J. Med. 354: 1901-1912 (2006). *

• Vanden Bush TJ, Buchta CM, Claudio J, Bishop GA. Cutting edge: importance of IL-6 and cooperation between innate and adaptive immune receptors in cellular vaccination with B lymphocytes. J. Immunol. 183: 4833-4837 (2009).

• Vandenbark AA, Abulafia-Lapid R. Autologous T-cell vaccination for multiple sclerosis: a perspective on progress. BioDrugs 22: 265-273 (2008).

• Vandenbark AA, Culbertson NE, Bartholomew RM, Huan J, Agotsch M, Latocha D, Yadav V, Mass M, Whitham R, Lovera J, Milano J, Theofan G, Chou YK, Offner H, Bourdette DN. Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunology 123: 66-78 (2008). *

• Vandiedonck C, Beaurain G, Giraud M, Hue-Beauvais C, Eymard B, Tranchant C, Gajdos P, Dausset J, Garchon HJ. Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia. Proc. Natl. Acad. Sci. U.S.A. 101: 15464-15469 (2004). *

• Vassaux G, Nitcheu J, Jezzard S, Lemoine NR. Bacterial gene therapy strategies. J. Pathol. 208: 290-298 (2006).

• Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis AJ. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J. Rheumatol. 35: 1271-1276 (2008).

• Vasudev M, Zacharisen MC. New-onset rheumatoid arthritis after anthrax vaccination. Ann. Allergy Asthma Immunol. 97: 110-112 (2006).

• Veerappan GR, Mulhall BP, Holtzmuller KC. Vaccination-induced autoimmune hepatitis. Dig. Dis. Sci. 50: 212-213 (2005). *

• Velin D, Favre L, Bernasconi E, Bachmann D, Pythoud C, Saiji E, Bouzourene H, Michetti P. Interleukin 17 is a critical mediator of vaccine-induced reduction of Helicobacter infection in the mouse model. Gastroenterology 136: 2237-2246.e1 (2009). *

• Velu V, Saravanan S, Nandakumar S, Shankar EM, Vengatesan A, Jadhav SS, Kulkarni PS, Thyagarajan SP. Relationship between T-lymphocyte cytokine levels and sero-response to hepatitis B vaccines. World J. Gastroenterol. 14: 3534-3540 (2008). *

• Venier C, Guthmann MD, Fernandez LE, Fainboim L. Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived immunological adjuvant. Clin. Exp. Immunol. 147: 379-388 (2007). *

• Venkataswamy MM, Baena A, Goldberg MF, Bricard G, Im JS, Chan J, Reddington F, Besra GS, Jacobs WR Jr, Porcelli SA. Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin. J. Immunol. 183: 1644-1656 (2009).

• Verma A, Rathinam SR, Priya CG, Muthukkaruppan VR, Stevenson B, Timoney JF. LruA and LruB antibodies in sera of human cases of leptospiral uveitis. Clin. Vaccine Immunol. 15: 1019-1023 (2008). *

• Verstak B, Hertzog P, Mansell A. Toll-like receptor signalling and the clinical benefits that lie within. Inflamm. Res. 56: 1-10 (2007). *

• Verstraeten T, Davis R, DeStefano F. Immunity to tetanus is protective against the development of multiple sclerosis. Med. Hypotheses 65: 966-969 (2005).

• Verstraeten T, Descamps D, David MP, Zahaf T, Hardt K, Izurieta P, Dubin G, Breuer T. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 26: 6630-6638 (2009). *

• Vial T, Descotes J. Autoimmune diseases and vaccinations. Eur. J. Dermatol. 14: 86-90 (2004).

• Vida Perez L, Gomez Camacho F, García Sanchez V, Iglesias Flores EM, Castillo Molina L, Cerezo Ruiz A, Casais Juanena L, De Dios Vega JF. Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease. Med. Clin. (Barc.) 132: 331-335 (2009).

• Vierling JM. Chapter 30. Clinical use of immunosuppressive drugs to control the immune response. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 391-407 (2007). *

• Villamor E, Fawzi WW. Effects of vitamin A supplementation on immune responses and correlation with clinical outcomes. Clin. Microbiol. Rev. 18: 446-464 (2005). *

• Villena J, Medina M, Vintini E, Alvarez S. Stimulation of respiratory immunity by oral administration of Lactococcus lactis. Can. J. Microbiol. 54: 630-638 (2008).

• Vintini E, Villena J, Alvarez S, Medina M. Administration of a probiotic associated with nasal vaccination with inactivated Lactococcus lactis-PppA induces effective protection against pneumoccocal infection in young mice. Clin. Exp. Immunol. Dec 14 [Epub ahead of print] (2009). *

• Visus C, Ito D, Amoscato A, Maciejewska-Franczak M, Abdelsalem A, Dhir R, Shin DM, Donnenberg VS, Whiteside TL, Deleo AB. Identification of human aldehyde dehydrogenase 1 family member a1 as a novel CD8+ T-cell defined tumor antigen in squamous cell carcinoma of the head and neck. Cancer Res. 67: 10538-10545 (2007). *

• Viswanathan K, Daugherty C, Dhabhar FS. Stress as an endogenous adjuvant: augmentation of the immunization phase of cell-mediated immunity. Int. Immunol. 17: 1059-1069 (2005). *

• Viswanathan K, Dhabhar FS. Stress-induced enhancement of leukocyte trafficking into sites of surgery or immune activation. Proc. Natl. Acad. Sci. U.S.A. 102: 5808-5813 (2005). *

• Vitalis TZ, Zhang QJ, Alimonti J, Chen SS, Basha G, Moise A, Tiong J, Tian MM, Choi KB, Waterfield D, Jeffries A, Jefferies WA. Using the TAP component of the antigen-processing machinery as a molecular adjuvant. PLoS Pathog. 1: e36 (2005). *

• Vlad G, Chang CC, Colovai AI, Berloco P, Cortesini R, Suciu-Foca N. Immunoglobulin-like transcript 3: a crucial regulator of dendritic cell function. Hum. Immunol. 70: 340-344 (2009).

• Vohra N, Verhaegen M, Martin L, Mackay A, Pilon-Thomas S. TNF-alpha-treated DC exacerbates disease in a murine tumor metastasis model. Cancer Immunol. Immunother. Nov 17 [Epub ahead of print] (2009).

• Vollmer J. Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9. Expert Opin. Biol. Ther. 5: 673-682 (2005).

• von Bergwelt-Baildon MS, Shimabukuro-Vornhagen A, Klein-Gonzalez N, Kondo E. T-cell responses to cyclin B1 are not restricted to p53-overexpressing tumors. Clin. Cancer Res. 15: 7106 (2009). *

• von Meyenn F, Schaefer M, Weighardt H, Bauer S, Kirschning CJ, Wagner H, Sparwasser T. Toll-like receptor 9 contributes to recognition of Mycobacterium bovis Bacillus Calmette-Guerin by Flt3-ligand generated dendritic cells. Immunobiology 211: 557-565 (2006).

• Vordermeier HM, Villarreal-Ramos B, Cockle PJ, Macaulay M, Rhodes SG, Thacker T, Gilbert SC, McShane H, Hill AV, Xing RZ, Hewinson RG. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect. Immun. 77: 3364-3373 (2009). *

• Vujanovic L, Whiteside TL, Potter DM, Chu J, Ferrone S, Butterfield LH. Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus. Cancer Immunol. Immunother. 58: 121-133 (2009). *

• Wagner H. The immunogenicity of CpG-antigen conjugates. Adv. Drug Deliv. Rev. 61: 243-247 (2009).

• Wahid R, Salerno-Goncalves R, Tacket CO, Levine MM, Sztein MB. Generation of specific effector and memory T cells with gut- and secondary lymphoid tissue-homing potential by oral attenuated CVD 909 typhoid vaccine in humans. Mucosal Immunol. 1: 389-398 (2008).

• Waisbren BA. Acquired autoimmunity after viral vaccination is caused by molecular mimicry and antigen complimentarity in the presence of an immunologic adjuvant and specific HLA patterns. Med. Hypotheses 70: 346-348 (2008).

• Wakabayashi H, Takakura N, Yamauchi K, Tamura Y. Modulation of immunity-related gene expression in small intestines of mice by oral administration of lactoferrin. Clin. Vaccine Immunol. 13: 239-245 (2006). *

• Wakefield AJ. MMR vaccination and autism. Lancet 354: 949-950 (1999).

• Wakefield AJ. Measles, mumps, and rubella vaccination and autism. N. Engl. J. Med. 348: 951-954 (2003).

• Wakefield AJ, Montgomery SM. Autism, viral infection and measles-mumps-rubella vaccination. Isr. Med. Assoc. J. 1: 183-187 (1999). *

• Wakefield AJ, Montgomery SM. Measles, mumps, rubella vaccine: through a glass, darkly. Adverse Drug React. Toxicol. Rev. 19: 265-283 (2000).

• Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, Berelowitz M, Dhillon AP, Thomson MA, Harvey P, Valentine A, Davies SE, Walker-Smith JA. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 351: 637-641 (1998). *

• Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6: 595-601 (2006). *

• Waldmann TA. Effective cancer therapy through immunomodulation. Annu. Rev. Med. 57: 65-81 (2006). *

• Walker DR. Autism, inflammatory bowel disease, and MMR vaccine. Lancet 351: 1355 (1998). *

• Walker J, Tough DF. Modification of TLR-induced activation of human dendritic cells by type I IFN: synergistic interaction with TLR4 but not TLR3 agonists. Eur. J. Immunol. 36: 1827-1836 (2006). *

• Walzer T. NK-cell education: KIR-S come into play. Blood 115: 1110-1111 (2010). *

• Wan Y, Xue X, Li M, Zhang X, Qin X, Zhang C, You Y, Wang W, Jiang C, Wu S, Liu Y, Zhu W, Ran Y, Zhang Z, Han W, Zhang Y. Prepared and screened a modified TNF-alpha molecule as TNF-alpha autovaccine to treat LPS induced endotoxic shock and TNF-alpha induced cachexia in mouse. Cell. Immunol. 246: 55-64 (2007). *

• Wan Y, Yuan S, Xue X, Li M, Qin X, Zhang C, Wang W, Jiang C, Wu S, Liu Y, Zhu W, Ran Y, Zhang Z, Han W, Zhang Y. The preventive effect of adjuvant-free administration of TNF-PADRE autovaccine on collagen-II-induced rheumatoid arthritis in mice. Cell. Immunol. 258: 72-77 (2009). *

• Wang B, Henao-Tamayo M, Harton M, Ordway-Rodrigues D, Shanley C, Basaraba RJ, Orme IM. A Toll-like receptor-2 directed fusion protein vaccine against tuberculosis. Clin. Vaccine Immunol. 14: 902-906 (2007). *

• Wang B, Tisch R. Parameters influencing antigen-specific immunotherapy for type 1 diabetes. Immunol. Res. 41: 175-187 (2008). *

• Wang B, Tisch R. Parameters influencing antigen-specific immunotherapy for type 1 diabetes. Immunol. Res. 42: 246-258 (2008). *

• Wang BZ, Quan FS, Kang SM, Bozja J, Skountzou I, Compans RW. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J. Virol. 82: 11813-11823 (2008). *

• Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 39: 978-988 (2004). *

• Wang E, Monaco A, Monsurró V, Sabatino M, Pos Z, Uccellini L, Wang J, Worschech A, Stroncek DF, Marincola FM. Antitumor vaccines, immunotherapy and the immunological constant of rejection. IDrugs 12: 297-301 (2009).

• Wang H, Yang J, Jin L, Feng J, Lu Y, Sun Y, Li T, Cao R, Wu J, Fan H, Liu J. Immunotherapy of autoimmune diabetes by nasal administration of tandem glutamic acid decarboxylase 65 peptides. Immunol. Invest. 38: 690-703 (2009). *

• Wang HY, Wang RF. Regulatory T cells and cancer. Curr. Opin. Immunol. 19: 217-223 (2007).

• Wang J, Jarvis GA, Achtman M, Rosenqvist E, Michaelsen TE, Aase A, Griffiss JM. Functional activities and immunoglobulin variable regions of human and murine monoclonal antibodies specific for the P1.7 PorA protein loop of Neisseria meningitidis. Infect. Immun. 68: 1871-1878 (2000). *

• Wang RF. Molecular cloning and characterization of MHC class I- and II-restricted tumor antigens recognized by T cells. Curr. Protoc. Immunol. Chapter 20: Unit 20.10 (2009).

• Wang RF. Functional control of regulatory T cells and cancer immunotherapy. Semin. Cancer Biol. 16: 106-114 (2006). *

• Wang RF, Peng G, Wang HY. Regulatory T cells and Toll-like receptors in tumor immunity. Semin. Immunol. 18: 136-142 (2006). *

• Wang W, Uzzau S, Goldblum SE, Fasano A. Human zonulin, a potential modulator of intestinal tight junctions. J. Cell Sci. 113: 4435-4440 (2000). *

• Wang X, Barnes PF, Dobos-Elder KM, Townsend JC, Chung YT, Shams H, Weis SE, Samten B. ESAT-6 inhibits production of IFN-gamma by Mycobacterium tuberculosis-responsive human T cells. J. Immunol. 182: 3668-3677 (2009).

• Wang X, Mosmann T. In vivo priming of CD4 T cells that produce interleukin (IL)-2 but not IL-4 or interferon (IFN)-gamma, and can subsequently differentiate into IL-4- or IFN-gamma-secreting cells. J. Exp. Med. 194: 1069-1080 (2001). *

• Wang XF, Kerzerho J, Adotevi O, Nuyttens H, Badoual C, Munier G, Oudard S, Tu S, Tartour E, Maillere B. Comprehensive analysis of HLA-DR- and HLA-DP4-restricted CD4+ T cell response specific for the tumor-shared antigen survivin in healthy donors and cancer patients. J. Immunol. 181: 431-439 (2008). *

• Wang Y, Krieg AM. Induction of autoantibody production but not autoimmune disease in HEL transgenic mice vaccinated with HEL in combination with CpG or control oligodeoxynucleotides. Vaccine 22: 2641-2650 (2004). *

• Wang YE, Li B, Carlson JM, Streeck H, Gladden AD, Goodman R, Schneidewind A, Power KA, Toth I, Frahm N, Alter G, Brander C, Carrington M, Walker BD, Altfeld M, Heckerman D, Allen TM. Protective HLA class I alleles restricting acute-phase CD8+ T cell responses are associated with viral escape mutations located in highly conserved regions of HIV-1. J. Virol. 83: 1845-1855 (2009). *

• Wardenburg JB, Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J. Exp. Med. 205: 287-294 (2008). *

• Warger T, Osterloh P, Rechtsteiner G, Fassbender M, Heib V, Schmid B, Schmitt E, Schild H, Radsak MP. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 108: 544-550 (2006). *

• Warger T, Rechtsteiner G, Schmid B, Osterloh P, Schild H, Radsak MP. Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection. Clin. Rev. Allergy Immunol. 32: 57-66 (2007).

• Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am. J. Gastroenterol. Jan 26 [Epub ahead of print] (2010). *

• Wat D, Gelder C, Hibbitts S, Bowler I, Pierrepoint M, Evans R, Doull I. Is there a role for influenza vaccination in cystic fibrosis? J. Cyst. Fibros. 7: 85-88 (2008).

• Watanabe Y, Watari E, Matsunaga I, Hiromatsu K, Dascher CC, Kawashima T, Norose Y, Shimizu K, Takahashi H, Yano I, Sugita M. BCG vaccine elicits both T-cell mediated and humoral immune responses directed against mycobacterial lipid components. Vaccine 24: 5700-5707 (2006). *

• Watchmaker PB, Urban JA, Berk E, Nakamura Y, Mailliard RB, Watkins SC, van Ham SM, Kalinski P. Memory CD8+ T cells protect dendritic cells from CTL killing. J. Immunol. 180: 3857-3865 (2008). *

• Watson DS, Huang Z, Szoka FC Jr. All-trans retinoic acid potentiates the antibody response in mice to a lipopeptide antigen adjuvanted with liposomal lipid A. Immunol. Cell Biol. 87: 630-633 (2009). *

• Watt V, Ronchese F, Ritchie D. Resting B cells suppress tumor immunity via an MHC class-II dependent mechanism. J. Immunother. 30: 323-332 (2007).

• Wawrzynowicz-Syczewska M, Underhill JA, Clare MA, Boron-Kaczmarska A, McFarlane IG, Donaldson PT. HLA class II genotypes associated with chronic hepatitis C virus infection and response to alpha-interferon treatment in Poland. Liver 20: 234-239 (2000).

• Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist 13 Suppl. 4: 16-25 (2008). *

• Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12: 864-872 (2007). *

• Weber JS. The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies. Melanoma Res. 16: 379-383 (2006).

• Weck MM, Grunebach F, Werth D, Sinzger C, Bringmann A, Brossart P. TLR ligands differentially affect uptake and presentation of cellular antigens. Blood 109: 3890-3894 (2007). *

• Wedemeyer H. Immunopathogenesis of hepatitis C infection. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 31. September 12 - 13 (2003). *

• Wei Foo DG, Macary PA, Alonso S, Poh CL. Identification of human CD4(+) T-cell epitopes on the VP1 capsid protein of enterovirus 71. Viral Immunol. 21: 215-224 (2008).

• Wei H, Wang H, Lu B, Li B, Hou S, Qian W, Fan K, Dai J, Zhao J, Guo Y. Cancer immunotherapy using in vitro genetically modified targeted dendritic cells. Cancer Res. 68: 3854-3862 (2008). *

• Wei WZ, Jacob J, Radkevich-Brown O, Whittington P, Kong YC. The "A, B and C" of Her-2 DNA vaccine development. Cancer Immunol. Immunother. 57: 1711-1717 (2008). *

• Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM, Kolbe T, Stulnig TM, Horl WH, Hengstschlager M, Muller M, Saemann MD. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 29: 565-577 (2008). *

• Weichold FF, Mueller S, Kortsik C, Hitzler WE, Wulf MJ, Hone DM, Sadoff JC, Maeurer MJ. Impact of MHC class I alleles on the M. tuberculosis antigen-specific CD8(+) T-cell response in patients with pulmonary tuberculosis. Genes Immun. 8: 334-343 (2007). *

• Weimer ET, Lu H, Kock ND, Wozniak DJ, Mizel SB. A vaccine containing OprF311-341-OprI-type A- and B-flagellin fusion proteins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa. Infect. Immun. 77: 2356-2366 (2009). *

• Weinbaum CM, Mast EE, Ward JW. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Hepatology 49: S35-S44 (2009).

• Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat. Rev. Immunol. 6: 404-416 (2006). *

• Weiss L, Botero-Anug AM, Hand C, Slavin S, Naor D. CD44 gene vaccination for insulin-dependent diabetes mellitus in non-obese diabetic mice. Isr. Med. Assoc. J. 10: 20-25 (2008). *

• Weiss T, Vitacolonna M, Zoller M. The efficacy of an IL-1alpha vaccine depends on IL-1RI availability and concomitant myeloid-derived suppressor cell reduction. J. Immunother. 32: 552-564 (2009).

• Weiss U. Infection and immunity. Nature 430: 241 (2004). *

• Weksler ME, Pawelec G, Franceschi C. Immune therapy for age-related diseases. Trends Immunol. 30: 344-350 (2009). *

• Weller S, Reynaud CA, Weill JC. Vaccination against encapsulated bacteria in humans: paradoxes. Trends Immunol. 26: 85-89 (2005). *

• Wells JW, Choy K, Lloyd CM, Noble A. Suppression of allergic airway inflammation and IgE responses by a class I restricted allergen peptide vaccine. Mucosal Immunol. 2: 54-62 (2009). *

• Wells JW, Cowled CJ, Farzaneh F, Noble A. Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity. J. Immunol. 181: 3422-3431 (2008). *

• Wells TS, Leardmann CA, Smith TC, Smith B, Jacobson IG, Reed RJ, Ryan MA; Millennium Cohort Study Team. Self-reported adverse health events following smallpox vaccination in a large prospective study of US military service members. Hum. Vaccin. 4: 127-133 (2008).

• Werling D, Jann OC, Offord V, Glass EJ, Coffey TJ. Variation matters: TLR structure and species-specific pathogen recognition. Trends Immunol. 30: 124-130 (2009). *

• Whalen RG, Beard C, Xu L, Sbai H. Creation of chimeric HBV surface antigens with novel immunogenicities using DNA shuffling and screening technologies. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 57. October 20 - 21 (2003). *

• Whary MT, Fox JG. Th1-mediated pathology in mouse models of human disease is ameliorated by concurrent Th2 responses to parasite antigens. Curr. Top. Med. Chem. 4: 531-538 (2004).

• Whittington PJ, Radkevich-Brown O, Jacob JB, Jones RF, Weise AM, Wei WZ. Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity. Cancer Immunol. Immunother. 58: 759-767 (2009).

• Wickelgren I. Immunology. Mouse studies question importance of Toll-like receptors to vaccines. Science 314: 1859-1860 (2006). *

• Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 16: 183-200 (2002).

• Wiendl H, Hohlfeld R, Kieseier BC. Muscle-derived positive and negative regulators of the immune response. Curr. Opin. Rheumatol. 17: 714-719 (2005).

• Wiersma ST. Hepatitis B vaccine continues to provide long-term protection to healthcare workers. J. Hepatol. 51: 826 (2009).

• Wiethe C, Debus A, Mohrs M, Steinkasserer A, Lutz M, Gessner A. Dendritic cell differentiation state and their interaction with NKT cells determine Th1/Th2 differentiation in the murine model of Leishmania major infection. J. Immunol. 180: 4371-4381 (2008). *

• Wigley P. Genetic resistance to Salmonella infection in domestic animals. Res. Vet. Sci. 76: 165-169 (2004).

• Wiker HG. MPB70 and MPB83 - major antigens of Mycobacterium bovis. Scand. J. Immunol. 69: 492-499 (2009). *

• Wille-Reece U, Flynn BJ, Lore K, Koup RA, Miles AP, Saul A, Kedl RM, Mattapallil JJ, Weiss WR, Roederer M, Seder RA. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med. 203: 1249-1258 (2006). *

• William BM, Corazza GR. Hyposplenism: a comprehensive review. Part I: Basic concepts and causes. Hematology 12: 1-13 (2007).

• Williams BB, Wall M, Miao RY, Williams B, Bertoncello I, Kershaw MH, Mantamadiotis T, Haber M, Norris MD, Gautam A, Darcy PK, Ramsay RG. Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer. Cancer Immunol. Immunother. 57: 1635-1645 (2008). *

• Williams MA, Bevan MJ. Effector and memory CTL differentiation. Annu. Rev. Immunol. 25: 171-192 (2007). *

• Wilson CB, Marcuse EK. Vaccine safety/vaccine benefits: science and the public's perception. Nat. Rev. Immunol. 1: 160-165 (2001). *

• Wilson HL, Dar A, Napper SK, Marianela Lopez A, Babiuk LA, Mutwiri GK. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides. Int. Rev. Immunol. 25: 183-213 (2006).

• Wilson NS, Behrens GM, Lundie RJ, Smith CM, Waithman J, Young L, Forehan SP, Mount A, Steptoe RJ, Shortman KD, de Koning-Ward TF, Belz GT, Carbone FR, Crabb BS, Heath WR, Villadangos JA. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat. Immunol. 7: 165-172 (2006). *

• Wilson RA. Immunity and immunoregulation in helminth infections. Curr. Opin. Immunol. 5: 538-547 (1993).

• Wines BD, Hogarth PM. IgA receptors in health and disease. Tissue Antigens 68: 103-114 (2006). *

• Winkler U, Wingender J, Jager KE. Infections of the respiratory tract with Pseudomonas aeruginosa in cystic fibrosis. Klin. Wochenschr. 63: 490-498 (1985).

• Winter H, van den Engel NK, Ruttinger D, Schmidt J, Schiller M, Poehlein CH, Lohe F, Fox BA, Jauch KW, Hatz RA, Hu HM. Therapeutic T cells induce tumor-directed chemotaxis of innate immune cells through tumor-specific secretion of chemokines and stimulation of B16BL6 melanoma to secrete chemokines. J. Transl. Med. 5: 56 (2007). *

• Winthrop KL. Serious infections with antirheumatic therapy: are biologicals worse? Ann. Rheum. Dis. 65 Suppl. 3: iii54-iii57 (2006). *

• Wiwanitkit V. Predicted binding affinity of candidate HDV epitope: a bioinformatics study. Ann. Hepatol. 6: 108-110 (2007). *

• Wobser M, Voigt H, Houben R, Eggert AO, Freiwald M, Kaemmerer U, Kaempgen E, Schrama D, Becker JC. Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression. Cancer Immunol. Immunother. 56: 1017-1024 (2007). *

• Wohlleben G, Erb KJ. Immune stimulatory strategies for the prevention and treatment of asthma. Curr. Pharm. Des. 12: 3281-3292 (2006).

• Wolska A, Lech-Maranda E, Robak T. Toll-like receptors and their role in hematologic malignancies. Curr. Mol. Med. 9: 324-335 (2009).

• Wolska A, Lech-Maranda E, Robak T. Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell. Mol. Biol. Lett. 14: 248-272 (2009). *

• Wong J, Sibani S, Lokko NN, Labaer J, Anderson KS. Rapid detection of antibodies in sera using multiplexed self-assembling bead arrays. J. Immunol. Methods 350: 171-182 (2009). *

• Wong LL, Tsai N, Limm W, Wong L. Liver transplant for hepatocellular cancer: a treatment for the select few. Clin. Transplant. 18: 205-210 (2004).

• Wong RM, Smith KA, Tam VL, Pagarigan RR, Meisenburg BL, Quach AM, Carrillo MA, Qiu Z, Bot AI. TLR-9 signaling and TCR stimulation co-regulate CD8(+) T cell-associated PD-1 expression. Immunol. Lett. 127: 60-67 (2009).

• Woodfolk JA. T-cell responses to allergens. J. Allergy Clin. Immunol. 119: 280-294 (2007). *

• Woodland DL, Blackman MA. Immunity and age: living in the past? Trends Immunol. 27: 303-307 (2006). *

• Woodland DL, Kohlmeier JE. Migration, maintenance and recall of memory T cells in peripheral tissues. Nat. Rev. Immunol. 9: 153-161 (2009). *

• Woolard MD, Hensley LL, Kawula TH, Frelinger JA. Respiratory Francisella tularensis live vaccine strain infection induces Th17 cells and prostaglandin E2 that inhibits generation of IFN-gamma+ T cells. Infect. Immun. 76: 2651-2659 (2008). *

• Worgall S. A realistic chance for gene therapy in the near future. Pediatr. Nephrol. 20: 118-124 (2005).

• Worns MA, Teufel A, Kanzler S, Shrestha A, Victor A, Otto G, Lohse AW, Galle PR, Hohler T. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Am. J. Gastroenterol. 103: 138-146 (2008). *

• Wozniak TM, Ryan AA, Britton WJ. Interleukin-23 restores immunity to Mycobacterium tuberculosis infection in IL-12p40-deficient mice and is not required for the development of IL-17-secreting T cell responses. J. Immunol. 177: 8684-8692 (2006). *

• Wozniak TM, Ryan AA, Triccas JA, Britton WJ. Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection. Infect. Immun. 74: 557-565 (2006). *

• Wraith DC. Therapeutic peptide vaccines for treatment of autoimmune diseases. Immunol. Lett. 122: 134-136 (2009).

• Wraith DC. Anti-cytokine vaccines and the immunotherapy of autoimmune diseases. Eur. J. Immunol. 36: 2844-2848 (2006). *

• Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence? Lancet 362: 1659-1666 (2003). *

• Wright JA, Polack C. Understanding variation in measles-mumps-rubella immunization coverage - a population-based study. Eur. J. Public Health 16: 137-142 (2006).

• Wu CW, Glasner J, Collins M, Naser S, Talaat AM. Whole-genome plasticity among Mycobacterium avium subspecies: insights from comparative genomic hybridizations. J. Bacteriol. 188: 711-723 (2006). *

• Wu Y, Zheng Z, Jiang Y, Chess L, Jiang H. The specificity of T cell regulation that enables self-nonself discrimination in the periphery. Proc. Natl. Acad. Sci. U.S.A. 106: 534-539 (2009). *

• Wulf M, Hoehn P, Trinder P. Identification and validation of T-cell epitopes using the IFN-gamma EliSpot assay. Methods Mol. Biol. 524: 439-446 (2009).

• Wuttke M, Papewalis C, Jacobs B, Schott M. Identifying tumor antigens in endocrine malignancies. Trends Endocrinol. Metab. 20: 122-129 (2009). *

• Wysocki PJ, Zolnierek J, Szczylik C, Mackiewicz A. Recent developments in renal cell cancer immunotherapy. Expert Opin. Biol. Ther. 7: 727-737 (2007).

• Xiao BG, Huang YM, Link H. Tolerogenic dendritic cells: the ins and outs of outcome. J. Immunother. 29: 465-471 (2006).

• Xiao J, Li ST, Wang W, Li Y, Zhao WM. Protective effects of overexpression TCR Vbeta5.2-HSP70 and TCR Vbeta8.2-HSP70 against collagen-induced arthritis in rats. Cell. Mol. Immunol. 4: 439-445 (2007). *

• Xiao T. Innate immune recognition of nucleic acids. Immunol. Res. 43: 98-108 (2009). *

• Xicohtencatl-Cortes J, Lyons S, Chaparro AP, Hernandez DR, Saldana Z, Ledesma MA, Rendon MA, Gewirtz AT, Klose KE, Giron JA. Identification of proinflammatory flagellin proteins in supernatants of Vibrio cholerae O1 by proteomics analysis. Mol. Cell. Proteomics 5: 2374-2383 (2006). *

• Xu B, Dong CY, Zhang F, Lin YM, Wu KF, Ma XT. Synergistic antileukemia effect of combinational gene therapy using murine beta-defensin 2 and IL-18 in L1210 murine leukemia model. Gene Ther. 14: 1181-1187 (2007).

• Xu J, Wu J, Wang X, Zhang Y, Li W, Zhu Z, Zhu D, Hu Z, Roque RS, Liu J. The hinge region fragment of immunoglobulin G improves immunogenicity of recombinant gonadotrophin-releasing hormone conjugated to the T-helper epitope in designing peptide vaccines. Immunology 128: e506-e513 (2009).

• Xu L, Zhang F, Xu W, Xiong S. Specific antibodies induced by DNA vaccination with extracellular domain of CD25 gene protect against ConA-induced autoimmune hepatitis. Clin. Immunol. 132: 412-419 (2009). *

• Xu S, Koldovsky U, Xu M, Wang D, Fitzpatrick E, Son G, Koski G, Czerniecki BJ. High-avidity antitumor T-cell generation by Toll receptor 8-primed, myeloid- derived dendritic cells is mediated by IL-12 production. Surgery 140: 170-178 (2006).

• Xu Y, Darcy PK, Kershaw MH. Tumor-specific dendritic cells generated by genetic redirection of Toll-like receptor signaling against the tumor-associated antigen, erbB2. Cancer Gene Ther. 14: 773-780 (2007).

• Xue X, Feng G, Li M, Qin X, Wu S, Zhang C, You Y, Wang W, Jiang C, Liu Y, Zhu W, Ran Y, Zhang Z, Yan Z, Han W, Zhang Y. Amelioration of experimental autoimmune encephalomyelitis by BLyS autovaccine. Vaccine 26: 2873-2881 (2008). *

• Xue X, Wang Z, Yan Z, Shi J, Han W, Zhang Y. Production and purification of recombinant human BLyS mutant from inclusion bodies. Protein Expr. Purif. 42: 194-199 (2005). *

• Yamamoto M, Fujihashi K, Kawabata K, McGhee JR, Kiyono H. A mucosal intranet: intestinal epithelial cells down-regulate intraepithelial, but not peripheral, T lymphocytes. J. Immunol. 160: 2188-2196 (1998). *

• Yamamoto M, Kamigaki T, Yamashita K, Hori Y, Hasegawa H, Kuroda D, Moriyama H, Nagata M, Ku Y, Kuroda Y. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer. Oncol. Rep. 22: 337-343 (2009).

• Yang F, Chen IH, Xiong Z, Yan Y, Wang H, Yang XF. Model of stimulation-responsive splicing and strategies in identification of immunogenic isoforms of tumor antigens and autoantigens. Clin. Immunol. 121: 121-133 (2006). *

• Yang J, Pospisil R, Mage RG. Expression and localization of rabbit B-cell activating factor (BAFF) and its specific receptor BR3 in cells and tissues of the rabbit immune system. Dev. Comp. Immunol. 33: 697-708 (2009).

• Yang YC, Cheng YW, Lai CS, Chen W. Prevalence of childhood acne, ephelides, warts, atopic dermatitis, psoriasis, alopecia areata and keloid in Kaohsiung County, Taiwan: a community-based clinical survey. J. Eur. Acad. Dermatol. Venereol. 21: 643-649 (2007). *

• Yano A, Onozuka A, Asahi-Ozaki Y, Imai S, Hanada N, Miwa Y, Nisizawa T. An ingenious design for peptide vaccines. Vaccine 23: 2322-2326 (2005). *

• Yawn BP, Wollan P, Gazzuola L, Kim WR. Diagnosis and 10-year follow-up of a community-based hepatitis C cohort. J. Fam. Pract. 51: 135-140 (2002). *

• Yeh SH, Ni YH, Jeng YM, Chen HL, Wu JF, Chang MH. Emerging importance of autoimmune hepatitis in children in Taiwan, an endemic area for viral hepatitis. Pediatr. Neonatol. 50: 65-69 (2009).

• Yerly D, Di Giammarino L, Bihl F, Cerny A. Targets of emerging therapies for viral hepatitis B and C. Expert Opin. Ther. Targets 10: 833-850 (2006).

• Yeung LT, Roberts EA. Current issues in the management of paediatric viral hepatitis. Liver Int. 30: 5-18 (2010). *

• Yewdell JW, Bennink JR. Mechanisms of viral interference with MHC class I antigen processing and presentation. Annu. Rev. Cell. Dev. Biol. 15: 579-606 (1999). *

• Yewdell JW, Haeryfar SM. Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design. Annu. Rev. Immunol. 23: 651-682 (2005). *

• Yin R, Zheng W, Hao F, Yang XC, Zhong BY, Li QJ. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity. J. Dermatol. Sci. 55: 116-122 (2009).

• Yokoyama Y, Grunebach F, Schmidt SM, Heine A, Hantschel M, Stevanovic S, Rammensee HG, Brossart P. Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells. Clin. Cancer Res. 14: 5503-5511 (2008). *

• Young LJ, Wilson NS, Schnorrer P, Mount A, Lundie RJ, La Gruta NL, Crabb BS, Belz GT, Heath WR, Villadangos JA. Dendritic cell preactivation impairs MHC class II presentation of vaccines and endogenous viral antigens. Proc. Natl. Acad. Sci. U.S.A. 104: 17753-17758 (2007). *

• Yrlid U, Cerovic V, Milling S, Jenkins CD, Klavinskis LS, MacPherson GG. A distinct subset of intestinal dendritic cells responds selectively to oral TLR7/8 stimulation. Eur. J. Immunol. 36: 2639-2648 (2006). *

• Yu AS, Cheung RC, Keeffe EB. Hepatitis B vaccines. Clin. Liver Dis. 8: 283-300 (2004). *

• Yu JJ, Goluguri T, Guentzel MN, Chambers JP, Murthy AK, Klose KE, Forsthuber TG, Arulanandam BP. Francisella tularensis T cell antigen identification using Humanized HLA-DR4 transgenic mice. Clin. Vaccine Immunol. Dec 16 [Epub ahead of print] (2009). *

• Yu S, Xia M, Xu W, Chu Y, Wang Y, Xiong S. All-trans retinoic acid biases immune response induced by DNA vaccine in a Th2 direction. Vaccine 23: 5160-5167 (2005). *

• Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok JD. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl. Acad. Sci. U.S.A. 105: 20410-20415 (2008). *

• Yun CH, Lundgren A, Azem J, Sjoling A, Holmgren J, Svennerholm AM, Lundin BS. Natural killer cells and Helicobacter pylori infection: bacterial antigens and interleukin-12 act synergistically to induce gamma interferon production. Infect. Immun. 73: 1482-1490 (2005). *

• Yun CH, Son CG, Chung DK, Han SH. Chlorophyllin attenuates IFN-gamma expression in lipopolysaccharide-stimulated murine splenic mononuclear cells via suppressing IL-12 production. Int. Immunopharmacol. 5: 1926-1935 (2005).

• Zafrir Y, Agmon-Levin N, Shoenfeld Y. Post-influenza vaccination vasculitides: a possible new entity. J. Clin. Rheumatol. 15: 269-270 (2009).

• Zaia AA, Sappington KJ, Nisapakultorn K, Chazin WJ, Dietrich EA, Ross KF, Herzberg MC. Subversion of antimicrobial calprotectin (S100A8/S100A9 complex) in the cytoplasm of TR146 epithelial cells after invasion by Listeria monocytogenes. Mucosal Immunol. 2: 43-53 (2009). *

• Zaia JA, Li X, Franck AE, Wu X, Thao L, Gallez-Hawkins G. Knock-out of CMVpp65 nuclear localization: biologic and immunologic effects. Clin. Vaccine Immunol. 16: 935-943 (2009). *

• Zapata Velandia AM, Ng SS, Brennan RF, Simonsen NR, Gastanaduy M, Zabaleta J, Lentz JJ, Craver RD, Correa H, Delgado A, Pitts AL, Himel JR, Udall JN Jr, Schmidt-Sommerfeld E, Brown RF, Athas GB, Keats BB, Mannick EE. Association of the T allele of an intronic single nucleotide polymorphism in the colony stimulating factor 1 receptor with Crohn's disease: a case-control study. J. Immune Based Ther. Vaccines 2: 6 (2004). *

• Zarate-Blades CR, Bonato VL, da Silveira EL, E Paula MO, Junta CM, Sandrin-Garcia P, Fachin AL, Mello SS, Cardoso RS, de Sa Galetti FC, Coelho-Castelo AA, Ramos SG, Donadi EA, Sakamoto-Hojo ET, da Silva Passos GA, Silva CL. Comprehensive gene expression profiling in lungs of mice infected with Mycobacterium tuberculosis following DNAhsp65 immunotherapy. J. Gene Med. 11: 66-78 (2009).

• Zaunders JJ, Munier ML, Seddiki N, Pett S, Ip S, Bailey M, Xu Y, Brown K, Dyer WB, Kim M, de Rose R, Kent SJ, Jiang L, Breit SN, Emery S, Cunningham AL, Cooper DA, Kelleher AD. High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J. Immunol. 183: 2827-2836 (2009).

• Zetterman RK. Clinical topics in liver disease. American College of Gastroenterology 68th Annual Scientific Meeting and Postgraduate Course, October 10 - 15, 2003, Baltimore, Maryland (2003).

• Zhang H, Lundegaard C, Nielsen M. Pan-specific MHC class I predictors: a benchmark of HLA class I pan-specific prediction methods. Bioinformatics 25: 83-89 (2009). *

• Zhang JW. T cell vaccination as an immunotherapy for autoimmune diseases. Cell. Mol. Immunol. 1: 321-327 (2004). *

• Zhang Q, Xue X, Xu X, Wang C, Chang W, Pan W. Influence of HLA-DRB1 alleles on antibody responses to PfCP-2.9-immunized and naturally infected individuals. J. Clin. Immunol. 29: 454-460 (2009). *

• Zhang R, Yang PZ, Wu CY, Jin HL, Li B, Huang XK, Zhou HY, Gao Y, Zhu LX, Kijlstra A. Role of T-cell receptor V beta 8.3 peptide vaccine in the prevention of experimental autoimmune uveoretinitis. Chin. Med. J. (Engl.) 119: 740-748 (2006). *

• Zhang S, Bernard D, Khan WI, Kaplan MH, Bramson JL, Wan Y. CD4(+) T-cell-mediated anti-tumor immunity can be uncoupled from autoimmunity via the STAT4/STAT6 signaling axis. Eur. J. Immunol. 39: 1252-1259 (2009). *

• Zhang W, Jin H, Hu Y, Yu Y, Li X, Ding Z, Kang Y, Wang B. Protective response against type 1 diabetes in NOD mice after co-immunization of insulin and DNA encoding pro-insulin. Hum Gene Ther. Sep 29 [Epub ahead of print] (2009).

• Zhang WW, Matlashewski G. Immunization with Toll-like receptor 7/8 agonist vaccine adjuvants increases protective immunity against Leishmania major in BALB/c mice. Infect. Immun. 76: 3777-3783 (2008). *

• Zhang WX, Zhao W. Adenosine deaminase deficiency associated severe combined immunodeficiency with disseminated varicella infection after vaccination: a case report. Zhonghua Er Ke Za Zhi 46: 597-600 (2008).

• Zhang X, Castelli FA, Zhu X, Wu M, Maillere B, Benmohamed L. Gender-dependent human leukocyte antigen (HLA)-DR-restricted epitopes identified from the herpes simplex virus type 1 glycoprotein D. Clin. Vaccine Immunol. 15: 1436-1449 (2008). *

• Zhang Y, Gaekwad J, Wolfert MA, Boons GJ. Modulation of innate immune responses with synthetic lipid A derivatives. J. Am. Chem. Soc. 129: 5200-5216 (2007). *

• Zhang YL, Guo YJ, Bin Li, Sun SH. Hepatitis C virus single-stranded RNA induces innate immunity via Toll-like receptor 7. J. Hepatol. 51: 29-38 (2009).

• Zhao C, Wood MW, Galyov EE, Hopken UE, Lipp M, Bodmer HC, Tough DF, Carter RW. Salmonella typhimurium infection triggers dendritic cells and macrophages to adopt distinct migration patterns in vivo. Eur. J. Immunol. 36: 2939-2950 (2006). *

• Zhao Y. The two simultaneously occurring processes in one immune response: the positive immune reaction and immune tolerance. Med. Hypotheses 67: 1384-1385 (2006).

• Zheng G, Wang Y, Xiang SH, Tay YC, Wu H, Watson D, Coombes J, Rangan GK, Alexander SI, Harris DC. DNA vaccination with CCL2 DNA modified by the addition of an adjuvant epitope protects against "nonimmune" toxic renal injury. J. Am. Soc. Nephrol. 17: 465-474 (2006). *

• Zheng J, Kohler ME, Chen Q, Weber J, Khan J, Johnson BD, Orentas RJ. Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen. BMC Immunol. 8: 4 (2007). *

• Zheng R, Cohen PA, Paustian CA, Johnson TD, Lee WT, Shu S, Koski GK. Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. Cancer Res. 68: 4045-4049 (2008). *

• Zhi-Hua L, Huai-Liang W, Bo Z, Yuan-Qiang W, Yong L, Yu-Zhang W. Estimation of affinity of HLA-A*0201 restricted CTL epitope based on the SCORE function. Protein Pept. Lett. 16: 561-569 (2009).

• Zhong J, Rist M, Cooper L, Smith C, Khanna R. Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus. PLoS ONE 3: e3256 (2008). *

• Zhou J, Weng D, Zhou F, Pan K, Song H, Wang Q, Wang H, Wang H, Li Y, Huang L, Zhang H, Huang W, Xia J. Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses. Cancer Immunol. Immunother. 58: 1587-1597 (2009).

• Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) - United States, 1991-2001. MMWR Surveill. Summ. 52: 1-24 (2003).

• Zhu F, Liao YH, Li LD, Cheng M, Wei F, Wei YM, Wang M. Target organ protection from a novel angiotensin II receptor (AT1) vaccine ATR12181 in spontaneously hypertensive rats. Cell. Mol. Immunol. 3: 107-114 (2006). *

• Zhu Q, Egelston C, Vivekanandhan A, Uematsu S, Akira S, Klinman DM, Belyakov IM, Berzofsky JA. Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proc. Natl. Acad. Sci. U.S.A. 105: 16260-16265 (2008). *

• Zhu X, Ramos TV, Gras-Masse H, Kaplan BE, BenMohamed L. Lipopeptide epitopes extended by an N(epsilon)-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. Eur. J. Immunol. 34: 3102-3114 (2004). *

• Zimmerman DH, Taylor P, Bendele A, Carambula R, Duzant Y, Lowe V, O'Neill SP, Talor E, Rosenthal KS. CEL-2000: a therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model. Int. Immunopharmacol. Jan 11 [Epub ahead of print] (2010).

• Zinkernagel RM. On natural and artificial vaccinations. Annu. Rev. Immunol. 21: 515-546 (2003). *

• Zintzaras E, Germenis AE. Performance of antibodies against tissue transglutaminase for the diagnosis of celiac disease: meta-analysis. Clin. Vaccine Immunol. 13: 187-192 (2006). *

• Zipfel PF, Hallstrom T, Hammerschmidt S, Skerka C. The complement fitness factor H: role in human diseases and for immune escape of pathogens, like pneumococci. Vaccine 26 Suppl. 8: I67-I74 (2008).

• Zivny JH, Moldoveanu Z, Vu HL, Russell MW, Mestecky J, Elson CO. Mechanisms of immune tolerance to food antigens in humans. Clin. Immunol. 101: 158-168 (2001). *

• Zobywalski A, Javorovic M, Frankenberger B, Pohla H, Kremmer E, Bigalke I, Schendel DJ. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J. Transl. Med. 5: 18 (2007). *

• Zonneveld-Huijssoon E, Ronaghy A, Van Rossum MA, Rijkers GT, Van Der Klis FR, Sanders EA, Vermeer-De Bondt PE, Hoes AW, Van Der Net JJ, Engels C, Kuis W, Prakken BJ, Van Tol MJ, Wulffraat NM. Safety and efficacy of meningococcal C vaccination in juvenile idiopathic arthritis. Arthritis Rheum. 56: 639-646 (2007). *

• Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6: 295-307 (2006). *

• Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137: 1593-1608.e2 (2009). *

• Zuckerman AJ. Safety of hepatitis B vaccines. Travel Med. Infect. Dis. 2: 81-84 (2004).

• Zygmunt BM, Rharbaoui F, Groebe L, Guzman CA. Intranasal immunization promotes Th17 immune responses. J. Immunol. 183: 6933-6938 (2009).

Number of references = 2330

www psc-literature.org